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Abstract 
 
Background and Aims:  
Non-infectious posterior segment uveitis is a potentially blinding disease that 
usually affects people of working age group. Like other immune mediated 
diseases, uveitis is a complex polygenic disease.  Several cytokines have been 
identified as important regulators of the immune system during, induction, 
progression and remission of ocular inflammation in uveitis. The work 
described in this thesis is based on the hypothesis that polymorphisms in 
chemokine and cytokine genes can predict clinical outcome in non-infectious 
uveitis.  
Methods: 
Functional polymorphisms in sixteen chemokine and cytokine genes were 
genotyped and there associations were studied in a cohort of British 
Caucasians suffering with non-infectious posterior segment uveitis.   
Results: 
This study has shown that polymorphisms in IL-18, IL-10 & CCR2 genes can 
influence the susceptibility to certain phenotypes of non-infectious uveitis.  
Polymorphisms in many genes particularly, IL-1β, IL-6, CCR5 & IL-18 are found 
to affect the visual outcome and severity of the disease. 
Conclusion: 
The identification of these genetic variants that add susceptibility or resistance 
to uveitis has provided us further insights into the pathogenesis of uveitis. This 
work will help us identify patients who are at a greater risk of losing sight with 
this disease. This, in turn would allow tailored aggressive therapy to be given at 
presentation when vision is still good with a precise aim to prevent significant 
amount of blindness. 
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1.1 Overview 
 
Uveitis is traditionally defined as inflammation of the uveal tract however most 
of the time the surrounding tissues are also affected. This inflammation could 
be either due to a direct insult by infectious agents or through an immune 
mediated process where infectious pathogens, environment or genes could be 
a trigger.  
Uveitis is a relatively common inflammatory eye condition with reported annual 
incidence between 11.4 and 52.4 per 100,000 and prevalence between 38 and 
730 per 100,000. (Paivonsalo-Hietanen et al. 1997) (Tran et al. 1994) (Mercanti 
et al. 2001) (Gritz and Wong 2004) It predominantly affects patients in the 
working age group (Suttorp-Schulten and Rothova 1996) and despite current 
advances in diagnosis and management, visual loss occurs in 35-50% of 
patients with this condition. (Durrani et al. 2004) (Rothova et al. 1996)  
The most widely used classification of uveitis is the one devised by the 
International Uveitis Study Group, (Bloch-Michel and Nussenblatt 1987) and is 
based on the anatomic location of the inflammation. (Table 1-1) It broadly 
divides uveitis into anterior, intermediate, posterior and pan uveitis. 
Nevertheless, there are ambiguities in its use, and it does not provide criteria 
for the diagnosis of specific uveitic entities.  
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Table 1-1: The SUN Working Group anatomic classification of uveitis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SUN: Standardization of Uveitis Nomenclature 
 
Uveitis can also be classified on the basis of presence of obvious infectious 
entity.  
a) Infectious uveitis, if it is present and 
b) Non-infectious, with no discernible cause.  
However, immune responses to infectious or non-infectious causes are not too 
dissimilar; furthermore, infections can play a major role in both the initiation and 
perpetuation of “autoimmune” diseases. Thus, it is often difficult to clinically 
identify infectious versus non-infectious uveitis. Therefore, in many cases of 
uveitis, the exact contribution of infectious agents in the cause of non-infectious 
uveitis remains unclear. For example, there is conflicting evidence that acute 
anterior uveitis is associated with Yersinia and chlamydial infections. 
(Wakefield et al. 1986) (Wakefield et al. 1990) 
However once the diagnosis of infectious uveitis is made the treatment is 
primarily anti-microbial, (though steroids are needed to limit the inflammation) 
and the prognosis depends upon the sensitivity of the organism to medical 
therapy. Conversely the treatment of non-infectious uveitis is mainly immuno-
suppression. This treatment is largely topical in anterior segment non-infectious 
1. Type Primary Site of Inflammation Includes 
Anterior uveitis Anterior chamber Iritis 
  Iridocyclitis 
  Anterior cyclitis 
Intermediate uveitis Vitreous Pars planitis 
  Posterior cyclitis 
  Hyalitis 
Posterior uveitis Retina or choroid Focal, multifocal, or 
  diffuse choroiditis 
  Chorioretinitis 
  Retinochoroiditis 
  Retinitis 
  Neuroretinitis 
Pan uveitis Anterior chamber,  
 vitreous, and retina or  
 choroid  
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uveitis and predominantly systemic if the inflammation is in the posterior 
segment. This posterior segment uveitis is the most common cause of loss of 
vision in uveitis and is hall marked with the presence of inflammation in the 
vitreous. It may include inflammation of the choroid, retina, retinal vessels, 
vitreous and ciliary body either in isolation or as a part of pan uveitis. Anterior 
uveitis and posterior segment uveitis are two distinct pathogenic entities 
demonstrating a spectrum of clinical signs that reflect both the predominant 
anatomical site and pathological features of either anterior uveitis or posterior 
segment uveitis. (Forrester 1991) For this posterior group the term posterior 
segment intraocular inflammation (PSII) has been adopted. (Forrester JV et al. 
1998) This inflammation can be an isolated phenomenon in the eye like pars 
planitis or it may be associated with systemic disease like sarcoidosis or 
Behcet’s disease as shown in Table 1-2. Whatever the clinical phenotype is, 
histopathologically and immunologically they are all similar characterized by 
lymphocytic infiltration, with many macrophages and few plasma cells. 
(Lightman 2001) (Boyd, Young, and Lightman 2001)  In this thesis this non-
infectious posterior segment uveitis will be referred as PSU 
 
Table 1-2 Main causes of non-infectious posterior segment uveitis 
 
Immune-mediated ocular * Immune-mediated systemic 
  
Intermediate Uveitis Sarcoidosis 
White dot syndromes Behcet’s disease 
Multifocal choroiditis Vogt-Koyanagi-Harada 
Birdshot chorioretinopathy Multiple sclerosis 
Serpiginous choroiditis Sympathetic ophthalmia 
 
 * may have associated systemic involvement but insufficient to cause clinical disease 
 
.  
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Although there is a clear lack of uveal tissue available for histology in PSU an 
animal model has been developed known as experimental autoimmune uveitis 
(EAU) (Nussenblatt 1991) (Nussenblatt and Gery 1996) The clinicopathological 
features of EAU parallel well the clinicopathological features of PSU in humans 
in that experimental models can be modulated to display the cardinal signs of 
iridocyclitis, vitritis, retinal vasculitis, and choroidal granulomata.(Forrester et al. 
1992) The histological pattern of EAU clearly varies to some degree depending 
on the species, the antigen and the amount injected. However, in all cases the 
dominant feature of the disease in the posterior segment is the infiltration of T 
cells.  
1.2 Clinical features and epidemiology 
PSU comprises of heterogeneous phenotypes of uveitis ranging from isolated 
intermediate uveitis to uveitis associated with Behcet’s disease. The clinical 
phenotype varies and thus the prognosis, but the underlying pathogenesis is 
the same. (Boyd, Young, and Lightman 2001) The hallmark of PSU is 
inflammation in the vitreous cavity either in isolation or as a part of pan or 
posterior uveitis. Very often the adjacent structures like the retina, optic nerve 
and retinal blood vessel are also involved. Broadly PSU is divided into two 
categories. (Forrester JV et al. 1998) 
1) PSU predominantly involving the eye alone (with no clinically detectable 
other organ involvement) 
2) PSU associated with systemic disease. 
Epidemiological data suggest considerable variation in the frequency of 
PSU throughout the world depending upon the population studied. In 
general, the non-infectious uveitis syndromes are more common in 
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developed countries, mainly because of lower prevalence rates of the 
various infectious forms of uveitis. The most common type of non-infectious 
PSU is idiopathic. (Wakefield and Chang 2005), (Chang and Wakefield 
2002) (Rathinam and Namperumalsamy 2007)The most common 
associated disease with PSU is sarcoidosis which accounts for 5-18.1% of 
all the cases in the US, Netherlands and Japan, (Wakabayashi et al. 2003) 
(Merrill et al. 1997), (Smit, Baarsma, and de 1993) (Rothova et al. 1992) 
Sarcoidosis, however, appears to be rare in Italy, Israel and china where its 
prevalence among uveitis population is less than 1%.  (Mercanti et al. 2001) 
(Weiner and BenEzra 1991) (Yang et al. 2005) The Behcet's syndrome is 
the leading cause in Turkey, Saudi Arabia, Israel, China and Iran where it 
accounts for 6.5-28% of all cases of uveitis. (Sengun et al. 2005) (Islam and 
Tabbara 2002) (Weiner and BenEzra 1991) (Yang et al. 2005) (Soheilian et 
al. 2004) A study from North India highlights serpiginous choroidopathy as a 
leading cause of posterior uveitis with Vogt-Koyanagi-Harada Syndrome 
(VKH) and sympathetic ophthalmia as common causes of non infectious 
pan uveitis. (Singh, Gupta, and Gupta 2004)  Study from China also reveals 
a high proportion of VKH syndrome (15.9%) besides Behcet's syndrome 
(16.5%). (Yang et al. 2005)  
The clinical features and course of disease vary considerably between the 
different types of PSU, primarily because of the anatomical sites involved.   
Outlined below are the salient clinical details of various sub types of PSU. 
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1.2.1 PSU predominantly involving the eye alone 
1.2.1.1 Idiopathic intermediate uveitis 
Intermediate uveitis is a clinical term that describes inflammation located 
primarily in the peripheral retina, vitreous base, and pars plana region of the 
ciliary body. (Bonfioli et al. 2005) It is characterized by a mild bilateral anterior 
chamber reaction with vitreous cells, retinal vasculitis, and macular oedema. 
Some cases demonstrate a unique opacified ridge in the peripheral retina, 
especially inferiorly, known as a snow bank and when present the disease is 
called pars planitis. (Henderly et al. 1987b) Intermediate uveitis represents 4–
16% of uveitis patients in general ophthalmology practice (Lai and Pulido 2002) 
(Perkins and Folk 1984) and 6%- 23% in specialized uveitis clinics (Jakob et al. 
2009) (Al-Mezaine, Kangave, and bu El-Asrar 2010) (Cimino et al. 2010) 
Intermediate uveitis often presents with blurred vision and complaints of floaters. 
80% of cases are bilateral, (Henderly et al. 1987a) (Smith, Godfrey, and Kimura 
1973) but many years may elapse before the second eye is involved. Along 
with consistent vitreous inflammation, venous periphlebitis (vessel sheathing) 
may be found. Neovascularisation may occur at the optic nerve head and within 
peripheral snow banks. (Felder and Brockhurst 1982) Not infrequently, 
complications like posterior subcapsular cataract, secondary glaucoma, and 
cystoid macular oedema (CMO) can develop. Severe inflammation is not rare 
particularly if young, and visual loss is most commonly caused by chronic 
macular oedema or secondary glaucoma.  
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1.2.1.2 Posterior uveitis 
Clinically, posterior uveitis can present as white dots at RPE or choroidal level, 
vasculitis, choroiditis (focal or multifocal) either in isolation or as a combination 
of these. 
The white dot syndromes are a group of chorioretinal disorders of unknown 
aetiology that manifest multiple white dots in the deep layers of the retina, 
retinal pigment epithelium (RPE), or choroid. (Nussenblatt et al. 1995b) Small 
white dots are typically found early in disease and in some cases are discrete 
and evanescent; in others they are large with poorly defined borders and tend 
to coalesce over time. Fluorescein angiography is similar in most cases with 
patchy choroidal filling, early hypo fluorescence, and late hyper fluorescence, 
with more spots seen angiographically than clinically. The type and site of spots, 
along with angiographical findings and clinical course help us to differentiate 
white spots into punctate inner chorioretinopathy (PIC), presumed ocular 
histoplasmosis syndrome (POHS), acute multifocal posterior placoid 
epitheliopathy (AMPPE), multifocal choroiditis (MFC) with pan uveitis, and 
multiple evanescent white dot syndrome (MEWDS). Development of choroidal 
neovascular membrane (CNV) is a feared complication in all white dot 
syndromes 
Punctate inner chorioretinopathy 
Punctate inner chorioretinopathy (PIC) typically occurs in moderately myopic 
young women who present with blurred vision, light flashes, or paracentral 
scotomas associated with small yellow-white lesions of the inner choroid and 
RPE.(Watzke et al. 1984) Acute lesions develop into pigmented atrophic scars; 
peripapillary chorioretinal atrophy may appear along with linear equatorial 
atrophic and hypertrophic scars. The disorder is often bilateral, and has no 
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associated vitritis or anterior segment inflammation, and choroidal 
neovascularisation may occur. PIC and POHS are indistinguishable based on 
clinical signs, but the latter is associated with infection with H. capsulatum in 
the Ohio–Mississippi valleys, where histoplasmosis is endemic, although no 
such association is found with clinically indistinguishable POHS outside these 
histoplasma-associated areas. No such association is described for PIC.  
Acute multifocal posterior placoid epitheliopathy 
AMPPE is characterised with multiple large plaque-like lesions occur transiently 
at the level of the RPE.(Gass 1968) It typically presents with visual loss in 
young patients, without sex predilection, and following a viral prodrome. (Ryan 
and Maumenee 1972) It is bilateral in up to 90% of cases, with the second eye 
becoming involved within 1 month. (Polk and Goldman 1999) Spontaneous 
resolution typically occurs over days or weeks, with the dots becoming 
progressively pigmented, leaving a mottled RPE. Isolated areas of choroidal no 
perfusion may be noted underlying the placoid lesions and suggest 
choriocapillary occlusion. (Young, Bird, and Sehmi 1980)  
Multiple evanescent white dots syndrome 
MEWDS is characterized by the appearance of small white spots at the level of 
the RPE and is associated with a marked drop in vision, scotoma, and 
shimmering photopsia.(Jampol et al. 1984) It typically occurs in young women, 
and, as with AMPPE, it usually follows a viral illness. Small, pale spots in the 
mid peripheral retina may be accompanied by a granular appearance of the 
macula and rare cells in the vitreous. Later clinical findings include multiple 
atrophic choroidal scars with peripapillary pigmentary changes, choroidal 
neovascularisation and an absence of vitreous inflammation. The disorder 
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typically resolves in 6–7 weeks with return to normal visual acuity and fading of 
the fundus changes.  
Multifocal choroiditis with panuveitis 
MFC with panuveitis is also associated with multiple choroidal lesions but 
additionally has anterior uveitis and vitritis. (Palestine et al. 1985)  
Birdshot retinochoroidopathy is an uncommon PSU characterized by vitritis and 
multiple ovoid, frequently ill-defined, cream-colored subretinal lesions  that may 
be found in a centripetal pattern in the retinal posterior and mid 
periphery.(Kaplan and Aaberg 1980), (Ryan and Maumenee 1980) It typically 
occurs in midlife and is more common in females.  Patients often present with 
floaters and decreased visual acuity associated with macular oedema. Macular 
oedema, vascular leakage, and CNV lead to significant visual impairment, with 
loss of useful vision in one or both eyes in 40% of patients. (Ryan and 
Maumenee 1980), (Cassoux and LeHoang 2000) 
Sympathetic Ophthalmia 
Sympathetic ophthalmia (SO) is a bilateral inflammatory disease that occurs 
following penetrating trauma to one eye. (Nussenblatt et al. 1995a) Incidence 
rates of 0.19% and 0.07% have been reported for accidental or surgical trauma, 
respectively. The onset may occur between 5 days and 66 years following 
trauma, although 65% of cases occur between 2 and 8 weeks. (Lubin, Albert, 
and Weinstein 1980), (Zaharia, Lamarche, and Laurin 1984) and 90% are 
noted within 1 year. (Green et al. 1972) (Kilmartin, Dick, and Forrester 2000)  
On clinical examination, sympathetic ophthalmia is characterized by mutton-fat 
keratic precipitates, anterior uveitis, vitreous cells, prominent choroidal 
thickening, and papillitis. (Nussenblatt et al. 1995a) Retinal detachment, 
subretinal neovascularization, and vasculitis may occur.  Visual prognosis in 
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sympathetic ophthalmia is variable, and the final acuity may correlate with the 
degree of inflammation. (Kilmartin, Dick, and Forrester 2000) 
 
 
1.2.2 PSU associated with systemic disease 
1.2.2.1 Sarcoidosis 
Sarcoidosis is a chronic granulomatous disease of unknown aetiology. It is 
a systemic disorder that can involve many organs, including lungs, eyes, 
skin, lymph nodes, liver, spleen, and the central nervous system. (Bonfioli 
and Orefice 2005) In American and European studies, sarcoidosis has an 
incidence of 6–10 per 100,000, (Henke et al. 1986), (Karma 1979), (Sartwell 
and Edwards 1974) but this varies considerably with race, geography, 
diagnostic criteria and referral patterns. There is an increased incidence 
among African-Americans, with estimates ranging between 8 and 15 times 
that of the Caucasian American population. (Bresnitz and Strom 1983)  
Sarcoidosis is characterized by formation of large granulomas within 
involved organs, such as the lung, where hilar lymphadenopathy is 
characteristic. Sarcoidosis is best diagnosed by the characteristic 
histological appearance of affected tissue on biopsy.  
About one fourth of the patients with systemic sarcoidosis have ocular 
involvement, (Lee et al. 2009a) (Heiligenhaus et al. 2011) with reports as 
high as 78.6%. (Iwata et al. 1976) The most common ocular manifestation is 
iritis or iridocyclitis. (Lee et al. 2009a) (Heiligenhaus et al. 2011)  The 
posterior segment is involved in 25%-60% of patients (Hassenstein et al. 
2003) (Obenauf et al. 1978) and can include the optic nerve.  Anterior 
segment examination may reveal conjunctival granulomata, aqueous cell 
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and flare, iris nodules, and posterior synechiae.  Yellowish-gray nodular 
lesions may appear in the choroid or outer retina and can be confluent, and 
vitreous cells or "snow-ball" opacities may be present. (Papadia, Herbort, 
and Mochizuki 2010) Patchy retinal phlebitis with branch vein occlusion and 
retinal or disc neovascularization may be found.  
 
1.2.2.2 Behcet’s disease 
Behcet’s disease (BD) is a chronic, relapsing, multisystem disorder that 
particularly affects the eye, skin, and the oral and genital mucosa. However 
quite often patient develop arthritis, intestinal ulceration, and abnormalities of 
the cardiovascular and central nervous systems. (Sakane et al. 1999) Behcet’s 
disease is characterized by an occlusive vasculitis of unknown aetiology with 
suggestions of genetic, infectious, and immune influence. Ocular findings in 
Behcet’s disease, known as ocular Behcet’s (OB) occur in a high proportion of 
patients and had been associated with blindness in 50–90% of the cases. 
(Chung, Liu, and Tsi 1986), (BenEzra and Cohen 1986) Recent data suggests 
that up to 48% of patients with OB experience severe visual loss. (Davatchi et 
al. 2010) The main cause of irreversible visual loss appears to be ischemic 
maculopathy, and use of biologic agents has significantly reduced the risk of 
severe visual loss. (Taylor et al. 2011) 
Although Behcet’s disease is found worldwide, it  has a predilection for the area 
corresponding to the old silk trading routes extending from Japan, across the 
Far and Middle East, and to the Mediterranean. (Verity et al. 1999)  
Patients with Behcet’s disease may present with ocular manifestations 2–3 
years after their initial systemic symptoms and carry a guarded visual prognosis. 
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(Saadoun et al. 2010) (Davatchi et al. 2010)  The inflammation is recurrent, 
explosive, and lasts several weeks, followed by quiescent periods. Signs are 
common in the anterior segment and include non-granulomatous anterior 
uveitis distinguished by hypopyon in approximately one-third of patients. 
(Altenburg et al. 2006) (Chavis and Tabbara 1995) Posterior segment findings 
include vitritis, retinitis, optic disc oedema, retinal vasculitis and CMO. (Deuter 
et al. 2008) (Cassoux, Fardeau, and LeHoang 1999) Vaso-occlusive events 
occur, and may be followed by retinal neovascularization.  
1.2.2.3 Vogt Koyanagi Harada 
Vogt–Koyanagi–Harada disease (VKH) is a systemic disorder characterized 
by bilateral chronic uveitis associated with cutaneous and central nervous 
system signs. (Moorthy, Inomata, and Rao 1995) Darkly pigmented races 
are more commonly affected, and it is especially prevalent in Asia, 
representing up to 6-9% of all uveitis in Japan, (Goto et al. 2007) (Shimizu 
1973) and up to 19% of all in Saudi Arabia. (Al-Mezaine, Kangave, and bu 
El-Asrar 2010) VKH is also well described in people with Hispanic and 
native North American ancestry and occurs at lower rates in Caucasians.    
In 1978, the American Uveitis Society established diagnostic criteria for 
VKH based on clinical findings. (Snyder and Tessler 1980) The criteria, 
however, failed to consider different manifestations of VKH at varying 
stages of this disease, including evaluation by fluorescein angiography and 
ultrasonography. This problem has been rectified by the new diagnostic 
criteria, suggested by Rao et al (Rao, Sukavatcharin, and Tsai 2007)   as 
shown in Table 1-3 
 
 31 
Table 1-3 Revised criteria for diagnosis of VKH * 
 
Complete VKH: Criteria 1–5 must be present 
Incomplete VKH: Criteria 1–3 and either 4 or 5 must be present 
Probable VKH (isolated ocular disease): Criteria 1–3 must be present 
 
1. No history of penetrating ocular trauma or surgery preceding the initial onset of uveitis 
2. No clinical or laboratory evidence suggestive of other ocular disease entities 
3. Bilateral ocular involvement (a or b must be met, depending on the stage of disease when 
the patient is examined) 
a) Early manifestations of disease 
(1) Evidence of diffuse choroiditis (with or without anterior uveitis, vitreous 
inflammatory reaction, or optic disk hyperaemia) which may manifest as (a) 
focal areas of subretinal fluid, or (b) bullous serous retinal detachments  
b) Late manifestations of disease 
(1) History suggestive of prior presence of early findings noted in 3a and either 
(2) or (3) below, or multiple signs from 3. 
(2) Ocular depigmentation: either (a) sunset glow fundus or (b) Sugiura’s sign 
(3) Other ocular signs including (a) nummular chorioretinal depigmented scars, 
or (b) retinal pigment epithelium clumping and/or migration, or c) recurrent or 
chronic anterior uveitis 
4. Neurological/auditory findings (may resolve by time of evaluation) 
a) Meningismus (malaise, fever, headache, nausea, abdominal pain, stiffness of the 
neck and back, or a combination of these factors); note that headache alone is not 
sufficient to meet the definition of meningismus 
b) Tinnitus 
c) Cerebrospinal fluid pleocytosis 
5. Integumentory finding (not preceding onset of central nervous system or ocular disease) 
a) Alopecia, or 
b) Poliosis, or 
c) Vitiligo 
 
*Rao NA, Sukavatcharin S, Tsai JH. Vogt-Koyanagi-Harada disease diagnostic criteria. Int 
Ophthalmol. 2007 Apr-Jun;27(2-3):195-9 
 
VKH typically presents with a prodrome of headache or meningism followed 
by an acute uveitic phase. The ocular signs are bilateral in approximately 
95% of cases and may be delayed in the second eye by up to 2 weeks.  
Many patients progress to a phase of chronicity characterized by repeated 
attacks of uveitis, most commonly of the anterior segment. In the posterior 
pole, chronicity may be associated with neovascularization, subretinal fluid 
or fibrosis, and frank chorioretinal atrophy.  (Kuo et al. 2000) (Sonoda, 
Nakao, and Ohba 1999) Visual prognosis is variable with 60% of patients 
achieving vision of 20/30 or better. (Moorthy, Inomata, and Rao 1995) 
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1.3 Immunopathology of Posterior segment uveitis 
1.3.1 Overview 
The development of inflammation in eye is multifactorial, including genetic 
susceptibility, nutritional status, innate stimuli such as injury or concomitant 
ocular and systemic infection, and the presence of autoreactive T cells. When 
no overt infectious agent is identified in uveitic patients, we presume that 
autoimmunity is the underlying pathogenesis. (Forrester 1992) Patients with 
non-infectious uveitis frequently exhibit immune responses targeted to ocular 
antigens such as uveal melanin, retinal arrestin (formerly known as the 48-kDa 
retinal soluble antigen [S-Ag]), interphotoreceptor retinoid–binding protein 
(IRBP), and recoverin (Gocho, Kondo, and Yamaki 2001) (Gery, Mochizuki, 
and Nussenblatt 1986). Although it is unclear whether these immune responses 
represent the etiological cause or an epiphenomenon of autoimmunization to 
the products of tissue breakdown they are believed to fuel progression of the 
disease. (Caspi 2010) Diseases in this group tend to have strong MHC 
associations (Pennesi and Caspi 2002), which is believed to indicate an 
autoimmune aetiology, as MHC molecules select and present antigens for 
recognition by T cells.  
Antigen is the initiator of all acquired immune responses, whereupon the 
primary function of the immune system is to recognise exogenous antigens and 
eliminate pathogens. Additionally, the maintenance of immune regulation is 
brought about by tolerance to self-antigens acquired during development 
(central tolerance) or actively during adult life (peripheral tolerance) and in the 
case of exogenous antigens (viral and bacterial) immune responses are, in part, 
kept in check by inhibitory cytokines and soluble cytokine receptors. The eye 
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has evolved to limit intraocular inflammation so as to protect the delicate visual 
elements from damage that would be detrimental to visual acuity. This ability of 
the eye to curb and control immune responses is known as ocular immune 
privilege. (Caspi 2010) While it is generally accepted that immune privilege 
protects the eye from day-to-day inflammatory insults and contributes to the 
extraordinary success of corneal grafts, its role in protection from ocular 
autoimmunity has been disputative. 
It has been demonstrated that elimination in the thymus of self-reactive T cells, 
(central tolerance), applies to retinal antigens (Avichezer et al. 2003). The 
mechanisms underlying central tolerance rely on an immature T cell interacting 
with its cognate tissue antigen through its specific T cell receptor (TCR). Tissue 
antigens, including the retinal antigens IRBP and arrestin, are ectopically 
expressed in the thymus under the control of the gene-regulatory protein 
autoimmune regulator (AIRE) (Gotter et al. 2004). 
T cells, which react to tissue antigens that escape control in the thymus are 
usually subjected to regulation by peripheral tolerance mechanisms that include 
clonal deletion, clonal anergy, and active suppression. (Miller and Basten 1996) 
This induces T cells to become tolerant to their specific antigen when they 
encounter that antigen in healthy tissues; however retinal antigens residing in 
the eye are relatively inaccessible. Thus, circulating retinal antigen–specific T 
cells are likely to be “ignorant” of their cognate antigen rather than tolerant and 
can be activated by a chance encounter with an antigen, possibly in the form of 
a microbial component that structurally mimics their cognate tissue antigen 
(Wildner and edrichs-Mohring 2003). Infection may break this regulation 
because it is also well recognized that autoimmune diseases may be triggered 
by infectious agents. (Hausmann and Wucherpfennig 1997) Thus the induction 
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of autoimmunity represents a failure of peripheral (extrathymic) regulatory 
mechanisms to control autoreactivity.(Read et al. 1998) Therefore, by 
sequestering retinal antigens within the eye and hindering peripheral tolerance, 
immune privilege may actually predispose to ocular autoimmunity.  Figure 1-1 
explains this phenomenon diagrammatically.  
 
 
 
Figure 1-1 Central and peripheral tolerance for eye antigen and role in autoimmune 
uveitis.  
Retinal antigen–specific T cells that have not been eliminated in the thymus encounter an activating stimulus in the context of 
costimulatory “danger” signals, escape from the control of nTregs, and differentiate into pathogenic effector T cells. These undergo 
clonal expansion, migrate to the eye, break down the blood-retinal barrier, and recruit inflammatory leukocytes from the circulation. 
The resulting inflammation results in damage to the tissue and release of ocular antigens, which triggers eye-specific regulatory 
mechanisms that terminate the disease and limit pathology. mTECs:  medullary thymic epithelial cells, MTB: Mycobacterium 
tuberculosis Bacillus, PTX: pertussis toxin 
Courtesy Caspi 2010, Journal of clinical investigation, 120 vol 9  
 
 
This dynamic and continual regulation of immune responses is orchestrated by 
cytokines, controlling leukocyte behaviour and activation including antigen-
presenting cells (APC) like, dendritic cells (DC), antigen-specific T cells, and 
non-specific leukocytes such as macrophages and granulocytes.   
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If CD4+ T cells mediate uveitis, then cells will recognize antigen (be it 
autoantigen or foreign antigen) only after the antigen has been processed and 
presented on the cell surface of antigen-presenting cells (APCs) as peptides 
within the peptide groove of major histocompatibility complex (MHC) class II 
antigens. APCs include DCs or macrophages. Antigen-specific T cells 
recognize peptide/MHC class II complex via their own unique T cell receptor 
(TCR), although the TCR can recognize several antigenic determinants (cross-
reactivity) and each T cell can express a range of TCR. T cells will, however, 
not undergo activation and clonal expansion unless, in addition to TCR-
MHC/peptide interaction, co-stimulation also takes place. To ensure T cell 
activation, resulting in receptor activation and cell signalling, there are key 
receptor-ligand interactions between T cell and APC in addition to CD4 antigen 
recognition. These include CD28-B7, CD40-CD40L, and CTLA-4- B7. Without 
co-stimulation T cells are rendered unresponsive (anergic). Figure 1-2 below 
explains this process schematically. 
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Figure 1-2: T-cell activation. 
T-cell activation is initiated by the presentation of antigen, in the context of the major histocompatibility 
complex (MHC) of the antigen-presenting cell (APC), to CD3-TCR. This interaction between the APC 
and the T cell provides signal 1. Signal 2, a costimulatory signal also required for T-cell activation, is 
provided by the interaction between T-cell surface receptors and their respective ligands on the APC (e.g., 
the interaction between B7 and CTLA4 or CD28, CD40 to the CD40 ligand). Interaction between 
accessory molecules, such as intercellular adhesion molecule (ICAM) 1 and ICAM2 with lymphocyte 
function-associated antigen (LFA)-1, increases the association between the APC and the T cell. 
Additional signaling pathways (e.g., CD48 and LFA-3 to CD2, CD72 to CD5) also participate in T-cell 
activation 
 
 
Irrespective of which triggering event breaks tolerance, antigen specific CD4+ T 
cells can only initiate autoimmune disease after peripheral clonal expansion 
and on further presentation of antigen at the target tissue, both of which serve 
to activate the T cell and initiate a proinflammatory cascade resulting ultimately 
in tissue damage. Naive T cells once activated differentiate into one of many 
types depending on cytokine environment present. (Figure 1-3)  
The first are the Th1 cells, which show a cytokine profile of IFN-γ production. 
The cytokine profile of Th2 cells comprises IL-4, IL-5, IL-13 and perhaps TGF-β, 
and IL-10. In many animal models of human disease Th1 cells are associated 
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with the initiation of disease, whereas Th2 cells are related to disease 
downregulation and allergy initiation, or are involved in parasitic diseases.  
Another subset of cells that has been the centre of great interest recently is that 
of the Th17 cells. (Chen and O'Shea 2008) These cells produce 
proinflammatory cytokines including IL-17 (hence the name), IL-21 and 22. 
These cells develop in different environments depending on whether we look in 
the mouse or the human. In humans, IL-1, IL-6, and IL-23 appear to promote 
these cells. The cells play a role in host defence mechanisms against fungi and 
bacteria, and also in autoimmune disease. 
One theory is that Th1 cells may initiate an immune response but the Th17 
cells are involved in more chronic activity. (Shi et al. 2009) (Yoshimura et al. 
2008) It would be interesting to find whether Th1 cells and Th17 are distinct 
cells, or they are merely a function of the immune environment, so that under 
certain circumstances they produce IL-17 and under others a Th1 repertoire. In 
fact under experimental conditions it has been seen that Th17 cells may switch 
to a Th1 character, but that Th1 cells maintain that phenotype and do not 
change. (Shi et al. 2008) Also under experimental conditions in animals, when 
comparing these cell the nature of the intraocular inflammatory response was 
seen to be different. (Cox et al. 2008)  Th17 did not induce a large lymphoid 
expansion and splenomegaly, as Th1 cells did; Th1 cells infiltrating the eye 
dissipate rapidly, whereas Th17 cells remain; and markers on the surface of 
these infiltrating cells were different. (Cox et al. 2008) There is another type of 
cells that suppress or modify an immune response and these are known as T-
regulatory (Treg) cells. (Piccirillo 2008) It is hypothesized that these derive from 
a naive T cell under the influence of cytokines different from those of either Th1 
or Th2 cells. The characteristic feature of these cells is their ability to produce 
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IL-10 and TGF-β. They are capable of down regulating both Th1 and Th2 cells 
but interesting by secreting TGF-β and in the presence of IL-6 Tregs can 
induce TH-17 proliferation. (Kimura and Kishimoto 2010) The diagram below 
(Figure 1-3) summarizes differentiation of T helper cells into sub categories 
depending upon cytokine environment.  
 
Figure 1-3: The CD4 T cell repertoire in inflammation and infection.  
Once activated by occupancy of the T cell receptor (TCR), naïve CD4+ T cells in the presence of IL-12 
differentiate to become Th1 cells, which produce IFN-γ. This process is regulated by Stat4 and T-bet. 
IFN- γ has important functions in host defence against intracellular pathogens. In response to IL-4, naïve 
T cells differentiate to Th2 cells through the activation of Stat6 and GATA3. The signature cytokine 
made by Th2 cells is IL-4, which plays a key role in host defence against helminth infections. In 
conjunction with TCR stimulation, naïve T cells cultured with TGFβ-1 can become CD4+CD25+Foxp3+ 
cells with suppressive effects. Although TGFβ-1 can upregulate Foxp3 expression, in the presence of IL-
6, mouse naïve T cells develop to become IL-17-producing Th17 cells. In human T cells, IL-1 synergizes 
with IL-6 and IL-23 inducing Th17 differentiation. Stat3 and RORγt are the key transcription factors 
regulating this process. Th17 differentiation is inhibited by IFN-γ, IL-4, IL-2, retinoic acid, and SOCS3 
(Suppressor of cytokine signalling 3). 
(Modified from Chen & O’Shea Immunol Res (2008) Vol:41 
 
 
Activation, of Th1 increases production of interleukin- 2 (IL-2) and subsequently 
other proinflammatory cytokines such as IFN-γ and tumour necrosis factor 
(TNF-α). Activated T cells express certain cell surface markers such as IL-2 
receptor (IL-2r), CD69, and an isoform of common leukocyte antigen, CD45Ro, 
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intercellular adhesion molecule-1 (ICAM-1) and secrete IL-2 and IFN-Ƴ, all 
which have been reported within the peripheral circulation and ocular fluids of 
uveitis patients.(rocker-Mettinger et al. 1990) (Feron, Calder, and Lightman 
1992) (Dick et al. 1992) (Muhaya et al. 1999) (Whitcup et al. 1992).  
However T cells, including activated antigen-specific T cells, cannot cross the 
blood-retinal barrier unless there has been some systemic signal, specific or 
nonspecific, which renders the retinal endothelial cells susceptible to T cell 
transmigration (Xu et al. 2003). Entry of cells into the retina requires prior 
upregulation of adhesion molecules on the retinal endothelium and specific 
interactions between ligand receptor pairs such as intercellular adhesion 
molecule-1 and lymphocyte function-associated antigen (Xu et al. 2004)  
As the disease progresses, many additional cells are recruited to the retina, 
including non-specifically activated T cells, granulocytes, macrophages and 
dendritic cells. Although EAU is CD4-T cell-mediated, macrophages play a 
central role in tissue damage. This has been demonstrated in macrophage 
depletion studies and also in studies in which T cells continue to infiltrate the 
tissue but the macrophage is disabled and tissue damage is attenuated (Dick et 
al. 2004). Recent studies have revealed the heterogeneity of macrophage 
populations, one set of which are pro-inflammatory while another, the 
alternatively activated macrophage, may have a role in modifying the 
inflammatory response. Other macrophages, particularly the resident 
macrophage, may have a scavenging role in clearing dead and dying cells in 
the absence of a marked inflammatory response (Taylor et al. 2005). 
In EAU, infiltrating myeloid cells consist of DCs and activated monocytes, many 
of which express major histocompatibility complex class II antigen. In the later 
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stages of the disease, macrophages lose their major histocompatibility complex 
class II. 
Factors regulating macrophage activity are not known though gamma 
Interferon (IFN-γ) and tumour necrosis factor alpha (TNF-α), both pro-
inflammatory cytokines, are known to be involved in macrophage activation in 
inflammation generally. 
However, while transgenic expression of IFN-γ in the rodent eye is associated 
with increased inflammation (Zhang et al. 2001), IFN-γ-deficient mice also 
develop EAU through a deviated immune response (Jones et al. 1997). Recent 
studies on accessory molecules involved in antigen presentation, such as 
CD40 and CD137, indicate a definitive requirement (Shao et al. 2005) 
(Bagenstose et al. 2005), while molecules involved in monocytes adhesion and 
trafficking, for example the chemokine macrophage inflammatory protein-1, are 
required at least for T cell entry into the retina (Crane et al. 2003)  
The understanding of immunopathologic mechanisms is hindered by the 
genetic and clinical heterogeneity of patients, and limited access to clinical 
material from the site of disease. So most significant advances in both our 
understanding of immune mechanisms and the development of immunotherapy 
have arisen from experimental models of PSU. 
1.3.2 Animal model 
The most commonly used model is experimental autoimmune uveoretinitis 
(EAU), which is a retinal antigen-specific Th1 CD4+ T cell mediated posterior 
segment inflammation resulting in destruction of the retinal photoreceptors. 
(Forrester et al. 1990) (Caspi et al. 1986) T cells play a central role in EAU. The 
disease cannot be induced in T cell-deficient animals even with repeated 
immunizations, is ameliorated by T cell targeting agents such as cyclosporin A, 
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and can be transferred to genetically compatible, naive recipients with immune 
T cells. (Caspi et al. 1986)  
Moreover, when varying the strain of animal (genetic susceptibility) or dose and 
type of immunizing antigen, more acute or chronic features of posterior 
segment inflammatory disorders can be elicited. The two most commonly 
studied uveitogenic retinal antigens are S-ag (also called S-Arrestin) and 
interphotoreceptor retinoid binding protein (IRBP).  These models demonstrate 
a pivotal role for antigen-specific CD4+ (Th1) T cells, (Smith et al. 1999) (Caspi 
et al. 1986) nonspecific leukocyte infiltration, (Caspi et al. 1993) and 
proinflammatory soluble cytokines, including IFN-γ , IL-2, TNF-α, and IL-12.  
EAU can be elicited not only by immunization with retinal antigens (Ags) but 
with their fragments (Agarwal and Caspi 2004), or by adoptive transfer of retinal 
Ag-specific CD4 + T cells between syngeneic rodents (Rizzo et al. 1996). 
Published data till 2007 provided evidence that a Th1-dominant response and 
the Th1 effector cell were critical for EAU development and that endogenous 
IL-12 was needed for EAU induction and its full expression (Caspi 2002) 
(Tarrant et al. 1998). However, susceptibility to EAU of IFN- γ deficient (GKO) 
mice, exacerbation of EAU by neutralization of endogenous IFN-γ, and the 
protective effects of high systemic IFN-γ in WT mice  (Caspi et al. 1994) (Jones 
et al. 1997) (Tarrant et al. 1999) were an apparent contradiction with the notion 
that “EAU is purely Th1 mediated” . This requirement for IL-12 mediated IFN-γ 
and Th1 responses in autoimmune inflammation were recently questioned by 
several studies in other disease models. Mice deficient in IFN-γ, IFN-γR, IL-
12Rb2, and the IL-12p35 chain were highly susceptible to experimental 
autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA). 
(Cua et al. 2003) (Gran et al. 2002) (Becher, Durell, and Noelle 2002) In 
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contrast, IL-23 and the IL-17 producing effector T cell were found to be 
necessary for induction of these diseases (Cua et al. 2003) (Murphy et al. 
2003). The activity of the IL-17 producing effector T cells (Th17) was 
associated with induction of proinflammatory cytokines such as TNF-α, IL-1, IL-
6, and IL-8, as well as with enhanced proliferation, maturation, and chemotaxis 
of neutrophils. These results led to the notion that the pathogenic effects 
previously attributed to the IL-12 – IFN-γ pathway are in fact largely if not solely 
mediated by IL-23 and the IL-23 driven Th17 effectors.  (Cua et al. 2003) 
(Langrish et al. 2005).  
In context with uveitis, Luger et al. then showed that lL-23 rather IL-12 is 
necessary for the induction of EAU. (Luger et al. 2008)  They demonstrated 
that IL-17 plays a role in the pathogenesis of EAU induced by immunization in 
CFA, and that targeting IL-17 even late in the disease process can ameliorate 
pathology, indicating an effector role for this cytokine in pathogenesis of this 
type of EAU. Notably, however, severe EAU could be induced by uveitogenic 
Th1 cells without participation of host IL-17, and pathology of EAU induced with 
uveitogenic Ag-pulsed DCs required induction of an IFN- y producing effector T 
cell response. Finally, genetically IL-17 deficient mice were able to develop 
substantial disease. Thus, in some situations Ag-specific IL-17 –producing 
effector T cells appear to be dispensable for pathogenesis. This means that 
EUA can be either Th1 or Th2 driven depending upon the initial exposure of 
antigen. Following Figure 1-4, explains their findings  
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Figure 1-4: Schematic representation of the patterns of effector T cell dominance in the 
different EAU models.  
Conditions of initial exposure to Ag that may determine effector dominance are the quality/ quantity of 
TLR signals and the type/variety of cells participating as APCs.  
IL-17 plays a dominant role in EUA induced by immunization with the retinal antigen (Ag) 
interphotoreceptor retinoid-binding protein (IRBP) in complete Freund's adjuvant; its neutralization 
prevents or reverses disease, and Th17 effector cells induces EAU in the absence of interferon (IFN)-γ. 
In a transfer model, however, a polarized Th1 line can induce severe EAU independently of host IL-17. 
Furthermore, induction of EAU with IRBP-pulsed mature dendritic cells requies generation of an IFN-γ–
producing effector response, and an IL-17 response by itself is insufficient to elicit pathology. Courtesy 
(Luger et al. Journal of Exp. Medicine Vol. 205, No. 4, April 14, 2008) 
 
 
The widely held view now is that autoimmunity to retina can be either Th17 or 
Th1 driven. The IL-23 / IL-17 pathway plays an important role in EAU, and 
intensity of IL-17 response systemically and locally correlates with disease 
severity in mice immunized with IRBP/CFA. However, the role of the Th17 
effector is redundant with Th1, and each effector phenotype by itself is 
sufficient to induce pathology in the absence of the reciprocal hallmark cytokine. 
It has also been noted that IL-12 and IFN-γ deficient mice, typically exhibit 
more severe disease than their WT counterparts. This suggests that the Th17 
effector may become more prominent in pathogenesis when the IL-12 / IFN-γ 
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pathway is reduced or eliminated. IFN-γ has been reported to inhibit 
commitment to the Th17 phenotype in vitro (Park et al. 2005). Also, congenital 
lack of IL-17 allows emergence of compensatory mechanisms involving Th1 
and other proinflammatory cytokines including IL-22, (Luger et al. 2008) and 
the enhanced Th1 response in lymph nodes and in the eyes of IL-17 KO mice 
raises the possibility that IL-17 may have an antagonistic effect on the 
development of Th1 effectors, just as IFN- γ inhibits development of Th17 
effectors. This has also raised the question of whether the Th17 effector 
response might be dominant particularly in situations where induction of 
disease occurs in the context of strong Toll-like receptor (TLR) signals, 
whereas in other conditions a Th1 response may predominate. (Luger et al. 
2008) 
Like the development of autoimmunity in animal models, current view in 
humans is that activation of autoaggressive antigen-specific T cells occurs 
systemically and that activated cells then “home” to the eye, where they are 
presented with antigen by local APCs. Once at tissue sites Th1 cytokine 
secretion is perpetuated via chemotaxis of nonspecific inflammatory cells and 
chemokine, TNF-α, and IFN-γ secretion by, activated retinal pigment epithelium. 
(Forrester et al. 1995) This results ultimately in immune-targeted tissue 
damage. In concurrence with such a theory, it has been shown experimentally 
that there are APCs within choroid (Forrester et al. 1994) and also within the 
retina, (Dick et al. 1995) and T cells can adhere to both the RPE and retinal 
vascular endothelium via ICAM-1. (Mesri, Liversidge, and Forrester 1994)  
The recruitment of leukocytes is a critical feature of ocular inflammation. 
Chemokines and their G-protein-coupled surface membrane receptors mediate 
innate and adaptive immunity through mechanisms of selection and recruitment 
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of cells to sites of inflammation and disease. The expression of CCL3 
[macrophage-inflammatory protein-1 (MIP-1)], MCP-1 [monocyte 
chemoattractant protein–1 (MCP-1)], and CCL5 [regulated on activation of 
normal T-cell-expressed and secreted (RANTES)] and CCR5 is increased in 
the choroid and retina during the course of uveitis. (Crane et al. 2000) (Elner et 
al. 1997b) (Crane and Liversidge 2008) 
Though the inflammation pathways in immune mediate uveal inflammation are 
grossly similar in various sub groups of PSU, but there is considerable 
difference in the initiating event and type of cells that initiate and propagate the 
inflammation. Following section explain the histopathology and immune events 
specific to major sub types of PSU.  
1.3.3 Immunopathology of Intermediate uveitis 
Histological studies of the peripheral retina and ciliary body demonstrate 
condensed vitreous, fibroblasts, spindle cells, hyperplastic non-pigmented pars 
plana epithelium, lymphocytes, and blood vessels. (Eichenbaum, Friedman, 
and Mamelok 1988) (Pederson et al. 1978) Prominent lymphocyte cuffing with 
mural infiltration of retinal veins is also described histologically. (Pederson et al. 
1978)  
Vitreous biopsy at the time of active disease demonstrates lymphocytes, 
epithelioid cells, macrophages, and giant cells. (Nolle and Eckardt 1992) 
Vitreous lymphocytes are mostly T cells with variable numbers of macrophages 
and few B cells. (Davis et al. 1992) (Nolle and Eckardt 1992) A prevalence of 
CD4+ T lymphocytes has been found in the pars plana and snow bank, and 
these outnumber CD8+ T lymphocytes by 10:1. (Wetzig et al. 1988)  
Cytokine analysis has shown elevated serum IL-8 (Klok et al. 1998) in active 
intermediate uveitis and seems to indicate a later predisposition to systemic 
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disease. Serum IL-1 receptor antagonist, which down regulates the immune 
response becomes elevated with successful treatment. (BenEzra, Maftzir, and 
Barak 1997) Circulating T lymphocytes have been identified that recognize 
several retinal antigens but are not specific to intermediate uveitis. (deSmet et 
al. 1990) In addition, as with the other uveitides antibodies against several 
retinal antigens have been found. (Nolle 1992) 
It is tempting to speculate that an antecedent or subclinical infection could 
initiate disease through the process of molecular mimicry. The presence of glial 
elements in the pars plana, the glial targeting of MS and the potential for cross-
reactivity of an antiviral response against myelin basic protein, together support 
this contention. The frequent association with infections such as Lyme disease 
(Bartonella borgdorferi), cat-scratch fever (Bartonella henselae), toxoplasmosis, 
and human lymphotrophic virus type I (HTLV-1) also points towards molecular 
mimicry. Some viral peptides can induce an auto reactive T lymphocyte 
response against myelin basic protein, (Wucherpfennig and Strominger 1995) 
but again, evidence for this proposed molecular mimicry in disease has not 
been demonstrated.  
1.3.4 Immunopathology of Posterior uveitis  
Post mortem studies of eyes with multifocal choroiditis, (Dunlop et al. 1998) 
(Charteris and Lee 1990) have shown a long-standing perivascular infiltrate 
consisting of B lymphocytes, CD3+ T cells (a pan-T marker which does not 
distinguish between CD4+ and CD8+), and scattered macrophages in the 
choroid. Early stage neovascular membranes and RPE hyperplasia were seen 
over the most intensely inflamed choroidal vessels, although Bruch's 
membrane remained intact. Scattered macrophages were found in the retinal 
pigment epithelium along with minor atrophy of the overlying photoreceptor 
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layer. Vitrectomy specimens also report a preponderance of T cells. (Nolle and 
Eckardt 1993) A single pathologic specimen of an enucleated phthisical eye 
showed focal lymphocyte and plasma cell infiltration of the iris and ciliary body 
(Nussenblatt et al. 1982). Diffuse granulomatous inflammation was noted in the 
outer retinal layers with epithelioid, giant, and plasma cells.   
Elevated serum titres of circulating antibodies or reactive immune cells has 
suggested numerous infectious associations: Lyme disease with AMPPE, (Wolf 
et al. 1992) Epstein–Barr Virus (EBV) with MFC, (Tiedeman 1987) and 
histoplasmosis with POHS. (Schlaegel, Jr. 1979) The association of EBV with 
MFC has not been supported by other studies, (Nolle and Eckardt 1993) and 
even in POHS, the most consistent association, the relevance of anti-
histoplasmosis titres, remain unknown. (Check et al. 1979) Several studies of 
patients with POHS failed to demonstrate evidence of H. capsulatum and 
attempts to identify intraocular constituents of the histoplasmosis cell wall have 
been negative. (Irvine et al. 1976), (Meredith et al. 1977) No antibacterial or 
antiviral titres have been found associated with MEWDS.  Likewise for AMPPE, 
the prodromal illness suggests an infectious cause but none has been identified. 
(Deutman et al. 1972)    
Antibody titres and studies of infectious agents in patients with birdshot 
retinochoroidopathy have not been informative. For example, prompted by the 
coexistence of seropositive ocular Lyme disease and HLA-A29 markers, 
(Suttorp-Schulten et al. 1993) a search for Bartonella burgdorferi was 
unsuccessful. Similarly, a postulated association with Q fever could not be 
established. (Kuhne et al. 1992) 
The close association between HLA-A29 and birdshot retinochoroidopathy 
suggests that genetic susceptibility to disease is paramount in its pathogenesis. 
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It is now appreciated that the A29.2 mutation interferes with T cell T cell-
receptor interactions, thus confirming the role of this function in disease 
pathogenesis. (Tabary et al. 1991) I  
Immunopathology of sympathetic ophthalmia 
The primary feature of sympathetic ophthalmia is a diffuse non-necrotizing 
granulomatous inflammation of the uvea, with prominent lymphocytic infiltration 
of the choroid. Within this infiltrate there are focal collections of epithelioid cells 
with occasional giant cells and rare plasma cells. (bu El-Asrar et al. 2007)  
These Dalen–Fuchs nodules are located between Bruch's membrane and the 
RPE. (Chan et al. 1986) Immunopathologic studies support the role of the T 
lymphocyte in the pathogenesis of sympathetic ophthalmia. (bu El-Asrar et al. 
2007) (Furusato et al. 2011) Whereas CD4+ T lymphocytes dominate early in 
disease, the CD8+ T lymphocytes are more common later. (Chan et al. 1986), 
(Towler and Lightman 1995) Post enucleation immunocytochemical studies 
have demonstrated activated T lymphocytes expressing IL-2 receptors (Towler 
and Lightman 1995) and secreting IL-2 and IFN-Ƴ. Significantly, elevated 
ocular and systemic levels of IL-1 and TNF-α have also been found. (Chan et al. 
1985b), (Palexas, Sussman, and Welsh 1992) B lymphocytes make up less 
than 20% of the cellular infiltrate [(Chan et al. 1985a), (Jakobiec et al. 1983) 
and may correlate with prolonged disease. Recent studies have shown that 
Non-granulomatous lymphocytes are predominantly CD3-positive and express 
more IFN-γ than cells within granulomas, consistent with Th1 cells. In contrast, 
granulomas and Dalen Fuchs’ contain mainly CD68+, CD163+/- and express 
more IL-17, IL-18, IL-23, CCL19, and CXCL11 than non-granulomatous cells. 
Macrophages are the predominant inflammatory cells within granulomas and 
Dalen Fuchs’ nodules.  (Furusato et al. 2011) 
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The monocyte/macrophage markers CD68 are expressed in scattered 
inflammatory mononuclear cells and within granulomas and Dalen-Fuchs 
nodules. (bu El-Asrar et al. 2007) Most of the inflammatory cells are HLA-DR 
(+). Immunoreactivity for gelatinase B, MCP-1, and SDF-1 are observed in cells 
within granulomas and in scattered epithelioid cells. Immunoreactivity for MCP-
1 are also noted in retinal pigment epithelial cells (bu El-Asrar et al. 2007) 
The favoured theory is one of autoimmunity generated by exposure of 
intraocular constituents, possibly the choroidal melanocyte, to an intact immune 
system.  Simultaneous contamination by pathogens may enhance this 
response. (Gasch et al. 2000)  
1.3.5 Immunopathology of Sarcoidosis 
Histopathological examination shows non-caseating granulomata in the 
absence of foreign material or infection. In the posterior segment, these 
granuloma may be found in retina and optic nerve and typically do not 
involve the choroid. They are composed of monocytes, macrophages, and 
epithelioid cells, the latter of which can fuse to form multinucleate giant cells. 
(Usui et al. 2002) (Chan et al. 1985a) Some investigators additionally 
identify a surrounding rim of lymphocytes, monocytes, and fibroblasts. 
Epithelioid cells are found in the vitreous and retina, and a sarcoid nodule 
has been found within an excised preretinal fibrovascular membrane. 
(Ogawa et al. 2000)  
Immunohistochemical study of a globe with active ocular sarcoidosis 
showed a predominance of CD4+ T lymphocytes in the uvea and retina with 
only rare CD8+ T cells. (Angi et al. 1990)  HLA class II antigens are present 
diffusely in granuloma and resident ocular immune cells. (Angi et al. 1990) 
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(Chan et al. 1987) Macrophages, epithelioid cells, and T lymphocytes within 
the granulomata express IL-2 receptors and IFN-γ. (Chan et al. 1987)  
Studies of pulmonary sarcoidosis provide considerable insight into the 
mechanism of disease. Numerous studies have demonstrated the activation 
of T cells in sarcoid tissues; analysis of bronchial fluid have shown T-cell 
antigen receptor (TCR) activation in alveolar T cells and a normal 
transcription of the IL-2 gene. T cells within the sarcoid granuloma also 
demonstrate expression of IL2, IL6, and INF-γ messenger ribonucleic acid 
(mRNA), indicating activation. (du Bois et al. 1992) In addition, these 
activated T cells secrete potent Th1 cytokines such as IL2 and IFN-γ 
(Agostini and Semenzato 1998) (Katchar, Eklund, and Grunewald 2003).  
In addition to the T cell, macrophages are also fundamental to the formation 
of the sarcoid granuloma. Not only do they process the antigen before 
presenting it to the T lymphocytes, they also produce a cascade of 
cytokines that are chemoattractants and thus indirectly assist in the 
recruitment of additional immunocompetent cells. (Chan, Sharma, and Rao 
2010) TNF-α is largely secreted by macrophages and has been implicated 
in the pathogenesis of granulomas in sarcoidosis (Chan, Sharma, and Rao 
2010) Chemokine regulation on activation normal T-cell expression and 
secretion (RANTES or CCL5), macrophage inflammatory protein 1β (MIP-
1β or CCL4), monocyte chemoattractant protein 1 (MCP-1 or CCL2), and 
IFN-γ–inducible protein 10 (CXCL10) are expressed in sarcoid granulomas 
and enhance the migration of effector cells. (Co et al. 2004) (Iannuzzi and 
Fontana 2011)  
Similar to observations in Behcet’s disease, T lymphocytes that are reactive 
against heat-shock proteins have been associated with sarcoidosis.  
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(Wilsher, Hallowes, and Birchall 1995) It was therefore postulated that the 
heat-shock proteins from various infectious pathogens may induce disease 
through molecular mimicry. Because of the predilection for sarcoidosis to 
the lung, several studies have focused on the role of inhaled pathogens and 
have found evidence for the presence of typical and atypical mycobacteria.  
(Kon and du Bois 1997) 
The apparent predilection for the lung has suggested a possible airborne 
pathogen or an abnormal response to inhaled antigen, (Milburn et al. 1997) 
whereas the observed HLA associations support the notion that the host 
response is relevant to the course of disease.  Although bacterial, viral, and 
environmental antigens have all been studied, none have been proven to be 
the cause for sarcoidosis. Mycobacterial antigens are probably on the top of 
the list. Mycobacterial tuberculosis catalase-peroxidase protein was 
identified in approximately 50% of sarcoidosis tissues sampled in a 2005 
study. (Song et al. 2005) Based on the current understanding, it appears 
that sarcoidosis may result not from a single agent, but rather from multiple 
inciting agents that are capable of generating this Th1-mediated response in 
a genetically susceptible individual. (Chan, Sharma, and Rao 2010) 
 
1.3.6 Immunopathology of Behcet’s disease 
Ocular Behcet’s is a non granulomatous vasculitis that primarily affects the 
retinal and anterior segment vasculature with little RPE or choroidal destruction. 
(Sakane, Suzuki, and Nagafuchi 1997) Other major observations in Behcet’s 
disease are neutrophil hyperactivity, endothelial injury, (Pivetti-Pezzi et al. 
1992) and autoantigenicity, together with enhanced T and B cell responses to 
heat-shock proteins. (Sakane, Suzuki, and Nagafuchi 1997)  Systemic Behcet’s 
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disease is a systemic perivasculitis in which early neutrophils infiltration, 
endothelial cell swelling, and fibrinoid necrosis are described. Significant 
neutrophil infiltration is seen in all early lesions including eyes. (Mendoza-Pinto 
et al. 2010)  Unlike many of the PSU, the choroid does not appear to be the 
major target of disease, and inflammatory cells are found in the anterior 
chamber, corneal endothelium, iris, and ciliary body. Occlusion of iris vessels 
and iris atrophy is found. The retina shows oedema with focal areas of 
infarction and necrosis while retinal vessels have thickened, hyalinized walls 
infiltrated by lymphocytes. (George et al. 1997) (Green and Bon 1967)   In the 
anterior chamber, evidence of clonal proliferation of T cells has been found. 
(Keino et al. 2000) There may be late loss of photoreceptors and retinal 
ganglion cells but the choroid is only rarely involved.  
Immunopathologic analysis shows that the CD4+ T lymphocyte is the major 
infiltrating cell in blood vessel walls and in the immediate perivascular 
area.(Charteris et al. 1992a)  (Charteris et al. 1992b) A proportion of these 
retinovascular lymphocytes are activated, expressing IL-2 receptors. CD8+ T 
lymphocytes are less common with a reported CD4+/CD8+ ratio of 1.5:1 or less. 
(Charteris et al. 1992b), (George et al. 1997) Aqueous fluid also contains a 
preponderance of T lymphocytes. (Jakobiec, Lefkowitch, and Knowles 1984)  
Macrophages have been found in virtually all studies, and polymorphonuclear 
cells have been in most. (Charteris et al. 1992a) Along with the altered T 
lymphocytic populations, there is a notable influx of granulocytes, particularly 
neutrophils, into active lesions. Neutrophil hyperactivity has been repeatedly 
noted, (Takeno et al. 1995) (Yamashita 1997)] unlike in other PSU entities. 
Elevated levels of granulocytes in Behcet’s disease may be consistent with the 
uniquely high incidence of acute hypopyon in this disorder and partially explain 
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the effective use of colchicine, an antigranulocytic drug, used to treat ocular 
and non-ocular manifestations in some centres.  
Expansion of circulating CD4+ T cell clones that recognize retinal antigens 
(Yamamoto et al. 1993) has been reported, as have anti-HLA-B lymphocyte 
responses which can cross-react with retinal S-antigen. (Kurhan-Yavuz et al. 
2000) A recent study has determined that the number of circulating lymphocyte 
precursor cells that recognize retinal S-antigen can be predictive of 
susceptibility to ocular disease. (deSmet and Dayan 2000)  
Analysis of peripheral blood has identified various abnormalities of cytokine 
profiles, including the spontaneous production of IFN-γ by circulating 
lymphocytes. (Ohno et al. 1982a) Several studies have reported increased 
cytokine levels in serum and body fluids from patients with BD. Elevated levels 
of IL-1β (Pay et al. 2006) IL-2 (Akdeniz et al. 2004), IFN-γ, (Hamzaoui et al. 
2003) IL-6  (Akdeniz et al. 2004)  IL-8 (Borhani et al. 2009), IL-12 (Turan et al. 
1997), IL-15  (Hamzaoui et al. 2006)  IL-18 (Musabak et al. 2006) (Oztas et al. 
2005) TNF-α (Akdeniz et al. 2004)  (Kotter et al. 2005) (Oztas et al. 2005), and  
IFN-α  (Kotter et al. 2005) suggest a hyper activated inflammatory response in 
patients with BD. Similarly, the serum IL-8 levels seem to correlate well with 
disease activity (Gur-Toy et al. 2005). Individual CD4+ lymphocytes can 
produce IL-2 and IFN-γ and may be a marker of disease activity. These Th1 
cytokines are reduced in patients treated successfully; whereas in patients with 
unresponsive disease, they remained high.  
Aqueous humour analysis have shown that a Th1 polarization and the 
presence of natural killer (NK) or CD8+ T cell-activating cytokines is a unique 
feature in ocular Behcet’s. Aqueous TNF-α, IFN-γ and IL-15 levels are higher 
compared to other uveitis entities. (Ahn et al. 2006) CD8+ cell population are  
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higher in the aqueous humour of Behcet’s patients with increase expression of 
CXCR3 and  Intraocular CXCL8 and CXCL10 levels are  higher in Behcet’s 
than in non-Behcet’s patients with uveitis (Kim, Chung, and Yu 2011) 
Antibodies against vascular endothelium and several ocular components such 
as retina and cornea have been detected. [(Aydintug et al. 1993), (Kasp et al. 
1989), (Chan et al. 1985b) Notably, in experimental systems, antibodies raised 
against bacterial or human heat-shock proteins are capable of cross-reacting 
with retinal antigens. (Tanaka et al. 1996) It therefore follows that exposure to 
exogenous or endogenous heat-shock proteins may stimulate a T lymphocyte 
response directed against both the target and retinal antigens. (Tanaka et al. 
1996) This form of molecular mimicry could contribute directly to autoimmune 
disease. 
The causative antigen in BD is unclear, and microbial, viral, and auto-antigens 
have been suggested as candidates. Several microbial antigens have been 
shown to stimulate T cells in BD patients, e.g., staphylococcal antigens, 
streptococcal antigens (Lehner 1997), Escherichia coli-derived peptides and 
Chlamydia pneumoniae (Ayaslioglu et al. 2004). Yanagihori et al. recently 
provided evidence for an anti-bacterial (streptococcal) host response toward 
Th1-immunity mediated by IL-12 (Yanagihori et al. 2006). HSP of various 
microbes could be involved in the pathogenesis of BD. A cross-reactive 
response to human HSP60 was suggested as causative in BD (Direskeneli and 
Saruhan-Direskeneli 2003) Herpes simplex virus had also been implicated in 
the pathogenesis of Behcet’s disease due to similarity of the oral and genital 
ulcers, (Hamza and Slim 1991) (Hamzaoui and Ben Ammar 1992). Interestingly, 
the only studied animal model of Behcet’s is that induced by inoculation with 
herpes simplex virus in which animals show several symptoms similar to 
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BD.(Sohn 1997) In summary, possibly triggered by a heat-shock protein, 
phosophoantigen, or superantigen, an abnormal T cell repertoire, may induce 
disease in susceptible individuals. 
 
1.3.7 Immunopathology of VKH 
Histopathologically, VKH disease shares many similarities with sympathetic 
ophthalmia and includes extensive granulomatous infiltration of the choroid and 
anterior uvea. (Lubin, Ni, and Albert 1982) (Rao 1997) The predominant cells 
are the T lymphocytes, (Matsuda 1970) (Sakamoto, Murata, and Inomata 1991) 
which are accompanied by collections of melanin-containing epithelioid cells 
and occasional multinucleate giant cells. There is little apparent necrosis, and 
the RPE and retina are largely intact with only focal disruption of morphology at 
sites of Dalen–Fuchs nodules. (Rao 1997)  
 Various investigators have proposed an underlying T-cell-mediated 
autoimmune process directed against melanocytes. It has also been postulated 
that such an autoimmune response might be triggered by an infectious agent in 
a genetically susceptible individual. (Sugita et al. 2006)  
As VKH syndrome occurs most commonly in pigmented individuals, it has been 
hypothesized that VKH represents a T-cell-mediated autoimmune disorder 
against melanocytes of all organ systems. (Sheu 2005)  
It is unclear what triggers the immune system of an individual with the genetic 
background to induce an autoimmune response against the target cells and 
antigens. Viruses, such as the Epstein-Barr virus, have been hypothesized as a 
possible triggering factor. (Bassili et al. 1996) The manifestations in the 
prodromal stage of VKH syndrome, such as meningismus and tinnitus, are 
perhaps consistent with this opinion. Epstein-Barr (EB) virus DNA has been 
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isolated from the vitreous of VKH patients. (Bassili et al. 1996) Sugita et al. 
(Sugita et al. 2007) studied the cross-reaction between tyrosinase peptides and 
cytomegalovirus (CMV) antigen by T cells in VKH patients. They found that 
CMV infection could stimulate the production of T cells that cross-react with 
tyrosinase by a mechanism of molecular mimicry. They suggested that these 
events may be responsible for the onset of VKH syndrome. During 
the past few years, several cases of VKH-like disease have been described in 
patients treated with IFN-α for chronic viral hepatitis C. (Touitou et al. 2005) It 
has been supposed that molecular mimicry between viral antigens and 
melanocyte-related antigens could lead to the development of auto reactive 
antibodies causing VKH like manifestations. 
Previous studies have shown that peripheral blood mononuclear cells (PBMC) 
from patients with VKH syndrome displayed a Th1 cytokine profile, such as IL-2, 
IFN-γ and IL-6, (Imai et al. 2001) (Norose and Yano 1996)  
Recent studies have shown that IL-23 plays a pivotal role in the development 
and maintenance of autoimmune inflammation by inducing the differentiation of 
IL-17-producing CD4+ T cells. Increased expression of IL-23 p19 mRNA in 
PBMCs, higher IL-23 protein in the serum and supernatants of PBMCs, and an 
increased production of IL-17 by polyclonally stimulated PBMCs and CD4+ T 
cells in patients with active uveitis have been noted. (Chi et al. 2007)  These 
results suggest that IL-23-stimulated production of IL-17 by CD4+ T cells may 
be responsible for the development of VKH syndrome.  
Other researchers have confirmed these findings.  Li et al. showed a 
significantly increased serum IL-21 level, as well as higher IL-21 mRNA 
expression by PBMCs, in patients having chronic or recurrent active VKH 
disease compared with patients having inactive VKH disease and with controls. 
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In vitro experiments showed that recombinant IL-21 significantly increased IL-
17 production by PBMCs and by CD4 (+) T cells from patients and from 
controls. They concluded that IL-21 may be involved in the pathogenesis of 
chronic or recurrent VKH disease, possibly by promoting IL-17 secretion (Li et 
al. 2010) 
Aqueous humour samples from patients with VKH show significantly higher 
levels of IL-15, IL-17, IFN-γ and TNF-α compared to healthy controls(El-Asrar 
et al. 2011) 
In short various entities in PSU share an underlying immune aetiology; however, 
they can be clinically and immunopathologically distinguished. Although the 
initiating stimuli are not known, it is believed that an exogenous agent, such as 
a bacterium or a virus or an endogenous molecule may induce disease. 
Sympathetic ophthalmia, Vogt–Koyanagi–Harada disease and sarcoidosis are 
the three granulomatous disorders characterized by diffuse infiltration of CD4+ 
T lymphocytes and localized macrophagic aggregates in the choroid.  Behcet’s 
uveitis besides having typical findings of PSU, have abundant neutrophils and 
increased IL-8 cytokine production. However in all of them Th1 and at least in 
VKH and sympathetic ophthalmia Th17 cells in conjunction with human 
leukocyte antigens are likely to be involved.  
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1.4 Genetics of uveitis 
1.4.1 Overview 
Although we know that uveitis is an immune mediated disease but exactly what 
triggers uveitis and why some people are more susceptible than other is not 
known clearly. The association with HLA serotypes clearly points towards 
genetic predisposition.  
Identifying genes that influence disease susceptibility can be done by studying 
a large number of unrelated, affected individuals for a specific association, or 
by studying a group of related individuals for an area of linkage. 
The PSU are complex genetic disorders, meaning that multiple genes 
contribute to the susceptibility. An important conceptual consideration is that 
disease manifests in individuals with a genetic predisposition coupled with an 
environmental trigger. This is well illustrated by the example of reactive arthritis, 
where an inflammatory synovitis occurs approximately 1 to 4 weeks following 
an intestinal infection. However, this only occurs in a minority of individuals, as 
illustrated by documented outbreaks of food-borne illness. Furthermore, an 
individual’s genetic risk will likely be due to specific alleles of different genes, 
and one can envision the interplay of multiple genes having various 
consequences on disease predisposition, severity, or outcome. Within the 
scope of this interplay, it is feasible that some genes will have a greater 
influence on inflammation in the uvea compared to others that may affect skin 
or joint inflammation. It is precisely this notion that fuels the current interest in 
searching for uveitis-specific genetic factors. 
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1.4.2 Major Histocompatibility complex 
Associations between HLA serotypes with uveitis were among the first such 
HLA associations with human disease described. In the more than three 
decades since the association of the HLA-B27 serotype and acute anterior 
uveitis was first made, both class I and class II HLA genes have been 
implicated in conferring risk for uveitis . (Table 1-4) 
 
 
Table 1-4 Human leukocyte antigen (HLA) associations with uveitis 
 
Disease/syndrome  HLA  Relative risk * 
   
Acute anterior uveitis  B27  26  
Behcet’s disease  B51, B52  5-10 
Birdshot chorioretinopathy  A29  50-220  
Idiopathic intermediate uveitis/pars planitis  DR15  3-7  
Tubulointerstitial nephritis and uveitis  DRB1*0102, DQA*01  167 
Vogt-Koyanagi-Harada syndrome  DR1, DR4 (DRB1*0405 in Asians)  4.2-17.4  
Sympathetic Ophthalmia DRB1*04 5.6 
* see text for references 
 
  
 
The HLA associations with human disease are strongest in uveitis among all 
diseases. In birdshot chorioretinopathy HLA-A29 confers a relative risk of about 
50–220 (Shah et al. 2005) and HLA-DRB1*0102, in tubulointerstitial nephritis 
and uveitis [TINU] syndrome increases the risk by 167 times. (Levinson et al. 
2003)  
Various observations have been made regarding the HLA associations of 
intermediate uveitis. (rocker-Mettinger et al. 1992), (Davis, Mittal, and 
Nussenblatt 1992), (Martin et al. 1995), (Tang et al. 1997) HLA associations 
include HLA-DR, B8, and B51, the most significant relation being that with HLA-
DR, which occurs in 67–72% of patients. (Davis, Mittal, and Nussenblatt 1992), 
(Malinowski et al. 1993) Among HLA-DR, the most striking association is with 
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DR15, which is also associated with multiple sclerosis. (Malinowski et al. 1993) 
(Tang et al. 1997) Association between pars planitis and HLA-DR2 has also 
been reported in 3 separate studies. (Malinowski et al. 1993) (Oruc et al. 2001) 
(Raja et al. 1999) and this association is actually due to HLA-DR15, 1 of the 2 
sub alleles of HLA-DR2. (Oruc et al. 2001) (Raja et al. 1999) However, the 
HLA-DR15 association could not be confirmed in a Scottish population (Greiner 
et al. 2003) or Mexican Mestizo patients. (Alaez et al. 1999) The latter study 
found the DRB1*0802/DQA1*0401/DQB1*0402 haplotype to be significantly 
increased in patients with classic pars planitis. 
Other forms of PSU with known HLA associations include VKH, BD, 
sympathetic ophthalmia, presumed ocular histoplasmosis, and sarcoidosis. 
(Kilmartin et al. 2001) (Davey and Rosenbaum 2000) (Yabuki, Inoko, and Ohno 
2000) (Levinson et al. 2003) 
HLA associations in the white dot syndromes have been variably reported 
(Desarnaulds et al. 1996) and are largely anecdotal. HLA-B51 was found with 
increased frequency in patients with MEWDS, (Desarnaulds et al. 1996) 
(Borruat et al. 1998) and HLA- DRw2 and B7 with POHS. (Meredith, Smith, and 
Duquesnoy 1980) There is increased prevalence of HLA-B7 and HLA-DR2 
antigens reported in patients with AMPPE. (Wolf et al. 1990) Multifocal 
choroiditis with panuveitis is associated with HLA-B7 but not DR2. (Spaide et al. 
1990) 
There is high correlation between birdshot retinochoroidopathy and HLA-A29, 
(Baarsma et al. 1986), (Nussenblatt et al. 1982) 271] which is found in less 
than 7% of the normal population, but in 80–98% of patients with BR. Its 
presence confers a relative risk of disease ranging from 50:1 to 224:1. 
(Nussenblatt et al. 1982) In particular, the HLA-A29.2 subtype is exclusively 
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associated with disease, whereas the similar HLA-A29.1, which differs only at a 
single amino acid, is not associated. (de Waal et al. 1992)  
BD is associated with the HLA-B*51 and HLA-B*52 alleles.  (Al-Mutawa and 
Hegab 2004) (Zierhut et al. 2003) Stronger associations are noted between 
HLA-B51 and Behcet’s disease in Japanese, Italian, and Greek pedigrees. 
(Balboni et al. 1992), (Ohno et al. 1982b) and (Yabuki et al. 1999a) (Yabuki et 
al. 1999b) HLA-B5101, in particular, and HLA-B5102, to a lesser extent, are 
associated with ocular Behcet’s, as is the extended haplotype B51-DR5-DQW3. 
(Balboni et al. 1992) and (Mizuki and Ohno 1996) 
There are strong HLA associations with VKH disease including HLA-DR4 and 
HLA-DRw53. (Ohno 1981) (Ohta 1996), (Sakamoto, Murata, and Inomata 
1991) (Zhao, Jiang, and Abrahams 1991) HLA-DRB1 has also been found in 
Korean and Mexican populations. (Alaez et al. 1999) (Ohta 1996) and (Kim et 
al. 2000b) Some of these are similar to the HLA associations of sympathetic 
ophthalmia. (Davis et al. 1990) (Ohta 1996) Familial cases of VKH have been 
described as well. (Davis et al. 1990) (Ohta 1996) 
Sympathetic ophthalmia occurs more commonly in association with HLA-DR4, 
DRw53, and Bw54 antigens. (Chan et al. 1986) (Davis et al. 1990) (Shindo et al. 
1997)  Kilmartin et al noted that HLA-DRB1*0404 allele could increase the risk 
of development of sympathetic ophthalmia by 5.6% and HLA-DRB1*0404-
DQA1*0301 haplotype by up to 11% (Kilmartin et al. 2001) 
The HLA associations in sarcoidosis are not clear cut. Association with HLA-
DR has been reported in the Scandinavian and African-American populations, 
but in Caucasian Americans, HLA-B8 was associated with spontaneous 
resolution. (Berlin et al. 1997), (Maliarik et al. 1998), (Smith et al. 1981) Yet 
others report that the incidence, disease expression, and prognosis may be 
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epidemiologically associated with HLA-B1, B8, B13, and DR3, DR14, DR15 
and DR17. (Bresnitz and Strom 1983), (Ishihara and Ohno 1997), (Rybicki et al. 
1997)   
HLA and genotype phenotype associations 
Researchers have also asked whether HLA associations correlate with ocular 
disease phenotype. This is not the case, at least for most entities. Class I 
associations confer risk for anterior uveitis (HLA-B27–associated acute anterior 
uveitis), chronic posterior uveitis (HLA-A29 and birdshot chorioretinopathy), and 
posterior or anterior, acute or chronic uveitis as in Behcet’s disease. Class II 
associations similarly can be associated with panuveitis (HLA-DRB1*01 and 04 
with VKH disease), intermediate uveitis (HLA-DR15 and pars planitis), or 
anterior uveitis (HLA-DR and DQ and TINU syndrome, HLA-DPB1*0202 in 
juvenile rheumatoid arthritis). There is evidence, on the other hand, that the 
disease phenotype may differ between HLA-B27–positive and HLA-B27– 
negative patients with acute anterior uveitis, with worse ocular manifestations 
and greater prevalence of systemic disease in HLA-B27–positive patients 
(Rothova et al. 1987). 
On the other hand, sympathetic ophthalmia is clinically and pathologically very 
similar to VKH disease, although the former is believed to be due to antigens 
released from immunologically privileged sites after surgery or injury and the 
latter has yet no established inciting event. Both are associated with HLA-
DR1*0405 in Asians and other HLA-DR4 subtypes in Caucasians  ((Levinson et 
al. 2004b), (Kilmartin et al. 2001), (Shindo et al. 1997)), implying that diseases 
with similar phenotypes but differing precipitating events can have the same 
HLA genotypes that confer risks for developing disease. 
HLA associations in different populations and HLA subtypes  
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Different populations can have different HLA associations with the same forms 
of uveitis depending on the prevalence of the relevant genes in the population. 
In Asian, the HLA-DRB1*0405 allele is very strongly associated with VKH 
disease ((Shindo et al. 1994b) (Shindo et al. 1994a), but this is not true for 
Mestizo patients. ((Levinson et al. 2004b) (Alaez et al. 1999) Mestizo patients 
in fact have quite weak associations with HLA-DR1 and DR4.  
The HLA-B*5101 subtype was found in 56 of 57 Japanese patients with 
Behcet’s disease ((Mizuki et al. 2001a) and 33 of 36 Iranian patients ((Mizuki et 
al. 2001b), but 18 Japanese control subjects who were HLA-B*51 positive had 
the B*0501 allele, and in the Iranian population, no particular subtype was 
believed to predominate compared with controls. In Greek patients with 
Behcet’s disease, HLA-B*5101 was found, but so was HLA-B*5108 (Mizuki et 
al. 2002).   
Similarly, while some reports suggested that HLA-29.1 was less common than 
HLA-A29.2 in patients with birdshot chorioretinopathy, when examining patients 
genotype with DNA-based techniques, neither HLA-A*2901 nor A*2902 
predominated (Levinson et al. 2004a).  
1.4.3 Non-classical HLA genes, class III MHC genes, and non-MHC 
genes 
 
It is not clear how HLA genes or their products play a role in the pathogenesis 
of ocular inflammatory disease. There is some evidence for a direct role of HLA 
molecules in the pathogenesis of disease, but indeed, such associations could 
be due to linkage disequilibrium with other genes in the MHC. Animals 
transgenic for HLA-B27 do not get inflammatory disease until they are taken 
from germ-free facilities, and it is believed that gut colonization with bacteria 
plays a role, a favoured theory being through “molecular mimicry”. This is 
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consistent with the evidence that mucosal bacteria may play a role in human 
diseases, albeit often with subclinical mucosal inflammation. Nonetheless, just 
as with systemic HLA-B27 disease, the role of antigen presentation and 
molecular mimicry remains unproven. A mouse transgenic for HLA-A*29 did 
develop spontaneous uveitis (Szpak et al. 2001) that did have features similar 
birdshot chorioretinopathy, which is very rare in animal models. Even in HLA-
B27 transgenic animals that develop spondylosis, skin lesions, or arthritis, 
uveitis is uncommon, and when present, often mild. It did not appear that 
surface expression of the HLA-A29 molecule was necessary in the HLA-A*29 
transgenic animal for disease to develop, implying that antigen presentation by 
the HLA-A29 molecule was not a critical step in disease pathogenesis. 
Although the HLA-A*29 transgenic mice should not have had any other human 
genomic material, it does remain possible that the HLA-A29 gene or its product 
interact with other genes on the MHC (or are in linkage equilibrium with them), 
resulting in the strong association with disease.  
Clearly, specific HLA genotypes are not necessary or sufficient for any form of 
uveitis. Investigators have searched for additional genes that may confer risk   
The immunogenetics of MHC class I chain-related gene A and gene B (MICA 
and MICB) in Behcet’s disease has also been explored. Recent refinements in 
genetic mapping suggest that some cases of Behcet’s disease in Japan and 
Greece are associated with the MICA gene, located near, but not within, B51. 
(Kimura et al. 1998), (Ota et al. 1999) While evidence of both positive and 
negative associations have been described, these again may have been due to 
linkage disequilibrium with HLA-B51 (Hughes et al. 2005). In addition, many of 
these studies have involved a very small number of patients. While a consistent 
picture has not emerged, the tantalizing suggestion that there may be 
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subgroups with particular disease phenotypes with specific MIC alleles remains 
an interesting observation, and several groups continue to examine this issue. 
(Levinson 2007) 
1.4.4 Cytokine Gene Polymorphisms 
Cytokines and cytokine receptors are major mediators of the immune response. 
Not surprisingly, polymorphisms in genes for cytokines are increasingly being 
associated with immune-mediated disease. 
1.4.4.1 Tumour Necrosis Factor Alpha 
The TNF-α gene resides in the MHC class III gene cluster, which is adjacent to 
HLA-B. Numerous studies have documented the major role that TNF plays 
during inflammation. Patients with inflammatory disease often have increased 
levels of TNF in their serum. Patients with uveitis have demonstrated higher 
concentrations of TNF in aqueous humour, (Santos et al. 2001b) and this 
difference is even more pronounced in HLA-B27–positive patients with uveitis 
compared to HLA-B27–negative patients. (Perez-Guijo et al. 2004) 
Furthermore, the newer TNF inhibitors have been efficacious in several 
inflammatory diseases, including Behcet’s disease, psoriatic arthritis, and 
Crohn’s disease. (Kalden 2002) (Tutuncu, Morgan, Jr., and Kavanaugh 2002). 
Anti-TNF treatment is now also available for uveitis associated with different 
immune-mediated conditions. (Neri et al. 2010) (Pleyer et al. 2011) (Neri et al. 
2011) 
From a genetic perspective, polymorphisms in the promoter region of TNF-α 
have been shown to alter expression of TNF-α. (Abraham and Kroeger 1999) 
(Kroeger, Carville, and Abraham 1997)  Hence, there is much interest in 
characterizing the TNF genotype of patients with inflammatory disease. 
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However, the problem in doing so is the fact that TNF-α is coded very close to 
the HLA genes, making it difficult to determine whether an association with 
disease is independent of linkage disequilibrium with HLA genes. A recent 
study by Ahmad et al was designed to detect TNF promoter polymorphisms 
independent of HLA-B by conducting linkage disequilibrium analysis across 6 
genes in a cohort of patients with Behcet’s disease. (Ahmad et al. 2003) The 
authors reported a TNF promoter allele (-1031C) that was associated with 
Behcet’s independently of HLA-B alleles. Other studies have also highlighted 
the role of TNF-α polymorphisms in Behcet’s disease. (Kamoun et al. 2007) 
A very interesting recent article reported an increase in a single-nucleotide 
polymorphism (SNP) (TNF-857T) in acute anterior uveitis. (Kuo et al. 2005) 
There was also a trend toward increased complications in HLAB27–positive 
subjects who were carriers of the TNFRSF1A 201T or TNFRSF1A -1135T 
alleles.  (Kuo et al. 2005) 
1.4.4.2 The Interferon Genes  
The interferons are a group of cytokines that play a pivotal role in antiviral 
responses and polarization of T-cells. Type I interferons include interferon 
alpha (IFN-α) and interferon beta (IFN-β) and bind the same cell surface 
receptor.  Type I interferons are produced in response to viral infection in a 
wide array of cell types. In contrast, interferon gamma (IFN-γ), the type II 
interferon, is primarily produced in activated T-cells and NK cells.  
The type I IFN genes are clustered on the short arm of chromosome 9. Linkage 
analysis on a cohort of patients with multiple sclerosis suggested a role for IFN-
α gene in the genetic predisposition to this disease. (Epplen et al. 1997) 
Multiple sclerosis is not the only disease with a uveitis component that has 
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been linked to IFN-α gene. Recently, a cohort of Japanese patients with 
sarcoidosis was studied by comparing various IFN SNPs in a case-control 
analysis. (Akahoshi et al. 2004) A variant allele (made up of 2 SNPs in linkage 
disequilibrium, IFNA10, 60A and IFNA17, 551G was found to be significantly 
associated with sarcoidosis compared to a healthy control population.  
IFN-γ production is the hallmark of a Th1 response and polymorphisms in its 
gene that result in higher production for a given stimulus might be expected to 
produce more severe inflammation and tissue destruction. In one study of 
patients with intermediate uveitis, (Stanford et al. 2005) the IFN-γ A874T 
polymorphism, which reflects a constitutively higher production of IFN, was 
significantly associated with disease and, although not statistically significant, 
there was a trend towards an association with disease outcome.  
1.4.4.3 Interleukin-10 
IL-10 is an anti-inflammatory cytokine that was shown to suppress IFN-γ 
production, inhibit the Th1 response and promote the Th2 response. (de Vries 
1995). In a recent study in patients with sympathetic ophthalmitis  (Atan et al. 
2005) significant associations were found between the IL-10 -1082 SNP and 
disease recurrence from previously stable disease and the level of steroids 
required for maintenance therapy. In addition, the GCC IL-10 promoter 
haplotype (IL-10 -1082G, -819C, -592C) was found to be protective against 
disease recurrence. The authors concluded that polymorphisms were markers 
for the severity of disease in sympathetic ophthalmitis. In another study on 
intermediate uveitis, analysis of disease outcome showed an association 
between IL-10–1082 AA homozygosity and bad outcome. (Stanford et al. 2005) 
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1.4.5 Chemokine and Chemokine Receptor Genes  
The hallmark of uveitis is the infiltration of leukocytes into the eye, especially 
the uveal tissues. The specificity of this process is dependent on various 
chemokines and their receptors, many of which have been studied in animal 
models of uveitis. In addition to studies in animals, chemokines or chemokine 
receptors have been shown to be expressed in human uveal tissues (Silverman 
et al. 2003) and upregulated in peripheral blood or plasma of patients with 
uveitis compared to healthy controls. (Kaburaki et al. 2003), (Klitgaard, Ogard, 
and Krogh 2004)  
Research directed at the examination of polymorphisms in chemokine and 
chemokine receptor genes, which may alter chemokine expression or function, 
in patients with uveitis is emerging. Chen et al compared cohorts of patients 
with Behcet’s disease, idiopathic retinal vasculitis, and healthy controls for the 
frequencies of selected polymorphisms in the promoter regions of 2 chemokine 
genes, MCP-1 and RANTES. (Chen et al. 2004) They found evidence for 
gender-specific disease association with polymorphisms in both genes in the 
patients with Behcet’s disease. In another study by the same group, a particular 
haplotype of the fractalkine (CX3CL1) receptor, CX3CR1 (I249/M280), was 
found to be associated with uveoretinitis in a cohort of patients with retinal 
vasculitis. (Wallace et al. 2006) This particular CX3CR1 mutant exhibits a lower 
binding affinity for fractalkine and is associated with an increased risk of 
acquired immune deficiency syndrome (AIDS) progression in human 
immunodeficiency virus (HIV)-positive individuals. (Faure et al. 2000)  
In another study an odds ratio of 2.1 was found for the MCP-2518G in HLA-
B27–positive patients with acute anterior uveitis compared with HLA-B27 
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positive control subjects (Wegscheider et al. 2005). Table 1-5 summarizes the 
various genetic associations noted in uveitic syndromes. 
 
Table 1-5: Non–Human Leukocyte Antigen immunogenetic associations with uveitis 
Disease/syndrome   Suspected genes/loci 
   
Acute anterior uveitis   MIC; D95137 (9p21p24), 1q23-1-q31,  
  TNF-857T; TNFSRF1A-201T,  
  TNFSRF 1A-1135T;CCL2/MCP-2518G  
   
Behcet’s disease   MIC, interleukin-1, tumour necrosis  
  factor promoter region  
   
Birdshot   Myelin oligodendrocyte glycoprotein  
   
Blau syndrome   CARD/NOD  
   
Intermediate uveitis   Cytokine gene polymorphisms  
 
 
1.4.6 Genome-Wide Scans  
Family-based studies searching for regions of linkage across the genome have 
been conducted for several inflammatory or autoimmune diseases such as 
rheumatoid arthritis, systemic lupus erythematosus, autoimmune thyroiditis, 
and psoriasis. This approach has also proven informative for diseases that 
have a uveitis component, including inflammatory bowel disease, (Hampe et al. 
1999) Blau syndrome, (Tromp et al. 1996) multiple sclerosis, (Ebers et al. 
1996) sarcoidosis, (Schurmann et al. 2001) ankylosing spondylitis (Laval et al. 
2001) and Behcet’s disease. (Mizuki et al. 2010) For diseases in which uveitis 
occurs in only a small minority of affected individuals, such as inflammatory 
bowel disease or multiple sclerosis, the genetic contribution of each 
susceptibility locus to uveitis will be difficult to ascertain due to the small size of 
these patient populations. However, diseases such as ankylosing spondylitis, 
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sarcoidosis and BD which have a high frequency of uveitis, offer the ability to 
conduct genetic studies with relatively larger cohorts, even when stratifying the 
analysis for uveitis. Recently GWAS have been done on subjects with Behcet’s 
disease. (Mizuki et al. 2010) (Remmers et al. 2010) 
The first genome-wide scan to specifically focus on the uveitis phenotype 
predominant in ankylosing spondylitis (AS) patients has recently been 
performed. (Martin et al. 2005) This study analyzed 76 affected sibling pairs 
with uveitis and compared the results to an analysis of 245 affected sibling 
pairs with AS. In both groups, strong linkage to the MHC region on 
chromosome 6 was observed, undoubtedly due to the association of 
spondyloarthritis and anterior uveitis with HLA-B27. Two other genetic regions 
showed significant linkage to anterior uveitis, areas at chromosome 1q25-31 
and chromosome 9p21-24. Of these, 1q25-31 overlaps with a locus previously 
identified for ankylosing spondylitis. (Laval et al. 2001), (Zhang et al. 2004) In 
contrast, the other region (9p21-24) did not reveal a significant result in the 
companion ankylosing spondylitis scan, (Zhang et al. 2004), (Martin et al. 2005) 
but did overlap with an area of weak linkage in previous studies. (Laval et al. 
2001) Therefore, it is likely that this region contains a uveitis-specific candidate 
gene. The locus includes a number of genes with known roles in inflammation 
including the type I interferon genes. However, additional studies will be 
needed to fully delineate the role of this region in predisposition to uveitis. 
The GWAS in Behcet’s disease did not specifically looked into association with 
uveitis, however loci have been noted on IL-10 and IL-23R genes. (Mizuki et al. 
2010) (Remmers et al. 2010) 
In short, immunogenetic studies on uveitis patients have revealed loci other 
than HLA gene that may play crucial role in inflammation. Immunogenetic 
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studies hold promise for revealing additional pathologic mechanisms, 
monitoring or predicting the response to treatment, and diagnosis of uveitis. 
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1.5 Genetics of complex traits 
1.5.1 Overview 
Complex diseases are caused by many, possibly interacting, genes and 
environmental factors. This is in contrast to Mendelian diseases, such as 
Huntington's disease and cystic fibrosis, which are the results of some specific 
and rare mutations. These mutations alter or destroy the function of a single 
gene. There are many disorders caused by single genes, but these are rare in 
the population, often occurring in less than one in five thousand individuals 
(Botstein and Risch 2003). 
Diseases inherited as complex traits are often much more common in the 
population. Examples of complex diseases include asthma, heart disease, 
chronic inflammatory diseases, and diabetes. There is a lot of interest in 
understanding these diseases better and in particular determining the extent to 
which genetics play a role in predisposing individuals to disease. 
Complex diseases may result from genetic variants that are relatively common 
in the general population and are involved in the normal human health and 
development (Lander et al. 2001). In addition, some of these variants may have 
major effects, but many of them have minor effects (Thornton-Wells, Moore, 
and Haines 2004). Factors that influence these traits are:  
 
a) an incomplete penetrance, i.e. not all susceptible individuals are 
affected, 
b)  the interactive effects between genetic loci and environmental 
factors, 
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c)  heterogeneity, so that many genes participate in the development of 
disease phenotypes (Khoury et al. 2004) (Thornton-Wells, Moore, 
and Haines 2004).  
These genes usually interact in complex networks whose expression is tightly 
regulated and coordinated. This gene-gene interaction is called epistasis or 
modifier genes, which is defined as the interaction between two or more genes 
to control a single phenotype. Epistasis can be antagonistic or synergistic 
depending on whether variational effects overlap or reinforce each other 
(Sanjuan and Elena 2006). These factors also complicate the efforts to identify 
genetic regions involved. 
The relative contribution of both genes and environment to a disease varies in 
different diseases. Many diseases cluster in families demonstrating that 
genetics may play a role in determining disease susceptibility, but it is difficult 
to determine the true genetic association in complex traits since families share 
environmental factors and exposed to similar antigens and have similar 
activities (Wandstrat and Wakeland 2001). 
1.5.2 Approaches to Gene Mapping in Complex Traits 
An important step towards understanding a genetic disease is to identify the 
gene, or genes, that play a role in the disease aetiology. The most commonly 
used approaches for mapping genes associated with disease are linkage 
analysis and case-control association studies. In a linkage analysis, large 
numbers of DNA markers, that are closely spaced, are typed in families with 
multiple affected relatives. Markers that segregate with affected relatives, more 
often than expected, are used to localize the disease locus. This approach has 
the advantage of being an unbiased and comprehensive and has been 
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successfully applied to diseases with simple Mendelian inheritance such as 
cystic fibrosis (Salvatore, Scudiero, and Castaldo 2002).  
However, linkage analysis has been less successful with regards to complex 
genetic disorders, mainly because of a limited power to detect the effect of 
common alleles with modest effects on the disease (Risch and Merikangas 
1996) (Hirschhorn and Daly 2005). Another disadvantage of linkage studies is 
the preferable need for more than one generation: DNA needs to be collected 
from grandparents, parents and children. Moreover, when the disease occurs 
late in life, parental information is often lacking.  
Therefore, for analysing the complex human disorders; such as uveitis, 
candidate gene-case control association studies are commonly used (Vink and 
Boomsma 2002). These studies look for evidence for a significant association 
between an allele/haplotype of a candidate gene and disease/phenotype 
characteristics (Newton-Cheh and Hirschhorn 2005). In these studies, there is 
no need for information derived from grandparents or children. Therefore, this 
strategy is often the preferred route for late-onset diseases (Hirschhorn and 
Daly 2005).  
Candidate gene-case control studies are relatively easy to perform in a short 
period, which is one of the reasons why they have increasingly become popular. 
Genes rarely act alone, therefore, interactions between different genetic 
variants in a pathway or across different pathways is important (candidate 
pathway approach) (Suh and Vijg 2005). 
However, there are several important statistical issues in the use of case-
control association studies. Population stratification is the biggest criticism of 
case-control association studies (Hirschhorn et al. 2002). The control group 
must genetically be representative of the population under the study. False 
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association may arise in a case-control study when allelic frequencies vary 
across subpopulations. In a review of literature, and excluding perhaps the 
most important complex disease locus of all, the MHC where replication is high, 
only six of 166 positive associations were replicated by subsequent studies 
(Hirschhorn et al. 2002).  
By typing several dozens of random panels of genetic markers, it is possible to 
detect and correct the control stratification (Pritchard and Rosenberg 1999). 
Moreover, a positive finding in a case–control study always needs confirmation 
in another group of subjects, which are not related to the first group (Hirschhorn 
et al. 2002).  
1.5.3 SNPs and the Pathogenetics of Complex Traits 
Genetic markers scattered throughout the genome can be used as a means to 
understand the pathogenetics of complex diseases. These markers include, 
variable number tandem repeats, short sequence repeat polymorphisms and 
Single Nucleotide Polymorphisms. SNPs are the simplest type of genetic 
variants. SNPs may have no significant function, however, depending on their 
position they may alter protein’s structure and function through a single 
nucleotide base substitution in a gene’s coding region. In addition, they may 
increase or decrease gene expression by altering transcription factors binding 
site when occurring in the promoter region or by affecting mRNA stability when 
occurring in 3` UTR region.  
SNPs are important tool for complex genetic disorders studies. The studies 
look for a significant statistical association between SNP alleles and a disease, 
in order to pinpoint candidate causative genes (Newton-Cheh and Hirschhorn 
2005). The Complex Trait Consortium suggested that a susceptible gene 
should meet more than one of these seven criteria (Abiola et al. 2003): 
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1. Polymorphisms in either coding or regulatory regions have been found. 
2. Its function has been linked to the quantitative trait being analyzed. 
3. Its function has been tested in vitro. 
4. Its function has been tested in transgenic animals. 
5. Its function has been tested in knock-in animals. 
6. Its function has been tested by mutational analysis. 
7. A homologous quantitative traits loci for the same phenotype in another 
species has been found.  
In comparison with different types of genetic variants, such as microsatellites, 
there are several advantages of using SNPs as a mean to study the 
pathogenetics of complex diseases (Collins et al. 1998) (Xiong and Jin 1999). 
SNPs are plentiful throughout the human genome and alleles at some of these 
polymorphisms may be functional (Hoogendoorn et al. 2004). In addition, 
groups of SNPs might exhibit patterns of linkage disequilibrium called 
haplotypes which could be used to enhance gene mapping.   
Since the identification of functionally relevant polymorphic sites is the ultimate 
goal of any genetic study, the more polymorphic loci one can type on a set of 
individuals, the more likely to identify the causal allele. Large SNP collections 
can therefore provide the necessarily means from which the putative SNPs can 
be obtained. However studying SNPs without prior knowledge of their functions 
or studying non-functional SNPs adds some difficulties. If a significant 
association with a SNP is noted, it is difficult to assert whether this association 
is true or it is a result of linkage with some other unknown SNP that may be 
functional.  
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1.5.3.1 Linkage Disequilibrium 
When a particular allele is found together with a second allele more often than 
expected by chance, the loci are in disequilibrium. This non-random association 
of alleles at different loci is called Linkage Disequilibrium (LD). Recent studies 
have proposed that the underlying structure of LD in the human genome can be 
described by using a relative simple framework in which the data is dissected 
into series of discrete haplotype blocks (Daly and Day 2001) (Wall and 
Pritchard 2003). Patterns of LD are well known for being unpredictable. For 
example, pairs of sites that are tens of kilo bases apart might be in complete 
LD, whereas nearby pairs of sites from the same region might be in weak LD 
(Ardlie, Kruglyak, and Seielstad 2002). 
Many different methods have been proposed for measuring the strength of LD. 
The most commonly used measures are D′ and r2. (See chapter 2 for 
calculations) (Devlin and Risch 1995) Both measures range from zero (no 
disequilibrium) to one (complete disequilibrium), but their interpretation is 
slightly different. D′ is equal to one if just two or three of the four possible two-
locus haplotypes are observed in the sample, and it is <1 if all four possible 
haplotypes are present. Therefore, the statistical significant values of D′ that 
are near 1.0 provide a useful indication of minimal historical recombination 
(Hudson and Kaplan 1985). However, intermediate values are more difficult to 
interpret. Therefore, they should not be used for comparisons of the strength of 
LD between studies or measuring the extent of LD (Ardlie, Kruglyak, and 
Seielstad 2002).  
The measure r2 is the correlation of alleles at the two sites. r2 = 1 if, and only if, 
the markers have not been separated by recombination and have the same 
allele frequency. In this case, exactly two out of the four possible two-locus 
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haplotypes are observed in the sample. So, observations at one marker provide 
complete information about the other marker, making the two redundant. It is 
also the most relevant measure for associational mapping, because there is a 
simple inverse relationship between r2 and the sample size required for the 
study (Wall and Pritchard 2003). For example, suppose that SNP1 is involved 
in disease susceptibility, and the other is a nearby marker (SNP2) in LD with 
the SNP1. To have the same power to detect the association between the 
disease and the marker locus, the sample size must be roughly increased by 
1/r2 when compared with the sample size for detecting association with the 
susceptible locus itself (SNP1) (Pritchard and Przeworski 2001). This also 
makes intermediate values of r2 are easy to be interpreted (Ardlie, Kruglyak, 
and Seielstad 2002). 
LD patterns in human populations are influenced by many factors (Ardlie, 
Kruglyak, and Seielstad 2002).  
1) Genetic Drift is “the random fluctuations in gene and haplotype 
frequencies from one generation to the next due to the random 
sampling of gametes that occurs during the production of a finite 
number of offspring” (Tishkoff and Verrelli 2003). The effect of 
genetic drift on variation is a function of effective population size. It is 
particularly severe in a population that has undergone a bottleneck 
event which can be defined as a severe reduction in population size 
or a founding event that happens when a small group splits off from a 
larger group and colonizes a new region (Pritchard 2001). In contrast, 
genetic drift has a smaller effect on growing populations, and 
preserves any LD that existed when the populations started to 
expand (Tishkoff and Verrelli 2003). 
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2) Gene Conversions are short exchanges between chromosomes 
that are not accompanied by crossing over during meiosis. The effect 
can break down the LD in a manner similar to recombination or 
recurrent mutation (Ardlie et al. 2001).  
3) Admixture or Migration can change LD between populations. 
Population admixture may mask, change or reverse genetic effects of 
genes underlying complex diseases (Deng, Chen, and Recker 2001). 
This may lead to the inconsistent results from association studies in 
admix populations (Deng, Chen, and Recker 2001). 
1.5.3.2 Haplotypes 
A haplotype is simply a unique combination of alleles found at neighbouring loci 
on a single chromosome or haploid DNA molecule. The original application of 
the haplotype method was to HLA allele frequency calculations, where groups 
of epitopes are distributed in a non-random manner. This distribution is due to 
certain alleles of different HLA genes, which are found in a linkage more often 
than what would be expected by chance. 
 However, it is important to identify the exact sequence variance that 
contributes to disease risk (Hafler and De Jager 2005). For example, the 
association of the MHC region with Multiple Sclerosis has been known since 
early 1970s, but it still unknown whether the association with the 
HLADQB1*0602, HLA-DRB1*1501 haplotype is mainly due to a risk allele in 
the HLA-DQB1 or HLA-DRB1 gene (Hafler and De Jager 2005). Therefore, the 
extent of the haplotype association in the studied population must be 
investigated for further variation discovery (Crawford and Nickerson 2005).  
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Role of Haplotype in Association Studies 
Most candidate gene-association studies rely on the one-SNP at-a-time 
approach. However, the fact that these SNPs are not independent of one 
another emphasizes the necessity of studying the variations in these genes as 
phased haplotypes, i.e. co-segregation of alleles in the same chromosome 
(Clark 2004).  
Phased haplotyping plays an important role in the candidate gene-association 
studies for many reasons. Firstly, haplotypes directly correspond to the unit of 
biological function, the protein. The protein products of the candidate genes 
occur in polypeptide chains whose properties may depend on particular 
combinations of a group of amino acids. The properties of the protein may 
depend on interactions between pairs or combinations of amino-acid sites. If 
these interactions are important, then haplotypes are of direct biological 
relevance. Secondly, the genomic variation in a population is structured into 
haplotypes. Finally, haplotypes can have statistical advantages by reducing the 
dimension of statistical tests for association studies (Clark 2004). 
Unfortunately, haplotypes are costly to measure directly (Crawford and 
Nickerson 2005). Therefore most investigators rely on computerised statistical 
methods to either infer the most likely pair of haplotypes per subject, or to 
account for all possible haplotypes that are consistent with the observed un-
phased marker data (Clayton, Chapman, and Cooper 2004). 
1.5.3.3 Assessing the Function of Genetic Variants 
Knowledge of SNP’s function is crucial to direct the appropriate design and 
interpretation of the candidate gene-association studies. Assessing the function 
of a SNP can be done by using experimental systems, such as the effect of 
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SNP on transcription factor binding affinity, mRNA expression and stability, and 
the effect on protein structure and expression (Knight 2003). However, variants 
in multifactorial diseases may often have a moderate effect rather than a crucial 
one on the gene’s function, making it difficult to find such functional relevance. 
For example, the functional effect of a SNP in an experimental system may be 
minute, but it might become more important in a specific human tissue. 
Therefore, the functional effects of the SNP cannot be detected in experimental 
systems (Knight 2003).   
DNA regulatory regions are widely dispersed in the genome. They may be 
located in the 5′ or 3′ of the gene, or in the introns of a neighbouring irrelevant 
gene (Arnone and Davidson 1997) (Mancini-DiNardo et al. 2003). Variations in 
the regulatory regions may affect Transcription Factor Binding Site (TFBS) 
thereby it may affect gene expression. Defects in binding of these factors have 
been implicated in human diseases such as cancer and inflammation (Shaulian 
and Karin 2001).  
Assessing SNPs that affect transcriptional regulation is commonly done by 
protein-DNA interaction assays and plasmid reporter gene expression. (Fried 
1989) (Hoogendoorn et al. 2004) Transcription factors show a high degree of 
specificity in their DNA-binding domains for the DNA sequence to which they 
will bind. This DNA sequence is typically 5–8 nucleotides in length and specific 
to a given family of transcription factors.  
The ability to screen the transcription factor activity is, therefore, important in 
gene regulation studies. A number of computational algorithms have been 
developed to predict the impact of nucleotide variations on the gene expression 
(Nardone et al. 2004). For example, by using online transcription factor 
databases, such as the TRANSFAC database, (http://www.gene-
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regulation.com/pub/databases/transfac/doc/toc.html) researchers can find 
transcription factors binding sites in a given sequence (Wingender et al. 2000). 
Transcription Element Search System (TESS) is a web tool uses TRANSFAC 
database to predict transcription factor binding sites in the given DNA 
sequences.  http://www.cbil.upenn.edu/cgi-bin/tess/tess  
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1.6 Objectives of the study 
Genetic studies in medicine are often pursued in order to develop diagnostic 
tests or to allow the identification of individuals at risk for disease. In fact, HLA 
testing can play an important role in the diagnosis of ocular inflammatory 
disease. However, the predictive positivity of genetic testing in such rare 
diseases that are likely to be polygenic (and are also likely to have 
environmental contributions to disease pathogenesis) is too low to be useful in 
any practical way for screening populations at risk. 
Immunogenetic studies have been used to better understand the pathogenesis 
and nosology of ocular inflammatory disease, as well as the interactions of 
nature and nurture in ocular inflammation. There are large gaps in our 
understanding of the pathophysiology of ocular inflammation, in part because it 
is very difficult to obtain tissue to study. While we can often observe the results 
of intraocular inflammation by clinical examination and adjunctive clinical 
testing, the risks to the eye of obtaining intraocular tissue for research purposes 
are considered too great to pursue.  Intraocular specimens are sometimes 
available for research purposes, but these are often from eyes that have 
received treatment, and may be obtained late in the course of the disease, 
limiting the ability to perform systematic studies. Animal models have been 
helpful, but they involve artificial experimental protocols such as sensitizing a 
susceptible animal with retinal antigens and adjuvant so may not be directly 
applicable to human disease. In addition, some aspects of the immune 
response differ between animals commonly used in the laboratory and humans.  
Most of the literature on the immunogenetics of uveitis consists of studies with 
relatively small numbers of subjects, looking for associations of disease with 
specific genes. More sophisticated genome scans and population and family 
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studies are difficult mostly because these diseases are so rare and involvement 
of multiple family members is very rare for most of these diseases.  
The most feasible way to identify the genes involved in the pathogenesis of 
uveitis is the candidate gene approach.  
Association-based studies, in which the frequency of alleles at polymorphic loci 
are compared between an affected and a control population, are since long 
considered to be more effective tools for studying complex traits because they 
have greater statistical power to detect genes with small effect (Risch and 
Merikangas 1996) (Long and Langley 1999). However, the small number of 
known SNPs and the lack of high-throughput genotyping methods have, in the 
past, severely constrained this approach with respect to its systematic 
application to the unravelling of the genetic component of human complex 
disease phenotypes. The identification of large numbers of SNPs in the human 
genome and the wealth of novel opportunities for genotyping at low cost has 
now brought association analysis into the realm of the feasible. By comparing 
the frequency of SNPs in unrelated cases and controls, association studies can 
detect genes that are in linkage disequilibrium with one of such SNPs. When 
they occur in a gene, SNPs could actually be the causative genetic variant that 
changes the protein function or its expression, directly contributing to variation 
in phenotype. But rather than applying this principle to whole genome, much 
more power is obtained by using candidate genes. Candidate gene approaches 
focus on genes that are selected because of a prior hypothesis about their role 
in the phenotype, rather than rely on markers that are evenly spaced 
throughout the genome without regard of their function or context in a specific 
gene (Tabor, Risch, and Myers 2002). Such studies, which may now involve 
hundreds to thousands of genes, participating in the same and different 
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pathways in interaction with environmental factors, would be the first step in 
unravelling the genetic determinants of complex disease. At present, direct 
association studies of functional variants are limited by incomplete knowledge 
about functional variants. However, progress in genomics information 
technology is rapid and may soon provide a strong basis for such an approach. 
Subsequent functional genomics analyses of the discovered gene variants, in 
relation to the observed phenotypic endpoints, would then ultimately reveal the 
causal factors of complex diseases. 
A major challenge in undertaking candidate gene–disease association studies 
is to choose Target SNPs that are most likely to affect the phenotype and that 
ultimately contribute to disease development. Variants in biologically plausible 
candidate genes are usually selected for study on the basis of both variant 
allele frequency and the functional effect of the variant on relevant traits. 
Although there is often sufficient information to assess the allele frequency of a 
candidate variant, understanding the functional significance of genetic variants 
is usually more difficult. Knowledge of gene and SNP function is crucial to 
direct the appropriate design and interpretation of candidate gene association 
studies. 
 A logical starting point for candidate gene study is to restrict analysis to known 
putative functional SNPs in the candidate pathway. Since PSU is predominantly 
Th1 mediated disease the focus of this study has been on the genetic role of 
Th1 mediating cytokine and chemokine genes in the predisposition to PSU. It 
must be pointed out here that when this research was started the role of Th17 
cells in pathogenesis of PSU was not known.  
Given the position of these cytokine and chemokine molecules in the pathway 
of inflammation, even minor variation in these genes could be critical for the 
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inflammatory response. This is relevant to the current clinical trails of uveitis 
since treatments in these trials are targeted at these inflammation stages of the 
disease. (Accorinti et al. 2007) (El-Shabrawi and Hermann 2002) (Joseph et al. 
2003) (Nussenblatt 2005) 
In the present work, I have studied the contribution of the cytokine and 
chemokine genes in susceptibility and severity of PSU using genetically 
homogeneous Caucasian populations. I employed the candidate pathway 
approach, taking advantage of its high power of detection of weak associations. 
I mainly studied functional SNPs so that the relation between the phenotype 
and genotype could be correlated more logically. Gene haplotypes were re-
constructed when more than one SNP on a gene were studied. To increase the 
likelihood that a candidate gene would harbour the variations relevant to traits, I 
studied a wide variety of information, including previous genetic studies, animal 
models, and knowledge of biologic pathways.  
The aims of the study were 
1) To identify genes that may be involved in the pathogenesis of PSU 
2) To identify SNPs that may predispose subjects to PSU 
3) To identify SNPs that can predict the phenotype and act as indicator 
of visual outcome and response to treatment 
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2.1 Populations and Study Design 
This is a retrospective study of a cohort of patients suffering from non-infectious 
posterior segment uveitis. 205 Caucasian patients who attended the uveitis 
clinic at Moorfield’s Eye Hospital were recruited for this study. (During the last 
part of research, 24 samples were ruined; hence 176 patient samples were 
available for cytokine genes analysis [Chapter5]). 
 There were two main cohorts of subjects who served as control populations. 
(N=283) 
1) 169 healthy subjects who were admitted to Whipps Cross Hospital 
(WXH) for cataract surgery and 
2) 114 healthy subjects who were seen at King’s College Hospital (KCH) 
eye department for age related macular degeneration. 
3) However, 142 Caucasian healthy subjects whose DNA were stored and 
used in other studies, (Spagnolo et al. 2005) were also available for 
CCR2 & CCR5 SNPs analysis in idiopathic PSU and OB. (Chapter 4) 
(Again, during the last part of research, 3 samples from WXH and 9 samples 
from KCH were ruined; and I had total of 271 control samples for cytokine gene 
analysis [Chapter 5]).   
Besides this there were 29 Caucasian patients with Behcet’s disease with no 
ocular involvement, 30 non Caucasian patients with OB, and 56 non Caucasian 
controls used for CCR2 gene analysis in OB. (Chapter 4) 
2.1.1 Patients:  
After approval from the Ethics Committee, patients with PSU were recruited 
from the Uveitis Clinic in Moorfield's Eye Hospital. PSU was defined as any 
non-infectious inflammation of choroid, retina, retinal vessels, vitreous or cilliary 
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body either in isolation or as a part of pan uveitis. Since non-infectious posterior 
segment uveitis includes a variety of conditions, inclusion in the study was 
restricted to idiopathic PSU and uveitis secondary to sarcoidosis and Behcet’s. 
By definition this excluded patients suffering from the VKH syndrome, 
sympathetic ophthalmia, and Birdshort choroidopathy, uveitis related to multiple 
sclerosis or any other auto-immune condition. The reason for including 
sarcoidosis and Behcet’s uveitis was that these two are the most common 
identifiable causes of PSU.  
Thus depending upon cause and site of inflammation the patients were divided 
into four main groups.  
1) Idiopathic intermediate uveitis,  
2) Idiopathic posterior uveitis  
3) Sarcoid related uveitis, and 
 4) Behcet’s related uveitis.  
All the Caucasian patients were UK resident patients whose ancestry was 
traceable back to the UK.  
The non Caucasian patients with non ocular Behcet’s disease were from 
Middle East. 
Clinical Details: 
Informed verbal and written consent was obtained from each patient and they 
then underwent complete ophthalmic examination. This included visual acuity, 
intra-ocular pressures, anterior segment slit-lamp examination, and dilated 
fundus exam. Where necessary fundus flourescein angiography, optical 
coherent tomography, B scan, visual field tests and electro diagnostic tests 
were performed.   
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Clinical details were obtained for each patient’s notes and included:  Age of 
onset, follow up period, laterality of disease, fluctuation of visual acuity 
throughout the progress of disease, minimum visual acuity during an episode of 
active inflammation, visual acuity in each eye at the end of follow up and  final 
visual acuity with both eyes.  The pattern of disease e.g., single event, 
recurrent with remissions or chronic, and if recurrent, the number of attacks 
during the follow up period were also noted. Also noted was the presence of 
complications like, cystoid macular oedema, glaucoma, choroidal 
neovascularization, cataract retinal detachment and phthisis bulbi.  
The treatment given to the patient was recorded giving particular emphasis to 
use of systemic steroids, duration of steroids (whether or not on long term 
steroids of 10mg/day or more), number of second line immunosuppressive 
drugs used, and number of times intra-vitreal or periocular steroids were given. 
Although most of the information was gathered from the patient notes, on their 
day of recruitment to study, The SUN Working Group Anatomic Classification of 
Uveitis (Jabs, Nussenblatt, and Rosenbaum 2005) was used to determine the 
course and activity of the disease. The National Eye Institute system for 
grading vitreous haze was adopted (Nussenblatt RB 1985) Since this was a 
retrospective study, particular attention was paid on reporting the visual acuity 
particularly final visual outcome. 
2.1.2 Definition of disease characteristics 
2.1.2.1 Sarcoidosis: 
 In all patients sarcoidosis was diagnosed histologically and according to the 
criteria defined in the American Thoracic Society (ATS), the European 
Respiratory Society (ERS) and the World Association of Sarcoidosis and Other 
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Granulomatous Disorders (WASOG) statement on Sarcoidosis (Costabel and 
Hunninghake 1999) 
The diagnosis of systemic disease and biopsy were performed at Department 
of Respiratory Medicine, Royal Brompton Hospital.  
Recently an updated criterion for the diagnosis of sarcoidosis has been 
recommended (Herbort, Rao, and Mochizuki 2009). (Table- 2-1) The criterion is 
shown as follows. Since all of my cases were biopsy proven sarcoidosis, the 
new criterion did not affect the suggested diagnosis of my cohort 
Table- 2-1 Diagnostic criterion for Ocular Sarcoidosis 
Table A Clinical signs suggestive of ocular sarcoidosis 
 
1. Mutton-fat keratic precipitates and/or iris nodules at papillary margin or on stroma 
2. Trabecular meshwork nodules and/or tent-shaped peripheral anterior synechiae 
3. Snowballs/strings of pearls vitreous opacities 
4. Multifocal peripheral chorioretinal lesions (active and atrophic) 
5. Nodular and/or segmental periphlebitis (with or without candle-wax exudate) and/or macroaneurysm 
6. Optic disc nodules/granuloma and/or solitary choroidal nodule 
7. Bilateral inflammation (evident on clinical examination or on investigational imaging 
 
 
Table B Laboratory investigations in suspected ocular sarcoidosis 
 
1. Negative tuberculin test in a patient who either had BCG vaccination or previously had a  positive 
tuberculin test 
2. Elevated serum angiotensin converting enzyme and/or elevated serum lysozyme* 
3. Chest X-ray: bilateral hilar lymphadenopathy 
4. Abnormal liver enzyme tests (any two of: alkaline phosphatase; 
aspartate transaminase; alanine transaminase) 
5. Chest CT scan in patients with normal chest X-ray 
* Lysozyme is required in patients treated with ACE inhibitors. 
 
 
Table C Diagnostic criteria for ocular sarcoidosis 
 
1. Biopsy-supported diagnosis with compatible uveitis:    
Definite ocular sarcoidosis 
 
2. Biopsy not done; bilateral hilar lymphadenopathy with compatible uveitis    
Presumed ocular sarcoidosis 
 
3. Biopsy not done; chest X-ray normal; 3 suggestive ocular signs and 2 positive investigational tests 
Probable ocular sarcoidosis 
 
4. Biopsy negative; 4 suggestive ocular signs and 2 positive investigations   
Possible ocular sarcoidosis 
 
Herbort CP, Mochizuki M, Rao NA, and Members of Scientific Committee of 1st IWOS. International criteria for the 
diagnosis of ocular sarcoidosis: results of the first international workshop on ocular sarcoidosis (IWOS). Ocul Immunol 
Inflamm. 2009; 17: 160–169. 
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2.1.2.2 Behcet’s uveitis:   
Behcet’s was diagnosed according to the Criteria described by “International 
Study Group for Behcet’s Disease”, (Criteria for diagnosis of Behcet's disease. 
International Study Group for Behcet's Disease 1990) which is shown in Table 
2-2 
 
Table 2-2: Diagnostic criteria for Behcet’s Disease  
In the absence of other clinical explanations, patients must have: 
 
(1): Recurrent Oral Ulcerations (aphthous or herpetiform) recurring at least three 
times in one 12-month period;  
 
(2): and two of the following: 
 
      a) Recurrent Genital Ulceration. 
      b) Eye Lesions: 
                anterior or posterior uveitis, cells in the vitreous by slit lamp examination 
                or retinal vasculitis observed by an ophthalmologist 
      c) Skin Lesions:  
                erythema nodosum, pseudofolliculitis, papulopustular lesions or acneiform 
                nodules in post adolescent patients not on corticosteroids. 
      d) positive Pathergy 
 
2.1.2.3 Glaucoma  
Glaucoma was defined as consistent intraocular pressure above the 24 mm Hg, 
as the risk of glaucoma appears to increase substantially as the intraocular 
pressure increases beyond this level. (Sommer et al. 1991) The threshold for 
considering a rise in intraocular pressure substantial (for example, as in a rise 
in intraocular pressure attributable to corticosteroid use) was 6 mm Hg or 
greater.   
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2.1.2.4 Cataract  
Cataract was defined as lenticular opacity that was a direct result of 
inflammation rather than age or any other cause. For unilateral eyes, it was 
quite easy as other eye usually served as control. In case of bilateral disease 
logistic regression analysis was used to correct for age and other causes of 
cataracts particularly diabetes and steroid use. The type was cataract also 
helped in the diagnosis as cataract associated with uveitis is usually posterior 
sub-capsular.  
2.1.2.5 Cystoid macular oedema:  
The clinical criterion was deemed sufficient for the diagnosis of cystoid macular 
oedema and epiretinal membrane. However OCT scan or Fundus flourescein 
angiography was utilized for diagnosis where needed. 
2.1.2.6 Choroidal Neovascular membrane:  
The presence of choroidal neovascular membrane was always confirmed with 
FFA. 
2.1.2.7 Permanent Visual Loss: 
 The presence of permanent visual loss was defined as any visual acuity of 
6/15 or less caused by macular scar, optic atrophy, macular ischemia, 
refractory macular oedema or choroidal neovascular membrane. This did not 
include loss of visual acuity secondary to cataract, vitreous debris, or transient 
CMO. 
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2.1.2.8 Visual acuity measurement and conversion to LogMAR 
Since this was a retrospective study so visual acuity was measured exclusively 
as Snellen acuity. However for statistical purpose reporting 1 or 2 lines of loss 
of visual acuity on a standard Snellen chart is problematic because of the 
inconstant relationship of “lines” with changes in the visual angle. For example, 
a decrease of 1 line of visual acuity from 6/9 to 6/12 represents a small 
decrement (33%) in the angle of resolution, whereas loss of 1 line from 6/36 to 
6/60 represents almost doubling of the visual angle. For this precise reason it is 
recommended (Jabs, Nussenblatt, and Rosenbaum 2005) to use logarthrimic 
charts. (first devised by Bailey and Lovie) (Bailey and Lovie 1976) The major 
advantage of this notation especially for research purposes is the ability to 
measure and score low VA accurately, which can then be included in statistical 
analysis. (Lovie-Kitchin 1988) Another advantage is the regular progression of 
the optotype sizes from one line to the other in geometric format as each 
optotype on one line is 1.2589 times larger than the optotype on the next. 
(Bailey and Lovie 1976; Ferris, et al. 1982)  These features permit inter-row 
interpolation of VA values. When each line has five optotypes such as EDTRS 
chart, an interpolated logMAR (logarithm of the minimal angle of resolution) 
score can be created by assigning 0.02 logMAR units for each optotype read 
correctly(Ferris, III et al. 1982) 
 Since logarithmic visual acuities were not available, Snellen visual acuities 
were converted to LogMAR and a doubling of the visual angle analyzed. This 
was calculated by finding the Logarithm of the reciprocal of decimal visual 
acuity 
 
                               Log MAR =  -log10 (visual acuity fraction) 
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Although this logMAR reporting is superior to the number of lines on a Snellen 
chart approach, there remained problems introduced by the limitations of 
Snellen charts, particularly in the poorer ranges of visual acuity (that is 6/36 or 
worse), where a line was represented by one or two letters.  This increased the 
likelihood of skewing the data towards very poor vision. So before interpreting 
the visual acuity data it should be kept in mind that this data is logarithmic 
conversion of Snellen acuity and not actually recorded from logarithmic format 
charts  
Although calculations were done in log MAR visual acuity, the results were 
described in Snellen acuity because it is clinical easy to comprehend. For 
visions described as hand movement or perception of light LogMAR vision was 
converted as suggested by Johnson et al. (Johnson et al. 2003) The table was 
slightly modified to accommodate counting fingers and hand movement visual 
acuity, which is not mentioned in their  table. Counting fingers was given a 
value of 2 and hand movement a value of 2.5. (Table 2-3) 
 
Table 2-3: Visual acuity notions (conversion table) 
Snellen 6m Snellen 20ft Decimal LogMAR 
    
6/6 20/20 1.00 0.0 
6/9 20/32 0.63 0.2 
6/12 20/40 0.50 0.3 
6/18 20/60 0.33 0.5 
6/24 20/80 0.25 0.6 
6/36 20/120 0.17 0.8 
6/60 20/200 0.10 1.0 
3/60 20/400 0.05 1.3 
1/60 20/1200 0.02 1.8 
CF CF CF 2.0 
HM HM HM 2.5 
PL+ PL+ PL+ 3 
NPL NPL NPL 4 
 
Modified from: The Epidemiology of Eye Diseases. Johnson GJ. London 2003, Arnold (Johnson et al. 2003) 
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The standardization of uveitis nomenclature (SUN) working group 
recommendations were used for reporting visual loss. (Jabs, Nussenblatt, and 
Rosenbaum 2005) Moderate visual loss was defined as VA of 6/15 or less and 
severe visual loss as VA of 6/60 or less.  
 
 
2.1.2.9 Event rate 
Although there was a minimum follow up of 24 months, the follow up period 
varied between patients. Since uveitis is a chronic disease and a complication 
or flare up can develop anytime during the course of the disease event rates 
were used to analyze the results. “Rate is the number of events in those at risk 
for the event divided by total follow-up person time” It reports the proportion at 
presentation (or study entry) and the rate during follow-up (incidence). It is 
calculated by dividing the number of events (e.g., patients with elevated 
intraocular pressure) by the sum of the patients’ follow-up time (typically 
expressed as person years). 
2.1.2.10 Event rate to explain “Final Visual acuity” 
Same problem is reporting of final visual acuity, because visual acuity 
outcomes, as a whole, are influenced by the duration of follow-up. “Variable 
follow-up” does not account for the effect of time. The reporting of rates can 
avoid the incorrect conclusion made from analysis of final visual acuity. 
Final visual acuity results were reported as rates, and life table (Kaplan-Meier) 
were generated.  The most appropriate ways to report visual acuity outcomes 
are rates falling below given thresholds, such as  6/15 or worse or (6/60) or 
worse, or as a doubling of the visual angle. However survival analyses also 
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lead to overestimating of event rate because the event rate (ie end point) was 
recoverable. For example, loss of four lines of visual acuity due to macular 
oedema is recoverable, in contrast to an event from which one could not 
recover, such as death. In my study I only used survival analysis when there 
was evidence of permanent visual loss. This condiserably decreased the 
number of subjects and hence power to detect significant difference.  
 
2.1.2.11 Bilateral eye disease 
Another problem in reporting is that the two eyes of a single patient often are 
linked (i.e. behave more similarly than chance alone), so reporting all eyes is 
statistically problematic because it violates the basic principle of statistical 
analysis that events are independent. The problem can be addressed by 
appropriate analyses that correct for linked events such as generalized 
estimating equations. Simpler solutions were used, however. Firstly I analyzed 
the results of “involved eye/s” (worst eye) and the results of the “better eye” 
(e.g., the eye with better acuity). This approach gave an estimate of what 
happened to each eye with disease. Secondly I analyzed what happened to 
patient because of the disease or genotype and this included analysis like best 
corrected visual acuity with both eyes open or in other words visual acuity of 
better eye. (BEVA) 
 
2.1.2.12 Outcomes Reporting 
To report the anterior chamber or vitreous activity, improvement in the 
inflammation was defined as either a two-step decrease in the level of 
inflammation or a decrease to “inactive,” and worsening of the inflammation 
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was defined as either a two-step increase in the level of inflammation or an 
increase to the maximum grade. This reporting system is based on the 
recommendations by International Uveitis Study Groups. (Jabs, Nussenblatt, 
and Rosenbaum 2005) 
2.1.2.12.1 Remission: 
 Term remission was reserved for inactive disease for at least 3 months after 
discontinuing all treatments for eye disease 
2.1.2.12.2 Steroid Sparing:  
Reduction in the dose of prednisone to 10 mg per day or less (or its equivalent 
for other corticosteroids) while maintaining inactive uveitis was considered 
successful corticosteroid sparing.  
2.1.2.12.3 Intensity of Uveitis:  
Amount of visual impairment was used to report intensity of the disease. It was 
defined as amount of visual impairment during the episode of inflammation and 
attributed directly to the inflammation or macular edema. Since it was a 
retrospective study this VA assessment gave a crude indirect estimate of 
intensity of inflammation.  It was graded into  
a) mild to moderate (doubling of visual angle from base line 
b) and severe (quadrupling  of visual angle from base line)   
2.1.2.12.4 Response to treatment  
The long term use of systemic steroids or use of second line immuno-
suppressants, are indirect measure of severity of disease. It also means failure 
of treatment to control the inflammation. However it should be noted that some 
times second line of immuno-suppressants are used as steroid sparing agents 
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(to prevent side effects of steroids). While considering the use of second line 
immuno-suppressants as an indirect measure of severity or failed response to 
steroids, it was made sure not to include their steroid sparing role. This was 
done by proper history taking from patients and from entries in the clinical notes.  
Response to treatment was graded depending upon how quickly and effective 
the initiation of treatment controlled the acute episode of inflammation  
 
 
2.1.3 SNP selection 
 
In the present work, I have studied the contribution of the cytokine and 
chemokine genes in susceptibility and severity of PSU using genetically 
homogeneous Caucasian populations. I employed the candidate pathway 
approach, taking advantage of its high power of detection of weak associations. 
I mainly studied functional SNPs so that the relation between the phenotype 
and genotype could be correlated more logically. Gene haplotypes were re-
constructed as wells. To increase the likelihood that a candidate gene would 
harbour the variations relevant to traits, I studied a wide variety of information, 
including previous genetic studies, animal models, and knowledge of biologic 
pathways.   
As suggested by the Complex Trait Consortium and discussed in chapter 1, a 
candidate gene should meet more than one of these seven criteria (Abiola et al. 
2003): 
1. Polymorphisms in either coding or regulatory regions have been found. 
2. Its function has been linked to the quantitative trait being analyzed. 
3. Its function has been tested in vitro. 
4. Its function has been tested in transgenic animals. 
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5. Its function has been tested in knock-in animals. 
6. Its function has been tested by mutational analysis. 
7. A homologous quantitative traits loci for the same phenotype in another 
species has been found. 
Since candidate gene approaches focus on genes that are selected because of 
a priori hypotheses about their role in the phenotype, rather than rely on 
markers prior knowledge is foremost important (Tabor, Risch, and Myers 2002).  
First of all extensive literature search was done to get, up to date knowledge of 
biological pathways involved in the pathogenesis of immune mediated uveitis. 
Since the main focus was on cytokine and chemokine genes, involvement of 
these molecules in uveitis was studied by gathering original research work from 
pubmed, and ImmPort (The Immunology Database and Analysis Portal). This 
included studies in transgenic and knock-out animals, and human in-vivo and 
in-vitro studies.  Once the candidate genes were selected online databases 
were looked to identify functional polymorphisms in these genes. The following 
Table 2-4 lists some available public resources from where I gathered the main 
information about the functional SNPs. Researchers should use different 
sources because limiting their resources to one database would miss a great 
deal of information. (Marsh, Kwok, and McLeod 2002)
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Table 2-4: Publically available internet sources for SNP studies 
Name URL Description 
SNPper http://snpper.chip.org/bio/snpper-enter  The Children's Hospital Informatics Program (CHIP) at Children's 
Hospital in Boston serves as the bioinformatics core for several 
national genomics investigations. Primarily interests in genes of the 
innate immunity pathway in humans. 
GeneSNPs http://www.genome.utah.edu/genesnps  Operated by the University of Utah, this site contains information 
about SNPs resulting from the US National Institute of Environmental 
Health’s initiative to understand the relationship between genetic 
variants and response to environmental stimuli. 
The genetic annotation 
initiative 
http://cgap.nci.nih.gov/GAI/ A National Institutes of Health-operated site that contains information 
on candidate genes related to cancer and tumour genesis. 
dbSNP http://www.ncbi.nlm.nih.gov/SNP  A more comprehensive NIH-operated database containing 
information on SNPs with broad applicability in research. 
HUGO mutation database 
initiative 
http://www.hgvs.org  Maintained by the Human Genome Organization (HUGO), this 
database provides access to information about human mutations.  
Human SNP database 
 
http://www-
genome.wi.mit.edu/SNP/human/index.html  
Managed by the Whitehead Institute for Biomedical, this site contains 
information about SNPs collected by the Whitehead projects. 
Gene Canvas http://www.ecgene.net/genecanvas/  A database of cardiovascular candidate genes and their 
polymorphisms managed at INSERM, France. 
ALFRED http://alfred.med.yale.edu/alfred/index.asp Supported by the US National Science Foundation, this site provides 
data on different populations in order to enhance their differences in 
frequency and to facilitate the study of haplotypes 
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I also studied few non- functional SNP. There were two main reasons to study 
the non-functional SNPs 
1) Either non-functional SNPs in candidate genes were found to be associated 
with immune mediated disease in the medical literature 
2) Or Non-functional SNPs were in a well defined haplotypes that has been 
associated with immune mediated diseases. 
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2.2 Laboratory Methods 
2.2.1 DNA Extraction 
DNA was extracted from peripheral blood using modified high salt method 
(Bunce, Fanning, and Welsh 1995) or with commercial kits (Qiagen UK Ltd, 
UK) according to the manufacture’s instructions 
2.2.1.1 Modified high Salt method 
Eight mls of peripheral blood, collected in vacutainers containing tri-sodium 
citrate as anticoagulant, were transferred to a 15 ml polypropylene tube 
(Beckton Dickenson, UK). Blood samples were centrifuged at 2500 rpm for 20 
minutes at room temperature to separate blood components. The buffy coat of 
white blood cells was aspirated from the top of the red blood cells and was 
placed into a fresh 15 ml tube. Ten mls of red cell lysis buffer  were added to 
remove erythrocytes contaminating the white blood cells .Tubes were inverted 
several times and were left at room temperature for 15 minutes or until 
complete haemolysis was evident. Samples were then centrifuged at 2500 rpm 
for 20 minutes to pellet the WBC. The supernatant was discarded into Hycolin 
and white cell pellets were washed with red cell lysis buffer. Pellets, at this 
stage, were either stored at –20 °C for future DNA extraction or the DNA was 
immediately extracted. The DNA extraction involved re-suspension of the WBC 
pellet in three mls of nuclei lysis buffer. The proteins were then precipitated by 
adding of 1 ml of 6 M NaCl and separated from the DNA by adding 2 mls of 
24:1 Chloroform-Iso-amyl alcohol. Samples were agitated until a homogenous 
milky solution was formed and were centrifuged at 3000 rpm for 30 minutes. 
After the centrifugation, three visible phases were evident: A lower phase 
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containing chloroform and dissolved lipids and lipoproteins, an interface of 
precipitated proteins and cell debris, and an upper phase containing DNA from 
the lysed WBC. The upper phase, approximately 3 mls, was transferred into a 
new tube and 10 mls of an absolute ethanol were added. The tubes were 
inverted several times resulting in the precipitation of DNA. The DNA was 
transferred into a sterile 1.5 ml tube and left to air dry for 30 minutes to allow 
evaporation of the excess ethanol. The DNA was then re-suspended in an 
appropriate amount of sterile distilled water and was stored frozen at –20 °C in 
aliquots until required. 
2.2.1.2 Qiagen Kit DNA extraction 
Ten mLs of peripheral venous blood were collected for DNA extraction in all 
patients and controls. Genomic DNA was extracted from EDTA-chelated 
peripheral whole blood, with commercial kits (Qiagen UK Ltd, UK) according to 
the manufacture’s instructions. Briefly, 500 µL of QIAGEN Protease was 
pipetted into the bottom of a 50 mL centrifuge tube and 10 mL of blood was 
added and mixed briefly. A further 6 mL Buffer AL® (red cell lysis buffer) was 
added and mixed thoroughly by vortexing. The mixture was then incubated at 
70oC for 10 min. 10 mL of ethanol (96-100%) was added to the sample and 
mixed again by vortexing. Solution was then transferred onto the QIAamp Maxi 
column® placed in a 50 mL centrifugation tube and centrifuged at 3000 rpm for 
3 min. The filtrate was discarded and 5mL of Buffer AW1® was then added to 
the QIAamp Maxi column® and centrifuged at 5000 rpm for 1 min. A further 5 
mL of Buffer AW2® was added and the mixture centrifuged at 5000 rpm for 15 
min. The QIAamp Maxi column® was then placed in a clean 50 mL 
centrifugation tube and 1mL of Buffer AE® or distilled water was then added by 
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pipetting directly onto the membrane of the QIAamp Maxi column®. This was 
incubated at room temperature for 5 min and centrifuged at 5000 rpm for 5 min. 
The filtrate which then contained the extracted DNA was stored in tubes at -
20oC. 
2.2.1.3 PicoGreen Assay for DNA Quantitation 
The methodology for genotyping used in this study is highly dependent on the 
DNA concentration. Therefore, a reliable method for DNA quantification is 
required. PicoGreen (PG) (Molecular Probes, NL) is a fluorochrome that 
selectively binds to double strand DNA (dsDNA). It has an excitation maximum 
at 480 nm and an emission peak at 520 nm. There is a little background 
interference as the free dye does not fluoresce, but upon binding to dsDNA it 
exhibits a more than1000-fold fluorescent enhancement. This method has been 
found to be more accurate than the optical density method and it is not affected 
by ssDNA or RNA (Blotta et al. 2005) (Ahn, Costa, and Emanuel 1996)  
The PG lambda dsDNA stock solution, stored in darkness, was used to 
generate a standard curve as outlined in Table 2-5. The working solution was 
prepared by diluting PG stock 1:200 with 2 x TE (Tris-HCL EDTA) by mixing 
100 µL 20 x TE, 895 µL dH2O and 5 µL PG. 
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Table 2-5  Preparation of standards for PG quantification 
Final Standard 
Concentration 
Volume of known 
standard 
Volume of dH2O 
(A) 2000 ng/ml 40µl of stock (100 µg/ml) 1960 µl 
(B) 1000 ng/ml 500µl of A (2000 ng/ml) 500 µl 
(C) 500 ng/ml 500µl of B (1000 ng/ml) 500 µl 
(D) 200 ng/ml 50µl of A (2000 ng/ml) 450 µl 
(E) 50 ng/ml 50µl of C (500 ng/ml) 450 µl 
(F) 5 ng/ml 50µl of E (50 ng/ml) 450 µl 
(G) 0 ng/ml 0 500 µl 
(H) Blank   
 
DNA samples that were needed to be quantified were diluted 1:250 in distilled 
water (i.e. 2 µL DNA in 498 µL dH2O). Ten µL of DNA standards were added to 
wells A1 to A8 in a 96 well PCR plate (Corning International, NL), as set out in 
Figure 2-1, and 10 µL of each diluted DNA sample were added to the remaining 
wells. A further 10 µL of PG solution was then added to each well and the plate 
was briefly centrifuged. 
Plates were analysed by the Lambda FLUORO 320 plus fluorimeter, with 
kinetiCalc4 (KC4) analysis software (Bio-Tek Instruments Inc., Vermont USA). 
The KC4 software, from the average Fluorescent Unit Count (AFU) of the DNA 
standards, constructed the standard curves (Figure 2-2). The DNA 
concentration of the unknown samples was determined by reading off the 
standard curve using KC4. The concentration was then multiplied by the 
dilution factor, which was 500. 
Extracted DNAs were re-checked for quality by gel. Figure 2-3 shows an 
example for SSc DNA run in gel and the concentration of PG. 
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Figure 2-1 96 well plate layout 
 
 
Figure 2-2 Standard fluorescence-DNA concentration curve generated by lambda DNA 
quantification using PicoGreen 
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Figure 2-3: DNA quality evaluation. 
An example of using gel to test DNA, after extraction and PicoGreen measurement. 48 DNA samples  
from control population  
 
 
 
 
NO ng/uL Volume 
µL 
Gel 
Quality 
1135 274 250 Good 
1193 73 200 Good 
1200 113 350 Good 
1205 282 500 Good 
1221 72 300 Weak 
1230 252 50 Good 
1233 100 400 Weak 
1241 70 400 Weak 
    
1242 125 500 Good 
1262 44 1000 Weak 
1263 90 200 Weak 
1289 27 1000 Weak 
1314 476 350 Good 
1363 136 400 Bad 
1400 69 450 Weak 
1478 261 450 Good 
    
1537 196 400 Good 
1580 550 300 Bad 
1593 550 500 Good 
1605 311 450 Good 
1645 508 250 Good 
1677 550 500 Good 
1693 19 500 Bad 
17520 550 400 Good 
 
NO ng/uL Volume 
µL 
Gel 
Quality 
1805 2.7 250 Bad 
1814 449 400 Weak 
1840 470 500 Good 
1874 248 400 Good 
1879 259 200 Good 
1918 468 300 Good 
1953 418 150 Good 
28 129 200 Good 
    
134 193 200 Good 
510 393 150 Good 
904 366 400 Good 
983 306 100 Good 
17 70 100 Weak 
123 186 750 Good 
34 0 100 Bad 
58 390 100 Good 
    
69 337 100 Weak 
101 85 400 Weak 
101d 435 500 Good 
110 72 500 Weak 
29 223 400 Good 
116 273 500 Good 
118 198 500 Good 
118d 447 300 Good 
DNA quantification for 
sample in the 1st row of the 
above photo 
DNA quantification for 
sample in the 2nd row of the 
above photo 
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2.2.2 SNP Genotyping Methods 
 
2.2.2.1 SNP Analysis Using SSP-PCR 
SNP is a wide range term that includes the nucleotide substitutions, the 
insertions and the deletions. SSP-PCR can be used to genotype most SNP 
types with two SSP reactions giving an accurate representation of the genotype 
at a given locus within three hours. Also, large deletions can be genotyped 
sometimes by using SSP-PCR (Collins et al. 2002) (Spagnolo et al. 2003).  
SSP-PCR involves designing specific primers that will or will not allow 
amplification using the 3’-mismatch principle. For a single locus, two different 
PCR reactions detect two allelic variants: One containing a specific primer 
complementary to one variant, and the other containing a specific primer 
complementary to the other variant in conjunction with a consensus primer. The 
amplification of DNA will only occur if the 3’ nucleotide of the primer matches 
the 3’ nucleotide of the DNA target, allowing the DNA polymerase to bind to the 
target and amplify the desired sequence. (Figure 2-4) Any amplified DNA 
segments can be visualized by electrophoresis  
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Figure 2-4 Diagram shows SSP-PCR steps 
Adding A & G specific primer into a single reaction will lead to three possible outcomes 
depending upon which allele matches, as shown in gel photograph. The subject may be either 
homozygous for A allele DNA 1, homozygous for G allele DNA 3 or heterozygous DNA 2.  
 
 
2.2.2.1.1 Primer Design for SSP-PCR 
I designed all chemokine SNPs primers reported in this thesis for this method. 
The sequences and variations of the genes of interest were found through a 
variety of sources, including journals and on-line genomic databases. On line 
databases such as the SNPper database http://snpper.chip.org/bio/snpper-
enter and the university of Utah Gene SNPs database 
http://www.genome.utah.edu/genesnps/ were used in this study. All primers 
were designed to work under the same amplification procedures. For this 
reason, a set of primer design rules had to be established. Criteria of primer 
A 
G 
One Consensus  
Two specific primers 
5’ 3’ 
5’ 3’ 
Genomic DNA extraction 
DNA amplification using SSP 
       
Matched
  
 
Mismatched 
A G 
DNA1 
Gel 
Control bands 
Gel Photograph 
DNA1 
Homozygous for 
A allele 
DNA2 
Heterozygous 
DNA3 
Homozygous for 
G allele  
A  G A  G A  G 
Specific bands 
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design were; a length of 19 to 25 bases, a salt adjusted melting temperature 
(Tm) of 58 to 61 ˚C, a GC content of 45 to 55 % and with no secondary 
structures, for example, hairpin loops (Table 2-6 ). The specificity of primer 
product were tested against ladder control with known product size and in 
some cases the primer were used to genotype DNA sample which has known 
genotype. 
Table 2-6 General criteria for primer design 
 
The FastPCR programme by Ruslan Kalendar, University of Helsinki, Finland, 
(www.biocenter.helsinki.fi/bi/programs/fastpcr.htm) was used to calculate the 
primers Tm and GC content and to check for primer dimers and hairpin 
Allele Specific and Consensus Primers Criteria 
• Tm ~ 60 ˚C 
• GC content 45 - 55 % 
• Primer length = 19 - 25 bp 
• No hairpins 
• No primer dimmer 
• Can be either forward or reverse 
1 General Considerations 
• If possible avoid long GC stretches and primers longer than 21 
bases.  
• 3` mismatches are the critical ones. A mismatch within the first three 
nucleotides of a primer (from 3` end) is normally enough to ensure 
no amplification. Mismatches in the second half of the primer will 
under stringent conditions ensure no amplification, but may weakly 
amplify so it is better to avoid these. 
• Download the genomic DNA sequence (not mRNA) that contain the 
polymorphic site and highlight your primers. 
• If the specific primer is a sense primer then your consensus for that 
primer should be anti-sense and vice versa. 
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formation. In addition, the online program Oligonucleotide Properties Calculator 
(http://www.basic.northwestern.edu/biotools/oligocalc.html) was used to confirm 
the estimated Tm and GC content. Once designed, primer sequences used in 
SSP-PCR genotyping were screened against BLAST program from the NCBI 
http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST program has the capacity to 
compare the primer sequences with a comprehensive catalogue of all the 
known human DNA sequences. This process minimizes the possibility of the 
primers annealing to sites of non-specific interest or mis-priming during PCR 
amplification. 
Control primers were added to the reaction and amplified simultaneously with 
each PCR in order to confirm that PCR reaction was successful. For allele 
specific amplicons between 250 – 400 bp, the control primers termed 63/64 
(which give two bands sizes on a gel of approximately 650 and 1300 bp each of 
HLA-DRB1 intron 3) were used at a concentration of 2 µg/mL: 
63: 5’- TGC CAA GTG GGA CAC CCA A- 3’ 
64: 5’- GCA TCT TGC TCT GTG CAG AT - 3’ 
For amplicons size between 400 – 950 bp, control primers termed 210/211, 
which gives a 249bp amplicon from the Adenomatosis Polyposis Coli gene, at a 
concentration of 5 µg/ml: 
210: 5’- ATG ATG TTG ACC TTT CCA GGG - 3’ 
211: 5’ - TTC TGT AAC TTT TCA TCA GTT GC - 3’  
 
2.2.2.1.2 Primer Titration 
 
Generally, PCR reactions are optimised by adjusting cycling conditions and 
magnesium concentration. However, the SSP-PCR setup used in this study 
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includes several PCR reactions run simultaneously in the same plates using 
the same PCR conditions including the magnesium concentration. Therefore, 
the only parameters that can be altered are the primer concentrations. Specific 
and consensus primers were, therefore, experimentally titrated to obtain the 
optimal working concentrations to avoid false positive and false negatives. 
Depending on the quantity of PCR end product produced in the initial tests 
(shown by the strength of the bands seen on the gel), either an upward or a 
downward primer titration is performed. Altering specific and consensus 
primers have different effects. Increasing the concentration of specific primers 
will increase the amount of specific product, whereas increasing the 
concentration of consensus primers may increase both the amount of specific 
product and the amount of mis-primed product. Therefore, the ratio of the 
concentration of specific to consensus primers is important. 
To optimise primer concentrations, titration on 10 DNA samples were 
performed. Five µL stock specific and consensus primers (at 2000 µg/ml) were 
added to one ml primer mix (10 µg/ml) to prepare the primer master mix. PCR 
amplification was performed using this primer master mix. Based on end 
product results further primer mixes of higher or lower concentrations were 
made. Probable homozygous and heterozygous samples were identified for 
use in the subsequent optimisation experiments.  
For example, Table 2-7 shows a downward primer titration. 2.5 µL of each 
allele-specific primer were then added into five rows of 96-well plate, followed 
by adding 2.5 µL of consensus primers. The final primer volume is five µL. 
Figure 2-5 shows the primer titration for MCP-1 2518 polymorphisms and the 
optimum concentration used for genotyping. 
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Table 2-7 Grid showing layout of 96-well plate for downward primer titration 
2.5 µL of each allele-specific primer were added into five rows of 96-well plate, followed by adding 2.5 
µL of consensus primers. The final primer volume is five µL. Concentrations used here is an example. 
Depending on the strength of the bands seen on the first primer test, concentrations can be increased or 
decreased. 
 
          Specific 
Cons 
Allele 
1 
Allele 
2 
Allele 
1 
Allele 
2 
Allele 
1 
Allele 
2 
Allele 
1 
Allele 
2 
Allele 
1 
Allele 
2 
Volume used to 
prepare primer mix 
 
10 
 
10 
 
8 
 
8 
 
6 
 
6 
 
4 
 
4 
 
2 
 
2 
 
Final volume 
(µL) in 1 ml 
primer mix 
 
5 
 
5 
 
4 
 
4 
 
3 
 
3 
 
2 
 
2 
 
1 
 
1 
10 5           
8 4           
6 3           
4 2           
2 1           
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Figure 2-5 SSP-PCR primer titration experiment  
 
Figures in the table are volume of allele specific primer/ consensus primers in uL per 1 mL 
primer mix. Panel A shows an upward primer titration using increasing specific primers. 
Columns represent downward titration using decreasing consensus primers. Note the false 
positive reactions on the right hand side of the gel as the primer concentration increase. The 
highlighted concentrations were chosen as the optimum concentration. Panel B shows the 
optimized primer concentrations tested on six samples: two heterozygotes, two homozygotes 
for the first allele and two homozygotes for the second allele. There is clear discrimination  
between all three genotypes. 
 
 
          Specific 
Cons 
 
Allele 
1 
 
Allele 
2 
 
Allele 
1 
 
Allele 
2 
 
Allele 
1 
 
Allele 
2 
Volume used to prepare primer mix 8 8 10 10 12 12 
 Final volume (µL) in  
1 ml primer mix 
 
4 
 
 
4 
 
5 
 
5 
 
6 
 
6 
14 7 4/7 4/7 5/7 5/7 6/7 6/7 
12 6 4/6 4/6 5/6 5/6 6/6 6/6 
10 5 4/5 4/5 5/5 5/5 6/5 6/5 
8 4 4/4 4/4/ 5/4 5/4 6/4 6/4 
6 3 4/3 4/3 5/3 5/3 6/3 6/3 
 
 
Panel A 
Panel B 
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2.2.2.1.3 SSP-PCR Reactions 
 
Supplied primers (Sigma Genosys, UK) at concentration of 0.2 µM were re-
suspended in a sterile distilled water (not deionised) (Baxter, UK) to a 
concentration of 2000 µg/ml. Each primer mix comprised of appropriate amount 
of each specific and consensus primers, control primers (see primer sections 
2.2.4.1 and 2.2.4.2 for volumes) and cresol red indicator (Sigma, Poole, UK) 
(Appendix A), prepared in a sterile distilled water (Baxter, UK). Cresol red 
undergoes a pH related colour change from orange to purple when adding the 
acidic DNA. 
PCR-SSP amplifications were carried out using 96, 192 or 384-well thermal 
cyclers MJ Research 96V or PTC200 machines (GRI, Braintree, UK). The DNA 
was amplified in 13 µl reaction mixtures consisting of 5 µl of primer mix and 8µl 
PCR reaction mix: 1X PCR Buffer (Bioline) (Appendix A); 2 mM MgCl2; 200 µM 
of each dNTP (dATP, dGTP, dTTP, dCTP); approximately 0.08 µg of genomic 
DNA; and 0.175 units of Taq polymerase (Bioline, UK)). Reaction mixtures 
were dispensed under 10 µl of mineral oil (Sigma, Poole, UK) to prevent 
evaporation. PCR-SSP thermal cycling parameters are shown in Table 2-8 
Table. After PCR amplification, ten mls of orange G loading buffer (Appendix A) 
was added to each sample. PCR amplicons were identified by gel 
electrophoresis. 
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Table 2-8 Thermal cycling parameters for SSP-PCR 
 
No. of cycles 
 
Temperature (°C) 
 
Duration (seconds) 
 
1 
 
96 
 
60 
 
 
 
5 
 
96 
70 
72 
 
20 
45 
25 
 
 
 
21 
 
96 
65 
72 
 
25 
50 
30 
 
 
4 
96 
55 
72 
30 
60 
120 
 
 
1 
 
20 
 
30 
 
 
2.2.2.1.4 Agarose Gel Electrophoresis 
Amplicons were loaded into the wells of 2% agarose gels (Appendix A)(Bioline, 
UK) with 0.5X Tris Borate EDTA (TBE) buffer (Sigma, Poole, UK) and were 
stained with 0.14 µg/ml of ethidium bromide (Sigma, Poole, UK). Band 
separation was done by electrophoresis, which was carried out at 200 Volts for 
20 minutes. Gels were transferred onto a transilluminator and photographed on 
Polaroid film using the Polaroid MP4 Camera system over ultraviolet light (320 
nm). 
The stringent conditions outlined in this section ensured amplification using 
SSP-PCR occurred only with an exact primer match. Therefore, the presence 
of a specific allele was scored by observing an amplicon of the expected size in 
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association with a control PCR product. The absence of a specific allele was 
scored by observing only a control PCR product (Figure 2-6.). 
 
Figure 2-6 A typical gel photograph of SSP-PCR results 
 
 
 
All reactions in this photo were run with control primers 63/64. The allele specific product is formed 
only when that allele is present in the DNA sample. If the product is formed in both reactions, the 
individual is heterozygous, and if only in one reaction, the individual is homozygous for that allele. False 
positive reactions can occur for a number of reasons, such as mis-priming due to presence of excess 
primer or DNA contamination. 
 
 
 
 
 
 
True positive allele specific products 
 
 
Control bands 
DNA 
1 
DNA 
2 
Failed reaction 
False positive 
Failed reaction 
Spill over of PCR product from the 
neighbouring reaction lane during loading 
    1       2        3       4         5       6             7       8        9       10      11     12   
    1       2        3       4         5       6             7       8        9       10      11     12   
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2.2.2.2 SNP Analysis using 5’Nuclease Activity Assay  
 
I used TaqMan® 5’Nuclease Activity Assay, to study the SNPs in cytokine 
SNPs. 5’Nuclease Activity Assay was first described by Holland et al. in 1991. 
(Holland et al. 1991) The chief attributes of 5’Nuclease assay is that it is 
completely homogenous. After mixing the sample and the reaction components, 
the assay is run in a closed compartment with no post PCR processing step. 
Results are obtained by simply measuring the fluorescence of the completed 
reaction. By eliminating post PCR processing, allelic discrimination with 
flourogenic probes reduces the time of analysis, labour , supply cost of post-
PCR steps, reduces the risk of cross-over contamination and minimizes source 
of error. The assay has a sensitivity of PCR so that a minimum amount of 
genomic DNA is required. The use of endpoint fluorescence measurements 
maximize throughput.  
In the 5' nuclease PCR array, a hybridization probe included in the PCR is 
cleaved by the 5' nuclease activity of Taq DNA polymerase only if the probe 
target is being amplified. By using flourogenic probe, first synthesized by Lee et 
al. in 1999 (Lee, Connell, and Bloch 1993) cleavage of the probe can be 
detected without post PCR processing. The flourogenic probe consists of an 
oligonucleotide labelled with both a fluorescent reporter dye and a quencher 
dye. In the intact probe, proximity of the quencher reduces the fluorescence 
signal observed from the reporter dye due to Foster resonance energy transfer 
(FRET). Cleavage of the flourogenic probe during the PCR array liberates the 
reporter dye, causing an increase in fluorescence intensity. A Detection System 
measures this increase in fluorescence during the thermal cycling of PCR, 
providing "real time" detection of PCR product accumulation. 
 120 
For a Bi-allelic system, probes specific for each allele are included in the PCR 
array. The probes can be distinguished because they are labelled with different 
fluorescent dyes (FAM™ and VIC™). A mismatch between probe and target 
greatly reduces the efficiency of probe hybridization and cleavage. Thus, 
substantial increase in the FAM™ or VIC™ fluorescent signal indicates 
homozygosity for the FAM™ or VIC™ specific alleles. An increase in both 
signals indicates heterozygosity. 
 
ABI TaqMan® Allelic discrimination assay 
  
The TaqMan® Allelic Discrimination assay employs this probe technology that 
exploits the 5´-3´ nuclease activity of AmpliTaq Gold® DNA Polymerase to 
allow direct detection of the PCR product by the release of a fluorescent 
reporter as a result of PCR. This PCR system is optimized for yield. 
AmpErase® UNG is required for the prevention of PCR product carryover 
(Longo, Berninger, and Hartley 1990). 
The AmpliTaq Gold enzyme cleaves the TaqMan® probe with its 5´–3´ 
nuclease activity. The reporter dye and quencher dye are separated upon 
cleavage, resulting in increased fluorescence of the reporter (Figure 2-7). The 3´ 
end of the TaqMan® probe is blocked to prevent extension of the probe during 
PCR. Below is the brief account of all the reagents used in TaqMan® assay 
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Figure 2-7: 5´–3´ nuclease activity of DNA Polymerase during one phase of PCR   
The allele-specific labelled probe is located directly over the single nucleotide polymorphism of 
interest. During polymerase chain reaction, the reporter is cleaved from the probe and, at the 
endpoint, the genotype is determined according to the ratio of fluorescence attributable to each 
fluorophore 
 
 
2.2.2.2.1 PROBES 
The ABI probes have an exclusive MGB (minor groove binder) moiety added to 
the probe to increase the stability and specificity of probe hybridisation. 
Incorporating an MGB molecule allows TaqMan® Probes to be much shorter. 
Without the MGB, AT-rich probes often need to be over 30 and sometimes over 
40 bases long to satisfy amplicon design guidelines. Longer probes perform 
relatively poorly compared to shorter MGB equivalents. TaqMan® MGB probes 
are typically between about 13 and 20 bases long; approximately half the 
length of standard probes. 
MGB is a small crescent-shaped molecule that fits snugly into the minor groove 
of duplex DNA. In TaqMan® probes, the MGB group is attached at the 3' end 
along with the quencher dye. When the TaqMan® probe hybridizes, the MGB 
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stabilizes annealing by folding into the minor groove of the DNA duplex created 
between the probe and the target sequence. Stabilization is much more 
effective when the duplexes are perfectly matched (i.e. when there are no 
sequence mismatches).  
2.2.2.2.2 Dyes 
 
The quencher in TaqMan® probe is non-fluorescent quencher (NFQ) dye 
(sometimes called a “dark” quencher). A non-fluorescent quencher is 
essentially a chromophore that acts as the energy transfer acceptor from the 
reporter molecule that does not emit a detectable fluorescent signal of its own. 
The advantage is that a less complicated signal with lower fluorescent 
background is emitted from the reaction. This improves spectral discrimination 
and makes data interpretation easier. The NFQ used is a proprietary molecule 
that is effective over a broad wavelength range.  
The reporter dyes used in TaqMan® system are FAM™ and VIC™. FAM™ is 
6-carboxyfluorescein dye and emits blue light. VIC™ is 4-dichloro-6- 
carboxyfluorescein dye and emits green light. NFQ quenches the current range 
of reporter dyes (FAM™, VIC™ and TET™ dyes) effectively. 
The process of release of fluorescent dye occurs in every cycle and results in 
increase in fluorescence for each of the FAM™ and VIC™ reporters. The 
increase in fluorescence is measured, and is a direct consequence of target 
amplification during PCR.  
Both primer and probe must hybridize to their targets for amplification and 
cleavage to occur. The fluorescence signals are generated only if the target 
sequences for the probes are amplified during PCR. Because of these 
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requirements, non-specific amplification is not detected. (Lee, Connell, and 
Bloch 1993) 
 
The Sequence Detection Systems from Applied Biosystems are used to 
Detection measure the increase of reporter fluorescence following PCR. 
Reporter signals are normalized to the emission of a passive reference: 
 
Rn          =      Emission Intensity of Allele 1 Reporter 
(Allele1)  Emission Intensity of Passive Reference 
 
 
Rn          =  Emission Intensity of Allele 2 Reporter 
(Allele2)  Emission Intensity of Passive Reference 
 
 
 
2.2.2.2.3 Primers and probes designing.  
Primers and TaqMan® probes were designed using Primer Express software 
(version 2.0; sequences) and synthesised and supplied by Applied Biosystems 
UK. The reporter dyes chosen were 6-FAM™ and VIC™.  Applied Biosystems 
recommends the general use of TaqMan® MGB probes for allelic 
discrimination assays, especially when conventional TaqMan® probes exceed 
30 nucleotides. 
2.2.2.2.3.1 TaqMan® MGB Probe Design Guidelines 
The manufacturer guidelines were followed to design the probes: 
1)  Probes with a guanine residue at the 5´ end of the probe were avoided. 
A guanine residue adjacent to the reporter dye will quench the reporter 
fluorescence, even after cleavage. 
2) Probes with a Primer Express software–estimated Tm of 65–67 °C were 
selected. 
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3)  MGB probes were made as short as possible without being shorter 
than13 nucleotides. 
4)  Runs of an identical nucleotides were avoided. This is especially true for 
guanine, where runs of four or more should be avoided. 
5)  Polymorphic site was positioned in the central third of the probe. The 
polymorphic site can be shifted toward the 3´ end to meet the above 
guidelines; however, the site must be located more than two nucleotides 
upstream from the 3´ terminus. 
2.2.2.2.3.2 Primer Design Guidelines 
After selecting probes for the assay, primers were chosen based on the 
guidelines below. 
1) Runs of an identical nucleotides were avoided. This is especially true for 
guanine, where runs of four or more should be avoided. 
2)  The Primer Express software–estimated Tm for the primers was set 58–
60 °C. 
3)  Guanine + cytosine content were kept within 20–80%. 
4)  It was made sure the last five nucleotides at the 3´ end contain no more 
than two guanine + cytosine residues. 
5)  The forward and reverse primers were placed as close as possible to the 
probe without overlapping it. 
 
2.2.2.2.4 Premixes 
Though custom made Probes and primers were made for most of the cytokine 
SNPs, some of the SNPs were detected by using pre-made assays supplied by 
Applied Biosystems. TaqMan® SNP Genotyping Assays are validated primer 
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and TaqMan® MGB probe sets for the detection of human SNPs. Each product 
is delivered as pre-mixed primers and TaqMan® MGB probe(s) at a 20X 
concentration. (Proprietary formulation) 
 
2.2.2.2.5 Master Mix 
The TaqMan® Universal PCR Master Mix was used for real-time or plate read 
(endpoint) detection of DNA. The mix is optimized for TaqMan® reactions and 
contains AmpliTaq Gold DNA Polymerase, AmpErase UNG, (uridine, uracil-N-
glycosylase) dNTPs with dUTP, Passive Reference dye ROX, and optimized 
buffer Components (proprietary formulation).  The AmpliTaq Gold enzyme is a 
thermal stable DNA polymerase. The enzyme has a 5´ to 3´ nuclease activity, 
but lacks a 3´ to 5´ exonuclease activity (Holland et al. 1991).  
Prevention of PCR Product Carryover 
Treatment with uracil-N-glycosylase (UNG) can prevent the reamplification of 
carryover PCR products. This method involves substituting dUTP for dTTP in 
the Reagent Master Mix and adding AmpErase UNG to the mix prior to 
amplification (Longo, Berninger, and Hartley 1990). Products from PCR 
amplification contain uracil, and are readily distinguishable from native 
thymidine-containing DNA templates. UNG eliminate products from previous 
PCR amplifications by excising uracil residues and degrading the resulting a 
basic polynucleotide with heat. Therefore, only native nucleic acid templates 
are being PCR amplified. PCR products from previous amplifications are not 
reamplified. Misprimed, nonspecific PCR products created before thermal 
cycling are degraded, but native DNA template is not The 2-minute hold cycle 
at 50 °C is necessary for optimum AmpErase UNG clea vage of the uracil-
deoxyribose linkage. The 10-minute hold cycle at 95 °C necessary to activate 
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AmpliTaq Gold DNA Polymerase also cleaves the phosphate ester backbone of 
the PCR products that contained uracil nucleotides and reduces the AmpErase 
UNG activity substantially. Because UNG is not completely deactivated during 
the 95 °C incubation, it is important to keep the r eaction temperatures greater 
than 55 °C to prevent amplicon degradation. 
2.2.2.2.6 TaqMan® SNP Genotyping Assay Protocol 
 
Materials 
Optical 384-Well Reaction Plate 
Optical Adhesive Films  
TaqMan® Universal PCR Master Mix (stored at 4C) 
TaqMan® 10X Assay Mix (labelled probes and unlabeled primers) (stored at -
20 or -30 C) or Custom made primers and probes 
Method 
1 uL of 20ng/ul DNA template was pipetted into Optical 384-Well Reaction 
Plate for 384-well format. Reagents were added according each reaction well in 
the plate according to tables below per reaction. (Table 2-9) 
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Table 2-9 Concentrations of probes, primers and reagents for TaqMan® assay 
Reagent Volume Per Reaction Final Concentration 
DNA Template 20 ng -- 1uL of 20ng/ul  
Mol. Biol. Grade Water 1.0 - 
TaqMan® Universal 
PCR Master Mix 2.5 1X 
TaqMan® 10X Assay 
Mix 0.5 1X 
OR  
0.9 mM primers, and 0.2 
mM probes 
Variable (if more than 
0.5 then decrease water 
to make final volume of 
5uL 
 
Final Reaction Volume 
(384) 5.0 - 
 
 
Layout of 384 wells plate 
Because sample protein and fluorescent contaminants may interfere with this 
assay and give false positive results, it may be necessary to include a No 
Amplification Control well that contains the sample and no enzyme. If the 
absolute fluorescence of the No Amplification Control is greater than that of the 
No Template Control after PCR, fluorescent contaminants may be present in 
the sample.  In the 384 well plate, 8 wells contained template DNA but no 
enzyme, 8 wells just plain water, 8 wells with known Allele 1 (with enzymes and 
master mix) and 8 wells with known allele 2. (Figure 2-8) This will make allele 
calls at a 99.7% confidence level using the automated allele calling routine. 
(Manufacturer guidelines) 
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Figure 2-8: Layout of 384 wells plate. 
Shaded wells acting as reference. 
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Plate was centrifuged and then sealed with optical Adhesive seal or optical 
heat seal. 
Thermal Cycling conditions are given below: (Table 2-10) 
 
Table 2-10 Parameters for thermal cycles in TaqMan® assay 
 
Step Temperature (C)  Time (minutes) 
1 50o 2:00 
2 95o 10:00 
3 60o 1:00 
4 Go to Step 3 41 more cycles (total of 42) 
5 4o Hold 
 
Post-PCR plates were either analyzed straight away or stored for up to 48 
hours prior to reading. Plates were stored in a fridge with temperature of 4o and 
protected from light.   
 
2.2.2.2.7 Creating SDT Document for End-Point Read on ABI 7900  
 
The software that controls the ABI 7900 instrument and used for analysis is 
called “SDS 2.X”.  In order to read the fluorescence from the TaqMan® plate, 
the software needs to know what dye and dye channels to look for. Since for all 
TaqMan® assays I used FAM™ and VIC™ dyes, a template was set up to read 
all TaqMan® plates. 
In SDS software “Allelic Discrimination” programme was used. FAM™ & VIC™ 
dyes were added using “detector manager” tool. A file was thus created for a 
specific SNP. (Figure 2-9.) 
 
 
 130 
Figure 2-9 Steps used in making of TaqMan® assay file and allelic discrimination analysis 
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2.2.2.2.8 End Point Plate Read 
 
Once a new desired file was created, plate was placed in the instrument block. 
Using plate read tool the system analysed the fluorescence in less than 2 
minutes to finish whole process.  
 
Analysis of TaqMan® SNP Genotyping Assay Data 
 
 By using “analyse data” tab the analysis was shown as a graph  
The “Results” tab shows the FAM™ and VIC™ fluorescence for each well that 
was marked “Use”.  The “Y” axis is the normalized amount of FAM™ signal 
(Allele_1); the “X-axis” is the normalized amount of “VIC™” signal (Allele_2) 
Figure 2-10. 
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Figure 2-10: A typical example of allelic discrimination analysis.  
Homozygous samples for Allele 1 (Red Cluster) are along the “X-axis” with little VIC™ 
fluorescence. Homozygous samples for Allele 2 (Blue Cluster) are along the “Y-axis” with little 
FAM™ fluorescence. Heterozygous samples (Green Cluster) will be in between the two 
homozygous clusters. Negative Controls should be around the point of origin with low FAM/VIC 
fluorescence. 
 
 
 
 
 
If any samples are in between any two clusters, these samples were marked as 
“Undetermined” and whole experiment was repeated for those samples. 
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Allele 1 (FAM) 
Allele 2 (VIC) 
Undetermined Genotype 
Heterozygous Genotype 
Negative Control  
Examples of various genotype plots are given below: 
Figure 2-11 TaqMan® SNP Assay with Excellent Clustering  
Homozygous samples for Allele 1 (Red Cluster) are along the “X-axis” with little VIC™ 
fluorescence. Homozygous samples for Allele 2 (Blue Cluster) are along the “Y-axis” with little 
FAM™ fluorescence. Heterozygous samples (Green Cluster) are in between the two 
homozygous clusters. Negative Controls are around the point of origin with low FAM/VIC 
fluorescence. Note excellent clustering of alleles.  
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Fig 2.12 TaqMan® SNP Assay with Good Clustering (Dispersed but Genotype-able 
clusters) 
Homozygous samples for Allele 1 (Red Cluster) are along the “X-axis” with little VIC™ 
fluorescence. Homozygous samples for Allele 2 (Blue Cluster) are along the “Y-axis” with little 
FAM™ fluorescence. Heterozygous samples (Green Cluster) are in between the two 
homozygous clusters. Negative Controls are around the point of origin with low FAM/VIC 
fluorescence. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Allele 1 (FAM) 
Heterozygous Genotype 
Allele 2 (VIC) 
Undetermined Genotype 
 135 
Figure 2-12 TaqMan® SNP Assay with Poor Separation between VIC™ and NTC Clusters 
(Un-optimized Assay) 
Homozygous samples for Allele 1 (Red Cluster) are along the “X-axis” with little VIC™ 
fluorescence. Homozygous samples for Allele 2 (Blue Cluster) are along the “Y-axis” with little 
FAM™ fluorescence. Heterozygous samples (Green Cluster) are in between the two 
homozygous clusters. Negative Controls are around the point of origin with low FAM/VIC 
fluorescence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Allele 1 (FAM) 
Allele 2 (VIC) 
Negative Control  
Heterozygous Genotype 
Undetermined Genotype 
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2.3 Statistical Analysis 
All the statistical methods used and hypothesis tested in the thesis are 
described below. Significance testing, confidence intervals, regression models 
were all calculated by Statistical Package for Social Sciences (SPSS Version 
13.0) Chicago Illinois. It is among the most widely used programs for statistical 
analysis in social science. It is used by market researchers, health researchers, 
survey companies, government, education researchers, and others. In addition 
to statistical analysis, data management (case selection, file reshaping, 
creating derived data) and data documentation (a metadata dictionary is stored 
with the data) are features of the base software. 
2.3.1 Hypothesis Testing 
The most common ways to make an inference for the population from which 
the analyzed sample has been drawn are significance probability calculation or 
confidence interval (CI) estimation. A CI contains the result of a significance 
test, but a significance test cannot provide the confidence limit. The statistical 
tests are essentially a test of whether the confidence limits include unity. 
Each experiment starts with a null hypothesis which simply states that there is 
no difference between the two samples. A test statistics generally relies on the 
comparison with the observed distribution of what is expected if the null 
hypothesis is true. If the null hypothesis is rejected by statistical testing, the 
alternative hypothesis (the effect is not zero; there is a difference, etc.) is 
accepted. The general test statistics is as follows: 
Test statistics = (observed value - hypothesized value) / standard error of the 
observed value 
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Test statistics yield a probability of observing the value we found (or an even 
more extreme value) when the null hypothesis is true. If the statistics gives a P 
(probability of error) value of <0.05, this means that the observed value would 
have a probability of occurrence somewhere in the extreme 5% of the relevant 
distribution curve for the data and imply an unusual finding. 
In significance testing, a type I error (a false-positive finding) is considered to 
be more serious, and therefore more important to avoid, than a type II error 
(missing a positive finding). If 0.05 is the pre-determined level of statistical 
significance, this equals to reaching one incorrect conclusion (false positive) 
with no biological relevance in twenty tests. The value 0.05 is the probability of 
getting an erroneous result every time one compares two groups, which are in 
fact equivalent. This level of error can be accepted in the context of a single 
test of a prespecified hypothesis 
2.3.2 Design  
Population stratification can be thought of as confounding by ethnicity. If 
ethnicity of cases and controls are reliably known, a stratified analysis would 
eliminate this problem. However, it is the unknown stratification within the 
population that causes this undesirable effect.  Both my controls and patients 
were white Caucasians of United kingdom origin. This was simply determined 
by asking the patients about their ancestry.  
In case-control studies, ideally there should be at least one control per case. If 
the number of cases is limited and cannot be increased easily, it may be an 
idea to increase the number of control to increase statistical confidence. The 
law of diminishing returns, however, dictates that a maximum of five controls 
per one case is the limit (Coggon Rose Barker 1997). A higher control to case 
ratio will not provide further benefit and may even result in type I errors.  Since 
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PSU itself is a rare disease and recruiting ideal number of cases is always 
difficult. Hence I increased my control population as much as possible to 
increase the statistical confidence.  
 
2.3.3 Statistical Power Estimates 
Power calculations and expectation should be realistic in a genetic association 
study with a complex (multifactorial) disease. Genetic susceptibility to such 
diseases involves a large number of alleles, each conferring only a small 
genotypic risk (like odd ratio = 1.2 to 2.0), that combine additively or 
multiplicatively to confer a range of susceptibilities in interaction with 
environmental factors. Underpowered studies are one of the main reasons for 
failure to replicate an initial association study.  (Hirschhorn et al. 2002)  
Therefore, if the study is adequately powered, the chance of drawing the wrong 
conclusion is reduced. 
There are many factors that determine the power of a study: 
1. The sample size: The larger the sample size, the greater power for the 
study. However, it is important to determine the optimal sample size, 
because further increases in sample size may not increase the power, 
but only increase the cost and time of the study. 
2. The variability of the observation: The power increases as the variability 
decreases. 
3. The effect of the interest (frequency of the allele): The power is greater 
for alleles that are more common. 
4. The P value   
Recently, more factors have been reported to influence the power of 
association studies; the effect size of the susceptibility locus and the extent and 
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distribution of linkage disequilibrium in the region (Zondervan and Cardon 
2004). 
In prospective studies, the sample size calculations are performed to determine 
the number of subjects that will give the adequate power. However, in the 
retrospective studies, where the number of subjects is already given, the power 
to detect a certain difference afforded by the fixed sample size is determined. 
Since this was a study with fixed sample size, the determination of power was 
done retrospectively. Power calculations were performed using Quanto® 
Version 1.0, which is specifically designed for use in genetic studies 
Quanto®   is a program for computing either power or required sample size for 
association studies of genes, environmental factors, gene-environment (G×E) 
interaction, or gene-gene (G×G) interaction. The program is written in C++ and 
is designed to run under Windows. (Figure 2-13)Two types of outcomes are 
considered, a disease (binary) outcome and a quantitative (continuous) 
outcome.  
Quanto® uses logistic or log-linear model to calculate the effect of gene/genes 
on the disease trait. There are three genetic models to select from namely, 
dominant, recessive and log additive. Depending upon the effect of genes, 
model, and whether we are testing the association with disease or its traits and 
assuming a case control study the software was used to calculate the power of 
association.  Quanto® is freely available from the following website (Hydra). 
http://hydra.usc.edu/gxe/ 
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Figure 2-13 Quanto® programme showing gene model and effect  
Note there are three options for inheritance model selection that is Recessive, Dominant and Log 
Additive. 
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2.3.4 Multiple Testing 
The P value 0.05 is the probability of getting an erroneous result every time one 
compares two groups, which are in fact equivalent. This level of error can be 
accepted in the context of a single test of a prespecified hypothesis. The 
probability of getting at least one statistically significant result as a result of type 
I error in multiple comparisons is, however, much higher than this. This 
probability can be calculated with the formula: 
 1-(1-a)/ n  
Where n is the number of comparisons and a is the arbitrarily chosen 
significance level which corresponds to the accepted failure rate for each 
comparison. If the probability of getting the right result is 0.95 (P = 0.05) in a 
single test, it would be (0.95)20 = 0.36 in 20 tests. Thus, the probability of 
getting it wrong is 1 - 0.36 = 0.64. This is to say that, for 20 comparisons and 
the significance level of 0.05, the probability of getting at least one erroneous 
result is 0.64 (which is 0.92 for 50 comparisons). This probability is smaller 
when the significance level is lower (0.18 for 20 comparisons and the 
significance level of 0.01). This argument applies to situations when the 
multiple comparison tests are independent tests. 
To avoid a type I error, when independent multiple comparisons are carried out, 
and all genotypes examined have the same chance of being increased or 
decreased, a statistical safeguard should be applied. There is no definite limit 
for the number of comparisons that makes this necessary but it is a must if it is 
greater than 20. This is usually done by multiplying the P value by the number 
of comparisons (Bonferroni inequality method). (Bland JM, 1995) This is 
basically lowering the statistical significance level and making the statistical test 
more conservative. For small numbers of comparisons (say up to five) its use is 
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considered to be reasonable, but for larger numbers and for the multiple tests 
that are not independent (highly correlated), it is highly conservative. The 
precise correction is obtained by the formula: 
Pcorrected = 1 - (1-P) n 
Where P is the uncorrected P value and n is the number of comparisons. The 
number to use for correction is not (as frequently done) the number of alleles or 
genotypes detected in the study but the number of comparisons one or more of 
which shows a significant result. For P values of less than 0.01, this formula 
gives almost the same result as simple multiplication. If the 'corrected' P value 
is still less than the pre-determined significance level (such as 0.05), then the 
result is significant.  
There has always been a debate about what number to use in the multiplication. 
In contrast to the most common practice, this is not supposed to be just the 
number of alleles in the locus analyzed. If the allele frequencies are compared 
between patients and controls, the number of alleles is important as well as the 
number of comparisons in terms of age groups, sex groups, clinical subgroups, 
etc. In my work, if the SNP was not functional Bonferroni correction was applied 
by multiplying the p value with number of SNPs studied in that gene. In case of 
phenotypic traits, correction was done using multiple logistic regression.  
2.3.5 Data Mining 
Data mining is extracting the previous unknown, valid and actionable 
information from large databases and using that information to make critical 
decisions. KnowledgeSEEKER (KS) software (Angoss Software Corporation, 
Toronto, Canada) is a Windows based software application. Data mining is a 
key audit procedure. Genetic data and patients’ clinical data were combined in 
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an Excel database. This database was loaded in and mined using KS to 
determine whether the apparent independent variables were associated.  
There are many data tools to use in KS. For example, decision trees which 
were used to explain the relationship between several independent variables 
and a dependant variable and were used for analysis of the datasets in this 
thesis. The tree algorithm generates, for any selected node, a list of correlated 
variables from which a split can be chosen. The decision tree algorithms try to 
maximize the information gained in each split thus, KS will find the most 
significant split(s).  Additionally, a split can be forced in order to test a particular 
hypothesis. Trees were grown and variables were identified in splits using a 
stepwise linear regression until no improvement in the association was found. 
However, KS was used as a preliminary step in the analysis of databases and 
to select variables for further classical statistical analysis. 
 
2.3.6 Significance testing 
2.3.6.1 Constructing a 2x2 contingency table 
When two groups are to be compared in a case-control study, it is necessary to 
have a 2x2 contingency table cross-tabulating the frequencies. This table is 
required for significance testing, relative risk (RR) or odds ratio (OR) estimation 
and CI calculation. A contingency table may have more than two rows and 
columns (Table 2-11) but the 2x2 table approach stems from classic case-
control studies in epidemiology as the most elemental data structure leading to 
ideas of association. 
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Table 2-11: Typical 2x2 table used in the thesis, showing the association and P value 
  
Patients IN H-W Controls IN H-W GENE ID CCR2 Locus ID V64I 
  
                    
  Patients Control Genotype Differences Analysis of individual positions 
GENOTYPE Count  FREQ Count FREQ 
    
Position ID Chi2x2 p 
AA 7 0.04 30 0.12 Chi2x3 15.57 11 7.98 0.00472 
GA 59 0.34 110 0.43 p= 0.000417 12 3.91 0.04807 
GG 110 0.63 116 0.45   
  
22 12.35 0.00040 
Total 176   256             
                    
Allelic Carriage / 
phenotype                   
A  66 0.38 140 0.55     1-Carriage 12.35 0.000409 
G 169 0.96 226 0.88     2-Carriage 7.98 0.004725 
                    
                    
Allelic Frequency                   
A  73 0.21 170 0.33     Allele Freq 16.03 6.29E-05 
G 279 0.79 342 0.67           
Total 352   512             
 
2.3.7 Choice of a statistical test 
To check the statistical significance variety of tests were used depending size 
and type of variables. 
 
 
2.3.7.1 Chi Square 
The chi square test (χ2), which is based on a large sample approximation, is a 
statistical test that can be used to determine whether the observed frequencies 
are significantly different from the expected frequencies, i.e., to determine the 
differences or deviations in genotype frequencies between cases and controls. 
Results were typically compared using a chi-square with 2x3 or 2x2 
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contingency tables. Below is an example of a 2x2 contingency table. (Figure 
2-14) 
Figure 2-14: 2 X 2 contingency table 
Characteristic Cases Controls 
Present a b 
Absent c d 
 
The numbers are entered into a table and the chi square test is concerned 
whether the columns (disease states) are contingent on the rows 
(characteristics). The chi square test statistic was calculated with the formula: 
 
Where O is the observed frequency and E is the expected frequency. 
 
2.3.7.2 Yates correction  
When the Chi-squared test is used for small samples, Yates's correction may 
need to be used to make adjustments for continuity. The Chi-squared 
distribution is continuous. That means that the curve of the x2 distribution model 
is continuous without any breaks. The values we calculate in x2 are, however, 
discrete values. This is because observed frequencies vary in discrete units 
(the number of occurrences of an allele -the entries in the 2x2 table- may be 4 
or 5 but not 4.6). With degrees of freedom greater than 1 and with expected 
frequencies of at least 5 in each cell, this is not a problem as the difference 
between the statistics and the true sampling distribution is so small. For 
example, the difference between 100 and 101 is negligible (1%) compared to 
χ
2
 = ∑ 
(O – E) 2 
E 
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the difference between 4 and 5 (25%). Any difference between observed and 
expected frequencies will appear large when cell frequencies are small and 
may result in a type I error.  
The Yates's correction helps make the discrete data generated by the test 
statistics [∑ (O-E)2/E] more closely approximate to the continuous Chi-squared 
distribution. This is achieved by changing the above formula to 
[∑ (O-E -0.5)2/E]  
By doing so, the discrete data distribution and continuous data distribution are 
approximated better. This will result in a smaller calculated value of x2 and will 
reduce the risk of a type I error. In relatively large samples, this would not make 
an important difference. Most textbooks recommend that the Yates's continuity 
correction should be applied when the sample size is small or the contingency 
table contains any number less than 10. 
 
2.3.7.3 Fisher’s Exact Test 
When the Chi-squared test is used for small samples, Yates's correction may 
need to be used to make adjustments for continuity. This correction, however, 
does not remove the requirement for the expected frequencies. The expected 
frequencies in each cell (of a 2x2 table) should be at least five for the Chi 2 test 
to be reliable (note that the observed frequencies may be less than five). The 
general belief is that when there is one or more expected frequency of less 
than five, the alternative approach for significance testing is the Fisher’s exact 
test. 
The Fisher’s exact test also uses the frequencies in a 2x2 table but the 
calculations are different from that of the other significance tests. It is based on 
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the observed row and column totals. The method consists of constructing all 
possible 2x2 tables giving the same row and column totals as the observed 
data. For each table, probability for such data to arise if the null hypothesis is 
true is calculated. Then, the overall probability of getting the observed data is 
calculated. To get the probability, the probability of the observed data and all 
other probabilities for alternative 2x2 tables equal or more extreme than that of 
the observed data are added up. Calculations are mathematically very 
complex; include factorial calculations, which may be very cumbersome for big 
numbers. The Fisher’s exact test can now be applied by means of computers 
(which can cope with the calculations of factorials for large numbers) even to 
large samples. This test is essentially one-sided. To get the two-sided P value, 
if required, the P value may be doubled. 
 
2.3.7.4 Odds Ratio (OR) 
The OR is the ratio of the odds of the risk factor in a diseased group and in a 
non-diseased (control) group. (Table 2-12) OR is more appropriate for 
retrospective case-control studies. 
Table 2-12 Odds ratio table 
Groups Exposed to factor 
 Yes No 
Case a B 
Control c D 
Total a+c b+d 
 
 
 
The odds ratio was calculated as the odds of being a case in the exposed 
group divided by the odds of being a case in the unexposed group and is 
simplified to the formula below: 
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2.3.7.5 Confidence interval for odds ratio 
When a value (OR obtained from a sample) is the estimate of an unknown 
"true" value (within the population from where the sample has been drawn), 
confidence intervals CIs can be applied to them. In the case of comparing two 
groups, a CI enables the researcher to see how large the difference between 
two proportions may be, not simply whether it is different from zero.  
CIs can be calculated for different confidence levels. If a CI is calculated at a 
95% level (as usually done), 5% of the time the true population parameter will 
not be contained within the interval calculated from the sample statistics. More 
technically, it means that 95% of all samples drawn from the population will 
have the population parameter within this interval. In a way, this is the 
acknowledgement of the fact that a different sample from the same population 
may produce a different result. 
The width of the CI also gives us an idea about how uncertain we are about the 
unknown population parameter (the mean, for example). A very wide interval 
may indicate that the sample size should be increased to be more confident 
about the parameter.   
 
a x d 
b x c 
Odds Ratios (OR) = 
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2.3.7.6 Logistic regression: 
Regression models are used when there are multiple variable that can affect 
the outcome. The association between the outcome (phenotype/trait) and 
causative/associated variable has to be corrected for these confounding factors.  
Simple logistic regression is used when the outcome variable is binomial (such 
as visual loss/ no visual loss, glaucoma absent or present). It is ideally suited 
for the analysis of case-control studies where the outcome is either being a 
case or control. The explanatory variables may be binomial, categorical or 
continuous (such as glaucoma yes or no, mild moderate or sever inflammation, 
visual acuity, etc). When the model selection is done and computation is 
complete, the outcome is a logistic regression equation in the following format: 
Logarithm of odds = a + b1x1 + b2x2 + ... + bnxn 
Here, logarithm of odds is the natural logarithm of the overall odds ratio for all 
variables included in the model and by using different values of the explanatory 
variables in the formula, different odds ratios for any combination of the values 
the variables can take (for example, being male or female, age etc.) can be 
calculated. Each coefficient (b) provides a measure of the degree of 
association between each variable and the outcome. This coefficient is the 
logarithm of the odds ratio for that variable (OR = eb) controlled (adjusted or 
corrected) for the other variables in the model. It is also possible to calculate 
confidence intervals for the estimated odds ratio as well as the statistical 
significance of each coefficient. This property of logistic regression, which 
enables the calculation of controlled odds ratios, makes it unique in the 
analysis of multivariable data (Katz 2003). Model selection should not be left to 
the computer, which would use statistical stepwise methods to choose the best 
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selection, but the hypothesis and biological plausibility should be considered 
too. 
2.3.7.7 Statistical Calculations: 
As mentioned above, significance testing, confidence intervals, regression 
analysis were all calculated by Statistical Package for Social Sciences (SPSS 
Version 13.0) Chicago Illinois.  
 
2.3.8 Genetics specific statistical calculations 
2.3.8.1 Hardy Weinberg Equilibrium 
To make sure that the allele frequencies are an accurate representation of the 
given study population, it is important to assure that there is no biased selection 
in the chosen population. The Hardy Weinberg Equilibrium (HWE) model 
compares the difference between expected and observed frequencies in a non-
evolving population. Consider a population whose gene pool contains the 
alleles A and a and assign the letter p for the frequency of the dominant allele A 
and the letter q for the frequency of the recessive allele a. Since the sum of all 
the alleles must equal 100%, then p+q=1. In a diploid organism with alleles A 
and a at a given locus, there are three possible genotypes AA, Aa and aa. 
According to the model, the genotype frequencies are p2 for AA, q2 for aa, and 
2(p) (q) for Aa. Therefore, the equation for genotype frequencies is:  p2+ 2pq + 
q2=1.  
The frequencies of A and a will remain unchanged generation after generation 
if the basic assumptions of the HWE model are met: 1) the population is large; 
2) there is no population admixture  3) mutations are negligible; 4) individuals 
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are randomly mating; and 5) the natural selection is not operating on the 
population (i.e., the population is not evolving).  
Normal or control populations should fit the HWE, and the deviation from HWE 
could indicate a population bias or a genotyping error. By contrast, patients are 
a selected group and do not necessarily conform to all the conditions of HWE. 
Thus, it is possible for case populations to be out of HWE, if there is a strong 
genetic link with the disease. However, this is a rare occurrence, especially 
within complex genetic diseases. Therefore, it is important to check for HWE. 
To determine whether a population is in HWE model or deviated from the 
model, allele frequencies are determined by counting the number of 
observations of an allele and dividing this by the total number of chromosomes 
sampled (i.e., two times the number of individual studied). The expected 
genotype frequencies (number of homozygotes and heterozygotes) are then 
calculated from these allele frequencies using the above equation. This 
expected genotype distribution is compared with the observed genotype using 
chi-square test. Non-significant (p<0.05) differences between expected and 
observed genotype frequencies indicate that the study population is in HWE, 
and vice versa. An in-house Microsoft Excel calculation (a kind gift from Dr P 
Panteledis) was used to calculate the chi-square and identify any population 
with significant deviation from HWE. 
  
2.3.8.2 Linkage Disequilibrium (LD) Calculations 
Various statistical methods can be used to measure the LD. The two main 
measures are the absolute value of D` and the r2, both of which are based on 
the pair wise-disequilibrium coefficient D (Lewontin 1988). The D` measure is 
 152 
illustrated in Figure 2-15. If we assume that we have two markers A and B. D is 
the difference between the observed haplotype frequency A-B, and the 
frequency that would be expected to have if the alleles were randomly 
segregated [f (A1)f (B1)], where A and B have alleles labeled 1 and 2 and f is 
their frequency. D` is calculated by dividing D with Dmax (the maximum D is 
possible for a given set of allelic frequencies at the two loci).  
Figure 2-15 Illustration of D` measure 
 
 
 
 
The measure r2 represents the statistical correlation between two sites and it is 
described as shown in Figure 2-16. 
Figure 2-16 Formula for calculating r2 
 
2.3.8.3 Haplotyping Methods 
Most current methods for obtaining genotyping data test each SNP 
independently. This means that the primary data will be an un-phased, not 
indicating how the alleles are associated in a heterozygous individual. Studying 
A B 
D = x1 – f (A1) f (B1) 
D` = D/Dmax 
Assume we have two loci, A and B, which are located close to each other in the same chromosome. 
The term x1 is the observed haplotype frequency of the haplotype A-B.  f (A1) is the frequency of 
allele A1 and f (B1) the frequency of allele B1. 
D2 
r2 =  f (A1) f (A2) f (B1) f 
(B2) 
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phased data will give higher power for assigning a phenotype to a genetic 
region. Unfortunately, haplotypes are costly to be directly measured (Crawford 
and Nickerson 2005). Therefore, most investigators rely on the computerized 
statistical methods, using the knowledge of LD between markers, to re-
construct maximum likelihood haplotypes from un-phased data. 
Haplotyping Using Computerized Methods 
During the course of this thesis, I used two computerized algorithms to re-
construct un-phased data in order to predict the most probable haplotypes.  
 
2.3.8.3.1.1 Expectation-Maximization Algorithm 
The Expectation-Maximization (EM) algorithm is likelihood based method that 
assumes that alleles are in HWE. It then re-constructs and estimates haplotype 
frequencies using the genotype data (Excoffier and Slatkin 1995). It starts filling 
a preliminary list of haplotypes, which are inferred from a fixed starting position 
by examining the complete homozygotes and single-site heterozygotes. Then 
other individuals in the sample are screened for the possible occurrence of the 
previous recognized haplotypes (Excoffier and Slatkin 1995). The mathematics 
behind the EM is based on probability statistics and detailed discussion of its 
derivation is beyond the scope of this thesis. The accuracy of EM algorithm has 
been tested by Fallin and Schork who showed that haplotype frequency 
estimates via the EM algorithm do not deviate more than 5% compared with 
their true value for sample sizes more than 100 (Fallin and Schork 2000).  
Departure from HWE may be a substantial source of error in EM algorithm 
because EM simply relies on HWE. In addition, the algorithm cannot handle 
missing genotypes and tends to assign new haplotypes (assuming nulls) when 
missing data is present.  This was avoided by ensuring full genetic data was 
 154 
generated on all samples. Finally, EM does not assign actual haplotype to 
individual. However, it was used to calculate intra-gene haplotypes and pair 
wise haplotype frequencies, which is required in the subsequent calculation of 
D’. (See calculation above) 
A number of software packages perform the EM algorithm. Arlequin® was used 
to calculate haplotype frequencies and compute LD statistics. Arlequin® can be 
freely downloaded from http://anthro.unige.ch/arlequin/. 
 
2.3.8.3.1.2 Bayesian Methods  
The Bayesian methods for haplotype assignment treat the unknown haplotypes 
as random quantities and combine two aspects; the prior distributions (the 
patterns of haplotypes expected to be observed in population samples) with the 
information actually observed in the data (the likelihood). Then, the haplotype 
frequencies are calculated (Stephens and Donnelly 2003).  
 
PHASE is a program that implements the Bayesian method for reconstructing 
haplotypes from un-phased population genotype data (Stephens, Smith, and 
Donnelly 2001). PHASE determines haplotypes by repeatedly selecting an un-
phased genotype in a random way. Then it estimates individual’s haplotype 
whilst assumes that all the other haplotypes are correctly re-constructed. The 
computational algorithm behind PHASE is Gibbs sampling, which is a type of 
Markov chain-Monte Carlo (MCMC) algorithm (details are not included in this 
thesis). It is similar to the EM algorithm but predicts the structure of the next 
sample haplotype by comparing it with the haplotypes already assigned rather 
than to the genotypes. In addition, PHASE assigns haplotypes to each 
individual and can handle missing data. However, PHASE assumes a complete 
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linkage between markers and so cannot be used in large genetic distances 
(greater than 100kb or less if recombination hotspots are present). PHASE is 
freely available to download from:  
http://www.stat.washington.edu/stephens/software.html. 
2.3.9 Prediction of Functional effects of SNPs  
A major challenge in undertaking candidate gene disease association studies is 
to choose target SNPs that are most likely to affect disease phenotype and that 
ultimately contribute to disease development. Determining which 
polymorphisms are functional and concentrating on these offers great 
advantages and may be more fruitful than random disease associations on all 
SNPs, though this remains controversial (Risch 2000).  
Since this work focused on the effects of functional SNPs on PSU phenotype, 
hence most of the SNPs tested in my research were functional. However few 
SNPs with no known functional effects were studied as well either because of 
their associations with different immune mediated diseases or they lie in close 
proximity to functional SNPs I studied. If any of the “non-functional” SNPs were 
noted to have any significant association, bioinformatics tools were used to 
detect any potential deleterious effects as a result of the SNP.  
Two main online bioinformatics tools were used 
1) Function Analysis and selection tool for single nucleotide polymorphisms 
(FASTSNP) 
2) Transcription Element Search System (TESS) 
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2.3.9.1 FASTSNP 
  
By accessing a variety of heterogeneous biological databases and analytical 
tools, FASTSNP identifies SNPs that are most likely to have functional effects. 
(Yuan et al. 2006) FASTSNP provides SNP prioritization services based on the 
information collected from the Internet at query time. The priorization results 
are based on the predicted functional effects and their estimated risk proposed 
by Tabor et al. (Tabor, Risch, and Myers 2002) For example the following 
things are taken into account as potential functional effects:  
a)  Premature translation termination (nonsense; stop codon gained)  
b) Exons that cause an amino acid change (non-synonymous) 
c) Splicing sites 
 d) Transcription factor binding sites at promoter regions. 
e) Exonic splicing enhancer motifs 
f) Exonic splicing silencer motifs and  
g) 3utr post-transcriptional regulatory region.  
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Ranking Risk definition 
0 No effect 
1 Very low 
2 Low 
3 Medium 
4 High 
5 Very High 
Figure 2-17: The “FASTSNP” SNP prioritization decision tree  
The SNP prioritization result is based on the predicted functional effects and their estimated risk 
proposed by Tabor et al. in Nat Rev Genet. (Tabor, Risch, and Myers 2002) (Copied from FASTSNP 
website http://fastsnp.ibms.sinica.edu.tw) Institute of Biomedical Sciences and Institute of Information 
Science, Academia Sinica. Taipei 115, Taiwan 
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FASTSNP accesses following online databases to gather and analyse the 
information before presenting the results.  
______________________________________________________________________ 
1) NCBI dbSNP 
http://www.ncbi.nlm.nih.gov/SNP 
Provides the location of a SNP in a gene and its alleles, allele frequency, and context 
sequence. 
 
2) Ensembl 
http://www.ensembl.org 
Provides a cross-reference/alternative data source for dbSNP. Also provides 
alternative transcripts and protein domain information. 
 
3) TFSearch 
http://www.cbrc.jp/research/db/ TFSEARCH.html 
Predicts if a non-coding SNP alters the transcription factor binding site of a gene. 
  
4) PolyPhen 
http://www.bork.embl-heidelberg.de/PolyPhen 
Predicts if a non-synonymous SNP alters an amino acid in a protein resulting in 
structural changes (damaged or benign) in a protein. 
 
5) ESEfinder 
http://rulai.cshl.edu/ESE 
Predicts if a synonymous SNP is located in an exonic splicing enhancer motif, which 
would diminish the motif with a different allele. 
 
6) Rescue-ESE 
http://genes.mit.edu/burgelab/rescue-ese 
Provides a cross-reference/alternative data source for ESEfinder. 
 
7) NCBI GeneBank 
http://www.ncbi.nlm.nih.gov/Genbank 
Provides all spliced form mRNAs and their translated proteins of the gene sequence. 
 
8) SwissProt 
http://us.expasy.org/sprot 
Provides the information about protein domains to determine if a SNP causes an 
alternative splicing that leads to a protein domain being abolished. 
 
09) UCSC Golden Path 
http://genome.ucsc.edu 
Provides information about the final draft assembly of the genome sequence (i.e., 
Golden Path) for quality control of candidate SNPs. 
 
10) NCBI Blast 
http://www.ncbi.nlm.nih.gov/BLAST 
Sequence comparison and search tool for quality control of candidate SNPs 
 
11) HapMap 
http://www.hapmap.org/ 
Provides information about the haplotype and linkage disequilibrium around a SNP. 
 
12) FAS-ESS 
http://genes.mit.edu/fas-ess/ 
Predicts whether a coding SNP will abolish exonic splicing silencer motifs 
______________________________________________________________________ 
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2.3.9.2 TESS 
Advances in Bioinformatics give a great opportunity for researchers to select 
functional SNPs in the promoter region. TESS (Transcription element search 
system) software predicts transcription factor binding sites (TFBS) in a given 
DNA sequence (http://www.cbil.upenn.edu/tess/). It uses TRANSFAC ®, IMD, 
and CBIL-GibbsMat databases to identify these TFBS (Wingender 2004). With 
the increasing number of reported regulatory SNPs, our strategy should be to 
examine all known regulatory SNPs by TESS and select the putative functional 
SNPs. If any of these SNPs were found to have significant association TESS 
software was used to determine whether the change in allele had any putative 
effect on transcription of gene.  
 
Figure 2-18: Transcription Element Search system website 
TESS uses TRANSFAC, IMD, and CBIL-GibbsMat databases to identify these Transcription Factors 
Binding Sites 
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Chapter Three 
3 Chemokine gene polymorphism in posterior 
segment uveitis 
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3.1 Introduction 
3.1.1 Chemokines and their role in inflammation 
The salient feature of inflammation is infiltration of leukocytes into the site. The 
maintenance of leukocyte recruitment during inflammation requires intercellular 
communication between infiltrating leukocytes and the endothelium, resident 
stromal and parenchymal cells. These events are mediated via the expression 
of cell-surface adhesion molecules, and the production of chemotactic 
molecules, known as chemokines.(Springer 1994) They are polypeptides that 
act as potent chemotactic factors for neutrophils, eosinophils, basophils, 
monocytes, mast cells, dendritic cells, NK cells, and T and B lymphocytes. 
(Sallusto, Mackay, and Lanzavecchia 2000) Chemokines are often differentially 
induced in response to different stimuli and it is though that this is important in 
recruiting appropriate effector cells to the site of inflammation, including the 
differential recruitment of Th1 and Th2 cells. (O'Garra, McEvoy, and Zlotnik 
1998) 
Chemically they are a group of low molecular weight (~ 8-14 kDa) structurally 
related proteins  and so far 40 different types of chemokines have been 
discovered. Based on the configuration of cysteine residues near the NH2-
terminus of the proteins, they are divided into 4 types: CXC (α), CC (β), C (γ) 
and CX3C (δ). (Rollins 1997) 
CXC chemokines are, in general, clustered on human chromosome 4 and 
exhibit between 20% to 50% homology on the amino acid level. CC 
chemokines are, in general, clustered on human chromosome 17 and exhibit 
between 28% to 45% homology on the amino acid level. The one C chemokine, 
lymphotactin, is located on human chromosome 1, and the one CX3C, 
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fractalkine, is located on human chromosome 16. Main chemokines and their 
groups are shown in Table 3-1 
 
Table 3-1: Common Chemokines according to their groups 
Subgroup  Chromosome   common Members 
CXC   4q12-q13  GROα, GROβ, GROγ, IL-8, IP-10 
CC   17q11.2  MCP-1, RANTES, MIP-1α, MIP-1β 
C   1q23   Lymphotactin,  
CX3C   16q13   Fractalkine 
GRO: Growth related oncogene, MIP: Macrophage inhibitory protein, IP: Inducible protein. 
Chemokines are produced by virtually all somatic cells including monocytes, 
macrophages, neutrophils, platelets, mast cells, T and B lymphocytes, NK cells, 
keratinocytes, mesangial cells, epithelial cells, fibroblasts and endothelial cells. 
These cells can produce chemokines in response to a variety of factors, 
including viruses, bacterial products, IL-1, TNF, Complement 5a (C5a), 
Leukotriene B4, and IFNs. (Baggiolini, Loetscher, and Moser 1995) They are 
not expressed in most resting cells but are rapidly up regulated on activation. 
The production of chemokines by both immune and non-immune cells shows 
that these molecules may play a pivotal role in organising chronic inflammation.  
Chemokines mediate their actions via specific cell-surface receptors that are 
member of rhodopsin superfamily of seven transmembrane-spanning G-
protein-linked molecules. (Ben-Baruch, Michiel, and Oppenheim 1995)  All of 
these receptors are comprised of approximately 350 amino acids and a 
molecular weight of around 40kDa. The receptors can also be grouped into four 
major families, CR, CCR, CXCR and CX3CR, which interact with C, CC, CXC 
and CX3C chemokines respectively. 
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Chemokine-receptor interactions can be either exclusive (e.g. high affinity 
binding of IL-8 to its receptor) or promiscuous. (Rajagopalan and Rajarathnam 
2004) For instance, all four monocytes chemotactic proteins interact with CCR2, 
and at least MCP-2, MCP-3 and MCP-4 also recognize other receptors (CCR1 
and CCR3). 
Main chemokine receptors their ligands and expression on different leucocytes 
in shown in the Table 3-2 
 
Table 3-2: Expression of chemokine receptors in leukocyte populations 
 
Receptor                Main ligands                                                                   Main cells 
CCR1  MCP-3, RANTES, MIP-1 Mo, T, NK, iDC, Neu  
CCR2 B/A  MCP-1–4  Mo, T (act.) NK (act.)  
CCR3  Eotaxin-1–3, MCP-3, RANTES  Eo, Ba, T (Th2)  
CCR4  TARC, MDC  Th2, NK, iDC  
CCR5  MIP-1b, MIP-1a, RANTES  Mo, Th1, iDC  
CCR6  MIP-3a/LARC/Exodus  T, iDC (CD34)  
CCR7  ELC/MIP-3 T, Mo, mDC  
CCR8  I309, TARC  T cells, Mo  
CXCR1  IL-8, GCP-2  Neutrophils 
CXCR2  IL-8, GROs, NAP-2  Neutrophils 
CXCR3  IP-10, MIG, ITAC  T h1 
CXCR4  SDF-1  Widely expressed receptor  
CXCR5  BCA-1  B  
CX3CR1  Fractalkine  Mo, NK, T 
 
Mo: Monocytes, NK: Natural killer cells, Neu: Neutrophils, Eo: Eosinophils, iDC: Immature Dendritic 
cells, mDC: Mature Dendritic cells, T: T cells, act: activated, BCA: B cell attracting, SDF: stromal cell 
derived factor.  
 
In 2003, the international union of immunological societies (IUIS) in 
collaboration with WHO recommended the classification and nomenclature for 
chemokine and chemokine receptors. (Chemokine/chemokine receptor 
nomenclature 2003) This is shown in Table 8-1, Appendix B. The committee 
suggested systematic names for chemokine ligands and receptors starting from 
1(e.g. CCL1, CCL2…..CCR1, CCR2…..etc) 
As seen in the Table 8-1, systematic name for MCP-1 ligand is CCL2 and 
RANTES is labelled as CCL5. In my thesis I have continued using the name of 
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ligands rather than systematic name, as have many of the published studies in 
medical literature.    
Chemokines can also be divided broadly into two categories: inducible 
chemokines that recruit leukocytes in response to physiological stress and 
constitutive chemokines that are responsible for basal leukocyte trafficking and 
forming the architecture of secondary lymphoid organs. Expression of inducible 
chemokines can be elicited by almost any stimulus that alters cellular 
homeostasis and mRNA encoding induced chemokines can increase over 300-
fold within a few hours of activation. However, their inducibility and high 
expression also create the potential for persistent or inappropriately expression. 
In addition, collateral damage brought by activated leukocytes may not dampen 
the chemokine stimulus that initiated their recruitment. In fact, leukocyte-
mediated injury may simply induce higher expression of these or even new 
chemokines, creating a feed forward scenario, that result in more extensive 
tissue damage. (Gerard and Rollins 2001) This role of chemokines is 
particularly seen in chronic immune mediated disease like multiple sclerosis, 
rheumatoid arthritis, graft rejection diseases and models. (Gerard and Rollins 
2001) (MacDermott 1999) (Bodolay et al. 2002) (Dogan and Karpus 2004) 
3.1.2 Role of chemokines in uveitis 
In-vitro studies, animal experiments and studies on human subjects have 
provided considerable evidence to believe chemokines and their receptors play 
a key role in leukocyte recruitment into the eye in uveitis. 
3.1.2.1 Evidence from in-vitro studies  
The blood retinal barrier is maintained by RPE cells and retinal vascular 
endothelial cells. In the case of inflammation, the first chemotactic signals and 
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events should theoretically start at this barrier level. Various in-vitro studies 
have now shown that RPE cells are able to produce chemokines after being 
stimulated by cytokines. Elner et al demonstrated in 1990 that cytokine 
stimulated RPE cells were able to express IL-8 (Elner et al. 1990). The same 
group later showed that T-lymphocyte secretions induced IL-8 and MCP-1 gene 
expression and secretion in human RPE. They noted TNF and IFN-γ were 
necessary components of T-lymphocyte conditioned media for the induction of 
RPE IL-8 and MCP-1. (Elner et al. 1997a)  In another study the primary culture 
of RPE cells was stimulated with various cytokines. The mRNAs were isolated 
from the cells for Northern blot analysis. RPE showed increased IL-8 and MCP-
1 gene expression. Gene expression and protein production of IL-8 and MCP-1 
was also found to be stimulated by IL-1β and TNF-α. (Bian et al. 1999) 
Similarly Crane at el showed that RANTES was produced in vitro by RPE 
cultured cells in response to the pro-inflammatory cytokines IL-1β, TNF-α, and 
IFN-γ and proposed  a role of RANTES in the development of the inflammatory 
eye disease endogenous posterior uveitis (Crane et al. 1998) 
Cultured RPE cells were stimulated with IL-1β or TNF-α without and with 
dexamethasone or with cyclosporine-A. Secreted levels of RPE MCP-1 and IL-
8 were measured in the media using (ELISA). Both MCP-1 and IL-8 mRNA 
were analyzed by Northern blot. Results showed that both TNF-α and IL-1β 
induced expression of MCP-1 and IL-8 mRNA. IL-1β-induced chemokine 
secretion was sensitive to dexamethasone, whereas MCP-1 and IL-8 induced 
by TNF-α were inhibited by cyclosporine-A. (Kurtz et al. 1997) 
Along with RPE, retinal microvascular endothelial cells form the Blood retinal 
barrier. Studies have shown that these endothelial cells have the ability to 
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produce significant amounts of some of the major inflammatory chemokines, 
particularly MCP-1, RANTES, IL-8 and GROα. (Crane et al. 2000) 
To attract the leucocytes, the chemokine ligands that are released by RPE cells 
should then bind to receptors on these inflammatory cells. In vitro studies have 
given us insight into how different chemokine receptors are up regulated on 
effector cells in uveitis.  
Klitgaard et al. studied the expression of chemokine receptors on peripheral 
blood mononuclear cells using flow cytometry in 10 patients with acute anterior 
uveitis and in 10 healthy controls. They found a highly significant up-regulation 
of CCR5 on CD4+ T-cells in the blood of patients with AU compared to in 
healthy controls. (Klitgaard, Ogard, and Krogh 2004) Qiao measured 
CXCR1(IL-8R1) and CXCR2 (IL-8R2) levels on the circulating leukocytes of 
patients suffering from ocular BD. CXCR2 expression in relapsing phase was 
significantly higher than in remission-phase patients or normal individuals. 
(Qiao et al. 2005) 
 
3.1.2.2 Evidence from animal models of uveitis 
Most of the evidence for the role of chemokines in uveitis comes from animal 
models. During inflammation IL-8 (CXCL8) is released from stimulated 
endothelial cells and facilitates transmigration of polymorphonuclear cell. In 
normal mice treated with anti-CXCL8 antibody, or in murine IL-8 receptor 
homologue deficient mice (mIL-8Rh-/-) challenged with endotoxin injected into 
the vitreous cavity, the number of infiltrating cells was greatly reduced 
compared to wild-type mice. (Becker et al. 2000) (Verma et al. 1999) 
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Recent studies in EAU have shown that MCP-1, MIP-1α and RANTES were 
most strongly expressed at the peak of disease in retinal tissue. (Crane et al. 
2001) 
Lewis rats injected with myelin basic protein (MBP) also develop anterior uveitis, 
(AU) which coincides with the onset of experimental autoimmune 
encephalomyelitis (EAE). This model is known as “anterior uveitis with EAE”. 
Initially, MCP-1 is detected pre-clinically in the iris and ciliary body as well as 
the spinal cord, and mRNA expression correlated with increasing disease 
severity. These results imply that MCP-1 contributes to the initial recruitment of 
inflammatory cells into both the eye and the CNS (Adamus et al. 1997) 
Anterior uveitis can also occur in response to MBP in mice, and analysis of 
gene expression found increased levels of RANTES, MCP-1 and MIP-1α at the 
onset of clinical AU. MIP-1β was highest at the peak of AU. CCR2 was present 
at comparable levels throughout disease, while CCR3 and CCR5 were greatest 
at peak disease, and CCR1 was highest at onset. Treatment with anti-MIP-1β 
or anti-MCP-1 delayed onset and reduced duration of AU, while anti-RANTES 
had no effect on disease. T cells appear to be the main source of these 
chemokines (Adamus, Manczak, and Machnicki 2001) 
On recovery from EAE, animals are resistant to EAE but develop recurrent AU 
in response to a second challenge with MBP. MCP-1 mRNA expression was 
raised in the iris/ ciliary body of rats at the pre-clinical stage of the recurrence of 
AU and remained high through to the recovery phase. MIP-1β and RANTES 
mRNA were also seen throughout the course of recurrent AU with RANTES 
peaking at the pre-clinical stage while MIP-1β was highest at the peak of 
disease. MIP-1α mRNA was first seen at the onset of recurrent AU, and 
decreased at peak disease. Anti- MIP-1α, and particularly -MIP-1β suppressed 
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the development of recurrent AU (Manczak et al. 2002). Anti- RANTES was not 
effective in protecting against recurrent AU. (Manczak et al. 2002) 
 
3.1.2.3 Chemokines levels in patients with uveitis 
Further confirmation of the roles of chemokines in uveitis can be derived from 
studies on Human subjects with active disease 
Elevated levels of IL-8 have been found in the serum of patients with idiopathic 
AU (Klok et al. 1998). In a further study, aqueous humour was collected from 
patients with idiopathic AU and IL-8 was detected in 50% of patients with active 
untreated AU, but was not detected in quiescent disease. IP-10 levels were 
significantly greater in patients with active disease compared to non-active, as 
was MCP-1, which was undetected in non-active patients, and MIP-1β and 
RANTES were both higher in patients with ocular disease but remained at very 
low levels (Verma et al. 1997). A correlation between disease activity and 
levels of MCP-1 and MIP-1 β in serum has been demonstrated as both were 
controlled by treatment with prednisolone in patients with retinal vasculitis. 
(Wallace et al. 2003) Kramer et al measured serum levels of IL-8 in 25 patients 
during active uveitis and uveitis in remission and compared to age-matched 
controls. Levels of IL-8 were significantly elevated in patients with active 
disease and were decreased during remission. (Kramer et al. 2007).  Similarly, 
Belguendouz et al. measured high levels of serum IL-8 in patients with Behcet’s 
uveitis and idiopathic uveitis. In both groups corticosteroid therapy significantly 
reduced serum IL-8 levels. (Belguendouz et al. 2008) Serum levels of IL-8 were 
higher in active Behcet’s disease compared to inactive disease and were noted 
to be indicator of early vascular involvement (Durmazlar et al. 2009). Sijssens 
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et al analysed aqueous levels of chemokines using multiplex immunoassay in 
children with uveitis and found high levels of RANTES, IL-8 and IP-10 (Sijssens 
et al. 2007). Yoshida et al measured aqueous MCP-1 levels by using ELISA 
technique in 31 patients with uveitis and found significantly higher levels of 
MCP-1 in patients with infectious and non-infectious uveitis compared to 
controls. (Yoshida et al. 2008)  Similarly higher aqueous levels of MCP-1, 
RANTES and IL-8 were seen in active intermediate uveitis compared to levels 
in disease under remission. (Valentincic et al. 2011) 
Takeuchi et al measured serum levels of chemokines by cytometric bead array 
using flow cytometry and found levels of CXCL9 and IP-10 were elevated 
markedly in the patients with ocular sarcoidosis and correlated with ocular 
disease activity and ACE level. (Takeuchi et al. 2006) 
Klitgaard et al. studied the peripheral expression of chemokine receptors and 
early activation markers using flow cytometry in 10 patients with acute anterior 
uveitis and in 10 healthy controls. They found a highly significant up-regulation 
of CCR5 on CD4+ T-cells in the blood of patients with AU compared to in 
healthy controls. (Klitgaard, Ogard, and Krogh 2004) 
In another study, correlation between disease activity and levels of RANTES 
and MIP-1β in serum was demonstrated and levels were decreased by 
treatment with prednisolone in patients with retinal vasculitis. (Wallace et al. 
2003) 
These and similar studies have increased our understanding about the role of 
chemokines in uveitis, however the relationship is very complex and 
complicated by the fact that there is lot of redundancy and overlap in 
chemokines system. However it does appear that IL-8 MCP-1, RANTES, MIP-1 
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and IP-10 play significant role in recruiting monocytes and lymphocytes to the 
site of inflammation in uveitis.  
Aims:  
I hypothesized that genetic variability in genes encoding these chemokine 
molecules may play a role in the development and susceptibility of PSU.  The 
aim of this study was to determine whether functional single nucleotide 
polymorphisms in these chemokine genes involved in uveitis would predict the 
disease severity and response to the treatment. As discussed in detail, (Risch 
and Merikangas 1996) studying functionally significant polymorphisms rather 
than random polymorphisms in the gene of interest offers considerable 
advantages in terms of detecting disease associated genes.  
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3.2 Methods 
3.2.1 Experimental populations 
3.2.1.1 Patients: 
DNA of 205 Caucasian patients who attended the uveitis clinic at Moorfield’s 
eye hospital were available for this study.  Clinical phenotyping was done as 
discussed in detail in chapter 2. The patients were categorized into 2 main 
groups which were further sub divided into two.  
A) Idiopathic posterior segment uveitis 
1) Idiopathic intermediate uveitis 
2) Idiopathic posterior uveitis 
B) Uveitis associated with systemic diseases 
3) Behcet’s uveitis 
4) Sarcoidosis uveitis 
3.2.1.2 Controls 
1) 169 healthy subjects who were admitted to  WXH for cataract surgery 
and 
2) 114 healthy subjects who were seen at KCH eye department for age 
related macular degeneration.  
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3.2.2 SNP Selection 
After extensive literature search, functional polymorphisms in the chemokine 
genes involved in uveitis pathogenesis were gathered. Where the functional 
polymorphisms were not detected (in case of IL-8 receptors) any 
polymorphisms that had been associated with immune mediated disease was 
selected. 
As a result six chemokines genes were selected because they have been 
shown to be significantly involved in the pathogenesis of uveitis and secondly 
SNPs in their genes have been found to be functional and associated with 
other autoimmune diseases. These were MCP-1 and its receptor CCR2, 
RANTES and its receptor CCR5 and IL-8 and its receptor CXCR-2 (IL-8Rb). 
3.2.2.1 MCP-1 SNPs 
The gene encoding for MCP-1 is located on chromosome 17q11.2-q21.1. The 
most commonly studied functional SNP in MCP-1 gene is at position -2518. 
3.2.2.1.1 MCP-1 -2518G/A 
A biallelic polymorphism at the −2518 position of the MCP-1 gene promoter 
(G→A) was reported to influence the rate of MCP-1 induction. (Rovin, Lu, and 
Saxena 1999) IL-1β induced luciferase activity was significantly greater from 
cells transfected with constructs containing G at position -2518.  IL-1β treated 
peripheral blood mononuclear cells from individuals heterozygous or 
homozygous for G at -2518 produced more MCP-1 than cells from individuals 
homozygous for A at -2518.  
Gonzalez et al (Gonzalez et al. 2002) by utilising EMSA technique found that 
the mutant MCP-1 -2518G allele conferred greater transcriptional activity in 
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vitro. They also noted in-vivo, that this allele was associated with increased 
serum MCP-1 levels, as well as macrophages infiltration into interstitial tissues 
A study done on Behcet’s patients, (Cho et al. 2004) showed that when 
stimulated in vitro with IL-1βeta and LPS, the mononuclear cells from patients 
carrying the G allele showed a steeper increase in MCP-1 production than the 
boost observed in AA homozygotes. Similar results have been shown by other 
studies (Muhlbauer et al. 2003).  (Tabara et al. 2003) 
3.2.2.1.2 MCP-1-2076 
-2076 SNP was selected on the basis that research done by our group noted 
association of this SNP with idiopathic anterior uveitis. (Yeo et al. 2006) 
Although Rovin et al. (Rovin, Lu, and Saxena 1999) showed that polymorphism 
at site -2076 did not effect MCP-1 expression; it is worth mentioning that in their 
study the maximum transcriptional activity of MCP-1 promoter region was noted 
in subjects with the AC Haplotype (A at -2076 and G at -2518 in their study). In 
another study, the same AC haplotype was associated with accelerated 
progress to AIDS and death and a high risk of HIV associated dementia in HIV 
positive Caucasian Americans.(Gonzalez et al. 2002) 
Sedlmeier et al recently studied MCP-1 SNPs in 1630 subjects with metabolic 
syndrome and found that T allele at -2076 was associated with decreased 
serum levels of IL-6. (Sedlmeier et al. 2007) Since MCP-1 is involved in IL-6 
expression, an association seems conceivable. (Viedt et al. 2002) Using 
FASTSNP tool however did not predict that this SNP can have a functional 
significance. 
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3.2.2.2 RANTES SNPs 
The gene encoding for RANTES is located on the same chromosome 17q11.2-
q12 in the vicinity of other chemokines. Two functional SNPs in RANTES gene 
have been studied extensively for their role in immune mediated and other form 
of disease.  
3.2.2.2.1 -403G/A and -28C/G 
The two SNPs -28C/G and -403G/A in the promoter region of the 
RANTES gene have shown a possible association with RANTES gene 
expression. (Hajeer, al, and Ollier 1999) (al, Ollier, and Hajeer 1999) Liu et al 
did the functional analyses of RANTES promoter activity and demonstrated that 
the RANTES-28G mutation increases transcription of the RANTES gene (Liu et 
al. 1999). Another study also showed increase transcription of RANTES genes 
in subjects with -28G allele. (An et al. 2002)  
Nickel et al  transfected  the human mast cell line HMC-1 and the T cell line 
Jurkat with reporter vectors driven by either the mutant (A) or wild-type (G).  
They found an up to 8-fold higher constitutive transcriptional activity of the 
mutant promoter -403A allele compared to G allele. (Nickel et al. 2000) 
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3.2.2.3 IL-8 & IL-8Rb SNPs 
3.2.2.3.1 IL-8 
IL-8 is the first chemokine discovered and is a potent chemoattractant of 
neutrophils and some lymphocytes. (Baggiolini, Walz, and Kunkel 1989) 
(Larsen et al. 1989) The gene encoding for IL-8 has a length of 5.1 kb and 
contains four exons. It maps to human chromosome 4q12-q21.  
Two polymorphisms have been studied extensively for their functional effects 
T>A SNP at -251 position and C>T SNP at -845 position 
3.2.2.3.1.1 -251 T/A 
The functional effects of this SNP were first noted in 2000 when Hull et al noted 
that, A allele tended to be associated with increased IL-8 production by 
lipopolysaccharide stimulated whole blood. (Hull, Thomson, and Kwiatkowski 
2000) The transcriptional promoter activity of the IL-8 gene was assessed by 
luciferase assay. In the in-vitro assay, IL-8 −251A showed enhanced promoter 
activity in response to IL-1β or TNF-α. (Ohyauchi et al. 2005) In another study 
T > A change was associated with higher expression of IL-8 protein and more 
severe neutrophil infiltration (Taguchi et al. 2005). A Chinese study on patients 
with ulcerative colitis demonstrated higher serum levels of MCP-1 and severe 
clinical course in patients with A allele at -251 position. (Li et al. 2009) 
3.2.2.3.1.2 -845 C/T 
 The C/T polymorphism at the promoter site -845 was discovered in IL-8 gene. 
The C allele was noted to increase the expression of IL-8 and found to be 
associated with severe renal injury in SLE. (Rovin, Lu, and Zhang 2002).  The 
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authors also noted that the frequency of mutant allele was very low in 
Caucasians compared to Africans. 
3.2.2.3.2 IL-8Rb SNPs 
Cellular activities of IL-8 are mediated by two related receptors, CXCR-1 
(previously called IL8RA) and CXCR-2 (or IL8RB), which are encoded by 2 
single-copy genes and located on chromosome 2q34–q35. In a murine animal 
model of endotoxin induced uveitis, genetically IL-8Rh (human CXCR-2) 
deficient mice showed decrease inflammation as compared to normal mice. 
(Brito et al. 1999)  
3.2.2.3.2.1 CXCR2 (IL-8rb) +1208 T/C & +785 C/T 
Recently two polymorphisms on CXCR-2 gene, CXCR-2 +785 C/T and CXCR-
2 +1208 T/C have been shown to be associated with systemic sclerosis and 
cryptogenic alveolitis. (Renzoni et al. 2000) The CXCR-2 +785 C/T 
polymorphism is located in exon 11 and results in a silent codon change from 
CTC (leucine) to CTT (leucine) and is therefore unlikely to have functional 
significance., whereas the CXCR-2 +1208 polymorphism is in the 3’ 
untranslated region of exon 3, and has the potential of altering mRNA 
processing, stability, or translation. However, using FASTSNP tools, it was 
noted that +785 SNP has a low to moderate chance to be functional. No such 
association was noted for +1208 SNP. It is also possible that, both 
polymorphisms may be markers of a nearby polymorphism that is yet to be 
discovered, which in turn could have functional effects. Since there were no 
other functional SNPs in CXCR-2 genes, these two polymorphisms were 
selected for the study. 
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3.2.2.4 CCR2 and CCR5 SNPs 
CCR2 and CCR5 are mainly expressed by T cells and monocytes and they are 
receptors for MCP-1 and RANTES respectively. The gene encoding for CCR5 
has been mapped to chromosome 3p21-3 about 18 kb downstream of the 
CCR2 gene. 
3.2.2.4.1 CCR2 V64I 
A SNP at nucleotide position 46295 G/A, was identified in the open reading 
frame of CCR2. The G→A substitution leads to replacement of valine by 
isoleucine at amino acid 64 (CCR2 V64I) in the first transmembrane domain of 
CCR2. (Kostrikis et al. 1998) 
Until recently this SNP was thought to be non-functional, however recent 
studies have shown that this G to A substitution may be functional.   
Nakayama et al. observed up-regulation of CCR2A-64I compared to CCR2A 
without substitution. (Nakayama et al. 2004) Accordingly, a chemotaxis assay 
showed that cells expressing CCR2A-64I migrated more efficiently than those 
expressing CCR2A-64V. Pulse–chase experiments revealed that higher 
expression of CCR2A-64I was due to increased stability of CCR2A-64I. In 
parallel, the authors also measured CCR5 surface expression that was more 
severely blocked by co-expression of CCR2A-64I than by CCR2A-64V. 
Furthermore, this negative effect of CCR2A on CCR5 expression was shown to 
arise from the possibility of heterodimer formation between CCR2A and CCR5. 
Taken together, the authors concluded that CCR2A-64I polymorphism 
modulates CCR5 surface expression.   
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Mellado et al also showed that valine to isoleucine substitution gives CCR2 
receptor ability to heterodimerize with the CCR5 and/or CXCR4 receptor 
following MCP-1 binding. (Mellado et al. 1999) 
 Similarly the CCR2 V64I polymorphism was indicated to decrease CCR5 re-
expression after ligand induced internalization in CD4+ T cells (Sabbe et al. 
2001) 
3.2.2.4.2 CCR5 32bp deletion 
CCR5 32bp ∆ was first reported in 1996 and showed to confer near absolute 
resistance to HIV infection among HIV-exposed individuals homozygous for the 
Variant. (Dean et al. 1996) This genetic variant in the coding region of the 
CCR5 structural gene involves a 32 base pair deletion that shifts the open 
reading frame to create a truncated protein. This protein fails to reach the cell 
surface in individuals homozygous for the variant. (Samson et al. 1996a) (Liu et 
al. 1996) (Huang et al. 1996) CCR5 32bp ∆ heterozygotes have reduced levels 
of quantifiable CCR5 receptors on their cell surface, notably rather greater than 
the expected 50% reduction due to the gene dosage effect. The mean 
reduction to 20–30% of wild-type levels in CCR5-+/-32 ∆ heterozygotes is 
perhaps because nascent CCR5-/-32 polypeptides dimerize with their wild-type 
CCR5 counterparts in the endoplasmic reticulum, retarding the transport of 
CCR5 to the cell surface(Benkirane et al. 1997) 
3.2.2.4.3 CCR5 -59029 G/A 
The functional polymorphism G/A at nucleotide position -59029 in the promoter 
region of CCR5 was first noted by McDemott et al in 1998. (McDermott et al. 
1998) The researchers measured In-vitro promoter activity by chloramphenicol 
acetyltransferase reporter gene.  59029-G had 45% lower activity than 59029-A 
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as a result of reduced CCR5 mRNA production. Later another study showed 
that increased number of CD4 (+) cells expressing CCR5 correlated with 
CCR5-59029A homozygosity without the interference of both the CCR2-64 and 
the CCR5 32 bp ∆ mutations. (Shieh et al. 2000) 
Since all these eleven SNPs of six chemokine genes were either functional or if 
non-functional but associated with autoimmune diseases having pathogenesis 
similar to uveitis, it was planned to analyse these SNPs in patients with 
posterior segment non-infectious intra-ocular inflammation. Eight of SNPs alter 
the expression of genes on inflammatory cells which in turn affect the 
phenotype of the diseases. All of these chemokines are known to be involved in 
the pathogenesis of uveitis, so it is quite likely that similar effect occurs in 
posterior uveitis.  
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3.2.3 Genotyping 
3.2.3.1 DNA extraction 
The DNA extraction in patients and KCH controls was done with commercial 
kits (Qiagen UK Ltd, UK) according to the manufacture’s instructions and as 
discussed in chapter 2 
The DNA extraction of WXH controls was done by salt extraction method 
 
3.2.3.2 Primer Design 
 
To identify 11 SNPs multiple sequences for MCP-1, RANTES, IL-8 CCR2, 
CCR5 and IL-8Rb deposited in GenBank were analysed. To verify the 
presence of these potential polymorphisms, sequence-specific primer–
polymerase chain reaction (SSP-PCR) method  was used in 10 SNPs. IL-8 -
251 SNP was genotyped by 5’ Nuclease Array by TaqMan®   
The specific and control primer details for each polymorphism are shown in the 
Table 3-3 & Table 3-4. Table 3-5 shows the details of IL-8 -251 primers 
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Table 3-3: Details of primers designed for the ten chemokine polymorphisms (SSP-PCR) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene name Chr SNP  ID Locus Headed  primer seq 5'-------3' product size 
       
MCP-1 17q11.2-q12 -2518 PROMOTOR Sense AAG TGG GAG GCA GAC AGC TA/G 252 
    Antisense CTG ATA AAG CCA CAA TCC AGA G  
       
MCP-1 17q11.2-q12 -2076 PROMOTOR Antisense TTCATGGTAAAGGATGCACTAACT/A 264 
    Sense TCCCAGAGCAGAGACTCTAT  
       
RANTES 17q11.2-q12 -403 PROMOTOR Sense CAT GGA TGA GGG AAA GGA GG/A 285 
    Antisense GAG TCT CTG TCT CTC CCT CA  
       
RANTES 17q11.2-q12 -28 PROMOTOR Antisense GCC CTT TAT AGG GCC AGT TG/C 314 
    Sense GTC CTA ACT GCC ACT CCT TG  
       
IL8 4q12-q13 -845 PROMOTOR Antisense GAA TAG ACA AGT GGT ACT AAG ACA/G 309 
    Sense AGC AAC AGT GGC TGA ACC AG  
       
CCR2A 3p21-3 V64I EXON  Antisense TTT TTG CAG TTT ATT AAG ATG AGG AC/T 808 
    Sense GAA GGC AGA AGG TGA ATA GTT C  
       
CCR5 3p21-3 -59029 PROMOTOR Sense GAG TGG TAG TTA CAT GCA TGT G/A 400 
    Antisense AAC CTG GGT GAC AGC AAG C  
       
CCR5 3p21-3 ∆ 32 G/A EXON Sense GCT CTC ATT TTC CAT ACA GTC AG/A 827/808 
    Antisense TAT ACA TAA GGA ACT TTC GGA GTG  
       
CXCL-2 2q35 1208 EXON Sense CCC ATT GTG GTC ACA GGA AGT/C 673 
 
   Antisense GGT CTT GTG AAT AAG CTG CTA TG  
 
      
CXCL-2 2q35 785 EXON Sense TCG TCC TCA TCT TCC TGC TC/T 280 
    Antisense ACA AAG GAA GGC CTG CTG TC  
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Table 3-4: Control primers for SSP-PCR reaction 
 
 
Table 3-5: Primer details of IL-8 251 SNP (TaqMan® Assay) 
SNPs  Headed PRIMERS ALLELES PROBES ANNEALING  
          TEMERATURE 
        
IL-8-251 Forward GTCACATGGTCTATGATAAAGTTATCTAGAAATAA A 6-FAM-AAGCATACAATTGATAATT-MGB 60 
  Reverse TACATTTAAAATACTGAAGCTCCACAATTT T VIC-AAGCATACATTTGATAATT-MGB   
  
      
      Headed Control Primers Size 
63 DRB exon 3     FARWARD TGC CAA GTG GAG CAC CCA A 796 
64 DRB exon 4     REVESRE GCA TCT TGC TCT GTG CAG AT  
210 APC     FARWARD ATG ATG TTG ACC TTT CCA GGG 256 
211 APC     REVESRE TTC TGT AAC TTT TCA TCA GTT GC  
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3.2.4 Statistical Analysis 
Statistical analysis was performed as mentioned in detail in chapter two. For 
each subject group, genotype frequencies were counted and the allelic and 
allele carriage frequencies calculated. All genotype frequencies in each 
population were tested for deviation from the Hardy-Weinberg equilibrium using 
the chi-square test. Data mining for significant associations was performed 
using knowledge seeker®, (Angoss softwares UK) and statistical calculations 
were performed with SPSS 12.0 (Chicago USA). Confidence intervals were 
calculated at the 95 % level and a value of p < 0.05 was considered as 
significant. Chi-square test was used to compare the genotypic and allelic 
frequencies in patients and controls. A correction for multiple comparisons was 
made using the Bonferroni method, adding the formula pc = p × n where pc 
represents the corrected value, p is the uncorrected value, and n is the 
numbers of comparisons performed. Haplotypes were constructed by inference 
and confirmed by using the PHASE algorithm 
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3.3 Results 
 
205 patients were included in the study and were categorised into following 
groups shown in Table 3-6. 
Table 3-6: The four sub groups of posterior segment uveitis 
Idiopathic Intermediate uveitis            n=77 
Sarcoid uveitis    n=33 
Behcet’s uveitis    n=31 
Idiopathic Posterior uveitis             n=64 
Total                                  n=205 
 
 
 The mean age was 36.52 years with SD + 14.15. The female to male ratio was 
1.25: 1.  Salient clinical features are shown in the Table 3-7. 
Table 3-7: Clinical details of patients with PSU 
Follow up in years Mean 8.2 (2-42.6) 
Sex Males=94 females=111 
Laterality of disease at final follow up Bilateral=175, unilateral 30 
Age of onset (years) Mean=36.52  Range=(5-70.5) 
Relapses  (rate per year) Mean=2.01    Range=(0-7) 
Visual impairment during inflammation 
Mean=doubling of Visual Angle:     
Range=(Nil---x8 of visual angle) 
VA with both eyes open, after 24 months Mean=6/9      Range=(6/5-6/60) 
Permanent visual loss n=85   Mean=6/24  Range=6/15-NPL 
Need for systemic steroid n=151 
More than 10mg of steroids for long term control n=83 
On second line of immuno-suppressants n=84 
Cystoid macular oedema n=125 
Glaucoma n=71 
Cataract n=95 
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3.3.1 Genotype frequencies in patients and controls 
All genotype frequencies in case and control populations conformed to Hardy-Weinberg equilibrium. The genotype 
frequencies of patients versus Caucasian controls are shown in the Table 3-8. 
Table 3-8: Genotypic & Allelic Frequencies of chemokine SNPs in Caucasian controls and Patients 
 
GENOTYPE CONTROLS PATIENTS P value BEHCET P value INTERMEDIATE P value SARCOID P Value POST. P Value 
 
283 205  31  77  33  64  
MCP-1 -2518 A/G            
AA 151(53%) 112(55%)  15 (48%)  41 (53%)  15 (45%)  41 (64%)  
AG 109(39%) 78(38%)  13 (42%)  33 (43%)  13 (39%)  19 (30%)  
GG 23(8%) 15(7%)  3 (10%)  3 (4%)  5 (15%)  4 (6%)  
ALLELE FREQ  A/G 0.73/0.23 0.74/0.26  0.69/0.31  0.75/0.25  0.65/0.35  0.79/0.21  
 
 
 
 
 
 
 
     
 
MCP-1 -2076 A/T            
AA 150(53%) 137(67%) P=0.002 24 (77%) P=0.009 52 (68%) P=0.02 21 (64%)  40 (62%)  
AT 110(39%) 60 (29%) P=0.02 5 (16%) P=0.01 20 (26%)  12 (36%)  23 (36%)  
TT 23 (8%) 8 (4%)  2 (6%)  5 (6%)  0 (0%)  1 (2%)  
ALLELE FREQ A/T 0.72/0.28 0.81/0.19 P=0.001 0.85/0.15 P=0.026 0.81/0.19 P=0.04 0.82/0.18 P=0.1 0.80/0.20 P=0.06 
 
      
 
 
  
 
RANTES -403 G/A            
GG 179(63%) 129(63%)  21 (68%)  45 (58.4%)  22 (67%)  41 (64%)  
GA 90(32%) 67(33%)  9 (29%)  31 (40.3%)  9 (27%)  18 (28%)  
AA 14(5%) 9 (5%)  1 (3%)  1 (1.3%)  2 (6%)  5 (8%)  
ALLELE FREQ G/A 0.79/.21 0.79/0.21  0.82/0.18  0.79/0.21  0.80/0.20  0.78/0.22  
 
     
    
 
 
RANTES -28 C/G            
CC 267(94%) 196(96%)  31 (100%)  73 (95%)  32 (97%)  60 (94%)  
CG 15 (5%) 9 (4%)  0 (0%)  4 (5%)  1 (3%)  4 (6%)  
GG 1 (0.3%) 0 (0%)  0 (0%)  0 (0%)  0 (0%)  0 (0%)  
ALLELE FREQ C/G 0.97/0.3 0.98/0.02  1.00/0  0.97/0.03  0.98/0.02  0.97/0.03  
 
 
         
 
IL-8 -845 T/C            
TT 274(98%) 202(99%)  31 (100%)  76 (99%)  32 (97%)  63 (98%)  
TC 7 (2%) 3 (1%)  0 (0%)  1 (1%)  1 (3%)  1 (2%)  
CC 0 (0%) 0 (0%)  0 (0%)  0 (0%)  0 (0%)  0 (0%)  
ALLELE FREQ T/C 0.99/.01 0.99/0.01  1.00/0  0.99/0.01  0.98/0.02  0.99/0.01  
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GENOTYPE CONTROLS PATIENTS P value BEHCET P value INTERMEDIATE P value SARCOID P Value POST. P Value 
 
283 205  31  77  33  64  
IL-8 251T/A            
TT 69 (24%) 39 (19%)  8 (26%)  15 (19%)  6 (18%)  10 (16%)  
TA 145 (52%) 113(55%)  15 (48%)  40 (52%)  15 (46%)  43 (67%)  
AA 69 (24%) 53 (26%)  8 (26%)  22 (29%)  12 (36%)  11 (17%)  
ALLELE FREQ T/A 0.50/0.50 0.47/0.53  0.50/0.50  0.45/0.55  0.41/0.59  0.49/0.51  
 
 
         
 
CCR2 V64I     p=0.006       
GG 247(87%) 166(81%)  21 (68%) p=0.003 61 (79%)  29 (88%)  55 (86%)  
GA 35 (13%) 35 (17%)  9 (29%) p=0.012 14 (18%)  3 (9%)  9 (14%)  
AA 1 (0.3%) 4 (2%)  1 (3%)  2 (3%)  1 (3%)  0 (0%)  
ALLELE FREQ G/A 0.93/0.07 .90/.10 p=0.029 0.82/0.18 p=0.001 0.88/0.12 p=0.036 0.92/0.08 P=0.7 0.93/0.07 P=0.8 
  
 
         
 
CCR5 -59029A/G            
AA 82 (29%) 75 (37%)  15 (48%) p=0.027 27 (35%)  12 (36%)  21 (33%)  
AG 137(49%) 92 (45%)  12 (39%)  31 (40%)  17 (52%)  32 (50%)  
GG 63 (22%) 38 (19%)  4 (13%)  19 (25%)  4 (12%)  11 (17%)  
ALLELE FREQ A/G 0.53/0.47 0.59/0.41  0.68/0.32 p=0.030 0.55/0.45  0.62/0.38  0.58/0.42  
  
          
 
CCR5 32bp ∆            
wt/wt 216 77.6%) 162(79%)  26 (84%)  62 (81%)  27 (82%)  47 (73%)  
wt/∆ 61 (21.7%) 40 (20%)  5 (16%)  13 (17%)  6 (18%)  16 (25%)  
∆/∆ 5 (1.7%) 3 (1%)  0 (0%)  2 (3%)  0 (0%)  1 (2%)  
ALLELE FREQ wt/∆ 0.87/0.13 0.89/0.11  0.92/0.08  0.89/0.11  0.91/0.09  0.86/0.14  
  
          
 
CXCR2 1208 T/C            
TT 65 (23%) 50 (24%)  10 (32%)  17 (22%)  10 (30%)  13 (20%)  
TC 152(54%) 106 (52%)  12 (39%)  46 (60%)  14 (42%)  34 (53%)  
CC 66 (23%) 49 (24%)  9 (29%)  14 (18%)  9 (27%)  17 (27%)  
ALLELE FREQ T/C 0.50/0.05 0.50/0.50  0.52/0.48  0.52/0.48  0.52/0.48  0.47/0.53  
  
          
 
CXCR2 785 T/C            
TT 67 (24%) 49 (24%)  8 (26%)  14 (18%)  6 (18%)  21 (33%)  
TC 141 (50%) 96 (47%)  13 (42%)  42 (55%)  14 (42%)  27 (42%)  
CC 74 (26%) 60 (29%)  10 (32%)  21 (27%)  13 (39%)  16 (25%)  
ALLELE FREQ T/C 0.49/0.51 0.47/0.53  0.47/0.53  0.45/0.55  0.39/0.61  0.54/0.46  
 
(Continued; Table 3-8: Genotype Frequencies chemokine SNPs in Caucasian controls and Patients) 
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3.3.2 Risk of Genetic Predesposition: 
 
As seen in the previous Table 3-8 there were two SNPs that showed some 
association with the development of uveitis.  
3.3.2.1 1): MCP-1 2076 and risk of developing uveitis: 
As shown in detail in the Table 3-9 the wild type allele was more prevalent in 
the patients compared to the controls. Odds ratio 1.7 (95%CI: 1.2—2.5) the pc 
for allelic frequency difference was 0.002.  
 
 
Table 3-9: Genotypic frequencies of MCP-2076 A/T in controls and patients. 
 
Genotype   Patients   Controls  Chi 2X2 
MCP-1 -2076A/T N= (205) N= (283)  (P value) 
     
AA 137 (67%) 150 (53%)  0.00219 
AT 60 (29%) 110 (39%)  0.02801 
TT 8 (4%) 23 (8%)  NS 
Allelic Carriage / phenotype        
A 197 (96%) 260 (92%)  NS 
T 68 (33%) 133 (47%)  0.00219 
Allelic Frequency        
A 334 (81%) 410 (72%)  0.00108 
T 76 (19%) 156 (28%)   
 
 
As shown in the main Table 3-8, the frequency of -2076AA genotype was 
consistently high in all four groups but reached statistical significance in 
Intermediate uveitis [Odd ratio 1.8 (95% CI: 1.1—3.1) pc= 0.04] and Behcet’s 
uveitis group [Odd ratio 3.0 (95% CI: 1.3—7.3) pc=0.018]. It appears that 
because of the number of subjects it did not reach statistical significance in 
posterior uveitis  
 188 
The detailed genotypic frequencies of -2076 SNP in Behcet’s and intermediate 
groups are shown in Table 3-10 Table 3-11 respectively. 
 
Table 3-10: Genotype frequencies in Behcet’s patients and controls 
GENOTYPE MCP-1 -2076 A/T Patients Control 
  
p 
   
 
 
AA 24 (78%) 150 (53%)  0.00942 
AT 5 (16%) 110 (39%)  0.0126 
TT 2 (6%) 23 (8%)  NS 
Total 31 283    
Allelic Carriage / phenotype        
A 29 (94%) 260 (92%)  NS 
T 7 (23%) 133 (47%)  0.00942 
Allelic Frequency        
A 53 (85%) 410 (72%)  0.02671 
T 9 (15%) 156 (28%)    
Total 62 566    
 
Table 3-11: Genotype frequencies of MCP-1 -2076 in Intermediate uveitis patients and 
controls 
GENOTYPE MCP-1 -2076 A/T Patients Control  p 
     
AA 52 (68%) 150 (53%)  0.02274 
AT 20 (26%) 110 (39%)  0.03673 
TT 5 (6%) 23 (8%)  NS 
Total 77 283    
Allelic Carriage / phenotype        
A 72 (94%) 260 (92%)  NS 
T 25 (32%) 133 (47%)  0.02274 
Allelic Frequency        
A 124 (81%) 410 (72%)  0.04222 
T 30 (19%) 156 (28%)    
Total 154 566    
 
The two MCP-1 SNPs showed quite strong linkage. Subjects who were 
homozygous GG at -2518 were always homozygous for AA at -2076. Similarly 
subjects who were TT homozygous at -2076 were always homozygous for AA 
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at position -2518. Using Phase® software three common haplotypes were 
constructed as shown in the Table 3-12. 
 
 
Table 3-12: MCP-1 haplotype frequencies in patients and controls 
Haplotype MCP-1 Polymorphism PSU Control Odds Ratio  
 2076 2518 (n = 205) (n = 283)  p value 
1 A A 58.10% 47.00% - 0.055 
2 T A 13.80% 25.50% 2.3 (1.4-3.8) 0.001 
3 A G 23.90% 24.30% - ns 
Others   4.20% 3.20% - ns 
 
. As we can see the table above the TA Haplotype was less frequent in patients 
when compared with the controls (p=0.001) 
3.3.2.2 2): CCR-2 V64I and risk of development of Behcet’s uveitis 
CCR2 64I was significantly associated with the PSU, with an Odds ratio of 1.6 
(95% CI0.9—2.6) (p=0.029). Sub group analysis showed that it was mainly due 
to Behcet’s uveitis OR 3.2 (95% CI: 1.4—7.4) and to some degree intermediate 
uveitis, where allelic frequency of A allele was higher in patients (12%) 
compared to controls (7%).P=0.036 OR 1.7 (95% CI: 0.9—3.4) See Table 8-2, 
Appendix B 
Genotypic frequencies of CCR2-V64I in Behcet’s patients are shown in the 
Table 3-13   
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Table 3-13: Genotypic frequencies of CCR2 V64I SNP in Behcet’s uveitis and controls 
CCR2 V641 (G/A) Patients Controls  p 
     
GG 21 (68%) 247 (87%)  0.00389 
GA 9 (29%) 35 (13%)  0.01221 
AA 1 (3%) 1 (0%)  NS 
Total 31 283    
Allelic Carriage / phenotype        
G 30 (97%) 279 (100%)  NS 
A 10 (32%) 36 (13%)  0.00389 
Allelic Frequency        
G 51 (82%) 523 (93%)  0.00182 
A 11 (18%) 37 (7%)    
Total 62 560     
 
In posterior uveitis and Sarcoid uveitis the frequencies were similar to the 
controls. 
3.3.2.3 3): CCR-5 -59029 A/G association with Behcet’s uveitis.  
As shown in the main table 3.8 the CCR5 -59029 A allele was significantly 
more prevalent in Behcet’s patients compared to controls OR 2.3 (95% CI: 
1.1—4.8) p= 0.03). However this difference was modest and similarly in other 
three groups there was non-significant trend of higher prevalence of A allele. 
 
3.3.3 Genotype phenotype correlation 
3.3.3.1 MCP-1 
3.3.3.1.1 MCP-1 2518 and early age of onset of disease 
When the phenotypes of the patients were compared for different genotypes it 
was found that MCP-1 -2518 G allele had mild but significant association with 
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the age of onset of disease. The mean age of onset of disease in patients with 
A allele was 38 years compared to 34 years in patients with G allele (pc=0.04) 
as shown in  Figure 3-1. 
 
 
Figure 3-1: The mean age of onset in patients with MCP-1 2518 AA genotype versus 
patients with G allele carriers. 
The mean age of onset in patients with AA genotype was 38 years compared to 32 years in patients 
harbouring G allele.  
 
When patients were divided into 2 groups with 40 years as cut of, the G allele 
was more common in patient with age of onset before 40 years. (31% 
compared to 19% p=0.007 and pc=0.049). (See Table 8-3 Appendix B).  
Sub group analysis showed that this effect was mainly seen in idiopathic PU & 
IU and to a lesser extent in sarcoid uveitis. 
Intermediate uveitis 
This trend of association of G allele with early onset of disease was seen in IU 
group as well. The mean age of onset of disease in patients with AA genotype 
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was 44 years compared to 31 years in the group carrying G allele. p=0.01 
(Table 3-14) 
 
Table 3-14: Age of onset in intermediate uveitis according to MCP-1 -2518 genotype 
Age AT ONSET   P value 
MCP-2518 AG Mean N Std. Deviation 
AA 44.34 41 10.62  
AG/GG 31.26 36 10.34  
Total 37.89 77 10.41 0.01 
 
Posterior uveitis 
As noted in intermediate uveitis, the G allele was again associated with early 
onset of disease. This is shown in Table 3-15 
 
 
Table 3-15 Age of onset in posterior uveitis according to MCP-1 -2518 genotype. 
MCP-1 2518AG Mean Age (N) Std. Deviation P value 
     
AA 41.64341 41 13.62393  
AG 34.16553 19 8.344877  
GG 32.61826 4 2.587735  
Total 38.59289 64 12.1757 0.02 
 
 
In sarcoidosis patients the A allele of MCP-1 -2518 showed a non-significant 
trend towards early age of onset of disease. The mean age of onset was 36 
years in patients with GG genotype compared to 33 years among patients with 
A allele carriage p=0.06 
In Behcet’s group this association was not seen. 
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3.3.3.1.2 MCP-1 2518 and gender in Sarcoidosis 
In sarcoidosis patients MCP-1 -2518 showed association with gender. The wild 
allele A was significantly under represented among the male subjects as shown 
in the Table 3-16. The allelic frequency difference showed a significant p value 
of p 0.009, pc 0.03. 
 
Table 3-16: MCP-1 -2518 genotypes in sarcoidosis patients divided by gender 
MCP-1 -2518 
 males  females  P   P  
GENOTYPE Count  Count 
 3 X 2 2 X 2 
AA 2 (15%) 13 (65%) 7.83 0.00516 
AG 8 (62%) 5 (25%) 0.01998 0.03582 
GG 3 (23%) 2 (10%) 
  
NS 
Total 13 20     
Allelic Frequency         
A 12 (46%) 31 (78%)   0.00902 
G 14 (54%) 9 (22%)     
Total 26 40     
 
 
3.3.3.2 RANTES  
3.3.3.2.1 RANTES -403 and visual outcome 
It was also noted that the RANTES-403 polymorphism was associated with 
intensity of disease (VA impairment of 6 lines or more). (Figure 3-2)The GG 
genotype was more frequent in patients with more intense inflammation (n=74). 
The GG frequency was 76% as compared to 56% in patients with less severe 
inflammation (VA impairment of 3 lines) (n=131) (allele frequency difference 
p=0.006, pc=0.02) 
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Figure 3-2: Severity of inflammation and RANTES genotypes in PSU. 
The G allele was associated with severe inflammation during active episodes. Among patients who had 
at least one episode of severe inflammation (quadrupling of visual angle) 76% were homozygous for G 
allele.  
 
 
It was also noted that patients carrying A allele had better visual acuity more or 
less through out the course of disease. Using multiple regression analysis and 
correcting for age, and type of uveitis, the difference was very significant after 
first year of disease but it stayed significant till 5th year and even at 10th year 
there was a non-significant trend of better vision in patients with A allele 
carriage. See Table 3-17.  
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Table 3-17: Difference in mean vision between patients with RANTES -403 GG phenotype 
and patients carrying A allele 
Years from onset RANTES GG RANTES GA/AA  
 Mean VA Range of VA Mean VA Range of VA P value 
First Year 6/24  (6/6--6/60) 6/9  (6/5--6/24) 0.001 
Second Year 6/18  (6/9--6/60) 6/9  (6/6--6/24) 0.009 
Third Year 6/24  (6/9--6/60) 6/15  (6/9--6/36) 0.02 
Fifth Year 6/36  (6/12--4/60) 6/18  (6/9--6/60) 0.02 
Tenth Year 6/36  (6/18--NPL) 6/24  (6/12--3/60) 0.1 
 
Subgroup analysis showed that this association was seen in idiopathic IU and 
PU groups as discussed below 
Intermediate uveitis 
As noted in the entire group, the RANTES -403 G/A was predicting the visual 
outcome strongly in intermediate uveitis sub group. Patients carrying -403A 
allele had better visual acuity at year one, two, three, five and even at year ten 
there was a non significant trend of better vision with patients with -403A allele. 
See Table 3-18. This is shown graphically in the Figure 3-3. One can notice 
that after 5 years the difference between the two groups became insignificant. 
 
Table 3-18: Visual acuities in Intermediate uveitis comparing RANTES -403GG versus –
403 GA/AA 
Years from onset RANTES GG RANTES GA/AA  
 Mean VA Range of VA Mean VA Range of VA P value 
First Year 6/24 (6/6--6/36) 6/6 (6/5--6/24) 0.001 
Second Year 6/18  (6/9--6/60) 6/9 (6/6--6/24) 0.004 
Third Year 6/24 (6/9--6/60) 6/10 (6/9--6/24) 0.014 
Fifth Year 6/36 (6/12--4/60) 6/12 (6/9--6/60) 0.034 
Tenth Year 6/36 (6/18--1/60) 6/18 (6/12--5/60) 0.1 
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Figure 3-3: LogMAR Visual acuity trend between RANTES GG and RANTES GA/AA 
genotypes. 
 The IU patients with A allele carriage had a better visual acuity than GG genotype through out the 
course of the disease. However the difference in the visual acuities decreased as the disease progressed in 
time. . The values represent mean LogMAR VA (converted from Snellen) over period of times. For 
range of VA please refer to above Table 3-18 
 
 
In posterior uveitis there was similar association noted. Patients with GG 
genotype at 3 years have mean vision of 6/36 compared to 6/12 in patients with 
GA or AA genotype. As seen in the Table 3-19 the difference became 
insignificant after 3 years but this was mainly because of the decrease in the 
number of subjects hence the statistical significance decreased. As seen in the 
graph (Figure 3-4) the difference between the Visual acuity at least remained 
the same if not worsened  
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Table 3-19 Mean VA between RANTES GG & RANTES GA/AA genotypes in posterior 
uveitis 
Years from onset RANTES GG RANTES GA/AA  
 Mean VA Range of VA Mean VA Range of VA P value 
First Year 6/24 (6/6--6/60) 6/9 (6/6--6/24) 0.005 
Second Year 6/36  (6/12--5/60) 6/12 (6/9--6/24) 0.009 
Third Year 6/36 (6/18--6/60) 6/12 (6/9--6/36) 0.01 
Fifth Year 6/60 (6/18--1/60) 6/24 (6/12--6/60) 0.6 
Tenth Year 2/60 (6/18--HM) 6/30 (6/12--3/60) 0.12 
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Figure 3-4 : Trend of logMARVA between RANTES GG & RANTES GA/AA genotypes in 
posterior uveitis.  
Patients with GG genotype had consistently poorer VA throught the course of disease. The values 
represent mean LogMAR VA (converted from Snellen) over period of times. For range of VA please 
refer to above Table 3-19  
 
Since there was no significant difference noted between the alleles in context of 
permanent visual loss the Kaplan-Meier analysis was not perfomed 
 
Sarcoidosis 
In case of sarcoidosis I did not notice the same association but -403A allele 
was associated with better visual outcome in another way. The mean visual 
acuity with both eyes open after the minimal follow up of 2 years (all 
sarcoidosis patients) was 6/9 in patients carrying A allele compared to 6/36 in 
patients with GG genotype. See Table 3-20. 
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Table 3-20: Better eye vision at 2 years, in sarcoidosis patients when divided into 
RANTES -403GG genotype and RANTES -403GA or AA genotype 
RANTES403GA N Better eye VA Std. Deviation P value 
GG 22 6/36 (6/12--2/60) 0.455601867  
GA/ & AA 11 6/9 (6/5—6/18) 0.206249329 0.001 
 
I was unable to find association between -403 SNP and visual outcome in 
Behcet’s uveitis 
 
As seen in Table 3-8, the -28G polymorphism was quite rare and there were 
very few subjects who carried G allele (G allelic frequency was less than 3% in 
488 subjects tested). The two SNPs were in linkage disequilibrium. RANTES -
28 G/G was not found in subjects with -403 G allele, and RANTES -403G/G 
was not observed in subjects carrying -28 G allele.  
Since the G allele at -28 position was so rare, no attempts were made to 
construct the RANTES haplotypes. 
 
 
3.3.3.3 CCR2-V64I 
 
3.3.3.3.1 CCR2 V64I and visual outcome in posterior uveitis 
 
As seen in Table 3-21 below the CCR2 64I allele was associated with poor 
visual outcome in posterior uveitis. The difference in VA with both eyes open  
was  more noticeable with long term follow up. In first three years there were no 
significant differences in the BEVA between two groups however by year 5 the 
mean BEVA in patients with GG allele was 6/12 compared to 6/60 in patients 
with GA genotype. Similar difference was noted at year 10 as well. It must be 
noted that the difference in vision was corrected for age and high intra ocular 
pressure (as association with IOP was noted as well) 
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Table 3-21: Better eye VA in posterior uveitis patients at 5 years when divided between 
CCR2-64I allele carriers and wild types 
CCR2 V641(G/A) N Mean VA BE at 5 Years  P value 
     
GG 50 6/12 (6/9—6/24)   
GA 7 6/60 (6/18---2/60)   
Total 57 6/18 (6/9---2/60)  0.001 
     
 N Mean VA BE at 10 Years   
     
GG 41 6/24 (6/18---6/60)   
GA 5 4/60 (6/24---1/60)   
Total 46 6/36 (6/18---1/60)  0.03 
     
BE: Better eye 
 
 
 
3.3.3.3.2 CCR2 V64I and visual outcome in Intermediate uveitis 
Similar Results were noted in patients with intermediate uveitis, where patients 
with A allele carriage have poorer BEVA at third and fifth year. (See Table 
3-22) However, this difference disappeared at 10th year.  
 
Table 3-22: Better eye VA, in intermediate uveitis comparing the CCR2 V64I genotypes 
Years from onset CCR2 V (GG) Better eye VA CCR2 VI (GA) Better eye VA  
 Mean  Range Mean  Range P value 
Second Year  6/6 6/5---6/12 6/10 6/5---6/18 0.07 
Third Year 6/6 6/5---6/12 6/24 6/6---6/36 0.001 
Fifth Year 6/10 6/6---6/18 6/24 6/9---6/60 0.008 
Tenth Year 6/18 6/6---6/36 6/36 6/9---3/60 0.09 
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3.3.3.3.3 CCR2 V64I and high intra-ocular pressure in Intermediate and 
posterior uveitis 
It was also noted that among carriers of A allele (I) 60% (15/25) of the patients 
with idiopathic uveitis (both intermediate and posterior) developed raised intra-
ocular pressure compared to 26.7% (31/116) of the patients with wild type 
genotype. P=0.001, OR 4.11; 95%CI: 1.67-10.11). (Figure 3-5) After correction 
for duration of disease, age of patient and treatment the pc was0.007 
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Figure 3-5: Association of high IOP with CCR2 V64I in idiopathic PSU. 
More patients with high intraocular pressure carried A allele. 60% (15/25) of patients with A allele 
develop high intraocular pressure compared to 26.7% (31/116) in patients with GG genotype. 
 
CCR2-V64I and association with gender in Behcet’s 
As shown in the table 3, CCR-2 V64I SNP also showed association with gender. 
Whether it carries any clinical significance or not, it was noted that GG genotype 
frequency was 82% in males and 33% in females. (p=0.008). See Table 8-4 in 
Appendix B  
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3.3.3.4 CCR5-32bp deletion 
3.3.3.4.1 CCR5-32del and visual outcome in PSU: 
The CCR5 32bp ∆ was found to be associated with the visual outcome in the 
whole group. None of the patients who had VA of 6/12 or worse at minimum 
follow up of 2 years was ∆/∆. The mean LogMAR VA with both eyes (i.e VA of 
better eye) after 2 years in both groups are shown in Figure 3-6. As seen in the 
figure, the mean VA (from better eye) after 2 years was 6/6 in patients 
harbouring the deletion allele compared to 6/12 with wild type genotype. 
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Figure 3-6: Mean LogMAR VA after 2 years in PSU when divided into CCR5 32bp carriers 
and wild types.   
Mean VA in wild type is 6/12 (LogMAR=0) and is 6/6 (LogMAR=0.5) in ∆ carrying subjects  
 
When the sub group analysis was done significant differences in VA were 
achieved in idiopathic PU and IU. In Intermediate uveitis the p value was 0.002 
and in posterior uveitis the p value was 0.004 
It must be noted that in all the four groups the same association was noted but 
because of numbers in sarcoidosis and Behcet’s groups, significant p value 
was not achieved.  However collectively the association of CCR2 32bp ∆ with 
visual outcome was significant 
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3.3.3.5 CCR5-59029 
Some modest associations were noted between idiopathic PSU and steroid 
need.  
3.3.3.5.1 CCR5-59029 and steroids use in intermediate uveitis 
Many intermediate uveitis patients did not need steroids because the 
inflammation was not affecting the visual acuity. So the use of systemic 
steroids was the indicator of severity of disease.  
It was noted that among intermediate uveitis the patients who received 
systemic steroid treatment the G allele carriage frequency was 51% compared 
to 87% among patients who did no receive steroids (p=0.001, pc 0.004) [ 95% 
CI: 6.2 (1.88-20.6)] (Table 3-23) 
Table 3-23: CCR5 -59029 A allele and need for steroids in intermediate uveitis 
CCR-5 59029 G/A 
 steroids No  steroids P value  
GENOTYPE N=47  N=30   
      
GG 11 (23%) 8 (27%) NS 
GA 13(28%) 18 (60%) 0.004 
AA 23 (49%) 4 (13%) 0.001 
      
Allelic Carriage     
G 24 (51%) 26 (87%) 0.001 
A 36 (77%) 22 (73%)   
Total       
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3.3.3.5.2 CCR5-59029 and long term steroids in posterior uveitis 
30 patients were on long term (12 months or more) low dose steroids to keep 
the disease under control. Wild genotype GG (that has low CCR5 expression 
activity) was less prevalent in patients on long term steroids. P=0.03. Also A 
allele carriage was 93% in patients on long term steroids compared to 74% in 
patients with no long term steroids p=0.03 as shown in Table 8-5 in Appendix B 
 
3.3.3.6 IL8-251 
3.3.3.6.1 IL-8 251 and visual outcome in posterior uveitis 
Patients with mutant allele A generally fared poorly compared to wild type T 
allele.  90% of the patients with AA genotype had permanent visual loss of 
some kind, p 0.002 pc 0.008. Frequencies are shown in following Table 3-24.   
Table 3-24 Association of IL-8 251 genotype with permanent visual loss in posterior 
uveitis 
IL-8 251 T/A Permanent Visual loss No Visual loss P value  
GENOTYPE N=32  N=32   
    
TT 2 (6%) 8 (25%) 0.03887 
TA 20 (63%) 23 (72%) NS 
AA 10 (31%) 1 (3%) 0.00286 
Total 32 32 0.00375  
      
Allelic Frequency     
T 24 (38%) 39 (61%)   
A 40 (62%) 25 (39%)   
Total 64 64  0.008 
 
Among the patients with permanent visual loss, Kaplan-Meier analysis showed 
that patient with AA genotype had higher rate of moderate visual loss (VA 6/15 
or worse) compared with the patients with T allele carriage. As seen in Figure 
3-7, at two year of follow up, 50% of patients with AA genotype had moderate 
visual loss. On the other hand 80% patients with T allele carriage retained VA 
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of 6/15 or better at two years. (p=0.002) This difference however decreased 
with time and at five year and beyond it was non-significant.  
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Figure 3-7: Rate of moderate visual loss between IL-8 -251 AA and IL-8 -251 AT/TT in 
patients with posterior uveitis. 
Less proportion of patients with T allele developed permanent moderate visual loss compared to the 
patients with AA genotype.  
   
 
It was also noted that VA with both eyes open was better in patients having T 
allele. The mean VA with better eye after 2 years in patients with TT genotype 
was 6/6 compared to 6/36 in patients with AA genotype. See Table 3-25 for 
details. 
 
Table 3-25: Association of poor vision in posterior uveitis with IL-8 -251 A allele 
IL8251TA Mean Better eye VA N Std. Deviation P value 
TT 6/6 10 0.326777   
TA 6/12 43 0.293855   
AA 6/36 11 0.319978   
Total 6/12 64 0.323307  0.007 
Better eye VA at 2 years with AA gentotype was worse compared to T allele carriage 
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3.3.3.7 IL-8Rb 
3.3.3.7.1 IL-8Rb SNPs and development of cataract in Behcet’s uveitis 
As shown in the Table 3-26, IL-8R SNPs showed significant risk for cataract 
development. This association was very strong in case of +1208 SNP. As mentioned in 
the methods chapter the presence of cataract was always corrected for age and steroid 
use (two factors that independently can increase the risk of cataract development. 
 
Table 3-26:  IL-8 +1208 & +785 SNP and risk of cataract in Behcet’s patients 
IL8R 1208 No Cataract Cataract Significance 
GENOTYPE (N=10) (N=21) P value 
CC 0 (0%) 9 (43%) 0.013994 
TC 2 (20%) 10 (47%) NS 
TT 8 (80%) 2 (10%) 0.000008 
Allelic Carriage / phenotype    
C 2 (20%) 19 (90%) 0.000008 
T 10 (100%) 12 (57%) 0.013994 
Allelic Frequency    
C 2 (10%) 28 (67%) 0.000003 
T 18 (90%) 14 (33%)  
IL8Rb +785    
GENOTYPE    
CC 7 (70%) 3 (15%) 0.001922 
CT 2 (20%) 11 (52%) NS 
TT 1 (10%) 7 (33%) NS 
Allelic Carriage / phenotype    
C 9 (90%) 14 (66%) NS 
T 3 (30%) 18 (86%) 0.001922 
Allelic Frequency    
C 16 (80%) 17 (40%) 0.003549 
T 4 (20%) 25 (60%)  
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As seen, the T allele at +1208 position and C allele at +785 position were 
conferring protection against the development of cataract in Behcet’s uveitis. 
After correction using logistic regression the p values for allelic frequencies 
difference were still 0.00001 for IL-8R +1208 and 0.001 for IL-8R +785 SNPs 
There was strong linkage disequilibrium between the two SNPs. When the 
haplotypes were constructed the association became more striking. All the 
patients with CT haplotype (C at +1208 and T at +785) developed cataract and 
all the TC haplotype homozygous did not develop cataract. P=9.1E-09 
(0.000000009) pc 0.00000003 
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3.4 Discussion 
This study was undertaken to investigate the effect of chemokine gene 
polymorphism on the susceptibility of PSU. Its aim was to analyse the gene 
polymorphism as a predictor of disease severity and response to the treatment 
in the patients with PSU 
Patients with PSU were categorized into four groups depending on site and 
cause of inflammation.  
The control group consisted of healthy Caucasians numbered 283. All 
genotype frequencies in case and control populations conformed to Hardy-
Weinberg equilibrium.  
3.4.1 MCP-1 -2518A/G 
Two MCP-1 SNPs have been studied widely for their associations with different 
diseases including immune mediated diseases, cancers and arthrosclerosis. As 
mentioned previously, the -2518 is found to functional by many studies (Cho et 
al. 2004) (Gonzalez et al. 2002) (Rovin, Lu, and Saxena 1999). On the other 
hand the evidence that -2076 SNP may have functional role is sparse. 
(Sedlmeier et al. 2007)  -2518 SNP has been shown to effect disease 
predisposition and outcome in Sarcoidosis, Crohn’s disease, SLE and Behcet’s, 
all diseases in which uveitis is part of the spectrum of disease. (Navratilova et 
al. 2007) (Hou et al. 2010) (Lee et al. 2009b) (Palmieri et al. 2010) 
As far as -2518 SNP is concerned the frequencies in both patients and controls 
were similar to other published studies. (Rovin, Lu, and Saxena 1999) 
(Steinmetz et al. 2004) Recently, studies (Wegscheider et al. 2005) (Lan et al. 
2009) have shown that MCP-1 -2518 may be associated with anterior uveitis; 
however I did not notice any association of this SNP with my posterior segment 
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uveitis patients. Similarly I was unable to confirm the findings from China and 
Korea where -2518 allele was noted to be a risk factor for ocular Behcet’s. (Hou 
et al. 2010) (Cho et al. 2004) 
 However with -2076 SNP there was significant over representation of A allele 
and under representation of T allele in the patients. The genotypic frequencies 
in the control populations were similar to published studies (Rovin, Lu, and 
Saxena 1999) The frequency of AA genotype was consistently high in all four 
groups but reached statistical significance in Intermediate uveitis [Odd ratio 1.8 
(95% CI: 1.1—3.1)] and Behcet’s uveitis group [Odd ratio 3.0 (95% CI:1.3—
7.3)]. Because of the number of subjects it did not reach statistical significance 
in the other two groups but the odd ratio was 1.5 95%CI (0.9—2.74) 
In my study haplotype TA was more prevalent in controls as compared to PSU 
(p=0.001). This haplotype contains T allele at -2076 (noted to be a protective 
allele in my study) and A allele at -2518 (known to be associated with 
decreased MCP-1 expression). It appears that the presence of these two 
protective alleles together on the same gene exert a combined protective effect 
against PSU.  Although Rovin et al. (Rovin, Lu, and Saxena 1999) showed that 
polymorphism at site -2076 did not effect MCP-1 expression; it is worth 
mentioning that in their study the maximum transcriptional activity of MCP-1 
promoter region was noted in subjects with the AG Haplotype (A at -2076 and 
G at -2518 in their study). In another study, the same AG haplotype was 
associated with accelerated progress to AIDS and death and a high risk of HIV 
associated dementia in HIV positive Caucasian Americans. (Gonzalez et al. 
2002) In my study instead of the AC Haplotype being associated with the 
disease it was the TA haplotype (with both protective alleles), which was more 
common in the control group.  
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Alternatively, it is quite possible that the protective effective of T allele at -2076 
is independent of the -2518  polymorphism, as also noted by Modi et al. in 
AIDS patients, where the T allele frequency was significantly higher in high risk 
exposed uninfected subjects as compared to sero-converters (Modi et al. 2003). 
I also used transcription element search system (TESS) to predict the 
transcription factors binding sites at -2076. 
Using this web tool (http://www.cbil.upenn.edu/tess), it was noted that the A to 
T change at -2076 promoter site forms a DNA sequence where c-Myb can 
transactivate. c-Myb is an important transcription factor which is involved in T 
cell development and maturation. (Allen, III, Bender, and Siu 1999) Elevated 
levels of c-Myb proteins have been noticed in T cells involved in certain 
immune mediated diseases like rheumatoid arthritis, systemic sclerosis and 
systemic lupus erythromatosis,(Kahan et al. 1989) (Boumpas et al. 1986) but 
the role of these in uveitis is unknown. 
It has been proposed that the interaction of c-Myb transcription factors with the 
receptor gene leads to up regulation of expression of that gene by increasing 
DNA polymerase alpha   expression and thereby DNA production. (Venturelli, 
Travali, and Calabretta 1990) The presence of the A allele in MCP-1 -2076 may 
enhance c-Myb transactivation, whereas the T allele would prevent this c-Myb 
transactivation thereby conferring protection against uveitis. Whether -2076 is a 
functional polymorphism or not, it appears that MCP-1 promoter gene may 
harbour a genetic locus for uveitis particularly for Behcet’s as noted by studies 
in Korea and china. (Hou et al. 2010) (Cho et al. 2004)  
When I studied the effect of MCP-1 polymorphisms I noted that patients with G 
allele at -2518 (allele associated with increased MCP-1 expression) developed 
the disease at earlier age compared to the patients with A allele. This is in 
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keeping with other studies that have also noted an association with the MCP-1 
-2518 G allele and early onset of disease. (Nishimura et al. 2004) Sub group 
analysis replicated this effect in intermediate uveitis and posterior uveitis with 
very significant difference.  
Based on these findings one could say that G allele can affect the age of onset 
in idiopathic posterior segment uveitis but not in uveitis secondary to systemic 
diseases.  
I also noted that in sarcoidosis patients the AA -2518 genotype was 15% in 
males compared to 65% in females. Though the difference was very significant, 
the clinical value is questionable particularly after I was unable to notice any 
other effect of this SNP on sarcoidosis phenotypes. However there is at least 
one study in the published literature that have shown association of MCP-1 
haplotypes (-2518 & -2076) with gender in patients with ocular Behcet’s (Chen 
et al. 2004) 
 
3.4.2 RANTES -403G/A and -28C/G 
I studied two SNPs in the RANTES gene that are known to be functional. (al, 
Ollier, and Hajeer 1999) (Hajeer, al, and Ollier 1999) There was no significant 
difference in the genotypes between the patients and controls. The frequencies 
of both SNPs in both patients (and sub groups) and controls were similar to 
other published studies. (Hajeer, al, and Ollier 1999), (Gade-Andavolu et al. 
2004), (Simeoni et al. 2004) As expected the -28G polymorphism was quite 
rare and there were very few subjects who carried G allele (G allelic frequency 
was less than 3% in 488 subjects tested). As mentioned in other studies 
(Nakajima et al. 2003) the two SNPs were in linkage disequilibrium. RANTES -
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28 G/G was not found in subjects with -403 G allele, and RANTES -403G/G 
was not observed in subjects with -28 G allele.  
Since the G allele at -28 position was so rare, no attempts were made to 
construct the RANTES haplotypes. 
The study showed that G allele at poition -403 of RANTES, was a strong 
predictor of visual outcome in patients with PSU. Patients carrying A allele not 
only had better visual acuity during exacerbation of disease but compared to 
GG genotype exhibited good visual acuities through out the course of the 
disease. The difference was very significant up until 5 years of disease onset.  
Sub group analysis also showed that A allele was associated with better visual 
outcome in intermediate, posterior and sarcoid related uveitis. It must be noted 
that among sarcoidosis patients the difference was only significant until 18 
months of onset of disease. I was unable to replicate this association in 
Behcet’s uveitis group.  Based on the results, we can infer that -403 SNP is a 
predictor of visual outcome in patients with idiopathic posterior and 
intermediate uveitis. Its role in uveitis associated with systemic diseases need 
further studies.   
It appears that A allele which is associated with increased RANTES expression 
is having a protective effect in patients with posterior uveitis. This is in contrast 
with the studies where they have found association of disease susceptibility 
and severity with the A allele. Recently evidence has accumulated that 
RANTES can actually help in controlling uveitis 
Sonoda et al. (Sonoda et al. 2003) showed that in animal EAU which is the 
animal model for posterior uveitis, RANTES produced by ocular macrophages 
appears to suppress EAU. In another study (Adamus, Manczak, and Machnicki 
2001) RANTES levels remained high during the recovery phase of 
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experimental autoimmune uveitis associated with EAE, and anti-RANTES 
antibodies treatment was not effective in suppressing the uveitis. A similar 
finding was noted in recurrent anterior uveitis in Lewis rats, where Anti-
RANTES was not effective in protecting against the development of uveitis. 
(Manczak et al. 2002) 
Recently Kim et al. measured levels on RANTES in aqueous humour and 
peripheral blood in patients with different types of uveitis.  (Kim, Chung, and Yu 
2010) They noticed that the RANTES levels were constantly lower in aqueous 
humour in all types of uveitis during active disease. These studies show that 
decrease expression of RANTES may be associated with prolonged and 
severe inflammation. And hence A allele which increases the RANTES 
expression helps in controlling the posterior uveitis.  
 
3.4.3 IL-8 251T/A & -845T/C 
In IL-8 gene two SNPs are shown are shown to be functional, -251 T/A and -
845T/C (Ohyauchi et al. 2005) (Rovin, Lu, and Zhang 2002).  
The SNP at -845 is very rare in Caucasians, and Asians, however more 
common in African races. (Rovin, Lu, and Zhang 2002). In my study the mutant 
allele C frequency was 1% in both patients and controls. In the patient group 
there were only three subjects who were heterozygous TC and no one was 
homozygous for C allele. Similarly there was no homozygous CC in control 
population and only 7 carried C allele.   
As this SNP was so rare haplotype construction was not done as it would not 
have added any new information.  
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No association of this SNP was found with any of my patient sub groups and 
one of the reasons may be that because of the rarity of allele the sample size 
was too small to notice any associations 
The -251 SNP as shown in the results section was very polymorphic and the 
two alleles were more or less equally present in all the studied populations. I 
did not find any difference in the allelic frequencies between any of the 
populations and frequencies were similar to other published studies. (Howell et 
al. 2005) 
The only significant association noted was in patients with posterior uveitis, 
where A allele was associated with permanent visual loss. It was also 
associated with poor VA in both eyes. (BEVA) 
This functional SNP at -251 position has been studied widely for disease 
associations and strong associations have been noted in gastric carcinomas 
and asthma. However there are studies showing that this SNP is also 
associated with immune mediated diseases like vasculitis and multiple 
sclerosis. (Amoli et al. 2002) (Kamali-Sarvestani et al. 2006)  
There is no study in the literature that has noticed any association of -251 SNP 
with uveitis phenotype except one. (Lee et al. 2007) Here the authors found 
that two haplotypes carrying -251 alleles were common in patients with ocular 
Behcet’s when compared to controls. However it is interesting to know that one 
haplotype carried the A allele and the other carried the T allele, meaning that 
this particular SNP did not have any independent role in disease predisposition. 
 
3.4.4 CCR2 V64I 
CCR2 V64I polymorphism which substitutes isoleucine for valine at position 64 
(CCR2-64I), in the first transmembrane domain of CCR2 is correlated with 
 214 
significantly delayed progression to acquired immunodeficiency syndrome 
(AIDS), especially in African populations. (Kostrikis et al. 1998) (Anzala et al. 
1998) Since this polymorphism is common in Africans, it was proposed that 
CCR2 64I rather than CCR5 32bp ∆ (which is very rare) confers protection 
against AIDS in Africans. Although this amino acid changed is conservative, 
various studies have shown that 64I allele may be a protective factor in 
autoimmune diseases like sarcoidosis and multiple sclerosis. (Hizawa et al. 
1999) (Petrek et al. 2000) (Miyagishi et al. 2003)  A recent study has shown 
that the 64I allele could be a predictor of arthritis in psoriasis. (Soto-Sanchez et 
al. 2010) It is interesting to know that psoriatic arthritis but not psoriasis can be 
associated with uveitis. Initially thought to be a non-functional polymorphism, 
there is now increasing evidence that this SNP could be functional (Nakayama 
et al. 2004) (Sabbe et al. 2001) (Mellado et al. 1999) 
All the allele frequencies in Caucasian patients and controls were in hardy 
Weinberg equilibrium. The CCR2 V64I was tightly linked with CCR5 -59029 
and 32bp ∆. CCR2 64I homozygosity as not found in subjects with the CCR5 
59029G allele, while CCR5 59029G homozygosity was not observed in 
subjects with the CCR2 64I allele. 
This is in accordance with other studies. (Nakajima et al. 2002) Also CCR2 
V64I homozygous was never homozygous for CCR5 32bp ∆. 
In my study there was a significant difference in the allelic frequencies between 
the Caucasian patients as a whole and controls. The 64I mutation was 10% in 
patients as compared to 7% in controls (p=0.02). Subgroup analysis showed a 
striking association of 64I allele with Behcet’s uveitis (n=31). In this group the A 
allele (64I) was present in 17% of patient p=0.001 and the genotype difference 
was very significant as well p=0.006. Since there is no published study on the 
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frequency of 64I allele in Behcet’s disease, it is difficult to tell whether this 
difference is due to uveitis in Behcet’s disease or the disease itself. But I also 
noted increase frequency of 64I allele in patients with intermediate uveitis 
(n=77) 12% compared to 7% in controls. (p=0.03) 
It is interesting to note that the frequency of 64I allele in populations where 
Behcet’s disease is more common is between 13% [Turkish and Greek 
populations], (Karaali et al. 2010) (Apostolakis et al. 2005) to 27% in Korea. 
(Cheong et al. 2007) However this observation alone is not sufficient to assume 
that 64I can predispose to Behcet’s disease.  
Alternatively one can argue that my Behcet’s patients may have a Lineage from 
above mentioned ethnicities.  Although my patients were British Caucasians 
who’s both parents were Ethnically British, the chances of gene admixture in 
older generations cannot be ruled out.    
While studying the phenotype genotype associations of this SNP, 64I allele was 
associated with poor visual acuity in patients with idiopathic intermediate and 
posterior uveitis. It was also associated with high intra-ocular pressure 
episodes during the inflammation in patients with intermediate and posterior 
uveitis. Since there is no known role of CCR-2 gene in intra-ocular pressure, it 
is likely that this association is because of linkage of 64I allele with some other 
locus, yet to be identified  
While this SNP did not confer any genetic disposition to idiopathic posterior 
segment uveitis, it was affecting the phenotype. On the other hand it was 
associated with Behcet’s uveitis development but then not affecting the 
phenotype. No associations were noted with Sarcoid uveitis.  
Another interesting finding was gender association of this allele in Behcet’s 
disease. 67% of the females with Behcet’s disease carried the 64I allele. 
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However the numbers were too small to have any statistical power. Interesting 
a study from Iran (Mojtahedi et al. 2006) has shown a high prevalence of 32bp 
∆ allele in female patients with Behcet’s disease and as mentioned earlier the 
V64I SNP and CCR-5 32bp ∆ are in strong linkage. I however did not notice 
any association of 32bp ∆ and female gender in Behcet’s disease.  
 
3.4.5 CCR5 -59029G/A and CCR5 32bp ∆ 
Two functional SNPs in CCR5 gene were studied.  
The 32bp ∆, which is common in Caucasians compared to other ethnicities and 
play an important role against HIV infection and progress. However its role in 
autoimmune disease is not very clear. Individuals who are homozygous for a 
32 bp deletion in the CCR5 gene comprise 1% of all whites, whereas 
individuals heterozygous for this deletion represent 20% of whites. (Liu et al. 
1996) 
The ∆ 32 allele frequency is 2-5% in Asian and 1% in Africans. The presence of 
deletion results in a truncated form of the functional receptor and homozygous 
carriers of this mutation fail to express CCR5 on their cell surface.  
The other SNP, G/A at nucleotide position 59029 in the promoter region of 
CCR5 (G59029A), is also thought to be functional. (Shieh et al. 2000) 
(McDermott et al. 1998) Here the A allele is associated with increased 
expression of CCR5 receptors on cell surface. Initial studies in patients with 
AIDS showed that CCR5 -59029A homozygous progressed more rapidly than 
those who were homozygous for the G allele. (An et al. 2000).  
All genotype frequencies for the two SNPs were in H-W equilibrium in all 
populations and subsets. There was strong linkage between the two SNPs.  All 
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patients with ∆/∆ phenotype were homozygous for -59029 G allele. Similarly all 
AA homozygous for -59029 were also homozygous for wt Allele 
In my patients no significant difference was noted in the frequencies of CCR5 
32 bp ∆ between the patients and controls. In case of -59029 SNP, the AA 
homozygous were more frequent in all the four patients groups compared to 
controls but only showed non significant trend except Behcet’s uveitis. In this 
case the AA frequency was 48% compared to 29% in controls.  
 When the effects of these SNPs on the disease phenotype were studied, it 
became evident that the 32bp ∆ allele was associated with better visual 
outcome. Taking the whole group as one, none of the patients with a VA of 
6/12 or worse (at the end of minimum follow up) carried the mutant allele. 
Similarly the mean vision of patients carrying the mutant allele at every time 
point was better than patients with wild type genotype. It must be noted that 
when the four groups were analysed the separately, the same association was 
evenly seen but statistical significance was not reached in sarcoidosis and 
Behcet’s presumably because of the sample sizes. It is also possible that this 
SNP was exerting it effects only in idiopathic uveitis groups (i.e. IU and PU).  
My findings that 32bp ∆ could have a protective effect on the progress of uveitis 
is consistent with other studies. 
The 32bp ∆ allele was noted to be a protective factor against rheumatoid 
arthritis (Pokorny et al. 2005) and has been associated with less severe 
phenotype. (Zapico et al. 2000) (Garred et al. 1998) CCR5 32bp ∆ has also 
been noted to contribute to protection from the development of primary 
Sjogren's syndrome. (Petrek et al. 2002) 
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By contrast, 32bp ∆ allele has found to be associated with increase 
susceptibility and severity of diseases like multiple sclerosis, (Pulkkinen et al. 
2004) sarcoidosis. (Petrek et al. 2000) 
 The -59029 showed association with the use of systemic steroids in IU and PU.  
It was also noted that among intermediate uveitis the patients who received 
systemic steroid had low carriage frequency of protective allele G and similarly 
among PU patients who stayed on long term steroids had low G allele 
prevalence. In case of IU the use of steroids is a measure of intensity of 
disease as many patients with IU may have 6/6 vision and many a times this is 
managed conservatively.  
My results have shown that this SNP can be a predictor severity of the disease.  
Although association studies in immune mediated diseases have so far been 
unfruitful, recent studies have shown that A allele is associated with renal graft 
rejection. (Yigit et al. 2007) (Omrani et al. 2008) (Abdi et al. 2002) 
Given the functional effects of these two polymorphisms and role of CCR5 
gene in PSU, it is plausible to state that these polymorphisms can affect the 
phenotype in idiopathic PU and IU.  
 
3.4.6 IL-8Rb +1208T/C and +785C/T 
Recently +1208T/C and +785C/T polymorphisms in the exon 3 of CXCR2 (IL-
8Rb) have been shown to be associated with systemic sclerosis in Caucasians. 
(Renzoni et al. 2000) 
The study showed that T allele of +1208 and C allele of +785 which were in 
linkage were associated with the disease 
In my study I did find the linkage between T allele of +1208 with C allele of 
+785 but that was not 100%. I did not find any significant difference in the 
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genotypes between patients and controls. This is in line with association 
studies in Behcet’s and Multiple sclerosis where genetic predisposition could 
not be accounted because of these SNPs. (Duymaz-Tozkir et al. 2005) 
(Kamali-Sarvestani et al. 2006) 
One significant association was noted when the effect on disease phenotype 
was studied 
 In Behcet’s patients the C allele at +1208 and T allele at +785 were strongly 
associated (p=9.1E-09) with cataract development.  
The +1208 T/C is in the 3’ untranslated region of exon 3, and has the potential 
of altering mRNA processing, stability, or translation, but so far its functional 
effects are not known. Since association with cataract was very strong, further 
studies are needed to explore the role of IL-8Rb receptors in the development 
of cataracts in uveitis  
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3.5 Conclusion 
This study was done to see whether SNPs is chemokine genes can predict 
genetic predisposition and outcome in PSU 
Two SNPs showed that they can act as genetic risk markers 
1)  MCP-1 -2076 for PSU as a whole but particularly for Intermediate and 
Behcet’s uveitis 
2)  CCR2 V64I for Behcet’s disease only 
Following SNP associations were noted to predict the disease phenotype.  
 
Table 3-27: The effect of chemokine SNPs on posterior segment uveitis phenotype 
SNP & Allele Effect of Allele on gene  Association Group 
MCP-1 2518G G  increases expression Early age of onset of disease IU & PU  
RANTES -403A A increases expression Better visual outcome IU & PU 
CCR2 V64IA A  Increases expression Poor visual outcome / High IOP IU & PU 
CCR5 32bp ∆. Del. decreases expression Better visual outcome IU & PU  
CCR5 -59029A A increases expression Increased need for Steroids IU & PU 
IL-8 -251A A increases expression Poor vision PU 
IL-8Rb +1208C Non-functional Increase incidence of Cataract Behcet's 
 
From the above table one can deduce that certain genes were involved in 
pathogenesis of a particular type of PSU but not other. However both idiopathic 
IU and PU shared the same associations and this further confirms that 
immunologically they are similar disease. The RANTES and its receptor CCR-5 
appear to play a role in the disease process in IU and PU together with CCR-2 
whose SNP is tightly linked. These effects are either direct results of these 
SNPs or indirect through linkage disequilibrium with other SNPs in close 
proximity. It will be worth checking SNPs in the proximity and constructing 
extended haplotypes in patients with idiopathic uveitis (Both IU and PU) 
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 On the other hand effects of chemokine genes on Behcet’s patients were 
different, and the role of CCR2 V64I in Behcet’s needs to be further explored.   
No significant role of chemokine genes was noted in sarcoidosis group.  
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Chapter Four 
4 CCR5 & CCR2 polymorphisms in idiopathic 
posterior segment uveitis and Ocular Behcet’s  
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4.1 CCR5 & CCR2 polymorphisms in idiopathic 
posterior segment uveitis 
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4.1.1 Introduction 
In the previous chapter I have shown that CCR2 & CCR5 SNPs were 
associated with visual outcome in idiopathic intermediate and posterior uveitis.  
These associations were not noted in uveitides secondary to systemic diseases 
implicating that the inflammatory pathways may be different in these cases. 
The findings that genes involved showed similar association in both IU and PU 
groups, further confirms the notion that both disease entities share the same 
pathogenesis. (Forrester JV et al. 1998) The CCR5 32bp ∆ was associated 
with better visual outcome and CCR2 64I mutation was associated with poor 
visual outcome. Also noted was that CCR5 -59029 A mutant allele was 
associated with more and continuous need of steroids to control the 
inflammation. As already mentioned in the previous chapter, the 3 SNPs were 
in strong linkage and the subject homozygous for 64I allele or -59029 A allele 
(both noted to be pro-inflammatory) were never homozygous for 32bp ∆ (noted 
to be protective allele).  Although my study showed that the protective effects of 
64V allele or 32bp ∆ were independent of each other it is very likely that these 
effects may be a result of linkage to another locus yet to be identified. 
A large part of the information available on the functional consequences of 
CCR5 gene polymorphisms in vivo stems from studies of HIV-1–infected 
individuals as CCR5 is the major coreceptor for the HIV type-1 virus. Evidence 
is there that other SNPs in CCR5 gene may be functional. The cells from 
individuals with the wild-type for 32bp ∆ genotype showed a wide range of 
surface expression of CCR5. (Wu et al. 1997) Other rarely occurring CCR2 
SNP, m303A (V64I) is a nonsense mutation of coding region that exerts effects 
similar to those of CCR5∆32. (Quillent et al. 1998) An Asian-specific CCR5 -
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893 is a single nucleotide deletion in the CCR5 coding region, and the levels of 
CCR5 expression on the surface of CD4 positive cells are greatly reduced in 
individuals bearing the mutant allele (Shioda et al. 2001). The CCR2 mutation, 
CCR2 64I, is in strong linkage disequilibrium with another mutation CCR5 –
1835T in the second intron of the CCR5 gene, is also associated with a delay in 
HIV-1 disease progression (Mummidi et al. 1998) (Kostrikis et al. 1998). With 
respect to the promoter region, Martin et al. identified 10 polymorphic 
nucleotide positions in the 517 bp region of Caucasian CCR5 promoters, and 
described 10 haplotypes in this region. (Martin et al. 1998)  Of these, the P1 
haplotype has G, C, and A at the 208th, 627th, and 676th positions, 
respectively, from the transcription start site of the CCR5 gene. Although both 
CCR2 64I and CCR5∆32 were consistently found in the CCR5 P1 haplotype, 
the homozygotes for (CCR2 64V/CCR5 P1/lacking CCR5∆32) haplotype 
exhibited an epidemiological association with rapid progression to AIDS. 
McDermott et al. (McDermott et al. 1998) reported that the presence of 
homozygous for CCR5 59029G lacking CCR5∆32 and CCR2 64I caused a 
delay by 3.8 years in the progression to AIDS compared to that seen in patients 
homozygous for 59029 A. Position 59029 in McDermott’s report corresponds to 
position 303 from the transcription start site. Since different reports have 
adopted different numbering systems for the CCR5 gene Carrington et al. 
(Carrington et al. 1999) proposed a new numbering system starting from the 
translation start codon. Using this numbering system, Mummidi et al. reported 
six human haplogroups (HHA, B, C, D, E, F and G) involving CCR2 V64I, 
CCR5∆32, and eight polymorphic positions (–2733, –2554, –2459, –2135, –
2132, –2086, and –1835) in the 926 bp region of Caucasian and African-
American CCR5 promoters. This is shown in detail in following figure. 
 226 
 
Figure 4-1: CCR5 SNPs & haplotypes as described by Mummidi et al.  (Mummidi et al. 2000) 
a)  Scheme of CCR2 and CCR5 loci on chromosome 3 (not to scale; hatched marks denote gaps).  b) A phylogenetic tree depicting the 
relationships among the seven CCR5 human haplogroups (HHA–HHG). A chimpanzee CCR5 haplotype was used as an outgroup.  c) A schematic 
representation of the nucleotide sequences of the unique human CCR5 haplotypes (22761 to 21835). The sequences of human CCR5 haplotypes 
were compared with those found in the homologous region of chimpanzee CCR5.  d) Classification of CCR5 human haplogroups. Each haplotype 
within a haplogroup is characterized by the constellation of invariant polymorphisms indicated but differ from each other by additional SNPs.   
e) A model illustrating the potential evolution of human CCR5 haplogroups  
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Recently Lui et al. (Liu et al. 2007) showed that construct lacking -59029 site in 
the promoter region of CCR5, showed difference in the promoter activity, 
presumably due to -2135 and 2086 SNPs. The study also showed that the 
effects of CCR2 V64I SNP were independent of -1835 SNP to which it is tightly 
linked. The SNP CCR5 -1835C/T, located in the 50 cis-regulatory region of 
CCR5 has been shown to result in loss of novel nuclear factor 
binding.(Mummidi et al. 2000) Transcriptional activity of different haplotypes in 
the cis-regulatory region of CCR5 demonstrated that CCR5-haplotypes 
containing 1835T (HHF) had significantly different promoter efficiency 
compared to other haplotypes. (Mummidi et al. 2000) 
Aims and Objectives: 
To further increase our insight into the role of CCR5 gene in PSU, I 
hypothesized that theses CCR5 haplotypes can affect the disease susceptibility 
and prognosis in idiopathic PSU. I only examined the effects of these 
haplotypes in idiopathic patients because of the previous results showing role 
of CCR5 SNPs in IU and PU groups only. The aim of this study was to see 
whether CCR5 haplotypes can affect the genotype of idiopathic PSU and 
whether the effects seen in previous studies can be attributed to other SNPs 
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4.1.2 Material and Methods 
4.1.2.1 Subjects 
There were 141 Caucasian patients with idiopathic posterior segment uveitis. 
77 had intermediate uveitis and 64 had posterior uveitis.  
4.1.2.2 Controls  
Two groups of control subjects were used in this study: 169 healthy English 
Caucasian subjects who were admitted for cataract extraction and a cohort of 
142 Caucasian healthy subjects whose DNA were stored and used in other 
studies. (Spagnolo et al. 2005) All the subjects were negative for any history of 
autoimmune disease. 
4.1.2.3 Genotyping 
4.1.2.3.1 DNA extraction 
The DNA extraction in patients and was done with commercial kits (Qiagen UK 
Ltd, UK) according to the manufacture’s instructions and as discussed in 
chapter 2 
The DNA extraction of 169 controls was done by salt extraction method and 
other set of 142 controls already had DNA extraction.  
4.1.2.3.2 Primer designing and genotyping: 
The primers were designed as mentioned in chapter 2 in detail and the SNPs 
wee identified by using sequence specific primer-polymerase chain reaction 
(SSP-PCR) technique. All PCR reactions were run under identical conditions as 
mentioned previously in methods chapter. The Table 4-1 shows the details of 
the primers used to type CCR5 SNPs in idiopathic PSU patients and controls. 
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Table 4-1 Sequences of primers used for PCR-SSP detection of CCR5 polymorphisms 
 
SNP Position Locus 
Accession 
No. Position Primer Sequence  
Control 
Primers 
Product Size 
(bp) 
CCR2190G/A Exon,codingsequence U95626 46276-295 F-TGTGGGCAACATGCTGGTCG/A 63  64* 297 
 
  46554-573 R-AAGGTGACCGTCCTGGCTTT   
 5663A/G Promoter U95626 55830-852 R-GCTTGGTGAGTTTTGATATGCAT/C 63  64 290 
 
  55563-582 F-AGCCCGACTGTCTACTGAAC   
 3900C/A Promoter U95626 57568-592 F-GCTATCTATCTTTCGAAAAACCAAC/A 63  64 305 
 
  57852-872 R-CCTCCAGCTTCATTACTGCTA   
 3458T/G Promoter U95626 58030-049 R-AGCGATCAAGACACCCCCAA/C 210  211† 719 
 
  57331-349 F-AGCAAGTCAGCAGCAACGC   
 2459A/G Promoter U95626 59029-050 R-GGACTTCACATTAACCCTGTGT/C 210  211 760 
 
  58291-310 F-GCCGTGGATGCCTCATAGAA   
 2135T/C Exon U95626 59330-353 F-GTGAGAAAAGCCCGTAAATAAACT/C 210  211 951 
 
  60272-292 R-TGCCACCACAGATGAATGTCA   
 2086A/G Exon U95626 59402-423 R-AGAATCAGAGAACAGTTCTTCT/C 63  64 267 
 
  59137-158 F-AGCCTTACTGTTGAAAAGCCCT   
 1835T/C Exon/Intronboundary U95626 59653-674 R-AGCACTTGGTGTTTGCCAAATA/G 210  211 905 
 
  58772-792 F-ATCTGGCATAGTGTGAGTCCT   
Delta32wt/ 32 Exon,codingsequence U95626 62018-040 F-GCTCTCATTTTCCATACAGTCAG(wt) 63  64 244 
 
  62015-070 F-GCAGCTCTCATTTTCCATACATTA( 32) 215  
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4.1.2.4 Statistical Analysis 
For each subject group, genotype frequencies were counted and the allelic and 
allele carriage frequencies calculated. All genotype frequencies in each 
population were tested for deviation from the Hardy-Weinberg equilibrium using 
the chi-square test. Data mining for significant associations was performed 
using knowledge seeker® (Angoss software UK) and statistical calculations 
were performed with SPSS 12.0 (Chicago USA). A multiple logistic regression 
model was used to determine association between various genotype and the 
phenotypes. Power calculations were performed using QUANTO® ® Version 
1.0, which is specific software for power calculations in genetic studies 
(http://hydra.usc.edu/gxe).  
Haplotypes were identified by the computer program PHASE, version 2. 
(Stephens, Smith, and Donnelly 2001) Before generating haplotype, linkage 
between the SNPs was calculated by EM algorithm using Arlequin® population 
genetics software. Arlequin® is also freely available from 
http://cmpg.unibe.ch/software/arlequin3 
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4.1.3 Results 
The clinical and demographic details are shown in the following Table 4-2.  
Table 4-2: Characteristics of patients with Idiopathic posterior and intermediate uveitis 
 
Follow up in years  Mean=6.8  Range=(1.5-42.6)  
Sex  Males=59  Females=82  
Laterality of disease  Bilateral=118  Unilateral=23  
Age of onset (years)  Mean=37.82  Range=(5-70.5)  
Recurrence (rate per year)  Mean=1.92  Range=(1-7)  
Mean Visual impairment during 
inflammation  
Doubling of 
visual angle  Range=(Nil-PL)  
Better eye VA after 24 months  Mean=6/9  Range=(6/5-6/60)  
Permanent visual loss  n=55  Mean=6/24, Range=6/15-HM  
10 mg or more of long term steroids  n=51    
On second line of immuno-suppressants  n=51    
Cystoid macular oedema  n=85    
Raised intra-ocular pressure  n=46    
Cataract  n=55    
Idiopathic intermediate uveitis n= 77   
Idiopathic posterior uveitis n=64   
 
 
 
All the genotypic frequencies were within Hardy Weinberg equilibrium. As 
shown in the Table 4-3, there was no significant difference between the 
frequencies of SNPs in uveitis or any of the control groups.  
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Table 4-3: CCR5 promoter polymorphisms genotype frequencies in idiopathic segment 
uveitis and controls 
SNPs position Uveitis controls (A) Controls (B) Chi 2X2 
 N=141 (%) N=169 (%) N=142 (%)  
CCR2 190 
   1.51 
G/G 118 (84%) 139 (82%) 114 (80%)  
G/A 23 (16%) 30 (18%) 28 (20%)  
A/A 0 (0%) 0 (0%) 0 (0%)  
-5,663    0.5 
A/A 45 (32%) 55 (32%) 38 (27%)  
A/G 63 (45%) 91 (54%) 78 (55%)  
G/G 33 (23%) 23 (1 3%) 26 (18%)  
-3,900    1.69 
C/C 14 (10%) 21 (13%) 19 (13%)  
C/A 72 (51%) 92 (54%) 76 (54%)  
A/A 55 (39%) 56 (33%) 47 (33%)  
-3,458    1.47 
T/T 12 (9%) 19 (11%) 19 (13%)  
T/G 72 (51%) 88 (52%) 74 (52%)  
G/G 57 (40%) 62 (37%) 49 (35%)  
-2,459    1.31 
G/G 20 (14%) 32 (19%) 26 (18%)  
G/A 74 (52%) 87 (51%) 74 (52%)  
A/A 47 (33%) 50 (30%) 42 (30%)  
-2,135    1.31 
T/T 20 (14%) 32 (19%) 26 (18%)  
T/C 74 (52%) 87 (51%) 74 (52%)  
C/C 47 (33%) 50 (30%) 42 (30%)  
-2,086    2.32 
A/A 55 (39%) 56 (33%) 44 (31%)  
A/G 70 (50%) 89 (53%) 76 (54%)  
G/G 16 (11%) 24 (14%) 22 (15%)  
-1,835    1.15 
T/T 0 (0%) 0 (0%) 0 (0%)  
T/C 24 (17%) 31 (18%) 26 (18%)  
C/C 117 (83%) 138 (82%) 116 (82%)  
∆ 32    1.98 
wt/wt 109 (77%) 142 (85%) 111 (78%)  
wt/ ∆ 32 27 (19%) 26 (15%) 30 (21%)  
∆ 32/ ∆ 32 4 (3%) 1 (1%) 1 (1%)  
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There was extensive linkage disequilibrium between the SNPs. The -2459G/A 
SNP was in complete linkage with -2135T/C similarly CCR2 190G/A was very 
tightly linked with -1835C/T. Using PHASE®, 12 haplotypes were constructed 
including 5 common haplotypes. As seen in Table 4-4, the prevalence of 
haplotype HHC was 50% in uveitis group compared to 64% in both control 
groups. (p=0.004). The frequencies of other haplotypes were quite similar 
between the groups. The frequency of HHC was 50% in both IU and PU groups.  
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Table 4-4: CCR5 haplotype carriage frequencies in uveitis and controls 
CCR2 ∆ Int. Post  
Haplotype 190 -5663 -3900 -3458 -2459 -2135 -2086 -1835 32 
Uveitis 
 Uveitis Uveitis 
Controls  
Chi 2X2 
                    
n=(141) n=(77) n= (64) n=(311) P value 
HHA V A A G G T A C wt 14 (10%) 8 (10%) 6 (10%) 22 (7%) NS 
HHC V A C T G T G C wt 70 (50%) 38 (50%) 32 (50%) 199 (64%) 0.004 
HHC*1 I A C T G T G C wt 3 (2%) 2 (2%) 1 (2%) 6 (2%) NS 
HHC*2 V A C T G T G C ∆ 32 2 (1%) 1 (1%) 1 (1%) 3 (1%) NS 
HHC*3 V A A G G T G C wt 2 (1%) 1 (1%) 1 (1%) 12 (4%) NS 
HHE V G A G A C A C wt 72 (52%) 40 (52%) 32 (50%) 171 (55%) NS 
HHE*1 V G A G A C G C wt 1 (1%) 1 (1%) 0 3 (1%) NS 
HHE*2 V G A G A C G C ∆ 32 2 (1%) 1 (1%) 1 (1%) 0 (0%) NS 
HHE*3 V A C G A C A C wt 4 (3%) 2 (2%) 2 (2%) 6 (2%) NS 
HHF*1 V A A G A C A T wt 0 0 0 6 (2%) NS 
HHF*2 I A A G A C A T wt 23 (16%) 12 (16%) 10 (15%)  53 (17%) NS 
HHG*2 V G A G A C A C ∆ 32 27 (19%) 17 (22%) 10 (16%) 56 (18%) NS 
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4.1.3.1 Effect on phenotype: 
4.1.3.1.1 HHC and visual outcome 
It was also noted that 63% (44/70) of the patients with HHC haplotype needed 
systemic steroids to control the inflammation compared to 81% (58/71) of the 
patients not carrying HHC haplotype. P=0.007 OR: 0.3758, 95% CI: 0.37 (0.18-
0.78). (Figure 4-2 )When subgroup analysis was done no significant difference 
were noted between IU and PU groups suggesting that effects of HHC 
haplotype were generalized to the whole idiopathic PSU group.  
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Figure 4-2: CCR5 HHC haplotype and need for systemic steroids in idiopathic PSU. 
Less patients with HHC haplotype needed systemic steroids (does not include peri-ocular steroids) to 
control the inflammation 
 
Better eye visual acuity after 2 years (minimal follow up) was also noted to be 
better in patients carrying HHC haplotype in both IU and PU group. The 
difference remained significant after correcting for age, Table 4-5 shows this in 
detail. 
 236 
Table 4-5: Better eye VA at 2 years in IU & PU patients carrying HHC haplotype. 
 
This effect was however lost, as the time progressed and at third year and 
beyond and no significant difference in the visual acuities were found between 
the HHC and the rest of the haplotypes. So at least for a short term HHC 
carriers had better vision in both IU and PU groups  
4.1.3.1.2 HHF2 and Visual acuity: 
Patients carrying HHF2 had worse VA in effected eye at year one, two, three 
and 5. The effect was seen in both IU and PU but it was more pronounced in IU. 
(Table 4-6) 
Table 4-6: HHF2 Haplotype and VA in IU & PU. 
 
Patients with HHF-2 haplotype had worse mean visual acuities in both IU & PU group. The difference 
was more significant in early course of the disease. 
 
This difference was more significant to start with but by year five it became less 
significant (at least in PU).  
 Intermediate Uveitis (N=77)  P value Posterior Uveitis (N=64) 
 
P value 
       
HHC HHC +ve HHC -ve  HHC +ve HHC -ve  
 N =(38) N= (39)  N= (32) N= (32)  
Better eye       
VA 6/9 6/18 0.01 6/12 6/30 0.008 
Range (6/5---6/18) (6/6---6/36)  (6/6---6/18) (6/9---6/60)  
Intermediate Uveitis Mean Visual acuity (Range) 
HHF2 Haplotypes 1st year 2and Year 3rd year 5 year 
 
    
HHF2 +ve (12) 6/24 (6/6-6/36) 6/30 (6/9-6/60) 6/36 (6/9-6/60) 6/36 (6/12-4/60) 
HHF2 -ve (65) 6/7.5  (6/5-6/18) 6/12 (6/6-6/24) 6/9 (6/9-6/18) 6/12(6/9-6/60) 
P value 0.0001 0.009 0.003 0.01 
     
Posterior Uveitis Mean Visual acuity 
HHF2 Haplotypes 1st year 2and Year 3rd year 5 year 
     
HHF2 +ve (15) 6/18 (6/5-6/60) 6/30 (6/9-5/60) 6/36 (6/12-6/60) 6/36 (6/18-1/60) 
HHF2 -ve (49) 6/9 (6/5-6/24) 6/12 (6/9-6/60) 6/18 (6/9-6/60) 6/24 (6/12-6/60) 
P value 0.008 0.005 0.02 0.1 
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4.1.3.1.3 HHG2 and Visual Outcome 
HHG2 was associated with better visual acuity. This association was not as 
strong as with HHF2, but was still quite significant in first two years of life. 
Again as seen in HHF2 haplotype the association was stronger in IU group as 
compared to PU group and difference was only significant in the early years of 
the disease. (Table 4-7 ) 
 
 
Table 4-7: Association of HHG2 Haplotype with VA in patients with idiopathic PSU 
 
Intermediate Uveitis Mean Visual Acuity (Range) 
HHG2 haplotypes 1st year 2and Year 3rd year 5 year 
 
    
HHG2 +ve (17) 6/6 (6/5-6/36) 6/9 (6/6-6/24) 6/12 (6/9-6/24) 6/12 (6/9-6/36) 
HHG2 -ve (60) 6/12 (6/6-6/36) 6/18 (6/6-6/60) 6/18 (6/9-6/60) 6/36 (6/12-4/60) 
P value 0.009 0.01 0.07 0.05 
     
Posterior Uveitis Mean Visual Acuity  
HHG2 haplotypes 1st year 2and Year 3rd year 5 year 
     
HHG2 +ve (10) 6/9 (6/5-6/36) 6/12 (6/6-6/60) 6/18 (6/9-6/60) 6/24 (6/18-2/60) 
HHG2 -ve (54) 6/18 (6/5-6/60) 6/24 (6/9-5/60) 6/30 (6/9-6/60) 6/36 (6/12-1/60) 
P value 0.008 0.01 0.06 0.09 
 
Patients with HHF-2 haplotype had better mean visual acuities in both IU & PU group. The difference 
was more significant in early course of the disease. 
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The graphs below (Figure 4-3) show the trend of visual acuities in IU patients 
with HHF2 and HHG2 haplotypes.  
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Figure 4-3: Visual acuity of patients carrying HHF2 & HHG2 haplotype in intermediate 
uveitis 
IU patients carrying HHG-2 haplotype and patients not carrying HHF-2 haplotype consistently had better 
visual acuities. . The values represent mean LogMAR VA (converted from Snellen) over period of times. 
For range of VA please refer to above tables 4-6 & 4-7 
 
The Figure 4-4 below shows the trend in posterior uveitis patients 
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Figure 4-4: Visual acuity of patients carrying HHF2 & HHG2 haplotype in posterior 
uveitis. 
IU patients carrying HHG-2 haplotype and patients not carrying HHF-2 haplotype consistently had better 
visual acuities. . The values represent mean LogMAR VA (converted from Snellen) over period of times. 
For range of VA please refer to above tables 4-6 & 4-7 
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In short, the HHF2 haplotype was associated with poor visual acuity in both IU 
and PU groups. On the other hand, HHG2 and HHC carriers had better visual 
acuity in both IU and PU groups.  
When the individual SNPs (excluding the previously studied V64I, 32bp ∆ and 
59029) were analysed, no significant associations were noted except -1835C/T 
and -2135T/C. This was because of their strong linkage with previously studied 
SNPs. The -1835C/T which was tightly linked to CCR2 V64I showed similar 
associations with visual outcome and high intraocular pressures. The Table 4-8 
below shows (and as noted in chapter 3 with CCR2 V64I) the -1835 variant 
allele T was predictor of poor visual acuity in both groups. In case of 
intermediate uveitis the difference was more significant in early period of 
disease and in posterior uveitis it was more significant in later period of disease.   
 
 Table 4-8: Visual acuity in patients with intermediate and posterior uveitis, when  
categorised according to -1835 genotype.  
Intermediate Uveitis Mean Visual Acuity (Range) 
CCR5 -1835 C/T 2and year 3rd Year 5th year 10th year 
 
    
-1835CC 6/6 (6/6-6/60) 6/9 (6/9-6/36) 6/12 (6/9-6/12) 6/18 (6/12-6/36) 
-1845CT 6/10 (6/6-6/60) 6/24 (6/9-6/60) 6/24 (6/9-60) 6/36 (6/18-1/60) 
P value 0.06 0.001 0.008 0.09 
     
Posterior Uveitis Mean Visual Acuity  
 2and year 3rd Year 5th year 10th year 
 
    
-1835CC 6/10 (6/9-6/18) 6/18 (6/9-6/36) 6/18 (6/12-5/60) 6/24 (6/12-4/60) 
-1835CT 6/12 (6/9-6/60) 6/24 (6/12-6/60) 6/60 (6/18-1/60) 4/60 (6/18-HM) 
P value 0.1 0.2 0.05 0.001 
 
Similarly -2135T/C which was in 100% linkage with CCR5 (2459) 59029 
showed association with need of steroids in intermediate uveitis and need of 
long term steroids in posterior uveitis. Since the linkage was 100%, the results 
were exactly similar to CCR5 59029. The C allele of -2135 SNP was associated 
with need of systemic steroids. (See Table 8-7 Appendix B)  
 240 
It was also noted that -3900 SNP was associated with presence of cataract. 
This was mainly seen in intermediate uveitis although there was a non-
significant trend noted in posterior uveitis. Collectively patients who developed 
visually significant cataract after two years of onset of disease, (minimum follow 
up period) the A allele frequency was 82% compared to 58% of the patients 
who did not develop cataract. P=0.004, pc=0.02, 95% CI: 2.1 (1.2-3.5).  Data 
shown in Appendix B, Table 8-6 
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4.1.4 Discussion 
This study was done to demonstrate the role of polymorphisms in CCR5 gene 
in idiopathic non-infectious posterior segment uveitis. The CCR5 gene has 
been mapped to the short arm of chromosome 3 amongst a group of genes 
that encode multiple chemokine receptors including the CCR2 gene. The 
ligands for CCR2 and CCR5 are MCP-1, MIP-1α, MIP-1β, MCP-2 and 
RANTES, which are known to play an important role in uveitis. (Crane et al. 
2001) (Foxman et al. 2002) (Takase et al. 2006) (Verma et al. 1997) Recently 
Crane et al. (Crane et al. 2006) have shown that CCR5 is markedly expressed 
on mononuclear cell infiltrates present in the inflamed retina in EAU. They also 
demonstrated that CCR5 plays a role in the recruitment of antigen-specific, 
Th1-polarized cells across the specialized BRB and into the retina during an 
inflammatory reaction. It is very likely that CCR5 mediates its inflammatory 
effects via MIP-a, MIP-b and MCP-2 rather than RANTES; as I noted that high 
RANTES producing genotypes were associated with better visual outcome. 
This finding was consistent with various animal and human studies. (Kim, 
Chung, and Yu 2010) (Sonoda et al. 2003) 
All the SNPs were in Hardy Weinberg equilibrium and there was strong linkage 
disequilibrium between few SNPs. In my study the HHC was most frequent 
haplotype in patients and controls followed by HHE. The HHG2 and HHF2 were 
two other prominent haplotypes. These frequencies are similar to other studies 
in the literature. (Spagnolo et al. 2005) (Fischer et al. 2008) In my study, the 
frequency of HHC haplotype was significantly lower in IPSU groups compared 
to control groups. Not only this, among patients the frequency of this haplotype 
was lower in the group needing systemic steroids to control the inflammation. 
The need of steroid is the indirect measure of intensity of inflammation 
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particularly in case of IU. It was also noted that patients carrying HHC 
haplotype had better VA with both eyes open at two years time. This difference 
of visual acuity however lost it significant in long term follow up. It appears that 
HHC haplotype not only confers protection against the development of PSU, 
but also protects during the course of the disease. HHC is known to be 
associated with disease retardation and delayed progression to death in 
Caucasian patients with AIDS. (Gonzalez et al. 1999) Interestingly this HHC 
haplotype has also been found to reduce risk of developing Kawasaki disease. 
(Burns et al. 2005) Recently Mamtani et al. showed that subjects heterozygous 
for HHC may have a less risk of developing systemic lupus 
erythromatosis.(Mamtani et al. 2008) However the effect was not noted with 
subjects homozygous to HHC and they attributed this effect to HHF2 haplotype.  
At least two of the SNPs defining this haplotype contain putative protective 
alleles i.e. -2459 (59029G) and 190 (V64).  Another SNP in HHC at -2135 
harbour T allele which was recently shown to cause low promoter activity 
compared to C allele.(Liu et al. 2007) Same study showed that G allele at -
2086 position lead to lower promoter activity and this allele is also part of HHC 
haplotype. Interestingly, CCR5 haplotype HHC does not include the 32 deletion 
variant, suggesting that decreased gene expression is not the key mechanism 
of protection against PSU and supporting the hypothesis that promoter variants 
might result in altered CCR5 functions. 
Presumably four of the alleles in CCR5 gene promoter region that define HHC 
haplotype are in one way or other effect the functions of CCR5 gene. This is 
very interesting to note that in IPSU none of the allelic frequencies were 
significantly different from controls but collectively as HHC haplotype they were 
significantly less in patients compared to controls.  This is consistent with the 
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notion that complex diseases may result from genetic variants that are 
relatively common in the general population and  many of them have minor 
effects (Wang et al. 2005) (Hirschhorn 2005) (Hirschhorn and Daly 2005).  
Although I observed that HHC haplotype may have a protective effect in the 
development of uveitis, Spagnolo et al. (Spagnolo et al. 2005) noted that this 
same haplotype was associated with persistent lung disease in patients with 
sarcoidosis. They concluded that CCR5 HHC does not confer susceptibility to 
sarcoidosis per se but it only acts after “classic” sarcoid strikes. Recent study 
on 995 German Sarcoid patients however failed to replicate their findings. 
(Fischer et al. 2008) 
There were two other significant associations. HHF2 haplotype was associated 
with poor visual outcome and HHG2 was the predictor of better visual outcome. 
As seen in the table below, this haplotype had 4 alleles (shown in Italics) that 
putatively increase CCR5 gene expression or promoter activity and also 
contains CCR2 64I previously noted to be involved with poor visual outcome. 
The HHF2 also had wild type at exon 4 (no 32bp deletion) and hence the 
association with the visual acuity were more significant with HHF2 than HHC 
haplotypes. 
Haplotype CCR2 190 
-
5663 -3900 
-
3458 
-
2459 
-
2135 
-
2086 
-
1835 ∆ 32 
HHF*2 I A A G A C A T wt 
 
In case of HHG2 haplotype the putatively functional SNPs in the promoter 
region (2135, 2086) were similar to HHF2 so one can infer that the effects are 
just because of 32 bp deletion and V allele at CCR2 position 64. This is the 
reason that the visual acuity preservation noted in the presence of HHG2 was 
not as strong as seen in the absence of HHF2 haplotype.  
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Regarding 1835 SNP, where C to T change has some effect on the functional 
activity of CCR5 promoter region (Mummidi et al. 2000) it is not known whether 
this change increases or decreases the effects of CCR5 gene. However one 
must note that the protective haplotypes, HHC and HHG2 had C allele and 
HHF2 had T allele at site -1835. This does signify that C to T transition may 
have some proinflammatory effects; however the functional role of SNP -1835 
on CCR5 gene needs to be further explored. FASTSNP tool also predicts that 
there are mild to moderate chances that this SNP can be fuctional. 
 My conclusions are based on CCR5 haplotypes; therefore the reliability of the 
method used for haplotype reconstruction is critical. Although errors in 
haplotype assignment can originate from genotyping or calculation error as well 
as inherent marker ambiguity in the presence of SNP heterozygosity; however 
computational methods of haplotype inference such as PHASE (Stephens, 
Smith, and Donnelly 2001), the statistical method used in this study, have been 
shown to have high accuracy (Kraft et al. 2005) (Adkins 2004) (Stephens, 
Smith, and Donnelly 2001). Moreover, the frequencies of the deduced CCR5 
haplotypes in the cohort are consistent with those previously reported by 
Gonzalez et al (Gonzalez et al. 1999) (Fischer et al. 2008) strongly supporting 
the reliability of PHASE.  
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Conclusion: 
This study has highlighted the role of CCR5 gene in the prognosis of PSU. Few 
haplotypes have shown association with the susceptibility and phenotype of the 
disease. As CCR5 gene is not the sole gene controlling the influx of activated T 
cells and macrophages to the site of uveitis hence the association these 
haplotypes seen here are modest. It should be noted that there is great 
redundancy in the immune system and this concept is further strengthened by 
a recent study where EAU developed in CCR5 deficient mice. (Takeuchi et al. 
2005) It is also quite possible that the association seen here could be due to a 
yet unidentified locus in the Chromosome 3p21 region where this gene lies 
along with other chemokine receptor genes CCR1, CCR2 & CCR3.(Samson et 
al. 1996b) Chromosome 3 has been suggested as harbouring susceptibility loci 
for inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis. 
(Cornelis et al. 1998) (Duerr et al. 2002) (Pericak-Vance et al. 2004) These 
conditions having similar immuno-pathology like PSU.  Linkage studies on 
chromosome 3 can be done in future to confirm these findings. 
In short this study has shown that variations in CCR5 genotype can affect the 
phenotype and outcome in patients with posterior segment uveitis but further 
studies are needed to replicate my results 
 
. 
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4.2 CCR2 & CCR5 polymorphisms in Ocular Behcet’s 
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4.2.1 Introduction: 
Behcet’s disease (BD) is a relapsing multisystemic inflammatory disorder 
characterized by recurrent oral ulcers, genital ulcers and uveitis, but joints, skin, 
central nervous system, blood vessels and gastrointestinal tract are frequently 
involved and are the major cause of morbidity. The precise aetiology of the 
disease is unknown but it is widely believed that BD is a “profound 
inflammatory response triggered by an infectious agent in a genetically 
susceptible host.” (Kaneko, Oyama, and Nishibu 1997) (Sohn et al. 2001) 
(Sohn, Lee, and Lee 2001) While rare in UK, BD is fairly common in countries 
lying at latitudes of between 30 and 45° N includin g the traditional silk route. 
(Table 4-9) Its prevalence in these countries has been reported as high as 420 
per 100,000 (Azizlerli et al. 2003) compared to 0.5 per 100,000 in UK. 
(Chamberlain 1978) (Chamberlain 1980) Uveitis in BD often referred as  ocular 
Behcet’s (OB) occurs in about 30-70% of the patients with BD (Kural-Seyahi et 
al. 2003) (Tursen, Gurler, and Boyvat 2003) and leads to visual loss in 
approximately 25% of the patients.(Muhaya et al. 2000) 
 
Table 4-9:  Association between latitude and prevalence of Behcet’s disease (adapted 
from Demirkesen et al.) 
Latitude (°N)  Country/ethnic group  Prevalence of Behcet’s disease per 100000  
  
    
25 Saudi Arabia  20 
31 Palestinian  >10  
32 Iran  16.7 
32 Morocco  >15  
36 Japan  13.5 
39 Portugal  1.53 
39 Turkey  100 
42 Italy  2.5 
52 England  0.5 
56 Scotland  0.27 
60 Sweden  1.18 
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Geographical distribution of the disease & familial clustering points towards a 
genetic susceptibility. A well-documented association exists between the BD 
and HLA-B51 (Muhaya et al. 2000) in a wide range of ethnic groups, with the 
HLA-B*5101 subtype being the most frequently expressed and conferring a 
relative risk as high as 16. (Baricordi et al. 1986) The geographic distribution of 
HLA-B51 closely mirrors that of BD, with low prevalence of HLA-B51 and BD in 
the southern hemisphere and in Europe above 45oN. (Middleton et al. 2003) 
(Verity et al. 1999)The exact role of the B51 molecule remains elusive, but it 
might be primarily involved in the disease development through specific antigen 
presentation or molecular mimicry with microbial antigens, as well as 
participation in linkage disequilibrium with a presently unknown susceptibility 
gene.  
However, HLA-B*51 cannot be the sole causative factor for the simple reason 
that roughly a third of patients, even in countries with a high disease 
prevalence, do not possess this allele. Furthermore, the risk, or odds ratio of 
Behcet’s disease in an individual positive for HLA-B*51 shows a wide variation 
across Europe and Asia. Also among the North American indigenous 
populations of Alaska and in Sub Saharan Africa the frequency of HLA-B51 
allele is quite high but the BD is virtually absent. (Verity et al. 1999) However it 
could be accounted for by the absence of an environmental trigger factor. It has 
been proposed that contribution of the HLA-B locus to the overall genetic 
susceptibility to BD is about 20%. (Gul et al. 2001) 
SNPs in other genes in close proximity to HLA have also been noted as risk 
factors for BD, particularly Major histocompatibility complex class I-related 
chain A (MICA) and TNF-α. Ahmed et al showed that C allele at -1031 site of 
TNF-α promoter site was associated with Behcet’s disease independent of 
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HLA-b51 allele. (Ahmad et al. 2003) A recent meta-analysis has confirmed that 
Behcet's disease is associated with the -1031C, -238A and the -857T TNF-α 
promoter polymorphisms in various ethnic groups. (Touma et al. 2010) 
Similarly various studies have shown that MICA 006 and 009 loci are 
associated with BD susceptibility, however there is conflicting evidence whether 
this effect is independent or due to linkage with HLA-B51 locus.(Marin et al. 
2004) (Hughes et al. 2005) (Mizuki et al. 2007) (Park et al. 2002)     Modest 
associations have also been found in coagulation factor V, endothelial nitric 
oxide synthase and intercellular adhesion molecule-1 genes.(Gurgey, Balta, 
and Boyvat 2003) (Kim et al. 2003)   
Current understanding of the pathology of BD indicates that it is a Th1 
generated immune response (Frassanito et al. 1999) (Kulaber et al. 2007) 
(Hamzaoui et al. 2002) (Pay et al. 2007). The immunopathology of BD has 
been discussed in detail in chapter one, however Figure 4-5 here explains our 
current understanding of the pathogenesis of Behcet’s disease.  
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Figure 4-5: Hypothesis for the pathogenesis of BD. 
(1) Genetic factors, e.g. HLA-B*51, induce a general hyperactivity of the immune system (TH1-
response, granulocytes). (2) Bacterial or viral infection stimulate the expression of HSP60 (self) 
and MICA on different cells (e.g. endothelial cells), upregulation of adhesion molecules, 
activation of coagulation, stimulation of T cells (esp. gd and NK cells), continuing elevation of 
the cytokine production and finally induce (3) tissue damage by vasculitis. Additionally, a 
molecular mimicry with HLA-B*51 may play a role. In parallel, B-cells will be stimulated 
polyclonally (not shown on the figure) and may produce more antibody (e.g. against HSP). 
Courtesy Deuter, CM 2008 Progress in Retinal and Eye Research 
 
CC chemokine receptors play an important role in executing the immune 
response in Behcet’s disease. (Dalghous, Freysdottir, and Fortune 2006) 
(Houman et al. 2004) Active BD is associated with increased activity of MCP-1, 
MIP-1β and RANTES (Bozkurt et al. 2003) (Kaburaki et al. 2003) (Ozer et al. 
2005) which are ligands for CCR2 and CCR5 receptors 
A recent study using flow cytometric analysis of lymphocytes from aqueous 
humour of OB showed, increased expression of CCR5 and RANTES, which 
were comparable with non Behcet’s uveitis levels (Kim, Chung, and Yu 2010). 
Houman et al did flow cytometric analysis on peripheral blood lymphocytes that 
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showed increased expression of CCR5 in all forms of Behcet’s diseases. 
(Houman et al. 2004)  
 
In the previous chapter I showed that CCR2 V64I could be one of the genetic 
risk marker in patients with OB. Though this SNP is now thought to be 
functional but the role of CCR2 in OB is not clear. So it is difficult to say 
whether this association seen is independent or secondary to linkage with other 
loci in CCR2 or even in CCR5 gene as these two genes are in close proximity. 
The aim of this study was to see whether SNPs in nearby CCR2 and CCR5 loci 
show any association with OB 
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4.2.2 Methods:  
4.2.2.1 Subjects: 
31 British Caucasian patients diagnosed with OB were recruited for this study.  
Besides this I had 29 Caucasian patients with Behcet’s disease for more than 5 
years but no uveitis. 
I also had 30 non-Caucasian British patients with OB. This group included 
patients from Middle East.  
4.2.2.2 Controls: 
169 healthy subjects who were admitted to Whipps Cross hospital for cataract 
surgery and cohort of 142 Caucasian healthy subjects whose DNA were stored 
and used in other studies.(Spagnolo et al. 2005)  
I also had 56 non Caucasian (Middle East and West Asia) healthy subjects who 
were admitted for cataract surgery at WXH. 
 
4.2.2.3 DNA extraction and genotyping: 
As previously described the patients Genomic DNA was extracted from EDTA 
anticoagulated peripheral venous blood by Qiagen Kits using standard protocol 
supplied by the supplier. The controls DNA was extracted by salt extraction method as 
described in detail in chapter 2. Genotyping was performed using polymerase chain 
reaction with sequence-specific primers (PCR-SSP) method as described previously. 
The CCR2 and CCR5 primer designed to detect these polymorphisms are shown Table 
 4 10 &Table  4 11.  The locations of the SNPs on CCR2 & CCR5 gene are shown in  
Figure  4 6 & Figure  4 7
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Table 4-10: CCR2 primers for SSP-PCR 
SNP’s 
 position  Locus  
Accession 
 no  position  Primer sequence  primers*  bp  
              
 -6928 G/T  Promoter  U95626  39151-177  F-TGC ATA AAG AAT TCT AAG ATG TAC TG/T  210+211  799 
      39930-950  R-AGG GTG AAC AAA GGT TCA CCA      
 -6752 A/G  Promoter  U95626  39353-373  R-AAC CAG ATG GGA AGA GGG AAT/C  210+211  772 
      38602-623  F-GGA AAT TGC TAA GGG CAT CGT T      
190 G/A  Exon coding  U95626  46295-321  R-TTT TTG CAG TTT ATT AAG ATG AGG AC/T  210+211  808 
      45513-534  F-GAA GGC AGA AGG TGA ATA GTT C      
3000 A/G  Exon  U95626  49083-105  F-CCA GTG GGA ACT CCT AAA TCA AA/G  210+211  918 
      49981-50000  R-ATA GGT AGA CCC TCC GGG AT      
3547 T/C  3’UTR  U95626  49633-652  F-TAC AGG CCA CAC AAC CCC AT/C  210+211  851 
      50464-483  R-CCT GCT TAA CTC GAA CAG CC      
3610 A/G  3’UTR  U95626  49695-715  F-GAC ATC TGC CTC ATC CAA GCA/G  210+211  867 
      50541-561  R-TAT GCC AAG ACC CTT CCT TAC      
3671 C/G  3’UTR  U95626  49776-796  R-CTG TGT CTT CTC ATT CAC CAG/C  210+211  870 
      48927-946  F-TCG CTG TCA TCT CAG CTG GA      
4385 T/A  3’UTR  U95626  50470-490  F-TCG AGT TAA GCA GGT GGA AGT/A  210 +211  766 
      51214-235  R-AAG GCC CCA TTG AAA CAA TGA C      
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Figure 4-6 Map illustrating positions at which variations have been identified in the coding region of CCR2, CCR5, 
and 5_ upstream region of CCR5.  
The numbering system used designates the first nucleotide of the translation start 
site of CCR5 as position 1, and nucleotide immediately upstream of this as position _1. 
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Table 4-11: CCR5 primers for SSP-PCR 
 
SNP Position Locus 
Accession 
No. Position Primer Sequence 
Control 
Primers 
ProductSize 
(bp) 
CCR2190G/A Exon,codingsequence U95626 46276-295 F-TGTGGGCAACATGCTGGTCG/A 63  64* 297 
   46554-573 R-AAGGTGACCGTCCTGGCTTT   
 5663A/G Promoter U95626 55830-852 R-GCTTGGTGAGTTTTGATATGCAT/C 63  64 290 
   55563-582 F-AGCCCGACTGTCTACTGAAC   
 3900C/A Promoter U95626 57568-592 F-GCTATCTATCTTTCGAAAAACCAAC/A 63  64 305 
   57852-872 R-CCTCCAGCTTCATTACTGCTA   
 3458T/G Promoter U95626 58030-049 R-AGCGATCAAGACACCCCCAA/C 210  211† 719 
   57331-349 F-AGCAAGTCAGCAGCAACGC   
 2459A/G Promoter U95626 59029-050 R-GGACTTCACATTAACCCTGTGT/C 210  211 760 
   58291-310 F-GCCGTGGATGCCTCATAGAA   
 2135T/C Exon U95626 59330-353 F-GTGAGAAAAGCCCGTAAATAAACT/C 210  211 951 
   60272-292 R-TGCCACCACAGATGAATGTCA   
 2086A/G Exon U95626 59402-423 R-AGAATCAGAGAACAGTTCTTCT/C 63  64 267 
   59137-158 F-AGCCTTACTGTTGAAAAGCCCT   
 1835T/C Exon/Intronboundary U95626 59653-674 R-AGCACTTGGTGTTTGCCAAATA/G 210  211 905 
   58772-792 F-ATCTGGCATAGTGTGAGTCCT   
Delta32wt/ 32 Exon,codingsequence U95626 62018-040 F-GCTCTCATTTTCCATACAGTCAG(wt) 63  64 244 
   62015-070 F-GCAGCTCTCATTTTCCATACATTA( 32) 215  
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Figure 4-7: Positioning of the investigated single nucleotide polymorphisms across the 
C-C chemokine receptor 2 (CCR2) gene. 
 
4.2.2.4 Phenotyping 
Behcet’s was diagnosed according to the Criteria described by “International 
Study Group for Behcet’s Disease”, (Criteria for diagnosis of Behcet's disease. 
International Study Group for Behcet's Disease 1990) (Evaluation of diagnostic 
('classification') criteria in Behcet's disease--towards internationally agreed 
criteria. The International Study Group for Behcet's disease 1992) which is as 
follows: 
Table 4-12: Diagnostic criteria for Behcet’s disease 
In the absence of other clinical explanations, patients must have: 
 
(1): Recurrent Oral Ulcerations (aphthous or herpetiform) recurring at least three 
times in one 12-month period;  
 
(2):  and two of the following: 
 
      a) Recurrent Genital Ulceration. 
      b) Eye Lesions: 
                anterior or posterior uveitis, cells in the vitreous by slit lamp examination 
                or retinal vasculitis observed by an ophthalmologist 
      c) Skin Lesions:  
                erythema nodosum, pseudofolliculitis, papulopustular lesions or acneiform 
                nodules in post adolescent patients not on corticosteroids. 
      d) positive Pathergy 
 
 
 257 
Though the aim of this study was not to check HLA-B51 serotypes or alleles, 
but where available the presence of HLA-B51 antigen was also recorded from 
the notes.  This was done to reveal any association of this serotype/allele with 
CCR2 & CCR5 SNPs tested 
 
4.2.2.5 Statistical methods: 
 
The data were analyzed using the SPSS version 12.0 (SPSS Inc., Chicago, IL, 
USA). It has been discussed in detail in chapter 2. Since most of the SNPs 
tested were non-functional, Bonferroni correction was particularly applied for 
multiple alleles testing if association was noted in a non-functional allele. The 
correction was not applied in case association was noted with a haplotype.  
The genotype and allele frequencies between patients with BD and controls 
were compared by the two-tailed chi 2 test. Multiple logistic regression was 
done to correct for confounding traits 
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4.2.3 Results:  
The mean follow up period of the patients was 12.36 years and Table 4-13 
presents the clinical features of the 31 patients. Of particular interest was that 
74% developed some degree of permanent visual loss and 77% needed 
second line of immunosuppressive therapy.  
 
 
Table 4-13: Clinical characteristic of patients with Ocular Behcet’s. 
Follow up in years (2.2-38.2)  mean=12.36 
Age of onset (21-68years)  mean=32.5 
laterality of disease Bilateral: Unilateral 4:1 
Sex Ratio Males: Females  2.4:1 
Anterior uveitis (n=1) 3% 
Posterior Uveitis (n=5) 16% 
Pan Uveitis (n=25) 81% 
Vasculitis (n=22) 71% 
Optic Atrophy (n=9) 29% 
Ischemic Maculopathy (n=9) 29% 
Glaucoma (n=12) 39% 
Cystoid macular oedema (n=22) 71% 
Visual Acuity after 24 months in good eye 6/5-HM (mean=6/18) 
Permanent visual loss (n=23) 74% 
>10mg of steroids for long term (n=20) 65% 
second line of immuno-suppressant (n=24) 77% 
  
 
4.2.3.1 CCR2 V64I in Caucasian patients with OB 
 
As seen in Table 4-14 below, and as shown in chapter 3, CCR2 64I allele was 
more frequent in the Behcet’s patients. Besides the 283 controls used in 
previous study this time I had another cohort of controls numbering 142. (Total 
425)   The genotypic frequencies were not significantly different between the 
control populations. The allelic frequency of CCR2 64I in the new control cohort 
was 10% compared to 7% in the cohort used in the study throughout.  The 
pooled results are shown in the following table. With the addition of new control 
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group the 64I frequency difference decreased a bit but still the difference was 
statistically significant. 
 
 
Table 4-14: CCR2 V64I frequencies in OB and controls. 
GENOTYPE CCR2 190 G/A Patients  Control  Chi 2X3 Chi 2X2 
 N (%) N (%)   p 
GG 21 (68%) 361 (85%)   0.0122 
GA 9 29%) 63 (15%)   0.0362 
AA 1 (3%) 1 (0%)   0.0150 
Total 31 425 0.004   
          
Allelic Carriage / phenotype         
G 30 (97%) 424 (100%)   0.0150 
A  10 (32%) 64 (15%)   0.0122 
          
          
Allelic Frequency         
G 51 (82%) 785 (92%)   0.0055 
A  11 (18%) 65 (8%)     
Total 62 850     
 
 
(pc=0.025 and OR of 3.16 95% CI; 1.55-6.44). 64I was more common in 
females (n=9) where the allele carriage (V/I or VV) was 67% compared to 18% 
in males (n=22) (p=0.008). (Table 4-15) The allelic frequency of 64I was 33% in 
females compared to 11% in males. This allelic frequency of 33% in females 
was very significant compared to 6% in female controls p=0.0000005.    
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Table 4-15: CCR2 V64I prevalence in both sexes in ocular Behcet’s 
CCR2 V64I (G/A) Females Males Chi2x3= Chi2x2 
 N (%) N (%) P value P Value 
GG 3 (33%) 18 (82%)  0.008 
GA 6 (67%) 3 (14%) 0.01 0.003 
AA 0 (0%) 1 (5%)  NS 
Total 9 22   
Allelic Carriage / phenotype     
G 9 (100%) 21 (95%)  NS 
A 6 (67%0 4 (18%)  0.009 
Allelic Frequency     
G 12 (67%) 39 (89%)  0.04 
A 6 (33%) 5 (11%)   
Total 18 44   
 
4.2.3.2  CCR2 V64I in OB Vs BD 
 
Since all the patients in my group had uveitis, in order to see whether this high 
frequency of 64I allele is specific to Behcet’s disease or uveitis in Behcet’s, 29 
British Caucasians with Behcet’s disease but no ocular involvement (NOB) 
were typed for CCR2 V64I. 
As shown in Table 4-16, 10% (n=3) of NOB were carriers of 64I allele and 
when compared with OB group (32%) this difference was still significant despite 
low sample size. P=0.04 OR= 4.12 95% CI: 4.1 (1.00-16.94). Also the 
differences in the frequency between the sexes was also not significant in BD 
patients but when compared with OB the frequency of 64I allele carriage in 
females in BD group (10%) was significantly low then from females in OB group 
(67%) p=0.001 
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Table 4-16:  CCR2-64I frequency in ocular vs non-ocular Behcet’s 
Characteristics OB NOB p value 
  (n=31) (n=29) Chi 2x2 
      
Gender ratio M/F 22 / 9 9 / 20 p=0.002 
CCR2 VV 21 (68%) 26 (90%) P=0.03  
CCR2 V/I 9 (29%) 3 (10%)   
CCR2 II 1 (3%) 0 (0%)   
64 I allele carriage 10 (32%) 3 (10%) p=0.04 
    
 Male OB Male NOB  
 (n=22) (n=9)  
VV 18 (82%) 8 (89%)  
VI 3 (14%) 1 (11%)  
I 1 (5%) 0 (0)  
64I allele carriage in males 4 (18%) 1 (11%) P=0.61  
    
 Females OB Females NOB  
 (n=9) (n=20)  
VV 3 (33%) 18 (90%) P=0.001 
VI 6 (67%) 2 (10%) P=0.001 
II 0 (0%) 0 (0%)  
64I allele carriage in females 6 (67%)  2 (10%) p=0.001 
    
 OB NOB  
HLA-B51% (OB Vs NOB) 21.4% 24.10% P=0.9  
 
 
4.2.3.3 CCR2 V64I in non Caucasians with OB 
 
I than compared the frequency of 64I allele in 30 non-Caucasian patients with 
ocular Behcet’s with 56 non-Caucasian controls. The frequency of 64I allele 
was 22% in OB group compared to 13% in controls. This difference was not 
statistically significant, but the frequency of 64I allele was higher in both non-
Caucasian populations compared to Caucasians. (Table 4-17) 
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Table 4-17: CCR2 V64I genotypic frequencies in Non Caucasian OB and controls 
CCR2 V64I Genotype Non-Caucasian OB Non- Caucasian Controls  P Value  
       
GG 20 (67%) 44 (78%)  NS 
GA 7 (23%)  10 (18%)  
AA 3 (10%) 2 (4%)   
Total 30 56  
Allelic Carriage / phenotype      
G 27 (90%) 54 (96%)  NS 
A  10 (33%) 12 (21%)   
Allelic Frequency      
G 47 (78%) 98 (87%)  NS 
A  13 (22%) 14 (13%)   
Total 60 112   
    
 
When the group was divided according to gender, again it was noted that the 
frequency of 64I allele in females was significantly higher than males. There 
were 20 males and 10 females with OB and the allelic frequency of 64I was 
50% in females compared to 8% in males. P=0.0001.  Among the controls 
there were 22 females and the allelic frequency of 64I was 14% compared to 
50% with OB.  P=0.001. In short in non- Caucasians there were significant 
differences in 64I allele frequencies between female OB and female controls 
Details are shown in Table 4-18.  
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Table 4-18: CCR-2 V64I frequencies in non-Caucasian OB patients and controls and 
association with sex 
Non Caucasian OB Male OB  Female OB 
 P value P Value 
CCR-2 V64I N=20 N=10 Chi 2 X 3 Chi 2x2 
VV 17 (85%) 3 (30%)  0.002 
VI 3 (15%) 4 (40%) 0.004 NS 
II 0 (0%) 3 (30%)   0.009 
Allelic Carriage / phenotype         
V 20 (100%) 7 (70%)   0.009 
I 3 (15%) 7 (70%)   0.002 
Allelic Frequency         
V 37 (92%) 10 (50%)   0.0001 
I 3 (8%) 10 (50%)     
     
Non Caucasian Controls Male Controls Female controls    P 
 N=34 N=22   
VV 27 (79%) 17 (77%)  NS 
VI 6 (18%) 4 (18%)  NS 
II 1 (3%) 1 (5%)   NS 
Allelic Carriage / phenotype         
V 33 (97%) 21 (95%)   NS 
I 7 (21%) 5 (23%)   NS 
Allelic Frequency         
V 60 (88%) 38 (86%)   NS 
I 8 (12%) 6 (14%)     
     
Female OB Vs Controls  Female OB   Female Control    P 
 N=10 N=22   
VV 3 (30%) 17 (77%) 0.025 0.010 
VI 4 (40%) 4 (18%)  NS 
II 3 (30%) 1 (5%)   0.043 
Allelic Carriage / phenotype         
V 7 (70%) 21 (95%)   0.043 
I 7 (70%) 5 (23%)   0.010 
Allelic Frequency         
V 10 (50%) 38 (86%)   0.001 
I 10 (50%) 6 (14%)     
 
It must be noted that I did not have non-Caucasian patients with NOB so the 
comparison of 64I frequencies between OB and NOB in non-Caucasian group 
could not be performed 
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HLA-B51 and CCR2 V64I relationship 
28 patients out of total of 31 were serotyped for HLA-B51. Six (21.4%) were 
positive for HLA-B51. None of these six were carrier of CCR2 64I allele.  
Among NOB patients, 24% percent (n=7/29) were HLA-B51+ and the 
frequency was quite similar to OB group.  In NOB group only one out of these 
seven patients was heterozygous for 64I allele.  
The results suggested that there was no obvious linkage between the two loci 
and also raised the possibility that CCR2 64I allele plays its role in the 
susceptibility of Behcet’s disease in the absence of HLA-B51 serotype. 
 
4.2.3.4 CCR2 Haplotypes in Behcet’s Uveitis 
 
The allelic frequencies of the 8 CCR2 SNPs including V64I (190 G/A) are 
shown in the Table 4-19. As seen the table there were no significant differences 
of allele frequencies between the patients and controls. For each SNP the 
proportion of homozygous and heterozygous alleles were consistent with 
Hardy-Weinberg equilibrium.  
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Table 4-19: Allelic Frequencies of CCR2 SNPs in OB and controls 
SNPs Position Allele (n=62) % (n =338) % P value 
  Ocular Behcet’s Healthy Controls  
-6,928 T 4 6% 27 8% NS 
 G 58 94% 311 92% NS 
-6,752 A 16 25% 71 21% NS 
 G 46 75% 267 79% NS 
190 A 11 18% 20 6% 0.001 
 G 51 82% 318 94% 0.001 
3,000 A 17 27% 71 21% NS 
 G 45 73% 267 79% NS 
3,547 T 19 30% 71 21% NS 
 C 43 70% 267 79% NS 
3,610 A 22 35% 95 28% NS 
 G 40 65% 243 72% NS 
3,671 G 7 12% 47 14% NS 
 C 55 88% 291 86% NS 
4,385 T 18 29% 78 23% NS 
 A 44 71% 260 77% NS 
 
 
 
From the investigated CCR2 polymorphisms, I was able to deduce nine 
estimated haplotypes (Table 4-20). Haplotype 2 includes four SNPs (T at 
nucleotide position 4,385, T at 3,547, A at 3,000, and A at 6,752), which appear 
to be in 100% linkage, as they occur together in all subjects; these four SNPs 
were unique to this haplotype alone, being absent in all of the other haplotypes 
As seen in the Table 4-20, haplotypes 1, 2 and 3 were quite prevalent in both 
populations. In controls I was able to deduct 9 haplotypes but in patients 
Haplotypes 6, 7 & 9 were absent which is presumably because of the size of 
sample. The haplotype 8 (containing the I allele at 64 position (190 A) was 
more frequent in the OB group (12% Vs 2%) p= 0.01. However because of the 
small sample size the 95% CI was very wide and the power was only 50%.  
Genotype- phenotype studies failed to reveal any effect of CCR2 haplotypes on 
the clinical course and outcome of the OB. 
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Table 4-20: CCR2 Haplotypes in OB and controls 
 
 
 SNPs Behcet's Controls P Value 
Haplotype -6,928 -6,752 190 3,000 3,547 3,610 3,671 4,385 (n=31) (n =169) Chi 2x2 
 
          
 
1 G G G G C G C A 19 (60%) 110 (65%) NS 
2 G A G A T A C T 14 (45%) 68 (40%) NS 
3 G G G G C G G A 6 (20%) 42 (25%) NS 
4 T G G G C A C A 1 (3%) 17 (10%) NS 
5 G G A G C G C A 3 (9%) 11 (7%) NS 
6 T G G G C G C A 0 (0%) 7 (4%) NS 
7 G G G G C A C A 0 (0%) 5 (3%) NS 
8 G G A G C G G A 4 (12%) 3 (2%) 0.011 
9 T G G G C G G A 0 (0%) 3 (2%) NS 
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4.2.3.5 CCR5 haplotypes in Behcet’s uveitis 
CCR2 190 (V64I) is in close proximity with CCR5 genes and it is tightly linked 
to many SNPs (particularly -1835). To see whether CCR2 V64I association 
seen in OB is due to linkage with SNPs in CCR5 gene, I genotyped OB patients 
for CCR5 promoter SNPs. The SNPs studied here were the same typed for IU 
& PU and discussed early. 
All the SNPs were in consistent with Hardy-Weinberg equilibrium. As seen in 
the Table 4-21 apart from V64I, few SNPs showed moderate association with 
the OB group.  
Firstly, at -1835 position where T allele was more prevalent in OB group 
compared to the controls (3% Vs 0%) p=0.001, pc 0.009.  This was expected 
as this allele is tightly linked with V64I SNP, but interesting the linkage in OB 
group was not as tight as seen in the two control groups where it was almost 
100%.  
Secondly, at -5663 position where AA genotype was present in 52% of OB 
patients compared to 30% in the control group. (P=0.01, however after 
correction the significance was lost. pc 0.09) 
Thirdly, as studied in chapter 3, SNP -2459 (same as -59029) showed some 
week association p 0.03. This SNP was tightly linked to SNP at -2135 but no 
significant differences were noted with this SNP. 
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Table 4-21: CCR5 SNPs in OB and controls 
 
 
With these SNPs I was able to construct 11 haplotypes in control group 
including the common HHC, HHE haplotypes. (Table 4-22) In Behcet’s group 
only 7 haplotypes were present as the following rare haplotypes were absent 
HHC*2 HHE*1 HHF*1 & HHE*3. This is presumably because of small sample 
size of OB group. No significant differences in haplotype frequencies were 
noted between the two groups. 
Also I was unable to find any significant effect of theses haplotypes on the 
phenotype of uveitis in OB group.  
SNP  Genotype  Behcet’s Controls 1 Controls 2 P value 
    N= 31 % N=169 % N=142 %  
CCR 190 GG 21 68% 139 82% 114 80% NS 
  GA 9 29% 30 18% 28 20% NS 
  AA 1 3%  0 0% 0 0% 0.001 
-5663 A/A 16 52% 55 32% 38 27% 0.01 
  A/G 10 32% 91 54% 78 55% 0.01 
  G/G 5 16% 23 13% 26 18% NS 
-3900 C/C 8 26% 21 13% 19 13% NS 
  C/A 14 45% 92 54% 76 54% NS 
  A/A 9 29% 56 33% 47 33% NS 
-3458 TT 6 19% 19 11% 19 13% NS 
  TG 15 48% 88 52% 74 52% NS 
  GG 10 32% 62 37% 49 35% NS 
-2459 GG 4 13% 32 19% 26 18% NS 
  GA 12 39% 87 51% 74 52% NS 
  AA 15 48% 50 30% 42 30% 0.03 
-2135 TT 8 26% 32 19% 26 18% NS 
  TC 13 42% 87 51% 74 52% NS 
  CC 10 32% 50 30% 42 30% NS 
-2086 AA 14 45% 56 33% 44 31% NS 
  AG 13 42% 89 53% 76 54% NS 
  GG 4 13% 24 14% 22 15% NS 
-1835 TT 1 3% 0 0% 0 0% 0.001 
  TC 6 19% 31 18% 26 18% NS 
  CC 24 77% 138 82% 116 82% NS 
∆ 32 wtwt 26 84% 142 85% 111 78% NS 
  wt∆ 32 5 16% 26 15% 30 21% NS 
  ∆ 32 ∆ 32 0 0% 1 1% 1 1% NS 
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Table 4-22: CCR5 haplotypes in OB and controls 
CCR2 ∆ Behcet's 
Haplotype 
190 
-5663 -3900 -3458 -2459 -2135 -2086 -1835 
32 Uveitis 
Controls Significance 
          n= (31) n=(311) P value 
HHA V A A G G T A C wt 3 (10%) 22 (7%) NS 
HHC V A C T G T G C wt 17 (55%) 199 (64%) NS 
HHC*1 I A C T G T G C wt 2 (6%) 6 (2%) NS 
HHC*2 V A C T G T G C ∆ 32 0 3 (1%) NS 
HHC*3 V A A G G T G C wt 1 (3%) 12 (4%) NS 
HHE V G A G A C A C wt 15 (48%) 171 (55%) NS 
HHE*1 V G A G A C G C wt 0 3 (1%) NS 
HHE*3 V A C G A C A C wt 0 6 (2%) NS 
HHF*1 V A A G A C A T wt 0 6 (2%) NS 
HHF*2 I A A G A C A T wt 8(25%) 53 (17%) NS 
HHG*2 V G A G A C A C ∆ 32 4 (12%) 56 (18%) NS 
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However when individual SNPs were studied the CCR5 -5663 showed 
association with the need of second line of immunosuppressant. 24 patients out 
of total 31 patients needed second line of treatment and in this group the GG 
genotype was very infrequent (4%)  compared to (57%) in the group not 
needing second line of treatment p 0.0008, pc 0.007. However the power of this 
significance was low because of small sample size. The genotypic frequencies 
are shown in detail in the following Table 4-23 
 
 
Table 4-23: CCR5 -5663 SNP association with need of second line immunosupression in 
OB 
   
CCR5 -5663 
On Second line of 
Immunosuppressant 
Not on Second line of 
Immunosuppressant Chi 3X2 Chi 2X2 
 (n=24) (n=7)   
GENOTYPE Count Count  p 
AA 14 (58%) 2 (29%)  NS 
AG 9 (38%) 1 (14%) 0.0036 NS 
GG 1 (4%) 4 (57%)  0.0008 
Total 24 7   
Allelic Carriage     
A 23 (96%) 3 (43%)  0.0008 
G 10 (42%) 5 (71%)  NS 
 
Since -1835 and CCR2 V64I were linked, as expected I also noted the gender 
bias at -1835 locus as well. As shown in the Table 8-8 Appendix B however, 
the association was not as strong as seen with CCR2 V64I SNP.  
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4.2.4 Discussion: 
This study was done to further elucidate the role of CCR2 V64I SNP in the 
susceptibility of Behcet’s induced uveitis. Initially thought to be non-functional 
polymorphism there is ever growing evidence that this valine to isoleucine 
change can have functional consequences. Nakayama et al (Nakayama et al. 
2004) showed that cells expressing CCR2A-64I migrated more efficiently than 
those expressing CCR2A-64V. Pulse–chase experiments revealed that higher 
expression of CCR2A-64I was due to increased stability of CCR2A. Other 
studies have shown that this SNP can modulate the surface expression of 
CCR5 (Lee et al. 1998) (Mellado et al. 1999) (Sabbe et al. 2001).  This subject 
has been discussed in detail in chapter 3  
CCR2 is the receptor for MCP-1 and the role of MCP-1 and CCR2 in BD is 
becoming clearer.  Serum MCP-1 levels were noted to play a role in sustained 
low grade chronic inflammation in OB (Kaburaki et al. 2003) and high MCP-1 
levels are found in aqueous of patients with OB. (Curnow et al. 2005) Like wise 
high expression of CCR2 has been noted on the circulating T cells of patients 
with BD. (Houman et al. 2004) 
Both CCR2 and CCR5 genes have been mapped to chromosome 3p21.3-p24, 
and are clustered within a total distance of 350 kb on chromosome 3p21.3.  
(Daugherty and Springer 1997) (Samson et al. 1996b) CCR2 V64I is not only 
tightly linked to CCR5 promoter loci particularly -1835, it is also noted to effect 
the expression of CCR5 receptor. This has lead to believe that CCR2 and 
CCR5 work in close association and in vivo and in vitro studies have shown 
increased expression of CCR5 on inflammatory cells during active Behcet’s 
disease.  (Dalghous, Freysdottir, and Fortune 2006) (Houman et al. 2004) 
(Imamura et al. 2005) (Onder et al. 2003) 
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The frequency of variant allele 64I in OB was 18% in my patient population 
compared to 6%, 7% and 10% in three control groups. (Pooled frequency 8%) 
The addition of third control group further confirms that the 64I frequency in 
controls is the true representation of population, rather than selection biased. 
This can be further confirmed by the fact that the frequency of 64I allele in UK 
normal populations is around 6-7%. (Hampe et al. 2001) (Martinson et al. 2000) 
(Spagnolo et al. 2003) (Spagnolo et al. 2005). When the frequency of 64I was 
compared with NOB it again showed that the frequency of 64I allele was 10% 
in NOB which is closer to controls rather than OB.  Given that the frequency of 
HLA-B51 was quite the same in the OB and NOB groups it is quite possible 
that CCR2 64I allele could be a risk factor for uveitis in patients with Behcet’s 
disease. It is interesting to note that frequency of 64I allele is generally higher 
in countries where BD is more prevalent. For example in Korea the 64I allelic 
frequency in healthy subjects is around 27% (Cheong et al. 2007), in Japan 
around 26% Hizawa, 1999 1475 /id} and around 13-14% in Turkey and Greece.  
(Apostolakis et al. 2007) (Yigit et al. 2007)  
In my non-Caucasian patients (Middle East) the frequency in OB was 22% 
compared to 13% in non-Caucasian controls (Middle East & West Asia,). The 
frequency in the control population was similar to published studies, (Karaali et 
al. 2010) (Yigit et al. 2007) (Martinson et al. 2000) 
Although the frequency in non Caucasians were higher in OB patients but the 
difference was not statistically significant. I did not have enough non-Caucasian 
patients with NOB to perform meaningful analysis but based on my findings in 
Caucasian patients I expect that frequency of 64I allele in NOB would not be 
significantly different.    
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Another interesting finding was the high allele carriage frequency of 64I among 
female patients (67%) with OB compared to NOB and controls. If only the male 
patients with OB were considered the frequency was 11% not significantly 
different from controls and NOB patients. This difference was also seen in Non-
Caucasian OB patients where the 64I frequency in females was 70% compared 
to 15 % in OB males and 22% in female healthy controls. It appears that the 
risk of OB associated with 64I allele is higher for females compared to males. 
This is possible if we implicate virus exposure as an initiating event in Behcet’s 
disease. We know that males and females differ in their susceptibility to variety 
of infections particularly Herpes Simplex. (Barna et al. 1996) (Burgos et al. 
2005) (Suligoi et al. 2004) Herpes simplex not only is important in occurrence 
of Behcet’s disease, (Suzuki and Suzuki 2004) but also its clearance may 
require CCR5 molecule. (Sorensen and Paludan 2004) Besides Herpes virus 
can cause persistent expression of CCR2 and other chemokines at primary and 
latent sites which can cause immune mediated diseases. (Cook et al. 2004) 
Very interesting Mojtahedi et al from Iran (Mojtahedi et al. 2006) recently 
showed that CCR5 32bp ∆ could be a risk factor for Behcet’s disease in Iranian 
women but not in men. This gender bias in Behcet’s patients have been noted 
earlier by Chen et al (Chen et al. 2004), who found that genetic variation in 
MCP-1 and RANTES (which are ligands for CCR2 and CCR5 respectively) can 
predispose to Behcet’s disease depending on gender.  Interestingly a similar 
association has been noted in another genetic study, where risk of myocardial 
infarction was only seen in female carriers of 64I allele. (Petrkova et al. 2003)  
Studying further 8 SNPs in CCR2 gene did not reveal any effect on 
susceptibility to OB or on the phenotype of the disease. This may be a true 
finding, or it could be a false negative result because of relatively small sample 
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size. One important finding was that CCR2 64I allele though was conferring risk 
of OB development but it did not affect the severity or outcome of the disease. 
Increased stability of CCR2 as a result of 64I mutation theoretically should 
make more CCR2 available for MCP-1 and other ligands. Experimental animal 
studies have shown that while MCP-1 plays a role in the initiation of uveitis 
(Adamus et al. 1997) (Mo et al. 1999) (Tuaillon et al. 2002), the levels do not 
particularly follow the activity of uveitis. It has also been seen that the serum 
MCP-1 levels do not correlate with disease activity in BD but they are 
consistently higher than controls. (Kaburaki et al. 2003)  Hence any 
polymorphism that would lead to CCR2 over expression (in turn driving T 
cells/monocytes towards MCP-1) can increase the susceptibility to uveitis and 
may not affect the phenotype of disease. Hence in this study I noted that while 
V64I polymorphism acted as a risk factor for OB, it did not affect the severity, 
response to treatment or visual outcome. 
On the other hand when SNPs in the promoter region of CCR5 gene were 
studied, modest associations were noted with -5663 A allele, -2459 A allele and 
stronger association was seen with -1835 T allele. This is presumably because 
CCR2 V64I is strongly linked to these SNPs but one must not forget that -2459 
A allele has shown to increase the expression of CCR5 independent of CCR2 
64I allele. (Shieh et al. 2000) Similarly, C-1835-T substitution, results in loss of 
novel nuclear factor binding. (Mummidi et al. 2000)Investigations of the 
transcriptional activity of different haplotypes in the cis-regulatory region of 
CCR5 have demonstrated that CCR5-haplotypes containing 1835T (HHF) have 
significantly different promoter efficiency compared to other haplotypes. The -
5663 SNP is up until now is thought to be non functional and its effects are 
probably as a result of linkage to other functional SNPs in the proximity. 
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However in-vitro or in-silico studies can be done to find out functional effects of 
this SNP. 
Given that more associations were noted in CCR5 SNPs rather than CCR2 
SNPs it is possible that CCR2 64I allele exert its effects by altering CCR5 
expression either indirectly through linkage or through direct functional effects. 
There is ever increasing body of evidence that CCR2 64I allele can directly 
alter the expression of CCR5 receptor gene. Nakayama et al noted CCR5 
surface expression was more severely blocked by co-expression of CCR2A-64I 
than by CCR2A-64V. (Nakayama et al. 2004) This negative effect of CCR2A on 
CCR5 expression was shown to arise from the possibility of heterodimer 
formation between CCR2A and CCR5. Taken together, the authors concluded 
that CCR2A-64I polymorphism modulates CCR5 surface expression. 
 Mellado et al showed that valine to isoleucine substitution gives CCR2 
receptor ability to heterodimerize with the CCR5 and/or CXCR4 receptor 
following MCP-1 binding. (Mellado et al. 1999) Similarly the CCR2V64I 
polymorphism was indicated to decrease CCR5 re-expression after ligand 
induced internalization in CD4+ T cells (Sabbe et al. 2001) 
This theory seems attractive particularly if we believe that a pathogen is 
involved in the aetiology of Behcet’s disease and decreased CCR5 expression 
can lead to all sort of immune mechanisms. CCR5 deficient mice challenged 
with certain pathogens, e.g., HSV, influenza virus and mycobacterium 
tuberculosis, demonstrate symptoms ranging from increased inflammatory 
cytokine production and leukocyte infiltration to increased T cell clonal 
expansion (Nansen et al. 2002) (Sorensen and Paludan 2004) (Algood and 
Flynn 2004). These findings have frequently been reported in patients with BD 
(Gul 2001) (Suzuki and Suzuki 2004) (Houman et al. 2004). However this 
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theory should be interpreted with caution as I did not notice any association of 
CCR5 32bp ∆ which is known to decrease the expression of CCR5. However 
as discussed earlier, a report from Iran shows association of 32bp ∆ genotype 
with Behcet’s disease in females only. (Mojtahedi et al. 2006) 
The other possible way that 64I mutation can exert its effects is through reduce 
cell expression of CXCR4 by heterodimerisation of CCR2 with CXCR4.   (Lee 
et al. 1998) (Mellado et al. 1999) This chemokine receptor has recently been 
reported to enhance the active retention of highly differentiated primed T cells 
at sites of chronic inflammation. Use of topical steroids leads to up regulation of 
CXCR4 in primed T cells in uveitis (Curnow et al. 2004) signifying the protected 
role of CXCR4 in uveitis but whether down regulation of CXCR4 on monocytes 
plays any role in the triggering or propagation of uveitis  in OB is not known at 
all. Interestingly the aqueous levels of CXCL12 the ligand for CXCR4 are 
decreased in active Behcet’s uveitis and idiopathic anterior uveitis. (Curnow et 
al. 2005) 
The association of 64I seen with OB is unlikely to be due to linkage with HLA-
B51 gene. In fact the opposite is true as none of the carrier of 64I allele was 
positive for HLA-B51 antigen.  The frequency of HLA-B51 (22.27%) was quite 
similar to 26.3% reported from Irish patients with OB. (Kilmartin, Finch, and 
Acheson 1997). It is quite likely that CCR2 V64I can exert its risk of developing 
uveitis in the absence of HLA-B51 gene. 
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Conclusion:  
In summary this study has shown that 64I allele could be a genetic risk marker 
for uveitis in Behcet’s disease. 64I probably does not predispose to Behcet’s 
disease, nor does it affect the severity of the uveitis. But once BD is there it can 
precipitate the onset of OB and this effect is particularly seen in females in both 
Caucasian and non-Caucasian populations.  
64I SNP either exerts its effects directly through CCR2 stability and or 
CCR5/CXCR4 expression or indirectly through linkage with loci in CCR5 genes. 
Given the fact that among tested for HLA-B51, all the patients with 64I allele 
were negative for HLA-B51 it seems quite likely that CCR2 64I imparts risk of 
OB in the absence of HLA-B51. 
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Chapter Five 
 
5 Cytokine gene polymorphism in posterior segment 
uveitis 
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5.1 Introduction 
5.1.1 Cytokines and their role in inflammation 
Immune function depends on the biologic activities of numerous small 
glycoprotein messengers, termed cytokines. Typically, cytokines exhibit broad 
functional activities that mediate not only effector and regulatory immune 
functions, but also wider effects across a range of tissues and biologic systems.  
Most of the cytokines indeed manifest multiple biological activities on different 
target cells, and many cytokines are produced by a variety of cell types in 
response to different stimuli. Furthermore, the expression of a given cytokine 
gene is invariably influenced by other cytokines, forming a network of "cytokine 
cascades"(Kohase et al. 1987) 
 Historically cytokines were classified on the basis of their presumed function, 
cell of secretion, or target of action. They were categorized as follows 
• Interferons: IFNs (IFN-α, IFN-β, IFN-γ) 
• Tumour necrosis factors: TNFs (TNF-α, lymphotoxin-α, lymphotoxin-β) 
• Interleukins: ILs 
• Chemokines 
• Transforming Growth Factors: TGFs 
• Hematopoietic colony-stimulating factors (CSFs) 
It were Mosmann and colleagues (Mosmann et al. 1986) (Mosmann and 
Coffman 1989) who revolutionized the field of immunology by categorising T-
helper (Th) cells into two distinct populations with contrasting and cross-
regulating cytokine profiles.  
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Th2 cells, which produce the cytokines IL-4, IL-5, and IL-13, are involved in 
allergic responses and the clearance of extracellular pathogens, such as 
worms.(Mosmann and Coffman 1989) 
IFN-γ-producing Th1 cells, on the other hand, contribute to the elimination of 
intracellular pathogens and are involved in cell-mediated and delayed-type 
hypersensitivity responses.(Mosmann and Coffman 1989) This leads to the 
division of cytokines into Th1 mediating cytokines and Th2 mediating cytokines.  
In earlier studies, Th1 cells were implicated as the causal agents in the 
pathogenesis of autoimmunity as these cells possessed the ability to transfer 
disease and elevated levels of IFN-γ were detected in vivo in areas of 
inflammation. However, studies in several autoimmune disease models 
suggested a more complex story. Mice genetically deficient in IFN-γ gene not 
only were not protected but also exhibited enhanced susceptibility in many 
models of autoimmunity.(Ferber et al. 1996) (Jones et al. 1997) (Matthys et al. 
1998) The identification of Th17 cells, a CD4+T-cell subset that produces IL-17, 
(Aggarwal et al. 2003) has helped to shed some light on this apparent paradox. 
These cells, like Th1 cells, have the capacity to cause T-cell-mediated 
inflammation and autoimmune disease. Moreover, the Th17 response is 
remarkably elevated in mice lacking IFN-γ. However, in experimental 
autoimmune uveitis (EAU), mice lacking IL-17 are also not protected and 
display elevated numbers of IFN-γ-producing CD4+ T cells. (Haak et al. 2009) 
(Luger et al. 2008) This raises the possibility, that Th1 and Th17 cells might 
cooperate with one another to propagate the inflammatory response 
The human genome project has facilitated discovery of numerous cytokines, 
posing considerable challenges in resolving their respective and synergistic 
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functions in complex tissues in health and disease. Such understanding is 
essential with the advent of cytokine-targeting therapies in the clinic 
This all has lead to categorization of cytokines by structural homologies shared 
with related molecules. (Commins, Borish, and Steinke 2010) Table 5-1 shows 
in details the 7 superfamilies of cytokines.  The Superfamilies share sequence 
similarity and exhibit homology and some promiscuity in their reciprocal 
receptor systems; they however do not exhibit functional similarity 
 
 
Table 5-1: Structural classification of cytokines 
FAMILY MEMBERS 
    
Hematopoietic   
 Common g chain  IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 
Shared b chain (CD131)  IL-3, IL-5, GM-CSF 
 Shared IL-2b chain 
(CD122)  
 IL-2, IL-15 
Other hematopoietic   IFN-γ, IL-7, IL-13, IL-21, IL-31, TSLP 
    
IL-1 family  IL-1°, IL-1 β, IL-1ra, IL-18, IL-33  
    
gp130-utilizing  IL-6, IL-11, IL-27, IL-31, ciliary neurotrophic factor (CNTF),  
  cardiotrophin 1 (CT-1), leukaemia inhibitory factor (LIF),  
  oncostatin M (OSM), osteopontin 
    
IL-12  IL-12, IL-23, IL-35 
    
IL-10 superfamily  IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, IL-29 
    
 IL-17   IL-17A-F, IL-25 (IL-17E) 
Interferons    
Type I interferons   IFN-a, IFN-b, IFN-v  
Type II interferon  IFN-γ (also a hematopoietic cytokine)  
Type III interferons  IFN-l1 (IL-29), IFN-l2 (IL-28A), IFN-l3 (IL-28B) 
    
TNF superfamily   TNF-α, TNF-b, BAFF, APRIL 
    
 
BAFF: B cell activating factor, APRIL: A proliferation-inducing ligand  
From (Commins, Borish, and Steinke 2010) 
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However the classification that still proves more relevant in clinical and 
immunological practice still divides cytokines according to their functions and 
effects on inflammatory cells.  
The Table 5-2 below shows one way of classifying cytokines 
Table 5-2: Immunological classification of cytokines 
 
 
 
 
 
 
 
 
 
 
GM-CSF: Granulocyte-macrophage colony-stimulating factor 
(Commins, Borish, and Steinke 2010) 
 
Cytokine receptors 
In recent years, the cytokine receptors have come to demand the attention of 
more investigators than cytokines themselves, partly because of their 
remarkable characteristics, and partly because a deficiency of cytokine 
receptors has now been directly linked to certain debilitating immunodeficiency 
states. In this regard, and also because the redundancy and pleiomorphism of 
cytokines are, in fact, a consequence of their homologous receptors, many 
authorities think that a classification of cytokine receptors would be more 
clinically and experimentally useful. 
 
TH Cytokine Cytokines involved 
Family repertoire in differentiation 
TH1 IFN-γ, TNF-α, TNF-b, GM-CSF,  IL-12, IL-18,  IFN-γ, IL-27 
 IL-2,  IL-3  
TH2 IL-2, IL-3, IL-4, IL-5, IL-9, IL-13, Mainly IL-4 
 IL-24, IL-25, IL-31, TNF-α, GM-CSF  
TH9 IL-4, IL-9 TGF-β 
   
TH17 IL-17 (IL-17A), IL-17F, IL-21,  IL-22 IL-6 & IL-23: 
   
nTreg/iTreg IL-10 TGF-β, IL-10 & IL-2 
   
TH3 TGF-β, IL-10 IL-10, IL-4 
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A classification of cytokine receptors based on their three-dimensional structure 
has, therefore, been attempted. Such a classification, though seemingly 
cumbersome, provides several unique perspectives for attractive 
pharmacotherapeutic targets. (Table 5-3) 
 
Table 5-3: Classification of cytokine receptors 
Cytokine Receptors Typical ligands 
Type -1  
IL-2R---IL-7R, IL-12R, GM-CSFR IL-2, IL3, IL4, IL-5, IL-6, IL-7, IL-9, IL-12,  
  GM-CSF 
Type-2(immunoglobulin family)  
IFNR1, IFNR2, IL-10R, M-CSFR IFN-α , IFN-β , IFN-γ, IL-10, M-CSF 
   
Type-3(TNF receptors family)  
TNFR1, TNFR2,  TNF-α, TNF-β , CD40 
   
Type-4  
IL-1R1 IL-1α, IL-1β 
    
 
GM-CSFR: Granulocyte-macrophage colony-stimulating factor Receptor, M-CSFR: macrophage 
colony-stimulating factor Receptor   
 
Cytokines play a major role in orchestrating immune mediated inflammation. 
The proof not only comes from animal models, in-vitro or in-vivo studies, but 
also from the successful use of drugs targeted against cytokines in controlling 
immune mediated diseases. Similarly in uveitis, our knowledge about role of 
cytokines is ever expanding 
 
 
 
 
 
 284 
5.1.2 Cytokines in Uveitis 
 
Evidence for the role of cytokines in the pathogenesis of uveitis comes 
principally from:  
(a)  Detection of cytokines in ocular tissue or fluid 
(b)  Studies on experimental animal models and  
(c)  in-vitro studies such as cytokine arrays and gene expression. 
5.1.2.1 Animal Studies 
 
EAU serves as a model for several human ocular diseases of suspected 
autoimmune aetiology (Gregerson et al. 1986) (Caspi et al. 1986). EAU is 
elicited by immunization with retinal antigens (Ags) or their fragments (Agarwal 
and Caspi 2004), or by adoptive transfer of retinal Ag-specific CD4 + T cells 
between syngeneic rodents (Sanui et al. 1989) (Rizzo et al. 1996)  
Indeed, a pivotal role for antigen-specific CD4+ Th1 cells and pro-inflammatory 
cytokine-mediated disease has been demonstrated in both rat and mouse. In 
fact nude rats devoid of T cells, are unable to develop experimental 
autoimmune uveitis.(Nussenblatt 1991) IFN-γ is also considered to be a major 
effector cytokine in the pathogenesis of autoimmunity.(Baccala, Kono, and 
Theofilopoulos 2005) Concentrations of IFN-γ have been found to predominate 
in experimental autoimmune uveitis at peak inflammation in Lewis rats, and as 
such, susceptibility to experimental autoimmune uveitis in Lewis rats is thought 
to be connected with a Th1-dominant response involving IFN-γ. (Okada et al. 
1998), (Caspi et al. 1997) A slight peak in IFN-γ mRNA expression in the iris 
and ciliary body, again corresponding with maximal inflammation, has also 
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been observed in experimental autoimmune anterior uveitis. (de and 
Verwaerde 2002) 
IL-12, produced by macrophages and dendritic cells, has been reported to be a 
dominant factor in the development of Th1 cells. (Yoshida et al. 1994) IL-12-
deficient mice have shown resistance to induction of experimental autoimmune 
uveitis, but following IL-12 administration to cells from these mice, the cells are 
induced to produce large amounts of IFN-γ and can adoptively transfer 
experimental autoimmune uveitis to naïve recipients. (Tarrant et al. 1998) In 
addition, anti-IL-12 monoclonal antibodies administered prior to immunization 
prevented experimental autoimmune uveitis induction in mice. (Yokoi et al. 
1997) Furthermore, experimental autoimmune uveitis-susceptible mice show a 
greater amount of IL-12 receptor expression on Th1 cells correlating with IFN-γ 
expression. (Wu et al. 2003)  
 TNF-α is synthesized by monocytes, macrophages, neutrophils, mast cells, NK 
cells and T cells. (Pfeffer 2003) (Grivennikov et al. 2006) During the 
inflammatory process, it orchestrates the initiation of further leukocytic 
infiltration via adhesion molecule upregulation, dendritic cell maturation and 
survival, macrophage activation, and driving Th1 T cell responses within 
tissues in experimental autoimmune uveitis.(Dick et al. 2004)  Increased TNF-α 
expression in inflammatory cell infiltrates has been seen in experimental 
autoimmune uveitis near peak inflammation as well. (Okada et al. 1998) 
Increased TNF-α mRNA has also been detected in the iris and ciliary body at 
the peak of the disease in experimental autoimmune anterior uveitis.(de and 
Verwaerde 2002) Conversely, the neutralization of TNF-α activity with a p55 
TNF receptor fusion protein after the induction of experimental autoimmune 
uveitis delays its onset and attenuates tissue damage. (Dick et al. 1998) 
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 IL-2 is produced mainly by activated T lymphocytes and can activate T cells 
and NK cells. It has been detected in experimental autoimmune uveitis at 
concentrations approaching those of IFN-γ near maximal inflammation. (Okada 
et al. 1998) IL-2 has also been shown to induce anterior uveitis in a rabbit 
model after intravitreal injection. (Samples, Boney, and Rosenbaum 1993) 
Administration of IL-2 receptor mAb in efferent-stage experimental autoimmune 
uveitis in the Lewis rat has also achieved partial experimental autoimmune 
uveitis suppression. (Higuchi et al. 1991)   
In Lewis rats, IL-1α injected intravitreally has been demonstrated to induce 
intraocular inflammation in agreement with the concept of IL-1, initiating a 
cascade of inflammatory mediators. (Ferrick et al. 1991) IL-1β is also a pro-
inflammatory cytokine and is derived predominantly from activated 
macrophages but also from B cells and vascular endothelial cells. IL-1β 
injected intravitreally into Lewis rats is also associated with a breakdown in the 
blood-retinal barrier and induces an inflammatory response. (Claudio, Martiney, 
and Brosnan 1994)  Conversely, IL-1β blockers have been shown to inhibit 
experimental uveitis (Xuan et al. 1998).  
IL-6 is a macrophage-derived cytokine, also thought to be produced by 
endothelial and ocular parenchymal cells. (Ohta et al. 2000b)  It is a pleiotropic 
cytokine that is able to function in a pro- and anti-inflammatory manner. 
Macrophage activation and the differentiation of B cells to plasma cells are 
other known key effector roles for IL-6. It is readily induced by TNF-α, IFN-γ 
and IL-1. Evidence exists to suggest that IL-6 is involved in the direct induction 
of IL-2 receptor expression, differentiation and proliferation of T cells. (La 
Flamme and Pearce 1999)It is even thought to be more active in this respect 
than both IL-1 and TNF-α. (Joseph, Miner, and Croft 1998)  Increased levels of 
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IL-6 have been detected in the aqueous humour in a murine model of 
experimental autoimmune uveitis with serial sampling demonstrating an 
increased local production at disease onset followed by a decrease as the 
inflammation mounted. (Ohta et al. 2000a)    
TGF-β describes a group of pleiotropic cytokine isoforms that includes TGF-β1, 
-β2 and -β3. All are structurally and functionally similar having effects on many 
cell types including macrophages, T cells and B cells. For T cells, TGF-β 
inhibits T cell proliferation and suppresses cytotoxic T cells. (Kehrl et al. 1986)  
In the eye, TGF-β is present at high levels in the aqueous humour and is 
thought to be implicated in the maintenance of immune privilege through the 
inhibition of antigen-driven T cell activation and proliferation. (Cousins et al. 
1991)  TGF-β2 levels have been found to be increased in experimental 
autoimmune uveitis and are thought to be antagonized by IL-6, such that TGF-
β2 suppresses inflammation once IL-6 levels fall. (Ohta et al. 2000b) TGF-β2, 
in conjunction with α-melanocyte-stimulating hormone, has been demonstrated 
to reduce the incidence and severity of experimental autoimmune uveitis. 
(Namba et al. 2002)   
IL-4 is a multifunctional cytokine that can be secreted by several cell types. The 
most important producers of IL-4 in T cell-mediated disease are CD4+ Th2 
cells activated by antigen recognition through the T-cell receptor. Among the 
effector functions of IL-4 are induction of IgE production by B cells and direct 
differentiation of naïve CD4+ T cells into a Th2 population, (Gascan et al. 1991)   
thereby favouring the growth of cells which produce IL-4 and IL-5 while 
inhibiting the production of IFN-γ. (Seder 1994)  IL-4 is also involved in the 
inhibition of TNF-α and IL-1 production by activated monocytes, (Te Velde et al. 
1990) In experimental autoimmune uveitis, the addition of IL-4 has been 
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reported to block the production of IFN-γ, while anti-IL-4 mAb therapy has been 
shown to lead to enhanced IFN-γ production. In experimental models of uveitis, 
both IL-4 and IL-10 are thought to be important cytokines for the 
immunosuppressive effects of CD4+ T regulatory cells. (Yotsukura et al. 1997) 
The production of both IL-4 and IL-10 has been documented to correlate with a 
recession of disease, suggesting their possible importance in the spontaneous 
termination of experimental autoimmune uveitis.  
IL-10 is an essential anti-inflammatory multifunctional cytokine produced 
primarily from T cells and activated macrophages. IL-10 plays a key role in the 
differentiation and function of T regulatory cells which figure prominently in 
control of immune responses and tolerance in vivo. (Moore et al. 2001) T 
regulatory cells, themselves, produce IL-10, as well as TGF-β. (Levings et al. 
2002) In this scenario, IL-10 is thought to act as a positive autocrine factor for 
the development of T regulatory cells. (O'Garra and Barrat 2003) It has been 
proposed that the higher expression of the IL-10 gene in some rat strains may 
confer a greater resistance to experimental autoimmune uveitis.(Sun et al. 
2000) Furthermore IL-10 mRNA expression has been shown to coincide with 
downregulation of IFN-γ and TNF-α coinciding with the resolution of 
experimental autoimmune uveitis. (Rizzo et al. 1998) More recently, the local 
administration of an adeno-associated viral vector expressing IL-10 significantly 
decreased experimental autoimmune uveitis disease severity. (Broderick et al. 
2005)  
TH17 role 
The identification of Th17 cells, a CD4+T-cell subset that produces IL-17, 
(Aggarwal et al. 2003) subset has now broadened our understanding of 
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inflammatory processes in human disease and has helped to explain some of 
the anomalies seen in the Th1/Th2 axis. 
Susceptibility to EAU of IFN-γ deficient (GKO) mice, exacerbation of EAU by 
neutralization of endogenous IFN-γ, and the protective effects of high systemic 
IFN-γ in WT mice  (Caspi et al. 1994) (Jones et al. 1997) (Tarrant et al. 1999) 
are in apparent paradox with this notion that EAU is purely Th1 mediated. Mice 
deficient in IFN-γ, IFNGR, IL-12Rb2, and the IL- 12p35 chain were highly 
susceptible to experimental autoimmune encephalomyelitis (EAE) and 
collagen-induced arthritis (CIA) (Cua et al. 2003) (Gran et al. 2002) (Becher, 
Durell, and Noelle 2002). In contrast, IL-23 and the IL-17 –producing effector T 
cell whose differentiation and maintenance are promoted by IL-23 were found 
to be necessary for induction of these diseases (Cua et al. 2003) (Murphy et al. 
2003). The activity of the IL-17 producing effector T cells (Th17) was 
associated with induction of proinflammatory cytokines such as TNF-α, IL-1, IL-
6, and IL-8, as well as with enhanced proliferation, maturation, and chemotaxis 
of neutrophils. These results led to the notion that the pathogenic effects 
previously attributed to the IL-12/IFN- y pathway are in fact largely if not solely 
mediated by IL-23 and the IL-23 driven Th17 effector  (Cua et al. 2003) 
(Langrish et al. 2005). However, in EAU, mice lacking IL-17 are also not 
protected and display elevated numbers of IFN-γ-producing CD4+ T cells. 
(Haak et al. 2009) (Luger et al. 2008) 
Luger et al. showed that either Th1 or Th17 cells can drive tissue damage 
depending on the methods used to initiate disease. (Luger et al. 2008)   
Kroenke et al. showed that adoptive transfer of either Th1 or Th17 cells can 
induce EAE and clinical paralysis in mice, but the pathology induced by Th17 
cells differs from that induced by Th1 cells. (Kroenke et al. 2008) Thus Th17 
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cells are unlikely to be the sole players in driving tissue damage in these 
classical models of autoimmunity. Although Th17 is a welcome addition to our 
understanding of immune-mediated tissue damage, we still need the Th1/Th2 
axis and other inflammatory mediators to explain many aspects of human 
autoimmune, allergic, and infectious diseases. The diagram below explains our 
current understanding of role of cytokines in the induction of posterior segment 
uveitis based on animal models.  
 
Figure 5-1: Cytokine networks in pathogenesis of uveitis.  
Courtesy Caspi & Horai, 2011, Journal of interferon & cytokine research.  
Presentation of Ag in the periphery in the presence of cytokines and innate (environmental) stimuli 
induces T cell activation, differentiation, and clonal expansion. Activated effector (uveitogenic) T cells then 
migrate and extravasate into the eye. Upon breakdown of blood–retinal barrier (BRB), leukocytes and 
lymphocytes (Th1 and Th17) that are recruited from circulation, as well as inflammatory cytokines, amplify 
the inflammation, resulting in uveitis. RPE, retinal pigment epithelium; ONL, outer nuclear layer; OPL, 
outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer 
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5.1.2.2 Role of cytokines in Human uveitis 
 
Various pro-inflammatory cytokines have been investigated in patients with 
uveitis.  IL-1β and IL-6 have been detected in the vitreous aspirates of patients 
with idiopathic panuveitis and may act as a local amplification signal in 
pathological processes associated with chronic eye inflammation. (Franks et al. 
1992)  IL-2 has been demonstrated in the choroid and aqueous humour of 
patients with idiopathic uveitis, and serum levels have also been found to 
positively correlate with the aqueous humour levels. (Hooks, Chan, and Detrick 
1988) (Lacomba et al. 2000) 
Adult patients with idiopathic uveitis have also been shown to have elevated 
aqueous humour and serum levels of TNF-α (Santos et al. 2001b) IFN-γ, as 
well as IL-2.  (Lacomba et al. 2000) 
Elevated serum TNF-α levels seem to be positively correlated with recurrent 
episodes of uveitis of idiopathic origin. (Santos et al. 2001b)  Significantly 
increased levels of IFN-γ have also been detected in the aqueous humour of 
patients with chronic idiopathic anterior uveitis. (bi-Hanna, McCluskey, and 
Wakefield 1989)  
Multiplex analysis has recently enabled the detection of significant increases in 
IL-6, IFN-γ in the aqueous humour of patients with idiopathic uveitis, as 
compared to non-inflammatory control aqueous humour. (Curnow et al. 2005)  
TGF-β2 has been detected in patients with idiopathic uveitis at significantly 
lower levels than in control groups. (de Boer et al. 1994) (Curnow et al. 2005) 
IL-6 has been detected in vitreous, as well as aqueous humour aspirates of 
patients with idiopathic uveitis. (Franks et al. 1992)   More specifically, 
increases in vitreous levels of IL-6 have been detected in patients with active 
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intermediate and posterior uveitis, (Perez et al. 2004) reflective of on-going 
inflammation during disease hence, role in the propagation of uveitis. 
In humans, IL-4 has only been detected in low levels and at levels not 
significantly different from controls in the aqueous humour and serum of 
patients with idiopathic uveitis. (Lacomba et al. 2000) It has also been found to 
be produced at low levels by T cells derived from the vitreous humour of 
patients with uveitis. (Muhaya et al. 1999)  
 A decrease in aqueous humour IL-10 has been demonstrated in conjunction 
with an increase in activated CD4+ T cells in anterior uveitis. (Calder et al. 
1999) 
 
5.1.2.2.1 Ocular Behcet’s 
Significantly raised IL-2, IL-6, IFN-γ and TNF-α levels have, been found in the 
aqueous humour and serum of patients with OB. (Lacomba et al. 2000) (Santos 
et al. 2001b) (Santos et al. 2001a). Increased serum levels of IL-2 receptors, 
IL-6, TNF-α, IFN-γ have also been found by others in Behcet’s disease. 
(Bardak and Aridogan 2004) (BenEzra et al. 1993) (Hamzaoui et al. 2002) 
Furthermore, significant positive correlations appear to exist between elevated 
serum TNF-α levels and recurrent episodes of uveitis associated with BD. 
(Santos et al. 2001b)  IL-5 and IL-10 detection by multiplex analysis has 
revealed the aqueous humour levels in uveitis associated with patients with BD 
to be not significantly different from that of controls.(Curnow et al. 2005) 
Aqueous and vitreous humour levels of IL-10 were also reported as unchanged 
from controls in patients with OB.(Ongkosuwito et al. 1998) Significant 
reductions of TGF-β have, however, been detected as compared to controls. 
(Curnow et al. 2005) 
 293 
 
5.1.2.2.2 Sarcoid Uveitis 
Among patients with sarcoidosis, raised bronchoalveolar lavage levels of IFN-γ, 
TNF-α, (Wahlstrom et al. 2001) IL-12,(Kim et al. 2000a) IL-6 and IL-8 
(Takizawa et al. 1997) have all been detected, while only a few cells positive for 
IL-4 have been observed, suggesting a polarization towards a Th1 cytokine 
profile. (Wahlstrom et al. 2001) T cell clones derived from the aqueous humour 
of a patient with sarcoidosis in one study were shown to produce large amounts 
of IL-1α, IL-6 .(Sakaguchi et al. 1998) Analysis of aqueous and vitreous humour 
samples of patients with sarcoidosis has also documented significantly 
increased levels of IL-6 as compared to controls.(Xu et al. 1997) 
No significant differences in the levels of IL-4 have been found as compared to 
controls in the aqueous humour (Lacomba et al. 2000) and vitreous humour 
(Ongkosuwito et al. 1998) of patients with sarcoidosis. The expression of TNF-
α on peripheral blood CD4+ lymphocytes has been documented to be 
significantly increased in patients with presumed sarcoid intermediate 
uveitis.(Murphy et al. 2004) HighIL-2/IL-5 and IFN-γ/IL-5 ratios were also found 
in the peripheral blood lymphocyte culture supernatants further illustrating the 
polarization of the systemic immune response towards Th1 in this type of 
uveitis. (Murphy et al. 2004) 
5.1.2.2.3 IL-17 in Human uveitis 
Since the discovery that Th17 cells also play a part in animal models of 
immune mediated diseases, researchers have been studying the role of IL-17 
in human uveitis and related diseases. So far the studies are few and results 
not so convincing but results suggest that, IL-17 does play part in VKH and 
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Behcet’s disease. Expression of IL-23p19 mRNA, IL-23, IL-17, and IFN-γ is 
found to markedly elevated in OB. (Chi et al. 2008) However the frequencies of 
both IL-17-producing and IFN-γ-producing T cells from PBMCs are significantly 
upregulated in BD patients with active uveitis concluded that the IL-23/IL-17 
pathway together with IFN-γ is associated with the active intraocular 
inflammation in BD patients (Chi et al. 2008) 
Recently a study showed that significantly higher levels of IL-17 and IFN-γ were 
observed in active BD patients as compared with controls. (Chi et al. 2010) 
Treatment with CsA inhibited the production of both cytokines in association 
with an amelioration of intraocular inflammation. 
The patients with VKH disease with active uveitis showed an elevated level of 
IL-23p19 mRNA in PBMCs, higher IL-23 in the serum and increased production 
of IL-17 by polyclonally stimulated PBMCs and CD4(+) T cells. (Chi et al. 2007) 
Another study showed, that IL-17, IFN-γ, were upregulated in patients with 
active uveitis in VKH. (Liu et al. 2009)  Again CsA and corticosteroids were able 
to down regulate all these elevated levels which correlated with the clinical 
improvement of the uveitis. 
These and similar studies on animal models and human subjects have 
increased our understanding about the role of cytokines in uveitis, however the 
relationship is very complex and complicated by the fact that there is lot of 
redundancy and overlap in cytokine system. However it does appear that IL-1, 
IL-4, IL-6, IL-10, IL-12 & IL-18, IL-17 & IL-23, together with TNF-α and IFN-γ 
play significant role in orchestrating  immune response in uveitis.  
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Aims 
I hypothesized that genetic variability in genes encoding these cytokine 
molecules may play a role in the development and susceptibility of PSU.  The 
aim of this study was to determine whether SNPs in cytokine genes involved in 
uveitis would predict the disease severity and response to the treatment. As 
discussed in detail, (Risch and Merikangas 1996)studying functionally 
significant polymorphisms rather than random polymorphisms in the gene of 
interest offers considerable advantages in terms of detecting disease 
associated genes. 
This study was done to further explore the role of cytokine gene polymorphism 
in PSU and see whether these polymorphisms can predict the visual outcome 
and prognosis in patients with non-infectious posterior uveitis 
 
5.2 Material and Methods 
5.2.1 Subjects 
Samples of 176 Caucasian patients with PSU were available for genotyping. As 
mentioned in the chapter two, few samples were ruined before I could start my 
work on cytokine gene polymorphism. (I used 205 subjects in previous study) 
5.2.2 Controls  
Two groups of control were used in this study.  
1) 166 healthy Caucasian subjects who were admitted for cataract 
extraction at WXH 
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2)  And a cohort of 105 Caucasian patients attending the eye clinics for 
age related macular degeneration. All the subjects were negative for 
any history of autoimmune disease. 
Again along with the PSU samples, some control samples were ruined as well. 
(I used 283 control subjects in previous study) 
5.2.3 SNP selection 
Cytokines and their receptors have been shown to be highly polymorphic. The 
vast majority of polymorphisms found in cytokine genes and their receptors are 
located in the promoter, intronic and 3′ untranslated regions. Some polymorphic 
loci appear to consistently alter cytokine production; however, the majority of 
cytokine polymorphisms appear to have little or no influence on cytokine 
production and expression. Extensive literature search was performed to 
identify functional SNPs in cytokines involved in pathogenesis of PSU. It must 
be noted that at the time of my research the role of IL-17 in uveitis was just 
emerging and no functional SNP had been discovered at that stage. Hence the 
IL-17 gene did not form part of my research work. SNPs were selected on the 
basis of fact that 
1) SNPs were functional (proved by in-vitro or in-vivo studies) 
2) Cytokine genes, in which the SNPs were identified, had a proven role 
in the pathogenesis of uveitis 
3) SNPs role had been studied in other immune mediated diseases. 
Following SNPs were selected 
5.2.3.1 IL-1β -511 
IL-1β is a member of the IL-1 super family. This gene and eight other 
interleukin 1 family genes form a cytokine gene cluster on chromosome 2. A C 
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to T SNP at promoter position -511 is shown to be functional. Earliest study 
showed that mononuclear cells from carriers of allele T had a slight, but non-
significant, elevated capacity to produce IL-1β in vitro. (Santtila, Savinainen, 
and Hurme 1998). Hall et al. tested LPS-induced secretion of IL-1β protein as 
measured by an ex vivo blood stimulation assay. T allele at -511 was 
significantly associated with a 2-3-fold increase in LPS-induced IL-1β protein 
secretion.  (Hall et al. 2004) Another study demonstrated that carriers of IL1β -
511 T show a significantly higher plasma level of IL1β than those of IL1β -511 
C. (Hulkkonen, Laippala, and Hurme 2000) 
5.2.3.2 IL-4 -590 
IL-4 orchestrates its Th2 effects by inducing IgE production from B cells. The 
gene encoding is present on chromosome 5q31.1.  A SNP at position -590 was 
first discovered in 1995, when it was noted C to T change was associated with  
three fold increase in  total serum IgE levels and three fold increase in IL4 
transcription activity. (Rosenwasser et al. 1995)  Nakashima et al.  using 
intracellular cytokine detection assay showed that  peripheral Th cells in 
subjects  carrying T allele expressed more IL-4 compared to C allele carriers. 
(Nakashima et al. 2002) 
Further studies showed that the T allele was associated with high serum IgE 
levels in African (Vafa et al. 2009) and as well as Caucasian subjects. 
(Basehore et al. 2004) (Kabesch et al. 2003) 
5.2.3.3 IL-6 -174 
IL-6 gene is present on chromosome 7p21 and -174 SNP was first noted in 
1998. (Fishman et al. 1998) Luciferase reporter vector assay showed that -
174C construct had lower expression than the -174G construct. After 
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stimulation with LPS or IL-1, expression from the -174C construct did not 
significantly change after 24 h, whereas expression from the -174G construct 
increased by 2.35+/-0.10- and 3.60+/-0.26-fold, respectively, compared with the 
unstimulated level. Plasma levels of IL-6 were also measured in 102 of the 
healthy subjects, and the C allele was found to be associated with significantly 
lower levels of plasma IL-6. Using enzyme immunoassay, IL-6 concentrations 
were measured in serum samples of 65 subjects. (Belluco et al. 2003) The 
serum levels of IL-6 were more than double in the carriers of GG genotype 
compared to C allele carriage (wild type) 
5.2.3.4 IL-10 SNPs 
The functional polymorphisms in the promoter region of IL-10 were first 
reported in late 1990s, (Turner et al. 1997) (Rosenwasser et al. 1995) where it 
was noted that variants in promoter region could affect the transcription and 
expression of IL-10 gene and in turn lead to altered production of IL10 by 
PBMC. Crawley et al. used transient transfection studies to investigate the 
transcription of reporter genes driven by IL-10 promoter allele. They also 
performed whole blood cultures to assess IL-10 production by each genotype. 
The ATA haplotype (containing A allele at -1082 & -592) was associated with 
lower transcriptional and lower IL-10 production under lipopolysaccharide. 
(Crawley et al. 1999) 
Yilmaz et al. measured IL-10 levels of stimulated PBMCs in vitro. After 
stimulation with purified protein derivative (PPD) and Staphylococcus aureus 
Cowan strain I  SAC, -1082 A allele carriers produced significantly lower levels 
of IL-10 than non-carriers (Yilmaz, Yentur, and Saruhan-Direskeneli 2005) 
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Recent studies have again confirmed that the G allele at -592 and G allele at -
1082 lead to increased transcriptional activity, increased IL-10 expression, and 
increased IL-10 production. (Donati et al. 2008) (Claudino et al. 2008) (Larsson, 
Rymo, and Berglundh 2010) The IL-10 -592 is in complete linkage with other 
published SNP IL-10 -819, so only  IL-10 -592 & -1082 SNPs were selected for 
the study.  
5.2.3.5 IL-12 +1188 
IL-12 is a heterodimeric cytokine composed of a p35 and p40 subunit, encoded 
by IL12A (chromosome 3q25.33) and IL12B (chromosome 5q33.3), 
respectively. A polymorphism was discovered at +1188 3’ UTR site of IL12B 
gene in 2000. (Huang, Cancilla, and Morahan 2000) IL-12 p40 and p70 
secretion by monocytes, in relation to +1188 genotype was determined in 63 
healthy donors. After stimulation of monocytes with SAC and IFN-γ, there was 
3 folds increase in IL-12 p70 secretion among the carriers of CC (variant) 
genotype (Seegers et al. 2002). Individuals CC homozygous at IL12 +1188 had 
significantly higher IL-12 secretion levels from LPS and PPD stimulated PBMCs 
than AC heterozygotes or AA homozygotes (Yilmaz, Yentur, and Saruhan-
Direskeneli 2005). IL-12p70 levels in culture supernatants after stimulation with 
PMA+Ionomycin were assessed by ELISA. Healthy individuals with C allele 
had an increased production of IL-12 p70 compared with non-carriers. (varez-
Rodriguez et al. 2009) 
5.2.3.6 IL-18 SNPs 
Gene encoding IL-18 is located on chromosome 11q22.2-q22.3. Giedraitis et al. 
identified five SNPs: -656, -607, -137, +113 and +127 (Giedraitis et al. 2001). 
Using luciferase construct, they found that haplotypes 1 (G-C-G-TC) and 3 (T-
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A-G-T-C) resulted in increased expression in stimulated HeLa cells, compared 
to haplotype 2 (T-A-C-GT). The authors postulated that -137 G>C may be 
responsible for variation in gene expression. Latter studies showed the G/C 
change at -137 position and C/A change at -607 position leads to decrease 
expression of IL-18 gene. Zhou et al examined promoter activities by a dual 
luciferase assay system in a cell line, THP-1. (Zhou et al. 2005) The promoter 
activity of the haplotype -137G/-607C/-656G was significantly higher than that 
of the other common haplotype, -137G/-607A/-656T, accounting for the 
association between serum IL-18 levels and the SNPs. 
Serum IL-18 levels were determined using ELISA in patients with active 
untreated adult onset still’s disease. (Chen et al. 2009) Median levels of serum 
IL-18 were significantly lower in patients with -607 AA genotype compared to 
those with CA genotype or CC genotype.  
IL-18 -137 & IL-6 -607 SNPs were selected for my study 
5.2.3.7 IFN-γ +874 
The IFN-γ gene, IFNG, is located on 12q24.1, contains 4 exons that span 5.4 
kb. As with most cytokine genes, there are no common variants located within 
coding regions. Several polymorphisms have received attention in disease-
association studies, including the intron 1 +874 A>T 
This SNP was first noted by Pravica et al. who found T to A polymorphism 
coincides with a putative NF-kappa B binding site. (Pravica et al. 2000) EMSA 
demonstrated reduced binding to the T allele using excess unlabelled NF-kB 
consensus sequence. Authors concluded that this SNP might have functional 
consequences for the transcription of the human IFN-γ gene and could directly 
influence the level of IFN-γ production.  
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 A later study confirmed this finding.  (Hoffmann et al. 2001) Cytokine protein 
production was assessed by enzyme-linked immunosorbent assay after 
costimulation of cultured peripheral blood lymphocytes in healthy subjects. T 
allele was associated with higher cytokine production. Another study showed 
IFN-γ +874T-A polymorphism was related to the IFN-γ response to PPD 
antigen and the magnitude of the response decreases during transition from 
TT- to TA and to AA genotypes (Sallakci et al. 2007) 
5.2.3.8 IFNGR 
 
IFNGR1 is located on chromosome 6q23.3 and encodes IFN-γ receptor. A 
functional SNP at promoter site -56 was first noted by Juliger et al. who showed 
lower levels of luciferase reporter gene expression in the presence of the 
mutation, indicating the importance of this position for promoter activity, and 
suggesting that this SNP might negatively influence the expression level of 
IFNGR1 at the cell surface. (Juliger et al. 2003)   
This has now been confirmed by recent studies.  A reporter gene assay 
showed that, after stimulation with IFN-γ, the IFNGR1 gene promoter construct 
that contained the -56T allele, manifested higher transcriptional activity  than 
did the construct with the mutant -56C allele (Matsuda et al. 2007). In another 
luciferase reporter assay a 10-fold increase (p<0.001) in luciferase expression 
was associated with the IFNGR1-56*T allele.  (Canedo et al. 2008) 
5.2.3.9 TNF-α 
TNF is the most widely studied cytokine gene in relation with polymorphisms 
and disease. This is due to the location of TNF-α gene in the major 
histocompatibility complex (MHC). This has prompted speculation about the 
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role of TNF-α in the aetiology of MHC-linked diseases, particularly autoimmune 
diseases. 
The most commonly studied TNF- α polymorphism is -308 G/A.  A study in 
1997 (Kroeger, Carville, and Abraham 1997) examined functionality of this SNP 
using EMSA analysis, and found increased binding of a factor to the A allele. In 
luciferase assays that contained the region 993 to +110 of the TNF promoter 
with each -308 allele found that the A allele resulted in a 1.7-fold increase in 
luciferase expression 24 h after PMA-stimulation of Jurkat and U937 cells.  
Further in-vitro studies showed that the –308 A allele is a more powerful 
transcriptional activator than the –308G allele. Louis et al. and Brinkman et al. 
found that the peripheral blood mononuclear cells of the individuals having –
308 A/A genotype synthesized more TNF-α than the individuals having G/G 
genotype. (Louis et al. 1998) (Brinkman et al. 1995) 
Another putative functional promoter polymorphism, -238 G>A occurs within 
the TNF repressor site (Fong, Siddiqui, and Mark 1994) but has shown 
contradicting functionality in a number of studies. A study by Kaluza et al. 
transfected a 691 bp fragment of TNF- α promoter in a luciferase vector into the 
Raji and Jurkat cell lines and demonstrated a reduction in gene expression 
from the rare allele. (Kaluza et al. 2000)  They also found a non-significant 
decreased expression of TNF- α from PBMCs possessing the rare allele.  
TNF-α production in whole blood cultures upon stimulation with LPS was 
determined in 179 individuals (Huizinga et al. 1997) LPS-stimulated blood cells 
of −238G/A individuals yielded significantly less TNF-α than those of −238G/G 
individuals 
TNF-α -857 is another SNP that has noted to be associated with anterior uveitis. 
(Kuo et al. 2005) The functional effects of this SNP are however not known, but 
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since strong associations of this SNP with noted, I selected this SNP, along 
with -308 & -238 SNPs. 
LTA+252 
LTA gene is present on chromosome 6p21.3 and it encodes lymphotoxin-alpha 
also known as TNF-b. A, G to A SNP at position +252 intron -1 was first noted 
in 1991.  The variant allele was noted to be more transcription activator than 
the wild type allele (Messer et al. 1991) 
Whichelow et al. measured the secretion capacity of LTA of peripheral blood 
mononuclear cells (PBMC) from PHA stimulated healthy individuals and 
diabetic patients. (Whichelow et al. 1996) They showed that those with the 
variant allele secreted significantly higher levels of TNF-β than those with the 
wild type allele  
Knight et al. developed upon the principle of chromatin immunoprecipitation 
(ChIP) to examine in vivo the effect of nontranscribed polymorphism on gene 
expression (Knight et al. 2003).  The authors used this technique to examine 
the TNF region and showed that LTA +252 G allele is associated with 
increased LTA mRNA expression.  
 
5.2.4 DNA extraction and genotyping 
Qiagen commercial kit (Qiagen UK Ltd, UK) method was used to extract 
genomic DNA from 176 PSU patients and 105 controls from KCH.  
Salt extraction method was used to extract DNA of 166 healthy controls from 
WXH. 
Genotyping for 14 polymorphisms in 10 genes was performed using the 
5’Nuclease Activity Assay first described by Holland et al. (Holland et al. 1991) 
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Primers and TaqMan® probes were designed using Primer Express software 
(version 2.0; sequences shown in Table-1) and synthesised and supplied by 
Applied Biosystems UK. The reporter dyes chosen were 6-FAM and VIC™. 
Using the Applied Biosystems Allelic Discrimination PCR protocol, 5 ml PCR 
reactions containing 20 ng of DNA, 0.9 mmol primers, and 0.2 mmol probes 
(final concentrations) were performed in 384 well plates and run on the Applied 
Biosystems 7900 HT sequence detection system. PCR annealing temperatures 
ranged from 60˚C to 62˚C.  Thermal cycling consisted of 1 cycle of 50˚c for 2 
minutes and 95˚c for 10 minutes and then 45 cycles of 95˚c for 15 seconds and 
60˚c for 1 minute. SDS version 2.0 software was used to analyse real time and 
endpoint fluorescence. Table 5-4 describes the details of primers and probes 
used to type cytokine SNPs. 
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Table 5-4: Primers and probes used to detect cytokine SNPS 
SNPs   PRIMERS ALLELES PROBES ANNEALING  
          TEMERATURE 
        
IL-1β-511 Forward GGTCTCTACCTTGGGTGGTGTT T 6-FAM-TCTGCCTCAGGAGC-MGB 62 
  Reverse TCCTCAGAGGCTCCTGCAAT C VIC-TGCCTCGGGAGCT-MGB   
        
IL-4-590  Forward  CCT GTC CTT CTC AAA ACA CTA AAC TTG C  VIC-AGA ACA TTG TCC CCC AGT-MGB 60 
  Reverse  GCA GAA TAA CAG GCA GAC TCT CCT A T  6-FAM-AGA ACA TTG TTC CCC AGTG -MGB   
        
IL-6-174 Forward GCTGCACTTTTCCCCCTAGTT C 6'FAM-CTTTAGCATGGCAAGAC-MGB 62 
  Reverse GCTGATTGGAAACCTTATTAAGATTGT A VIC-CTTTAGCATCGCAAGAC-MGB   
        
IL-10-592 Forward GGT AAA GGA GCC TGG AAC ACA TC C VIC-CGC CTG TCC TGT AGG-MGB-NFQ 60 
  Reverse CCC TTC CAT TTT ACT TTC CAG AGA A 6-FAM-CGC CTG TAC TGT AGG A-MGB-NFQ   
        
IL-10-1082  Forward ACA CAC AAA TCC AAG ACA ACA CTA CTA A G VIC-ATC CCT ACT TCC CCC TCC CAA AGA A-TAMRA 62 
  Reverse GGA GGT CCC TTA CTT TCC TCT TAC C A 6-FAM-CCC TAC TTC CCC TTC CCA AAG AAG C-TAMRA   
        
IL-12 1188  Forward GGATCACAATGATATCTTTGCTGTATTT A VIC-CATTTAGCATCTAACTATAC-MGB 60 
  Reverse CTATACATAAATTAGCTGATTGTTTCAATGA C FAM-TTTAGCATCGAACTATAC-MGB    
        
IL-18-137. Forward GGCACAGAGCCCCAACTTT C 6-FAM CGGAAGAAAACATTT-MGB     60 
  Reverse CGAGTACTTCTTTTAATGTAATATCACTATTTTCA G VIC   CGGAAGAAAAGATTT-MGB   
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Contd: Table 5-4: Primers and probes used to detect cytokine SNPS 
 
      
IL-18-607  Forward  CCCAAGCTTACTTTCTGTTGCA A 6-FAM  AAGTGTAAAAATTATTAAATAAA-MGB  60 
  Reverse   AAGCCACACGGATACCATCATT C VIC  AAAAATTATTACATAAAATTCT-MGB   
        
IFNG+874 Forward ACATTCACAATTGATTTTATTCTTACAACA T 6-FAM TGTGTGTGAGATTTG -MGB    60 
  Reverse GTGCGAGTGTGTGTGTGTGTGT A VIC  TGTGTGTGTGATTTGA -MGB   
        
IFNGR1-56 Forward GGTGACGGAAGTGACGTAAGG T 6-FAM  CCAGCACTGCCCT -MGB   60 
  Reverse   CGCCTGCGGGACCAG C VIC  CCAGCGCTGCCCT -MGB   
        
TNFa-238 Forward ATC AGT CAG TGG CCC AGA AGA A VIC-CTG CTC TGA TTC CGA-MGB 60 
  Reverse GCA TCA AGG ATA CCC CTC ACA G FAM-CTG CTC CGA TTC CGA-MGB   
        
TNF-308  Forward CCAAAAGAAATGGAGGCAATAGGTT A 6-FAM-CCCGTCCtCATGCC-MGB 60 
  Reverse GGACCCTGGAGGCTGAAC G VIC-CCCGTCCCCATGCC-MGB   
        
LTA+252 Forward 5'-CAGTCTCATTGTCTCTGTCACACATT-3' G 5'-CCATGgTTCCTCTC-3' (FAM) MGB 60 
  Reverse 5'-ACAGAGAGAGACAGGAAGGGAACA-3' A 5'-CTGCCATGaTTCC-3' (VIC) MGB   
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5.2.5 Statistical Analysis 
For each subject group, genotype frequencies were counted and the allelic and 
allele carriage frequencies calculated. All genotype frequencies in each 
population were tested for deviation from the Hardy-Weinberg equilibrium using 
the chi-square test. Data mining for significant associations was performed 
using knowledge seeker®, (Angoss softwares UK) and statistical calculations 
were performed with SPSS 12.0 (Chicago USA). Confidence intervals were 
calculated at the 95 % level and a value of p < 0.05 was considered as 
significant. Chi-square test was used to compare the genotypic and allelic 
frequencies in patients and controls. A correction for multiple comparisons was 
made using the Bonferroni method.  A multiple logistic regression model was 
used to determine association between various genotype and the phenotypes. 
Power calculations were performed using Quanto® Version 1.0. Haplotypes 
were identified by the computer program PHASE, version 2.  
Before generating haplotype, linkage between the SNPs was calculated by EM 
algorithm using Arlequin® population genetics software.  
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5.3 Results 
. 176 Caucasians patients were recruited for this study out of which 81 were 
males and 95 females. The age of onset ranged from 4.6 to 70.5 years with a 
mean of 36.81 years. All the patients had a follow up of at least 2 years with a 
majority of patients had a follow up of 5 years. The follow up ranged from 2 
years till 42.6 years with a mean of 8.34 years. Salient features of the patients 
are shown in Table 5-5. 
 
Table 5-5: Clinical features of patients with PSU 
Phenotype Number % 
Idiopathic intermediate uveitis 67 38.0% 
Idiopathic posterior uveitis 58 33.0% 
Behcet's  27 15.4% 
Sarcoidosis 24 13.6% 
Total 176 100% 
   
Need of systemic steroids 130 73.86% 
On long term systemic steroids 69 39.20% 
On second line of immunosuppressive agents 74 42.05% 
Cystoid macular oedema 111 63.07% 
Cataract 81 46.02% 
Glaucoma 62 35.23% 
Permanent visual loss 76 43.18% 
Vasculitis 58 32.95% 
   
Follow up in years Mean=8.4 Range(2--42.6) 
Sex Males=79 females=92 
Laterality of disease Bilateral=148 Unilateral 28 
Age of onset (years) Mean=34.12 Range=(5-70.5) 
Relapses  (rate per year) Mean=2.1 Range=(0-7) 
Visual impairment during inflammation Mean=x2 of visual angle Range=(Nil-PL) 
Better eye visual acuity after 24 months Mean=6/9 Range=(6/5-HM) 
 
Genotyping of the SNPs showed that all genotypic frequencies were in HWE. 
The Table 5-6, Table 5-7, & Table 5-8 show in detail the frequencies of all 14 
cytokine SNPs typed. 
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Table 5-6: Frequencies of IL-1, IL-4, IL-6 & IL-10 SNPs in PSU and controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP Intermediate Posterior Behcet's Sarcoidosis Total PSU Total Controls P Value  
  N % N % N % N % N % N % 
PSU Vs 
Controls 
Between 
PSU groups 
IL-1β 511T/C 
                         NS  NS 
CC 30 44.80% 26 44.80% 9 33.30% 9 37.50% 74 42.00% 120 44.30%     
CT 23 34.30% 23 39.70% 18 66.70% 12 50.00% 76 43.20% 120 44.30%     
TT 14 20.90% 9 15.50% 0 0.00% 3 12.50% 26 14.80% 31 11.40%   0.01 
IL-4 590T/C 
                         NS  NS 
CC 47 70.10% 46 79.30% 18 66.70% 17 70.80% 128 72.70% 195 72.10%     
CT 18 26.90% 10 17.20% 9 33.30% 6 25.00% 43 24.40% 65 23.90%     
TT 2 3.00% 2 3.40% 0 0.00% 1 4.20% 5 2.80% 11 4.00%     
IL-6 174G/C 
                         NS  NS 
GG 28 41.80% 23 39.70% 14 51.90% 10 41.70% 75 42.60% 106 39.10%     
GC 34 50.70% 23 39.70% 9 33.30% 9 37.50% 75 42.60% 132 48.70%     
CC 5 7.50% 12 20.70% 4 14.80% 5 20.80% 26 14.80% 33 12.20%     
IL-10 592C/A 
                            
CC 44 65.70% 32 55.20% 9 33.30% 14 58.30% 99 56.30% 154 56.80%     
CA 21 31.30% 21 36.20% 14 51.90% 9 37.50% 65 36.90% 99 36.50%     
AA 2 3.00% 5 8.60% 4 14.80% 1 4.20% 12 6.80% 18 6.60%   0.0009 
                              
IL-10 1082G/A 
                         NS  NS 
GG 14 20.90% 14 24.10% 3 11.10% 6 25.00% 37 21.00% 62 22.90%     
GA 41 61.20% 30 51.70% 13 48.10% 11 45.80% 95 54.00% 148 54.60%     
AA 12 17.90% 14 24.10% 11 40.70% 7 29.20% 44 25.00% 61 22.50%     
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Table 5-7: Frequencies of IL-18, IFN-γ & IFNGR SNPs in PSU & controls 
 
P Value  
SNP Intermediate  Posterior Behcet's Sarcoidosis Total PSU Total Controls (Chi 2 X 2)  
  N % N % N % N % N % N % 
PSU Vs 
Controls 
Between 
PSU groups 
IL-12 1188A/C 
                         NS  NS 
AA 45 67.20% 41 70.70% 15 55.60% 13 54.20% 114 64.80% 176 64.90%     
AC 22 32.80% 15 25.90% 12 44.40% 10 41.70% 59 33.50% 83 30.60%     
CC 0 0.00% 2 3.40% 0 0.00% 1 4.20% 3 1.70% 12 4.40%     
IL-18 137G/C 
                            
GG 37 55.20% 25 43.10% 11 40.70% 14 58.30% 87 49.40% 157 57.90%     
GC 25 37.30% 23 39.70% 11 40.70% 8 33.30% 67 38.10% 99 36.50%     
CC 5 7.50% 10 17.20% 5 18.50% 2 8.30% 22 12.50% 15 5.50% 0.009   
IL-18 607C/A 
                            
CC 22 32.80% 14 24.10% 8 29.60% 12 50.00% 56 31.80% 110 40.60% 0.02   
CA 38 56.70% 29 50.00% 11 40.70% 8 33.30% 86 48.90% 125 46.10%     
AA 7 10.40% 15 25.90% 8 29.60% 4 16.70% 34 19.30% 36 13.30%     
IFNG 874 A/T                             
AA 15 22.40% 18 31.00% 5 18.50% 11 45.80% 49 27.80% 87 32.10%     
AT 35 52.20% 26 44.80% 13 48.10% 12 50.00% 86 48.90% 131 48.30%     
TT 17 25.40% 14 24.10% 9 33.30% 1 4.20% 41 23.30% 53 19.60%   0.005 
IFNGR 56C/T 
                         NS  NS 
TT 19 28.40% 22 37.90% 10 37.00% 9 37.50% 60 34.10% 93 34.30%     
TC 31 46.30% 31 53.40% 13 48.10% 13 54.20% 88 50.00% 134 49.40%     
CC 17 25.40% 5 8.60% 4 14.80% 2 8.30% 28 15.90% 44 16.20%     
 
 311 
 
 
Table 5-8: Frequencies of TNF & LTA SNPs in PSU and controls 
 
P Value  
SNP Intermediate  Posterior Behcet's Sarcoidosis Total PSU Total Controls (Chi 2 X 2)   
  N % N % N % N % N % N % 
PSU Vs 
Controls 
Between 
PSU groups 
TNF 238G/A 
                         NS  NS 
GG 62 92.50% 50 86.20% 24 88.90% 20 83.30% 156 88.60% 239 88.20%     
GA 5 7.50% 7 12.10% 3 11.10% 4 16.70% 19 10.80% 31 11.40%     
AA 0 0.00% 1 1.70% 0 0.00% 0 0.00% 1 0.60% 1 0.40%     
TNF 308G/A 
                            
GG 43 64.20% 41 70.70% 17 63.00% 18 75.00% 119 67.60% 192 70.80%  NS  NS 
GA 21 31.30% 16 27.60% 8 29.60% 5 20.80% 50 28.40% 69 25.50%     
AA 3 4.50% 1 1.70% 2 7.40% 1 4.20% 7 4.00% 9 3.30%     
TNF 857C/T 
                         NS  NS 
CC 52 77.60% 49 84.50% 21 77.80% 21 87.50% 143 81.30% 226 83.40%     
CT 13 19.40% 8 13.80% 5 18.50% 3 12.50% 29 16.50% 44 16.20%     
TT 2 3.00% 1 1.70% 1 3.70% 0 0.00% 4 2.30% 1 0.40%     
LTA 252A/G                          NS  NS 
AA 26 38.80% 29 50.00% 10 37.00% 13 54.20% 78 44.30% 119 43.90%     
AG 33 49.30% 25 43.10% 14 51.90% 10 41.70% 82 46.60% 120 44.30%     
GG 8 11.90% 4 6.90% 3 11.10% 1 4.20% 16 9.10% 32 11.80%     
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5.3.1 Effect of cytokine polymorphisms on genetic predisposition 
to uveitis 
 
5.3.1.1 Association of IL-18 & IL-12 SNPs with retinal vasculitis 
 
As shown in Table 5-7, the frequency of IL-18 -137 CC was significantly higher 
in PSU compared to controls p=0.009 pc 0.03. It was 12.5% in PSU more than 
double as compared to controls where it was 5.5%. The subgroup analysis in 
the table will show that CC phenotype was much common in Behcet’s and 
posterior uveitis. When further analysis was done, it was found that this IL-18 -
137 C allele was strongly associated with the development of retinal vasculitis. 
Though in sarcoidosis patient the over all frequency of CC was comparable to 
controls but in sarcoidosis patients who clinically exhibited retinal vasculitis it 
was 17%. There were 58 patients who developed vasculitis as a part of  the 
disease including patients with Behcet’s disease and sarcoidosis and the 
frequency of -137CC genotype was 19% compared to 6% among controls 
(p0.0001) and 9% among patients with no element of vasculitis pc>0.05. (Table 
5-9)There was a subgroup of patients in posterior uveitis that had idiopathic 
vasculitis (IRV) only with no other ocular structures involvement. In this sub 
group of 16 patients the frequency of -137CC genotype was 38% compared to 
6% in controls p=0.000001 pc=0.000008 and 10% in patients not including 
idiopathic retinal vasculitis p=0.001. (Table 5-9)  
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Table 5-9: IL-18 & IL-12 SNPs in patients with vasculitis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IL-18 -137 CC & IL-18 -607 AA was more common in patients with retinal vasculitis particularly idiopathic retinal vasculitis 
IRV: Idiopathic retinal vasculitis, PSU: Posterior segment uveitis
Genotype IRV PSU with Vasculitis  PSU PSU excluding IRV PSU without Vasculitis Controls P Value 
  n=(16) n=(58) n=(176) n=(160) n=(118) n=(271) 
IRV VS 
Controls 
IRV Vs 
rest  
IL-18 -137 
        
 
CC 38% (6) 19% (11) 13% (22) 10% (16) 9% (11) 5% (15) 0.0000001 0.001 
CG 31% (5) 40% (23) 38% (67) 39% (62) 37% (44) 37% (99) NS NS 
GG 31% (5) 41% (24) 49% (87) 51% (82) 53% (63) 58% (157) 0.03 NS 
          
 
C allele 53% (17) 39% (45) 32% (111) 29% (94) 28% (66) 24% (129)   
G allele 47% (15) 61% (71) 68% (241) 71% (226) 72% (170) 76% (413) 0.0002 0.005 
          
 
IL-18 -607 
        
 
AA 56% (9) 33% (19) 19% (34) 16% (25) 13% (15) 13% (36) 0.0000004 0.000008 
CA 31% (5) 41% (24) 49% (86) 51% (81) 55% (65) 46% (125) NS NS 
CC 13% (2) 26% (15) 32% (56) 34% (54) 32% (38) 41% (110) 002 NS 
          
 
A allele 72% (23) 53% (62) 44% (154) 41% (131) 40% (95) 36% (197)   
C allele 28% (9) 46% (54) 56% (198) 59% (189) 60% (141) 64% (345) 0.000005 0.0007 
          
 
IL-12 1188 
        
 
AA 69% (11) 66% (38) 65% (114) 64% (103 64% (76) 65% (176) NS NS 
AC 19% (3) 29% (17) 34% (59) 35% (56) 36% (42) 31% (83) NS NS 
CC 13% (2) 5% (3) 2% (3) 1% (1) 0% (0) 4% (12) NS 0.0004 
          
 
A 78% (25) 80% (93) 82% (287) 82% (262) 82% (194) 80% (435)   
C 22% (7) 20% (23) 18% (65) 18% (58) 18% (42) 20% (107) NS NS 
 314 
The other SNP in IL-18 gene at position -607 was in strong linkage with SNP at 
-137. Subjects homozygous for -137CC were always homozygous for AA at -
607 and also subjects homozygous for CC at -607 were never homozygous for 
CC at -137. 
This IL-18 -607 A allele also showed strong association with retinal vasculitis 
(see Table 5-9). The AA genotype was present in 56% of the patients with 
idiopathic retinal vasculitis compared to 13% in controls p=0.0000001, pc 
0.000008. The AA genotype frequency was 33% among patients who 
developed vasculitis compared to 13% who did not p=0.001. Using PHASE® 4 
haplotypes were deducted as shown in Table 5-10 and as expected patients 
with vasculitis had a frequency 69% of haplotype carrying C at -137 and A at -
607 compared to 22% in patients not having vasculitis or 27% in controls. 
P=0.0001 
Table 5-10:  IL-18 haplotypes in patients and controls 
 
IL-18 Haplotypes PSU Controls Retinal Vasculitis P Value 
  n=(176) n=(271) N= (16)  
     
  
137G/607C 52.9% 56.5% 17.8%  
137G/607A 14.9% 16.1% 13.2%  
137C/607A 32.2% 26.7% 69% 0.0001 
137C/607C 0.0% 0.7% 0%  
 
 
IL-12 another IFN-γ inducer and upon which IL-18 ability to induce IFN-γ 
depends also showed moderate association with idiopathic vasculitis. Again as 
shown in Table 5-9 the IL-12 -1188 CC genotype was present in 13% of 
patients with idiopathic vasculitis compared to 1 % in patients with PSU 
excluding idiopathic vasculitis p=0.0004, pc 0.003 
 
 
 315 
 
5.3.1.2 IL-1β -511 and Behcet’s Disease 
 
A glance at the Table 5-6 will show that in patients with Behcet’s disease none 
of them were homozygous for TT at IL-1β 511 site. Though the numbers were 
small to reach to any statistical significance but the difference compared to 
other sub groups was quite substantial.  The TT frequency was in the range 
from 12% in sarcoidosis and about 21% in Intermediate uveitis group as shown 
in the Table 5-6.  It must be noted that there was no significant difference in the 
genotypic frequencies between Behcet’s and control groups. Details are shown 
in the following Table 5-11 
 
Table 5-11: IL-1β -511 SNP frequency in OB. 
GENOTYPE PSU  OB Controls P value P value 
IL-1β -511 C/T N= 149  N=27 N= 271 OB Vs PSU OB Vs Controls 
CC 65 (44%) 9 (33%) 
 120 (44%) NS NS 
CT 58 (39%) 18 (67%) 120 (44%) 0.007 0.02 
TT 26 (17%) 0 (0%) 
 31 (11%) 0.018 NS 
Allelic Carriage      
  
   
C 123 (83%) 27 (100%) 
  
0.018 NS 
T 84 (56%) 18 (67%) 
  
NS NS 
Allelic Frequency     
  
   
C 188 (63%) 36 (67%) 
  
NS NS 
T  110 (37%) 18 (33%) 
     
Total 298 54 
     
OB: ocular Behcet’s 
5.3.1.3 IL-10 -592 and Behcet’s disease 
 
At position -592 of IL-10 the wild type allele C was less prevalent in Behcet’s 
disease compared to the rest of the groups and the controls. (Where the 
frequencies were comparable) As shown in the following Table 5-12 the allelic 
frequency of C allele was 59% in Behcet’s compared to 80% in rest of the 
group. P=0.0009 pc 0.003. 
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Table 5-12: IL-592 genotypic frequencies in OB 
GENOTYPE PSU  Behcet’s Controls P Value P Value 
IL-10 -592 C/A N= 149 N= 27 N=271 OB Vs PSU OB Vs Controls 
    
 
 
CC 90 (60%) 9 (33%) 154 (57%) 0.009 0.01 
CA 51 (34%) 14 (52%) 99 (37%) NS NS 
AA 8 (5%) 4 (15%) 18 (7%) NS  
Total 149 27 271   
Allelic Carriage       
C 141 (95%) 23 (85%) 253 (93%)  NS 
A  59 (40%) 18 (67%) 117 (43%) 0.009 0.01 
Allelic Frequency      
C 231 (78%) 32 (59%) 407 (75%) 0.004 0.01 
A  67 (22%) 22 (41%) 135 (25%)   
 
 
 
5.3.1.4 Sarcoidosis and IFN+874 A/T 
 
Compared to the rest of the group and the controls the T allele was less 
frequent among patients with sarcoidosis. As shown in the Table 5-13, the TT 
genotype was present in 4% of the sarcoidosis patients compared to 26% in 
rest of the group. P=0.01, the allelic frequency difference was quite significant 
as well p=0.005, pc 0.02. 
 
Table 5-13: IFN-γ +874 SNP frequencies in Sarcoidosis uveitis 
 
 
GENOTYPE Rest of PSU sarcoidosis P Value 
IFN+874 A/T N= 152 N=24 Chi2x2 
    
AA 38 (25%) 11 (46%) 0.034334 
AT 74 (48%) 12 (50%) NS 
TT 40 (26%) 1 (4%) 0.017055 
Allelic Carriage / phenotype    
A 112 (74%) 23 (96%) 0.017055 
T 114 (75%) 13 (54%) 0.034334 
Allelic Frequency    
A 150 (49%) 34 (71%) 0.005601 
T 154 (51%) 14 (29%)  
Total 304 48  
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5.3.2 Genotype phenotype correlation 
 
5.3.2.1 IL-1β -511 SNP  
5.3.2.1.1 IL- β -511 SNP and secondary glaucoma 
 
Sub group analysis also revealed that the minor allele T at position -511 of IL-
1β was less frequent in patients with PSU who developed glaucoma. As shown 
in Table 5-14, the IL-511b TT genotype was present in 5% of the patients with 
glaucoma compared to 21% in patients who did not develop glaucoma. The 
allelic frequency difference was very significant with a p value of 0.0001. After 
correcting for age and duration of disease this was still significant p 0.0007   
 
Table 5-14: IL-1β 511 SNP and risk of secondary glaucoma in PSU 
IL-1β 511 C/T PSU with Glaucoma PSU without glaucoma P value 
  n=(62) n=(114) Chi 2 X 2 
     
 
CC 36 (58%) 38 (33%) 0.001 
CT 23 (37%) 45 (46%)  
TT 3 (5%) 23 (20%) 0.006 
     
 
C allele 95 (77%) 129 (57%)  
T allele 29 (23%) 99 (43%) 0.0001 
  
 
 
However correcting for sub type of PSU revealed  that the effect was primarily 
seen in patients with idiopathic intermediate and posterior uveitis.(Table 5-15) 
In the idiopathic group (PU and IU) the T Allele frequency was 20% in patients 
with glaucoma compared to 46% in patients not suffering with secondary 
glaucoma. P=0.000005 
 318 
Table 5-15: IL-1β 511 SNP and risk of secondary glaucoma in idiopathic PSU 
IL-1β -511 C/T Glaucoma  No Glaucoma P Value 
Genotype N=43   N=81 Chi2x2 
     
CC 29 (67%)  27 (33%) 0.000281 
CT 11 (26%)  34 (42%) NS 
TT 3 (7%)  20 (25%) 0.015717 
Allelic Carriage / phenotype     
C 40 (93%)  61 (75%) 0.015717 
T 14 (33%)  54 (67%) 0.000281 
Allelic Frequency     
C 69 (80%)  88 (54%) 0.000005 
T  17 (20%)  74 (46%)  
 
5.3.2.1.2 IL-1β -511 and outcome in Behcet’s uveitis 
 
It must be noted that though this SNP showed some association with the 
development of Behcet’s uveitis but no effect was seen on the development of 
secondary glaucoma in Behcet’s patients. However there were some moderate 
effects of this SNP on prognosis and final vision of patients with Behcet’s 
uveitis. Although there was no homozygous for TT allele in Behcet’s group so 
the analysis was done between CC and CT genotype. It was noted that 
Behcet’s patients carrying CT genotype had poor vision at 5 and 10 years 
compared to patients with CC genotype as shown in the Table 5-16. Despite a 
very low number of subjects for the analysis the difference in the vision was 
very significant between Behcet’s patients with CC genotype and CT genotype.  
Table 5-16: The association of CT genotype with poor vision in patients with Behcet’s 
uveitis 
 1st year 2nd year 3rd year 5th year 10th year 
 
     
Asymp. Sig. 0.1 0.01 0.04 0.003 0.01 
Mean VA CT 6/12 6/24 6/36 6/60 1/60 
Range  6/6-6/24 6/9-6/60 6/12-3/60 6/12-1/60 6/18-NPL 
Mean VA CC 6/12 6/9 6/18 6/18 6/36 
Range 6/5-6/24 6/6-6/18 6/9-6/60 6/9-3/60 6/12-1/60 
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5.3.2.2 IL-6 -174 SNP and visual outcome 
 
The mutant allele C was noted to be associated with poor visual outcome and 
severity of the disease in the whole PSU group. There were 64 patients who 
had severe episodes of inflammation (as defined in chapter 2).  25% (16/64) of 
the patient with severe disease were homozygous for CC allele compared to 
9% (10/112) with mild to moderate disease. P=0.004.95% CI: 3.4 (1.4-8.0).  
(Figure 5-2)  Sub group analysis showed that this effect was seen in posterior 
uveitis mainly and to certain extent in intermediate uveitis group.  
 
0
20
40
60
80
100
120
IL6 174 CC 16 10
IL6 174 GG/GC 48 102
Severe Inflammation Mild to Moderate inflammation
 
 
Figure 5-2: IL-6 -174 SNP relation with intensity of inflammation in PSU. 
Among patients with severe inflammation (quadrupling of visual angle) IL-174 G allele was more 
prevelant than CC genotype.  
 
5.3.2.2.1 IL-6 -174 in Posterior uveitis 
 
As we can see in the Table 5-17 below, the C allele is associated with 
permanent visual loss and severe inflammation is patients with idiopathic 
posterior uveitis. Patients with severe inflammation had a CC frequency of 43% 
compared to 6% in patients with less severe inflammation: p=0.0005, pc 0.002 
95% CI: 12.69 (2.4-65.9) Details are shown in the table below (Table 5-17) 
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Table 5-17: IL-6 174 role in visual outcome PU. 
IL-6 -174 G/C PVL No PVL P VALUE 
 N=32 N=26 Chi2x2 
    
GG 9 (28%) 14 (54%) 0.046432 
GC 13 (41%) 10 (38%) NS 
CC 10 (31%) 2 (8%) 0.027622 
Allelic Carriage / phenotype    
G 22 (69%) 24 (92%) 0.027622 
C 23 (72%) 12 (46%) 0.046432 
    
    
Allelic Frequency    
G 31 (48%) 38 (73%) 0.007182 
C 33 (52%) 14 (27%)  
    
IL-6 -174 G/C Severe Disease Not severe  
 N=23 N=35  
    
GG 7 (30%) 16 (46%) NS 
GC 6 (26%) 17 (49%) NS 
CC 10 (43%) 2 (6%) 0.000514 
Allelic Carriage / phenotype    
G 13 (57%) 33 (94%) 0.000514 
C 16 (70%) 19 (54%) NS 
    
    
Allelic Frequency    
G 20 (43%) 49 (70%) 0.004423 
C 26 (57%) 21 (30%)  
  
PVL: Permanent visual loss 
 
Among the patients with permanent visual loss, Kaplan-Meier analysis showed 
that patient with CC genotype had higher rate of moderate visual loss (VA 6/15 
or worse) compared with the patients with G allele carriage. As seen in Figure 
5-3, at two year of follow up, 81% of patients with GG/GC genotype retained 
VA of better than 6/18 compared to 48% with CC genotype. (p=0.001) This 
difference however decreased with time and at five year and beyond it was 
non-significant. 
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Figure 5-3: Kaplan-Meier analysis showing rate of moderate visual loss between IL-6 -
174 CC & IL-6 -174 CG/GG genotypes in patients with posterior uveitis. 
 
5.3.2.2.2 IL-6 –174 in Intermediate uveitis 
 
Table 5-18 below shows the genotypic frequencies of IL-6 -174 SNP in patients 
with intermediate uveitis. As the table shows patients with severe inflammation 
had CC frequency of 21% compared to 2% in rest of the group: p=0.007. 
However this association was not as strong as seen in posterior uveitis group 
 
Table 5-18: IL-6 174 role in severity of uveitis in IU. 
 
IL-6 174 Genotype Mild to Mod. Int. Uveitis Severe Int. Uveitis P Value 
 N=48 N=19  
GG 23 (48%) 5 (26%) NS 
GC 24 (50%) 10 (523%) NS 
CC 1 (2%) 4 (21%) 0.007 
Allelic Carriage / phenotype     
G 47 (98%) 15 (79%) 0.007 
C 25 (52%) 14 (74%)   
Allelic Frequency     
G 70 (73%) 20 (53%) 0.02 
C 26 (27%) 18 (47%)   
 
Mild to moderate uveitis: Doubling of visual angle during inflammation. Severe uveitis: quadrupling of 
visual angle during inflammation 
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Among patients with intermediate uveitis this SNP was also affecting the 
response to treatment as well. The carriers of wild type allele were taking 
second line of immunosuppressants, and long term steroids less frequently 
than the carriers of the mutant allele. This is shown in the following Table 5-19 
 
Table 5-19: IL-6 -174 SNP and response to treatment in IU. 
IL-6 -174 G/C Long term steroid   No Long term  steroids  P value 
 N=20   N=47 Chi2x2 
GG 3 (15%)  25 (53%) 0.003 
GC 15 (75%)  19 (40%) 0.009 
CC 2 (10%)  3 (6%) NS 
     
 Steroids   No steroids needed  
 N= 42  N=25  
GG 11 (26%)  17 (68%) 0.0007 
GC 27 (64%)  7 (28%) 0.004 
CC 4 (10%)  1 (4%) NS 
     
 Sec. line of treatment  No sec. line of treatment  
 N=22  N=45  
GG 4 (18%)  24 (53%) 0.006 
GC 16 (73%)  18 (40%) 0.01 
CC 2 (9%)  3 (7%) NS 
 
 
Not only this, it was also noted that the mean number of second line of 
treatment needed in intermediate uveitis group was significantly less between 
the genotypes. The mean number was 1.1 for GG genotype, 1.9 for GC and 2.5 
for CC genotype, p=0.01. (Figure 5-4) 
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Figure 5-4: Comparison of number of second line of immunosuppressants needed to 
control inflammation between IL-6 174 GG or GC/CC carrying subjects in IU group.  
The mean number of second line of immunosuppressants needed among patients with GG genotype in 
IU was 1.1 compared to 2.2 in rest of the patients 
 
 
In posterior uveitis group the same association was noted between IL-6 174 
genotypes and need of second line of treatment. However the effect noted was 
modest. (Table 5-20) 
 
 
Table 5-20: IL-6 -174 SNP and need of second line of treatment in PU. 
IL-6 174 G/C Sec. line of treatment  No Sec. line of treatment P value 
 N=25  N=33 Chi2x2 
    
GG 10 (40%) 13 (39%) NS 
GC 6 (24%) 17 (52%) 0.03 
CC 9 (36%) 3 (9%) 0.02 
Allelic Carriage    
G 16 (64%) 29 (91%) 0.01 
C 15 (60%) 20 (61%) NS 
 
Again similar to intermediate uveitis mean number of second line treatment 
used was significantly less in carriers of wild type compared to mutant 
genotype. (1.6 Vs 2.9 p=0.03). (Data not shown) 
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5.3.2.3 Association of IL-10 592 with visual outcome and ischemic 
visual loss 
The A allele at position -592 was noted to be effecting the visual outcome. The 
carriers of A allele had poor visual acuity compared to C allele carriers. This 
effect was seen in all four groups but was more significant in posterior uveitis, 
Behcet’s and sarcoidosis. (Table 5-21) Though the effect seen in intermediate 
uveitis was not as significant as other groups, but the same allele was 
associated with permanent visual loss in patients with intermediate uveitis. 
Similar trend was seen in other groups but presumably did not reach 
significance due to numbers. Among IU patients with PVL (N=22) the A allele 
frequency was 30% compared to 12% in IU with no PVL (N=45) p=0.02. See 
Table 8-9, Appendix B 
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Table 5-21: IL-10 592 SNP and visual outcome in PSU groups 
 Disease First Year Second Year Third Year Fifth Year Tenth Year 
       
Asymp. Sig.  0.1 1 0.05 0.02 0.02 
Mean VA CC vs CA/AA Intermediate Uveitis 6/9 vs 6/12 6/12 vs 6/12 6/12 vs 6/24 6/12 vs 6/36 6/18 vs 6/36 
Asymp. Sig.  0.04 0.02 0.001 0.002 0.02 
Mean VA CC vs CA/AA Posterior uveitis 6/9 vs 6/18 6/12 vs 6/36 6/12 vs 6/60 6/18 vs 1/60 6/36 vs 2/60 
Asymp. Sig.  0.0002 0.0007 0.001 0.001 0.009 
Mean VA CC vs CA/AA Behcet's Uveitis 6/12 vs 6/36 6/18 vs 6/60 6/18 vs 1/60 6/24 vs 1/60 6/24 vs 1/60 
Asymp. Sig.  0.09 0.2 0.03 0.009 0.01 
Mean VA CC vs CA/AA Sarcoid uveitis 6/9 vs 6/12 6/9 vs 6/12 6/12 vs 6/36 6/18 vs 6/60 6/18 vs 4/60 
Asymp. Sig.  0.05 0.09 0.001 0.009 0.01 
Mean VA CC vs CA/AA Total 6/9 vs 6/15 6/12 vs 18 6/12 vs 6/60 6/18 vs 6/60 6/20 vs 1/60 
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The A allele was noted to be associated with vasculitis and ischemic visual loss 
as well. This was noted in the whole group and since number were too small 
(11) further subgroup analysis did not reveal any obvious significant association. 
The AA genotype was 27% in patients who developed ischemic visual loss 
compared to 5% in the rest of the patients p=0.002, pc=0.004. The allelic 
frequency difference between the two groups was p=0.0006, pc=0.001. (Table 
5-22) 
Table 5-22: IL-10 -592 association with ischemic visual loss 
IL-10 -592 Genotype PSU with  PSU with no  P Value 
 Ischemic visual loss ischemic visual loss  
 n=(11) n=(165)  
    
CC 2 (18.2%) 99 (60.0%) 0.008 
CA 3 (54.5%) 58 (35.2%)  
AA 6 (27.3%) 8 (4.8%) 0.001 
Allelic Frequency    
C allele 10 (45.5%) 256 77.6%)  
A allele 12 (54.5%) 74 (22.4%) 0.0006 
 
Using PHASE, 3 common haplotypes were deduced as shown in Table 5-23.  
  
 
Table 5-23: IL-10 haplotypes in PSU and controls 
IL-10 HAPLOTYEPS Patients Controls P Value 
  n=(176) n=(271)  
      
H1     592C / 1082G 79 (44.7%) 118 (43.5%) NS 
H2     592A / 1082A 45 (25.8%) 65 (24.1%) NS 
H3     592C / 1082A 50 (28.2%) 82 (30.2%) NS 
H4     592A / 1082G 2 (1.4%) 6 (2.2%) NS 
       
 
 
The haplotype 2, AA haplotype was associated with poor vision, and compared 
to the rest of haplotypes patient carrying this haplotype consistently had poorer 
vision as shown in the table. This effect was seen in more or less all four 
groups. (Table 5-24) 
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Table 5-24: Association of IL-10 haplotype AA (2) with visual outcome in PSU groups 
 Disease First Year Second Year Third Year Fifth Year Tenth Year 
       
Asymp. Sig.  0.1 1 0.05 0.02 0.01 
Mean VA Rest of 
Haplotypes Vs AA  Intermediate Uveitis  6/9 vs 6/12 6/12 vs 6/12 6/12 vs 6/24 6/12 vs 6/36 6/18 vs 6/48 
Asymp. Sig.  0.03 0.01 0.0009 0.002 0.01 
Mean VA Rest of 
Haplotypes Vs AA  Posterior uveitis 6/9 vs 6/18 6/12 vs 6/48 6/12 vs 1/60 6/18 vs 1/60 6/36 vs 2/60 
Asymp. Sig.  0.0009 0.0007 0.001 0.001 0.009 
Mean VA Rest of 
Haplotypes Vs AA  Behcet's Uveitis 6/12 vs 6/24 6/18 vs 6/60 6/18 vs 1/60 6/24 vs 1/60 6/36 vs 1/60 
Asymp. Sig.  0.1 0.2 0.03 0.009 0.01 
Mean VA Rest of 
Haplotypes Vs AA  Sarcoid uveitis 6/9 vs 6/15 6/9 vs 6/12 6/12 vs 6/36 6/18 vs 6/60 6/18 vs 5/60 
Asymp. Sig.  0.04 0.06 0.001 0.001 0.01 
Mean VA Rest of 
Haplotypes Vs AA  Total 6/9 vs 6/18 6/12 vs 6/18 6/12 vs 6/60 6/18 vs 6/60 6/24 vs 1/60 
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The haplotype 2, due to presence of A allele at -592 showed association with 
ischemic maculopathy. AA haplotype was present in 82% of the patient with 
ischemic maculopathy compared 39% in patients with no ischemic 
maculopathy p=0.008. It was also noted that patients carrying the common 
haplotype CG was associated with better visual prognosis. As shown in, Table 
5-25, 77% of the Patients with better eye vision  of 6/12 or better (at 24 months) 
carried the GG haplotype compared to 53% in patients not carrying GG 
haplotype p=0.006 pc 0.02. When group analysis was done a non-significant 
trend of better vision with CG haplotype was noted in all groups however 
significance was only achieved when they were all combined together.  
 
 
Table 5-25: IL-10 haplotype AA and ischemic visual loss 
Haplotype PSU with Ischemic visual loss PSU with no ischemic visual loss P value 
 n=(11) n=(165)  
592A / 1082A  10 (82%) 65 (39%) 0.008 
    
 Patients with VA BE 6/12 or better Patients with VA BE 6/15 or worse  
 n=(146) n=(30)  
592C / 1082G 113 (77%) 16 (53%) 0.006 
 
VA BE : VA from better eye at 24 months 
 
5.3.2.4 IL-18 137 & 607 and Behcet’s  
 
The IL-18 SNPs showed very significant associations with visual outcome and 
prognosis in patients with Behcet’s uveitis. Patients carrying the mutant alleles 
i.e. C  at 137 and A at 607 position had less severe inflammation, quicker 
response to treatment and less patients had permanent visual loss. (Table 
5-26)  However it must be noted that because of small number of patients 
these associations should be read with caution. As mentioned in the chapter 
two, whenever there were associations noted in case of permanent visual loss, 
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Kaplan-Meier analysis was performed. However, as the number of individuals 
with permanent visual loss in OB group were very low the survival analysis did 
not reveal any meaning full results.   
 
 
 
Table 5-26: IL-18 -137 SNP and prognosis in ocular Behcet’s 
IL18-137 G/C Permanent visual loss No Permanent visual loss P Value 
GENOTYPE N=19  N=8 Chi2x2 
GG 8 (42%) 3 (38%) NS 
GC 10 (53%) 1 (13%) NS 
CC 1 (5%) 4 (50%) 0.006 
Allelic Carriage    
G 18 (95%) 4 (50%) 0.006 
C 11 (58%) 5 (63%) NS 
 Good Response Bad Response  
GENOTYPE N=11 N=16  
GG 2 (18%) 9 (56%) 0.047 
GC 4 (36%) 7 (44%) NS 
CC 5 (45%) 0 (0%) 0.0028 
Allelic Carriage    
G 6 (55%) 16 (100%) 0.0028 
C  9 (82%) 7 (44%) 0.047 
Allelic Frequency    
G 8 (36%) 25 (78%) 0.0019 
C 14 (64%) 7 (22%)  
Total 22 32  
 Severe Inflammation Not Severe Inflammation  
GENOTYPE N=19 N=8  
GG 7 (37%) 4 (50%) NS 
GC 11 (58%) 0 (0%) 0.005 
CC 1 (5%) 4 (50%) 0.006 
Allelic Carriage    
G 18 (95%) 4 (50%) 0.006 
C 12 (63%) 4 (50%) NS 
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Table 5-27 shows the details of association between IL-18 -607 SNP and 
prognosis in ocular Behcet’s. 
 
Table 5-27:  IL-18 -607 SNP and prognosis in ocular Behcet’s 
 
IL-18 -607 C/A Good Response Poor Response P Value 
Genotype N=12 N=16 Chi2x2 
CC 1 (8%) 8 (50%) 0.019 
CA 3 (25%) 8 (50%) NS 
AA 8 (67%) 0 (0%) 0.0001 
Allelic Carriage    
C 4 (33%) 16 (100%) 0.0001 
A 11 (92%) 8 (50%) 0.019 
Allelic Frequency    
C 5 (21%) 24 (75%) 0.000005 
A 19 (79%) 8 (25%)  
Total 24 32  
 Severe Inflammation Mild Inflammation  
Genotype N=19 N=8  
CC 5 (26%) 3 (38&) NS 
CA 11 (58%) 0 (0%) 0.005 
AA 3 (16%) 5 (63%) 0.015 
Allelic Carriage    
C 16 (84%) 3 (38%) 0.015 
A 14 (74%) 5 (63%) NS 
 
 
Also patients harbouring wild type genotypes at both -137 and -607 positions 
had worse visual acuity through out the course of the disease compared to the 
mutant alleles (Table 5-28) 
 
Table 5-28: Association of IL-18 SNPs with long term visual outcome in OB 
 
 
 
 
 
 
 
 
SNP 1st year 2nd year 3rd year 5th year 10th year 
IL-18 -607 C/A 
     
Asymp. Sig. 0.013 0.023 0.0276 0.009 0.009 
Mean VA CC  6/18  6/24  6/36  6/60  1/60  
Range VA CC 6/6-6/24 6/9-6/60 6/9-3/60 6/12-2/60 6/24-NPL 
Vs CA/AA 6/9 6/12 6/18 6/18 6/36 
Range CA/AA 6/5-6/18 6/6-6/24 6/9-6/60 6/9-1/60 6/12-3/60 
IL-18 -137 G/C 
     
Asymp. Sig. 0.034 0.0177 0.0094 0.0204 0.009 
Mean VA GG  6/18  6/30  6/60  6/60  1/60  
Range VA GG 6/5-6/24 6/9-6/60 6/12-3/60 6/9-1/60 6/18-NPL 
Vs GC/CC 6/10 6/10 6/12 6/24 6/36 
Range GC/CC 6/6-6/18 6/6-6/24 6/9-6/36 6/12-2/60 6/12-3/60 
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IL-18 haplotype 1 (GC), containing wild type alleles at both positions was 
associated with poor response and poor visual outcome. 84% of the patients 
with haplotype 1(GC) had poor response and none with the patients with 
haplotype 2 (GA) or 3 (CA) had poor response. P=0.0000004 as shown in 
Figure 5-5 
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Figure 5-5: Association of IL-18 haplotypes with response to treatment in OB. 
Patients harbouring IL-18 Haplotype-1, had poorer response to steroids compared to 
rest of the patients with ocular Behcet’s  
 
Patients with IL-18 Haplotype 1 (GC), had poor visual acuity through out the 
course of disease compared with patients carrying the rest of the haplotypes as 
shown in Table 5-29 
Table 5-29: Association of IL-18 haplotype with visual outcome in OB 
 
 
 
IL-18 Haplotypes 1st year 2nd year 3rd year 5th year 10th year 
      
Asymp. Sig. 0.0013 0.01 0.00176 0.008 0.0009 
Mean VA Haplotype 1  6/20  6/36  6/60  4/60  1/60  
 6/12-6/24 6/12-6/60 6/18-3/60 6/18-1/60 6/12-NPL 
Vs Haplotype 2 and 3 6/7.5 6/10 6/18 6/20 6/24 
 6/5-6/12 6/6-6/18 6/9-6/60 6/9-6/60 6/12-5/60 
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5.3.2.5 IFNGR-56 C/T and sarcoidosis uveitis  
 
The frequency of rare genotype CC was around 16% in both PSU and patient 
groups. It frequency varied considerable among the PSU groups ranging from 
8.3% in Sarcoidosis to 25.4% in IU. Data mining did not reveal any obvious 
association of this SNP with phenotypic attributes except that the wild type 
allele was associated with poor response to treatment and worse visual acuity 
in patients with sarcoidosis. This effect was not seen in any other patients 
groups and even in sarcoidosis group the associations were modest. As seen 
in the Figure 5-6, the VA in patients after the minimal follow up period of 2 
years was 6/24 in patients with wild type genotype compared to 6/9 in patients 
carrying the rare allele p =0.005. However no significant differences were noted 
in the visual acuities between the two alleles beyond two years.  
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Figure 5-6: Association of IFNGR genotypes with VA in patient with ocular sarcoidosis 
Mean Snellen VA in patients after the minimal follow up period of 2 years was 6/24 in patients with wild 
type genotype compared to 6/9 in patients carrying the rare allele 
 
It was also noted that sarcoidosis patients who responded poorly to the 
treatment had a higher frequency of wild genotype CC (70%) compared to the 
ones who did not (15%). P=0.005 (Table 5-30) 
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Table 5-30: The association of IFNGR -56 SNP with response to treatment in ocular 
sarcoidosis 
 
IFNG-R -56 C/T Bad Response Good Response P Value 
GENOTYPE N=10 N=14 Chi2x2 
    
TT 7 (70%) 2 (14%) 0.005 
CT 2 (20%) 11 (79%) 0.004 
CC 1 (10%) 1 (7%) NS 
Allelic Carriage     
T 9 (90%) 12 (93%) NS 
C 3 (30%) 11 (86%) 0.005 
Allelic Frequencies    
TT 7 (70%) 2 (14%)  
CT/CC 3 (30%) 12 (86%) 0.005 
 
 
5.3.2.6 TNF-α and CMO 
 
 The three TNF-α SNPs did not show any significant associations with the 
clinical features of PSU except that there were some moderate associations 
between -238 SNP and CMO. Patients with rare allele A develop fewer 
episodes of CMO per year in and responded better to intra-vitreal injections of 
steroids in IU, PU and Sarcoid uveitis. (Table 5-31) However it should be noted 
that there was no difference in the genotypic frequencies between patient 
developing CMO and not developing CMO in general or at group levels. 
Table 5-31: TNF-α -238 SNP and association with CMO in PSU groups 
 
TNF -238 G/A CMO/ year P Value Mean Number of I/vitreals to control CMO P Value 
     
Intermediate Uveitis     
GG 3.4  3.1  
GA/AA 0.6 0.002 1 0.007 
Posterior Uveitis     
GG 3.9  2.7  
GA/AA 1 0.008 1.1 0.01 
Sarcoid Uveitis     
GG 2.8  2.9  
GA/AA 0.9 0.01 1.6 0.03 
 
I/Vitreals: Intra-vitreal steroid injections, CMO: cystoid macular oedema 
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TNF SNPs -308 and -857 showed moderate associations with type of treatment 
but lost the significance after Bonferroni correction and multiple logistic 
regression. Four TNF haplotypes were constructed as shown in Table 5-32.  
 
Table 5-32: TNF haplotypes in patients and controls 
 
TNF HAPLOTYPES Patients Controls 
 n=(176) n=(271) 
   
238G/ 308G/ 857C 58.9% 61.1% 
238G/ 308G/ 857T 12.5% 11.3% 
238G/ 308A/ 857C 21.1% 19.6% 
238A/ 308G/ 857C 7.5% 8.0% 
 
 
 
 
Haplotype GGT containing T at -857 showed modest association with the need 
of second line of immunosuppressive treatment. GGT haplotype was present in 
25% (19/74) of the patients needing second line of treatment compared to 12% 
(13/102) in rest of the patients p value was 0.029. See Figure 5-7.  Sub group 
analysis did not reveal any association with particular group and individual 
analysis did not reach to statistical significance because of numbers. 
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Figure 5-7: TNF haplotypes in PSU and their association with need of second line of 
immunosuppressive treatment.  
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5.4 Discussion 
 
This study was conducted to determine role of various functional 
polymorphisms of cytokine genes in PSU. Quite a few of the SNPs were noted 
to affect the phenotype of PSU and act as predictor of complications. The study 
showed that IL-18 polymorphisms were associated with retinal vasculitis and 
IL-10 polymorphism exhibited genetic susceptibility to development of Behcet’s 
uveitis. It was also noted that IL-1β, IL-6, IL-10 and IL-18 were affecting the 
genotypes of various sub groups of PSU.  
5.4.1  IL-18 & IL-12 
IL-18 is expressed in retinal pigment epithelial cells (RPE) (Jiang et al. 2001), 
although it does not play a significant role in EAU, IL-18 deficient mice produce 
low level of IFN-γ and TNF-α in EAU (Jiang et al. 2001). IL-18 is able to active 
Th1, Th2 or Th17 cell responses. In the present of IL-12 and IL-2, it can induce 
IFN-γ leading to Th1 response. (Tarrant et al. 1998) On the other hand in the 
presence of IL-23 it can active Th17 cells. (Boraschi and Dinarello 2006). High 
aqueous levels of IL-12 have also been noted in various forms of immune 
mediated uveitides. (El-Shabrawi et al. 1998) Recently Qiao et al has shown 
that IL-18 plays an important regulatory role in retinal vascular development. 
(Qiao et al. 2004) Their results on IL-18 knock out mice show that IL-18 plays 
an anti angiogenic role and absence of it may lead to up regulation of 
angiogenic factors and may lead to vascular leakage and non perfusion 
The G/C change at -137 position and C/A change at -607 position leads to 
decrease expression of IL-12 gene (Giedraitis et al. 2001) (Zhou et al. 2005). 
Association have been noted between these SNPs and susceptibility to 
inflammatory bowel disease, Behcet’s and SLE (Lin et al. 2007) (Keskin et al. 
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2009) (Ben et al. 2011) (Tamura et al. 2002). Interestingly in Behcet’s disease 
and SLE, vasculitis is a salient feature of the disease.  However it should be 
noted that the functional affects of these SNPs are very moderate and not 
replicated by all studies. My results show that the alleles that decrease the 
expression of IL-18 and IL-12 genes were strongly associated with retinal 
vasculitis. In the conditions where vasculitis is the primary pathology the serum 
levels of IL-18 have noted to be quite high denoting the role of IL-18 gene in 
vasculitis. (Hamzaoui et al. 2002) (Esfandiari et al. 2001) (Hultgren et al. 2007) 
(Novick et al. 2009) (Hamzaoui et al. 2002). Now these two statements seem 
contradictory, but as mentioned the functional effects of the SNPs are at the 
best moderate, and the associations seen here are more likely to be related to 
another allele with definite functional role. This SNP is yet to be identified; 
however these results indicated presence of genetic susceptibility marker for 
retinal vasculitis on IL-18 gene. Recently Sanchez et al. tested the effect of the 
IL18 -1297 T/C rs360719 polymorphism on the transcription of IL18 by 
electrophoretic mobility shift assay and western blot. They found a significant 
increase in the relative expression of IL18 mRNA in individuals carrying the 
rs360719 C-risk allele; in addition they showed that the polymorphism creates a 
binding site for the transcriptional factor OCT-1. (Sanchez et al. 2009). They 
also suggested that this SNP may play an important role in determining the 
susceptibility to SLE which is one of the most common systemic vasculitis. 
Another recent study (Palomino-Morales et al. 2010) showed association of this 
SNP with biopsy proven giant cell arteritis in 212 Caucasian patients. The gene 
mapping of IL-18 and particularly studying the IL-18 -1297 SNP should be the 
aim of further study.    
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The IL-18 SNPs showed moderate genetic susceptibility to Behcet’s but were 
strongly associated with visual outcome in Behcet’s uveitis. Patients with low 
producing alleles, develop less severe inflammation, better long term vision and 
less permanent visual loss. Studies have shown that not only serum IL-18 
levels are higher in patient with Behcet’s disease but the levels correspond to 
the disease activity (Musabak et al. 2006) (Hamzaoui et al. 2002) (Oztas et al. 
2005). This does mean that lower levels of IL-18 will be associated with less 
severe disease. If one accepts that these two functional polymorphisms 
decrease the expression of IL-18 gene than it is plausible that carriers of these 
allele among Behcet’s uveitis will develop less severe disease. Interestingly a 
study showed that the IL-18 gene polymorphisms were not associated with a 
susceptibility to BD in the Korean population, but the patients carrying the GG 
genotype at position -137 had a higher risk of developing the ocular lesions. 
(Jang et al. 2005) Other studies have also noticed the genetic susceptibility to 
Behcet’s disease with IL-18 SNPs (Lee et al. 2006) (Keskin et al. 2009) 
 
My results also showed association of IL-12 +1188 C allele with retinal 
vasculitis. The A/C change at +1188 position of IL-12 leads increase secretion 
of IL-12 from LPS stimulated PBMCs  (Seegers et al. 2002) (Yilmaz, Yentur, 
and Saruhan-Direskeneli 2005) Compared to the functional affects of IL-18, 
these changes are more significant and replicable. IL-12 also play a more 
definite  role in the pathogenesis of different autoimmune vasculitides, 
Frassanito et al showed that serum levels of IL-12 correlate with disease 
activity in Behcet’s vasculitis, (Frassanito et al. 1999) . Similar findings were 
noted in patients with Takayasu vasculitis (Verma et al. 2005). High +1188 C 
allele frequency was also noted in Turkish patients with Takayasu vasculitis 
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(Saruhan-Direskeneli et al. 2006). Another recent study has noted that C allele 
is more come in patients with Behcet’s disease compared to controls (Alayli et 
al. 2007). I did not notice any over representation of C allele in my Behcet’s 
population, but it must be noted that all OB patients who had clinical evidence 
of retinal vasculitis were carriers of C allele.  
5.4.2 IL-1β 
IL-1β being a potent inducer of IL-2 is though to play an important role in 
induction of uveitis. The C/T SNP at position -511 leads to increase secretion of 
IL-1β (Hall et al. 2004), (Santtila, Savinainen, and Hurme 1998), (Hulkkonen, 
Laippala, and Hurme 2000) and associations of this polymorphisms have been 
noted with ankylosing spondylitis and Crohn’s disease. (Nemetz et al. 2001) 
(Timms et al. 2004) both diseases in which uveitis can develop. The SNP did 
not affect susceptibility to PSU except in Behcet’s uveitis where the association 
was modest. Recent studies on Turkish subjects with Behcet’s disease have 
shown similar results where T allele was rare in patients compared to controls 
(Alayli et al. 2007). Other studies in Behcet’s patients failed to notice this 
association but nearby SNPs was noted to be affecting susceptibility to the 
disease denoting that there may be a genetic susceptibility locus in IL-1β 
gene(Karasneh et al. 2003) (Coskun et al. 2005). The -511 SNP also showed 
association with visual outcome but again the effects were modest, however 
needless to say other studies have also noted effect of -511 SNP on severity of 
Behcet’s disease. (Akman et al. 2008) 
What was more significant was that the high secretor allele T was rare among 
patients who developed secondary glaucoma. Studies have shown that as a 
result of high IOP, IL-1 is secreted from trabecular meshwork endothelial cells 
which act either by remodelling of juxta canallicular extra cellular matrix (the 
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sight of out flow obstruction) (Bradley et al. 2000) or control IOP  through 
activation of ELAM-1/IL-1/NF-kappaB response. (Wang et al. 2001) (Wang et al. 
2003) Recently, Birke et al showed on porcine eyes that trabecular cells treated 
with IL-1β augmented the outflow by three folds by inducing ELAM-1. (Birke et 
al. 2011) Hence the uveitic patients who have high secretor allele T will  
produce more  IL-1 in trabecular meshwork, so IOP is controlled and they do 
not progress to glaucoma, conversely uveitic  patients with C allele will have a 
higher chance of developing glaucoma. Based on similar hypothesis some 
authors have studied this SNP in glaucoma and have noted association 
between glaucoma and SNPs in IL-1β genes. (Lin et al. 2003) (Mookherjee et 
al. 2010) In short this SNP could act as a predictor of development of glaucoma 
in uveitic patients. 
5.4.3 IL-6 174 
 
IL-6 has been detected in vitreous, as well as aqueous humour aspirates of 
patients with idiopathic uveitis. (Franks et al. 1992)   More specifically, 
increased vitreous levels of IL-6 have been detected in patients with active 
intermediate and posterior uveitis, (Perez et al. 2004) reflective of on-going 
inflammation during disease hence, role in the propagation of uveitis. The 
medical literature lacks studies that have looked into association of IL-6 
polymorphisms and uveitis; however few studies in Behcet’s patients are 
present. Most of these studies found no association between IL-6 
polymorphisms and Behcet’s disease (Storz et al. 2008) (Chang et al. 2005). In 
my study I noted that IL-6 polymorphism was associated with severity of the 
disease and response to treatment in patients with idiopathic PSU. Patients 
with rare allele C were noted to have more severe disease and permanent 
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visual loss. This is contradictory to the observations that C allele was 
associated with decreased IL-6 expression.  (Fishman et al. 1998) (Belluco et 
al. 2003) Experiments however have shown that both C and G allele can be 
associated with increased IL-6 depending upon the cell lines used and initial 
stimuli. (Terry, Loukaci, and Green 2000). Also there is evidence now that 
some SNPs in distal promotor region may have more affect on the transcription 
of IL-6 gene and IL-6 174 SNP may be in linkage with these SNPs. (Samuel et 
al. 2008)  
This could be the reason that studies have failed to notice association between 
IL-6 -174 SNP and uveitis. 
However more interesting and consistent finding was effect of this SNP to 
response of treatment. The wild type carriers in intermediate uveitis needed 
less steroids and less second line of immunosuppression compared to rare 
type allele carriers. One interpretation is they have less severe disease but it 
also meant they responded very quickly and effectively to steroids and hence 
needed less treatment. This is in consistent with various studies that have 
shown that IL-6 174 genotypic differences can affect response to systemic 
immunosuppression.  Pawlik et al treated peripheral blood monocytes with 
dexamethasone and noted that although patients with C allele produced less 
IL-6 compared to wild type carriers, but dexamethasone was unable to 
decrease the production of IL-6 in CC genotype compared to GG genotype. 
(Pawlik et al. 2006) They also showed that patients with rheumatoid arthritis 
responded variably to glucocorticoids and methotrexate according to their IL-6 
174 genotype (Pawlik et al. 2005).  Fabris et al recently showed that among 
patient with rheumatoid arthritis, C carriers responded poorly to retuximab (anti 
CD20 antibody) compared to G carriers. (Benucci et al. 2010) (Fabris et al. 
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2010b) (Fabris et al. 2010a) My findings, further confirm these findings that IL-6 
genotypes can be a marker to drug response in idiopathic uveitis particularly 
intermediate uveitis. 
5.4.4 IL-10  
IL-10 is an anti-inflammatory cytokine that was shown to suppress IFN-γ 
production, inhibit the Th1 response and promote the Th2 response. (de Vries 
1995) A number of studies described beneficial effects of IL-10 administration 
in different models of cell-mediated autoimmunity however the regulation of 
cellular responses by IL-10 is complex and may be influenced by many factors. 
Intra-ocular transfer of IL-10 gene has shown to inhibit experimental 
autoimmune uveoretinitis (Verwaerde et al. 2003) (de et al. 2002) while 
injection of IL-10 can control EAU (Rizzo et al. 1998) 
In human studies it has been shown that IL-10 expression on T cells correlate 
with visual recovery in PSII   (Greiner et al. 2004) and levels of IL-10 increase 
in aqueous humour as the patients are treated with steroids (Ooi et al. 2006) 
Among cytokines, IL-10 gene is probably the most widely studied in uveitis 
gene association studies. Stanford et al. showed that in patients with 
intermediate uveitis IL-10-1082 AA homozygosity was associated with bad 
outcome. (Stanford et al. 2005). Another studied on patients with sympathetic 
ophthalmitis noted associations between the IL-10 -1082 SNP and disease 
recurrence from previously stable disease and the level of steroids required for 
maintenance therapy. In addition, the GCC IL-10 promoter haplotype (IL-10 -
1082G, -819C, -592C) was found to be protective against disease recurrence. 
(Atan et al. 2005) The same group recently showed that other SNPs in IL-10 
gene could predispose to PSU; (Atan et al. 2010) however they did not notice 
any association with -1082 SNP 
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Although I did not notice any difference in the frequencies of IL-10 SNPs 
between the patients and controls but at position -592 of IL-10 the wild type 
allele C was less prevalent in Behcet’s disease compared to the rest of the 
groups and the controls. (Where the frequencies were comparable) Just 
recently, (two years after my study was done) genome wide association study 
on 1215 patients with BD noted about 5 SNPs in IL-10 gene were strongly 
associated with BD, with one SNP, rs1518111 to be very significant. (Remmers 
et al. 2010) Another recent study in Turkish Behcet’s patients found that IL-10 -
1082 GA genotype was more frequent whereas the AA genotype was less 
common in the BD group compared to the control group. (Dilek et al. 2009) 
Wallace et al. found that -1082 and -819 SNPs may be relevant in influencing 
the immune response in Behcet's disease in some patient groups (Wallace et 
al. 2007). It should be kept in mind that this -819 SNP is in 100% linkage with -
592 SNP I found to be associated with ocular Behcet’s.  My finding is just 
another confirmation that genetic susceptibility locus for Behcet’s uveitis may 
lie in IL-10 gene.  
I also found that A alleles at both positions were associated with poor visual 
outcome in all the four sub groups of PSU. Similarly the G at -1082 and C at -
592 were associated with better visual acuity. This is consistent with the 
findings that polymorphisms in IL-10 gene can be the predictor of visual 
outcome in uveitis. Stanford et al genotyped 125 Caucasian patients with 
intermediate uveitis and found that IL-10 -1082 AA genotype was associated 
with poor visual outcome. (Stanford et al. 2005) Atan et al studied IL-10 SNPs 
in British patients with sympathetic uveitis. They noted associations between 
the IL-10 -1082 SNP and disease recurrence from previously stable disease 
and the level of steroids required for maintenance therapy. In addition, the GCC 
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IL-10 promoter haplotype (IL-10 -1082G, -819C, -592C) was found to be 
protective against disease recurrence (Atan et al. 2005). Compared to these 
studies, I showed the effect of IL-10 SNPs on visual outcome is seen in most of 
the types of PSU.  
 A strong association was also noted between the IL-10 -592 A allele, IL-10 AA 
haplotype (IL-10 -592A & -1082A) with ischemic maculopathy. As far as the 
association with vasculitis is concerned, it is known that IL-10 attenuates the 
injury and intimal thickness after inflammation.  (Zimmerman et al. 2004). 
Giachini et al showed that IL-10 confers vascular protection from ET-1-induced 
injury and vasoconstriction (Giachini et al. 2009) A recent study showed that 
endothelial nitric oxide synthase (eNOS) expression was reduced by TNF-α in 
in-vitro and in-vivo experiments, whereas IL-10 restored the eNOS expression  
(Zemse et al. 2010). This eNOS catalyzes NO production which is a potent 
vasodilator. These studies show that that IL-10 is involved in prevention of 
vascular injury and its related damage and in fact the AA haplotype has 
associated with more lesions in Kawasaki disease (Yang et al. 2003). One can 
derive from these studies that local low expression of IL-10 should lead to 
ischemia in retina/ macula and hence ischemic maculopathy. This is shown by 
my finding that low IL-10 producer alleles were associated with ischemic 
maculopathy in PSU. 
5.4.5 IFN-γ 874 & IFNR -56 
IFN-γ is the primary cytokine which defines Th1 cells. IFN-γ is secreted by Th1 
cells, cytotoxic T cells and NK cells, it promotes Th1 differentiation by 
upregulating the transcription factor T-bet, ultimately leading to cellular 
immunity.  
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Up until recently IFN-γ induced Th1 cell response in PSU was thought to be the 
main orchestrator of inflammation, (rocker-Mettinger et al. 1990) (Feron, Calder, 
and Lightman 1992) (Dick et al. 1992) (Muhaya et al. 1999) (Whitcup et al. 
1992).  However recent discovery of Th-17 cells has suggested that Th17 cells 
also play role driving tissue damage in posterior segment uveitis. 
In my study I did not notice any significant associations between IFN-γ or IFN-R 
SNPs and uveitis except in Sarcoidosis. Here the IFN-γ +874 T allele was less 
prevalent compared to rest of the groups and controls. (4.2% in Sarcoidosis, Vs 
19% in controls, and 28% in rest of PSU) Similarly IFNR -56 SNP showed 
some moderate association with visual outcome in Sarcoid uveitis group only. 
Here the T allele which increases the production of IFNR was associated with 
poor response and poor visual acuity after 2 years. Recent study have noted 
(Wysoczanska et al. 2004) association between IFN-γ polymorphisms and 
sarcoidosis however the association noted was very modest. It must be noted 
that +874T allele, which was rare in sarcoidosis patients, actually increases the 
IFN-γ production. This either means IFN-γ is decreased in sarcoidosis uveitis or 
it means that this association noted may be false positive (small sample size) 
or due to another SNP yet undetected that is in linkage with +874 SNP. The 
second explanation is likely as the role of IFN-γ in sarcoidosis is quite 
significant. Studies have shown that IFN-γ is spontaneously released by 
activated alveolar macrophages in active sarcoidosis, and levels of IFN-γ are 
higher in sarcoidosis and correlate with disease activity (Robinson, McLemore, 
and Crystal 1985) (Moller 1999) (Tsiligianni et al. 2005) (Kopinski et al. 2007) 
This will be consistent with my finding that IFNGR -56T, which increases 
expression of IFNGR is associated with poor outcome. There are not many 
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studies in medical literature about role of IFNGR SNPs in sarcoidosis and none 
have noted any significant association (Akahoshi et al. 2004) 
5.4.6 TNF SNPs 
During the inflammatory process, TNF orchestrates the initiation of further 
leukocytic infiltration via adhesion molecule upregulation, dendritic cell 
maturation and survival, macrophage activation, and driving Th1 T cell 
responses within tissues in experimental autoimmune uveitis.(Dick et al. 2004)  
Increased TNF-α expression in inflammatory cell infiltrates has been seen in 
experimental autoimmune uveitis near peak inflammation as well. (Okada et al. 
1998) These studies denote that TNF plays role in propagation of uveitis rather 
than induction of uveitis. None of the SNPs studied in my patients showed any 
association with genetic susceptibility to PSU. This is consistent with study 
where authors did not find significant differences in the allelic frequencies of 
TNF gene between controls and PSU (Atan et al. 2010). On the other hand 
studies have noted the role of TNF alleles in genetic predisposition of anterior 
uveitis particularly HLA-B27 negative iritis, (El-Shabrawi et al. 2006) (Kuo et al. 
2005)  
In my study, patients with -238 G allele (high producer allele) were noted to 
have more episodes of CMO. This was mainly seen in intermediate and 
posterior uveitis group and to some extent in Sarcoid uveitis group as well. It 
must be noted that patients with G allele were not prone to develop CMO 
compared to A allele carriers, however once CMO was there it was more 
common and more prolonged in patients with G allele carriers. This shows that 
TNF-α allele does not increase the risk of CMO, but if CMO is there it leads to 
more severe and more frequent episodes. In fact anti TNF therapy has been 
used successfully to control CMO in uveitis and other collagen vascular 
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diseases. (Fukuda et al. 2008) (Kachi et al. 2010) (Markomichelakis et al. 2011) 
(Markomichelakis et al. 2004)   
 
Moderate effect of TNF haplotypes was noted particularly TNFH-2 which is 
defined by C/T SNP at -857.  More patients with haplotype 2 needed second 
line of immunosuppression compared to rest of the haplotype. This effect was 
seen in all four groups to certain extent but only reached significance when the 
groups were combined together.  The -857 T allele has already been noted to 
predispose to idiopathic anterior uveitis (Kuo et al. 2005).  
Since the TNF genes lie in cross proximity to HLA gene complex, it is quite 
possible that associations seen between anterior uveitis and TNF SNPs may 
be simply due to linkage between HLA and TNF gene complexes. 
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5.5 Summary and Conclusion 
The study showed that few functional SNPs in Th1 mediated cytokine pathways 
could increase the genetic susceptibility and can affect the prognosis of 
posterior segment uveitis.  
Following were the notable findings:  
Table 5-33: Summary of associations of cytokine SNPs in PSU 
SNP & Allele Effect of Allele on gene  Association Disease Group 
IL-18-607A & 137C Both decrease expression Genetic susceptibility Retinal vasculitis 
IL-10 -592A A decreases expression Genetic susceptibility Behcet's 
        
IL-1β -511C C decreases expression Secondary glaucoma IU & PU  
IL-6 -174C C decrease expression Poor response to treatment IU & PU 
IL-10 1082A & 592A A decrease expression Poor visual outcome IU & PU 
IL-18 137C & 607A Both decrease expression Better visual outcome Behcet’s 
TNF- 238A A decrease expression Less CMO IU & PU  
IFNR -56T T increases expression Poor visual outcome Sarcoidosis 
 
 
The study also highlighted that intermediate and posterior uveitis shared same 
immunopathology as the gene pathway involves were more as less similar. On 
the other hand the SNPs associated with Behcet’s and sarcoidosis were 
different from each other and from idiopathic uveitis group. The study has 
confirmed the association of IL10 gene with visual outcome in PSU and genetic 
predisposition to Behcet’s uveitis. The study has shown that variations in IL-18 
gene can predispose to retinal vasculitis and IL-1β gene plays a role in the 
pathogenesis of secondary glaucoma. Further studies in different and bigger 
populations are needed to confirm these findings.  
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This study set out to test the hypothesis that genetic variants in cytokine and 
chemokine genes may affect the phenotype of PSU. Following significant 
associations were noted between the genotypes and clinical characteristics of 
the diseases: 
 
1) SNPs in CCR2 & IL-10 genes, increased genetic susceptibility to ocular 
Behcet’s. 
2) SNP in MCP-1 gene was associated with increased risk of developing 
PSU. 
3) SNPs in IL-18 gene increased genetic susceptibility to vasculitis. 
4)  SNPs in IL-10 gene were predictor of visual outcome in IU & PU. 
5) IL-1β SNP was associated with risk of secondary glaucoma in IU & PU. 
6) IL-6 SNP was associated with visual outcome in IU & PU. 
7)  SNPs in CCR5 gene were predictor of visual outcome in IU & PU. 
6.1 Verification of recent association studies in PSU 
This research has confirmed some of the recent findings in PSU 
immunogenetics. This is quite significant as PSU is a rare disease and it is very 
difficult to recruit enough number of patients for valid genetic studies. This is 
crucial as this decreases the power of the study. Repeating the experiments in 
different population and reproducing the results increase the power of the 
hypothesis. My work has verified following recent findings 
a) I found that allelic variations in IL-10 gene were associated with poor 
visual outcome in the four sub groups of PSU. This is confirmation of the 
findings that polymorphisms in IL-10 gene can be the predictor of visual 
outcome in intermediate uveitis (Stanford et al. 2005) and sympathetic uveitis 
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(Atan et al. 2005). Although my sample population did not contain sympathetic 
uveitis patients (a type of PSU) but my study confirmed this effect of IL-10 
genotypes in intermediate, idiopathic posterior and PSU secondary to 
sarcoidosis and Behcet’s. 
 
b) I also showed that at position -592 of IL-10 gene the wild type allele C 
was less prevalent in Behcet’s disease compared to the rest of the groups and 
the controls. (Where the frequencies were comparable) Recently, genome wide 
association study on 1215 patients with BD noted 5 SNPs in IL-10 gene 
strongly associated with BD, with one SNP, rs1518111 very significant. 
(Remmers et al. 2010)  Recent studies on Turkish Behcet’s patients (Dilek et al. 
2009) and Middle Eastern patients (Wallace et al. 2007) have also confirmed 
that IL-10 genotypes can be a genetic risk for the development of Behcet’s 
disease.  
6.2 Short falls of the study 
As discussed earlier, an important issue in genetic studies is the sample size of 
the studied population. The bigger the population sample is, the more powerful 
the study is. Indeed, one of the main weaknesses of genetic epidemiology 
studies based on candidate gene approaches has been the lack of replication. 
This was particularly the case for Sarcoidosis and Behcet’s groups in my study.  
Small sample size of OB and Sarcoid uveitis not only decreased the power of 
the study, but it lead to false negative results particularly in sarcoidosis group. 
Many a times associations were noted with good to moderate odd ratios, but 
because of the number of samples the confidence intervals were very wide and 
p value higher than significant. 
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There have been many studies exploring a previously published statistically 
significant finding for a genetic variant, which failed to reproduce those findings, 
suggesting a large number of false-positive reports (Ioannidis et al. 2001). The 
utilization of large validation studies as well as meta-analyses and pooled 
analyses to combine both statistically significant and non-significant results 
from individual studies has allowed for the validation of several candidate 
genes. Therefore, sufficient information of raw data should be published to 
facilitate future meta-analysis (Hirschhorn et al. 2002). However, results from 
different centres and studies might differ significantly because of genuine 
heterogeneity or publication bias, i.e. publication of only positive results 
(Ioannidis et al. 2003). Despite that, meta-analysis is widely accepted as the 
highest level of evidence in association studies and helps to minimise random 
error and identify publication bias (Ioannidis et al. 2006)    
Another way to increase the reproducibility is to increase the power of the study. 
This can be achieved by multi centre studies and this is particularly important 
with rare diseases. During this research I faced the problem of recruiting 
patients with ocular Behcet’s disease that is very rare in the UK unlike in 
Turkey and Far East. Studies involving rare diseases should be multicentre and 
in the context of posterior segment uveitis multi-centre study have been done in 
UK (Atan et al. 2005). Here the authors managed to collect 26 patients from the 
whole of the UK with sympathetic uveitis. Multicentre approach or repeating 
these experiments in different population set are needed if we want to replicate 
the findings of Behcet’s disease in this thesis. 
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6.3 Future Directions 
 
My work has explored the role of cytokine and chemokine genes in the 
pathogenesis of uveitis. The study has noted some novel associations that 
need to be confirmed 
IL-1β glaucoma: The role of IL-1β gene in secondary glaucoma should be 
further elucidated. There are quite a few studies that have noted an association 
between IL-1β gene and primary open angle glaucoma (Wang et al. 2006) (Lin 
et al. 2003) (Mookherjee et al. 2010). The study should be repeated in different 
population of PSU and also this association should be tested in patients with 
anterior uveitis, to determine whether secondary glaucoma is the most common 
reason for loss of sight.  
IL-18 vasculitis: Another significant finding was the association between IL-18 
gene and the development of retinal vasculitis. This association was seen in 
isolated retinal vasculitis and vasculitis secondary to Behcet’s and sarcoidosis. 
Since the sample size was relatively small it should be repeated in a bigger 
population sample. Further more the functional affects of IL-18 SNPs are 
modest, and there is a need to study further SNPs in IL-18 gene, to find a 
definite functional SNP or study the functional affects of these putative SNPs.   
CCR2 CCR5 and Visual outcome:  The role of CCR5 in visual outcome 
should be further assessed. The tag-SNPs and whole gene typing can be 
carried out to look for the loci. 
CCR2 and Behcet’s: Although there are no reports in the literature about 
association between CCR2 genotype and Behcet’s uveitis but the role needs to 
be further elucidated, particularly the role of CCR2 in the development of uveitis 
in female patients with Behcet’s disease.   
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The work in this thesis has further increase our insight into the pathogenesis 
and role of cytokine and chemokine genes in posterior segment uveitis. This 
work can be used in the following three domains of genetic studies 
6.3.1 Gene function identification (physiological genomics) 
Our current knowledge on gene functions is mainly based on highly 
specialized model organism-based experiments such as knockout, 
transgenic and subsequent homology studies. These study designs can 
easily shed light on the physiologic role of a gene, but give little insight into 
human pathogenic processes for which interventions could be designed 
effectively. The fact is that most common chronic human diseases are due 
to naturally occurring variation in genes (possibly at multiple sites or within 
multiple genes) as opposed to complete or partial gene deletions. Thus, the 
gross interruption of a genome, as in a knockout experiment, may give 
erroneous impressions about not only the role of that gene in more natural 
settings but also about its potential as a therapeutic target. In addition, a 
host of redundancy, feedback and compensatory mechanisms present in 
physiologic systems has been shown to complicate the generalizability of 
current functional genomic study design results for this reason. (Schork, 
Fallin, and Lanchbury 2000) Thus, knockout, transgenic and related 
experiments are simply not sufficient to provide an adequate and 
comprehensive picture of human disease processes that could lead to the 
design of effective therapies and pharmacologically based prevention 
strategies. Alternate methods are therefore needed and results from 
studying the functional SNPs here can play an important role. This work has 
shown the role of CCR2 and MCP-1 in posterior segment uveitis. Similarly 
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significant association were noted between retinal vasculitis and IL-18 
genes. On the contrary experiments on knot out mice have failed to notice 
this association.  Ultimately, the combination of SNP-based genetic 
technologies with genomic technologies (such as sequence structure 
analysis, expression profiling and protein level assays, etc., which assess 
molecular physiology and pathology) is the real future of medical and 
pharmaceutical research, rather than either one in isolation. (Schork, Fallin, 
and Lanchbury 2000) Knowledge gained can be used to develop drugs that 
specifically target against the cytokine molecules. There has been case 
reports of treatment refractory uveitis with anti IL-6 antibodies (Hirano et al. 
2011) and IL-1R antagonist anakinra (Teoh et al. 2007). However, mixed 
results have been seen with phase 1 and 2 trials using anti CCR2 and anti 
CCR5 antibodies to control rheumatoid arthritis. (Vergunst et al. 2008) (van 
Kuijk et al. 2010) 
6.3.2 Diagnostics/risk profiling 
One of the most promising roles of SNP association studies is the potential 
to use the information to develop diagnostic or prognostic tools. In fact 
some of the HLA genotypes have been used to help with the diagnosis 
particularly HLA-A29 in Birdshort choroiditis. Although my research showed 
that alleles in CCR2 V64I and IL-10 -592 acted as genetic marker for 
Behcet’s disease, but the power of the study was to low to generalize these 
findings. On the other hand quite a few of the SNPs particularly in IL-10, IL-
6 and CCR5 genes were a predictor of poor visual outcome and prognosis. 
My work not only reproduced previous findings but the associations were 
stronger as well. This research will play a stepping stone role in the future 
risk profiling studies in uveitis. However SNP-based risk assessment tool for 
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uveitis will require well designed large-scale epidemiological studies. This is 
because PSU is influenced by a number of genetic and non-genetic factors, 
each of which may make only a small contribution to disease risk in the 
population at large. Prediction of genetic risk will be useful in diagnosis, 
treatment, prognosis and prevention strategies, as family history is currently, 
but with greater power. (Schork, Fallin, and Lanchbury 2000) 
6.3.3 Prediction of response to drugs (pharmacogenomics) 
SNP association studies can help stratifying populations for the purposes of 
improving the effectiveness of interventions of one sort or another. This 
research demonstrated that IL-6 174 SNP and CCR5 59029 SNP were 
influencing the response to steroids in idiopathic intermediate and posterior 
uveitis. This work can be used in future pharmacogenomics studies in 
uveitis. However, if a gene that influences responsiveness to a particular 
compound has been identified then one will need to assess the frequency or 
penetrance of that gene in other populations and in light of other factors that 
may influence response to the compound. This is particularly important to 
find the responsiveness in population with heterozygous alleles. 
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6.4 Future of Genetic Studies in PSU 
6.4.1 In Silico analysis of SNP functions 
Since the start of the human genome project, a great deal of effort has been 
directed towards finding disease-causing SNPs. However, the functional 
aspects of most of these SNPs remain unknown. Functional analysis for these 
markers is becoming much more of an interest. As there is a vast number of 
SNPs, it might not be feasible for researchers to carry out wet laboratory 
experiments on every SNP to determine their biological significance. Thus, 
bioinformatics tools can be used to first screen for potentially functional SNPs. 
before further investigations be carried out using wet laboratory techniques. 
This translates into reduced costs and saved time. If prediction scores were 
available, quantitative ranking of functionally significant SNPs could be done to 
further prioritize SNPs 
For analysis different publicly available computational algorithms are available, 
such as:  
1) Sorting Intolerant From Tolerant (SIFT) (Ng and Henikoff 2003), 
 2)  Polymorphism Phenotyping (PolyPhen) (Sunyaev, Ramensky, and Bork 
2000), and  
3)  Function Analysis and selection tool for single nucleotide polymorphisms 
(FASTSNP) t. (Yuan et al. 2006).  
The SIFT algorithm predicts whether an amino acid substitution affects protein 
function based on sequence homology among related genes and domains over 
evolutionary time, and the physical-chemical properties of the amino acid 
residues (Ng and Henikoff 2006). Sequence conservation and the nature of the 
amino acid residues involved are also incorporated by PolyPhen, but it also 
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values the location of the substitution within known structures and structural 
features of the protein available in the annotated database SwissProt (Sunyaev, 
Lathe, III, and Bork 2001) [5, 27]. By accessing a variety of heterogeneous 
biological databases and analytical tools, FASTSNP is able to identify SNPs 
most likely to have functional effects, such as changes to the transcriptional 
level and pre-mRNA splicing (Yuan et al. 2006). These tools can be used to 
study the functional affects of SNPs in this thesis where roles were either not 
clear or in contradiction with the findings. In particular CCR2 V64I, IL-18 607 & 
137, MCP-1 -2076.  
6.4.2 High Throughput Genotyping 
As complex disorders, many other genes in the innate immune system and co-
stimulatory pathways are involved in the pathogenesis of PSU. The ultimate 
aims of the genetic studies in uveitis are to identify all the genes involved so 
that a diagnostic and prognostic profile can be developed. In the candidate-
gene approach with manual genotyping a few polymorphisms in a selected 
number of genes can be studied. A high throughput genotyping method and a 
whole genome approach are required for a comprehensive genetic analysis.  
Another important development during the course of this thesis is the 
completion of the International HapMap Project by The United States National 
Human Genome Research Institute (http://www.hapmap.org). Genotypic data 
on ~4 million different SNPs for three major continental groups are available 
from the HapMap Project, with more coming. The HapMap data can be used to 
select Tag-SNPs.   
The SSP-PCR technique, which was used in this study, has been proven 
robust and cost effective. However, the need for manual gel running and 
genotype reading reduces the productivity of this technique. In the later part of 
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my research I used TaqMan® 5’Nuclease Activity Assay. After mixing the 
sample and the reaction components, the assay is run in a closed compartment 
with no post PCR processing step. Results are obtained by simply measuring 
the fluorescence of the completed reaction. By eliminating post PCR 
processing, allelic discrimination with fluorogenic probes reduces the time of 
analysis, labour, supply cost of post-PCR steps, the risk of cross-over 
contamination and minimizes the source of error. TaqMan® is however a 
singleplex reaction: one tube, one SNP. It can be multiplexed to 3 or 4 
maximum SNPs per reaction with additional fluorescent colours. Recent 
advances in high through put genotyping has made it possible to study multiple 
SNPs in one reaction 
The SNaPshot Multiplex System® (Applied Biosystems) is a primer extension-
based method using capillary electrophoresis. It allows multiplexing up to 10 
SNPs starting from as little as 3 ng DNA per sample. (Edenberg and Liu 2009) 
The SNPlex® Genotyping System from Applied Biosystems (De, V et al. 2005) 
uses the oligonucleotide ligation assay to discriminate SNPs, followed by 
polymerase chain reaction and capillary electrophoresis. It allows genotyping of 
up to 48 SNPs at a time. The LightTyper® system (Roche Applied Science) 
uses melting curve analysis to discriminate individual SNPs. These methods 
use fluorescently labelled oligonucleotides for detection of the SNPs (Bennett 
et al. 2003).  
These and similar genotyping techniques are good for testing candidate genes 
and small regions. However, the basis of using haplotype tag-SNP analysis in 
complex traits assumes that the disease causative SNP is a common SNP. 
This is the basis of Common Disease/Common Variant (CD/CV) hypothesis. 
This hypothesis proposes that genetic risk for common diseases will often be 
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due to high frequency variants (Zondervan and Cardon 2004). If the complex 
diseases were due to large numbers of rare variants at many loci, haplotype 
tag-SNP strategy might fail because no single haplotype would harbour these 
individual variants (Suh and Vijg 2005). On the other hand, Hirschhorn and 
Daly suggested that “most rare alleles with frequencies <5% are likely to have 
arisen relatively recently, so there will have been less time for recombination 
and mutation to disrupt the haplotype on which they arose. Therefore, rare 
variants are expected to be on single, long haplotypes, as has been observed” 
(Hirschhorn and Daly 2005). 
Even samples that are large in terms of our ability to do sophisticated and 
reproducible phenotyping (1000-2000 cases and controls) are proving to be 
underpowered in studies of complex traits in which the contribution of any one 
genetic variant is small. Small samples can, however, be very useful in 
replicating results in candidate gene approach. In this case, the prior probability 
is much higher and the likelihood of confirming a finding is increased. It is 
however important to cover a larger fraction of the variation by genotyping 
multiple SNPs chosen based on LD in addition to hypothesised functional 
SNPs, although cost and time (and concerns about multiple testing) can 
preclude full coverage. It is useful first to visualize the LD structure in the region 
of interest, using Haploview (Barrett 2009) (which can be performed within the 
HapMap website). A program such as Tagger (de Bakker et al. 2005) can aid in 
the selection of SNPs; it can be run from a server (through HapMap or directly 
at http://www.broad.mit.edu/mpg/tagger). Parameters such as minimum allele 
frequency (MAF) of SNPs to be "tagged" and the degree of correlation (r2) to 
be accepted as adequate can be adjusted so that a set of SNPs reasonable for 
sample size, technology, and budget can be selected. 
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6.4.3 Genome-wide Association Studies 
An alternative to candidate gene approach is a genome wide association study. 
The number of SNPs per array has dramatically increased in the past few years, 
from ~10,000 to 100,000; 300,000; 600,000; and now >1 million. (Edenberg 
and Liu 2009) The Affymetrix Genome Wide Human SNP® Array 6.0 has more 
than 906,600 SNPs, and the Illumina Human1M-Duo Bead-Chip® assesses 
>1.1 million loci per sample.  
As the density of SNPs on arrays has increased and the costs have gone down, 
microarrays are increasingly used for GWAS on individual samples. This 
approach is much more powerful and allows analysis of multiple phenotypes 
and endophenotypes at once, as well as analysis of quantitative traits. This 
approach has been successful in studies of macular degeneration, and type 2 
diabetes (Klein et al. 2005) (Zeggini et al. 2008).  
GWAS must be followed up. One can either attempt replication of the leading 
SNPs in another population, using candidate gene approach or perform follow-
up GWAS on another population. 
6.4.4 Next Generation genome sequencing 
SNPs can, obviously, be detected by direct sequencing at high accuracy. This 
is the primary method of SNP discovery, and it demands the sequencing of a 
sufficient number of individuals at an accuracy and coverage that distinguishes 
real SNPs from sequencing artefacts. Next-generation sequencing technology 
is capable of sequencing from hundreds of thousands to hundreds of millions of 
DNA (or cDNA) fragments in a single instrument run in a massively parallel 
fashion. So far, three major platforms are commercially available: the Roche 
GS FLX Sequencer®, the Illumina Genome Analyzer (Solexa®), and the 
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Applied Biosystems SOLiD sequencer (SOLiD 3 System®). However, 
sequencing is not at this time an efficient way to genotype SNPs, although as 
sequencing technology progresses toward the much sought "$1000 genome", it 
will become the method of choice and will replace GWAS. (Edenberg and Liu 
2009) 
Despite exhaustive efforts, progress in gene mapping of posterior segment 
uveitis has been very slow. In the last 15 or so years, our knowledge of the 
association of HLA alleles in PSU has improved, but the exact mechanism 
involved remains elusive. Results showed in this thesis indicate that in addition 
to the HLA, cytokine and chemokine molecules also play an important role in 
the pathogenesis of these disorders. In the coming few years, accessory 
molecules, i.e. co-stimulatory molecules, innate immunity genes and trafficking 
molecules, are likely to play an even more important role and the acceleration 
in disease gene discovery will shed new light on the biological pathways 
involved in the pathogenesis of posterior segment uveitis.  
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7 Appendix A: Reagents Compositions 
 
7.1 DNA Extraction 
7.1.1 Salt Extraction Method 
 
7.1.1.1 a) Red Cell Lysis Buffer (RCLB)  
(144 mM NH4Cl, 1 mM NaHCO3) 
7.7 g Ammonium chloride (Sigma, UK) 
10 mL 100 mM (4.2 g 50 mL of H20) NaHCO3 (Sigma, UK) 
Made up to one litre with distilled H2O, autoclaved and stored at room 
temperature 
7.1.1.2 b) Nuclear Lysis Buffer (NLB)  
(10 mM Tris-HCl pH 8.2, 400 mM NaCl, 2 mM Na2EDTA pH 8.0) 
10 mL 1M Tris-HCl (Sigma, UK) 
80 mL 5M NaCl (BDH, UK)  
4 mL  0.5M N2EDTA (Sigma, UK) 
Made up to one litre with distilled H2O, autoclaved and stored at room 
temperature  
7.1.1.3 c) 5M Sodium Chloride Solution 
292.2 g NaCl in one litre distilled H2O 
7.1.1.4 d) Chloroform/Iso-Amyl alcohol (24:1) 
480 mL Chloroform (BDH, UK) 
20 mL  Iso-Amyl alcohol (BDH, UK) 
Stored wrapped in aluminium foil at room temperature 
7.1.1.5 e) Other Solutions 
Molecular biology grade absolute ethanol (BDH, UK) 
Sterile H2O (Baxter, UK) 
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7.1.1.6 f) Other Equipment 
Sorvall Refrigerated Centrifuge (Du Pont, UK) 
15 mL and 50 mL Falcon tubes (Becton Dickson, USA)  
7.1.2 QIAGEN® kit DNA Extraction: 
7.1.2.1 QIAGEN Protease 
Lyophilized powder (20 mg/ml)   
Activity: 45 mAU/mg protein One mAU is the activity that releases folin-
positive amino acids and peptides corresponding to 1 µmol tyrosine per 
minute   
7.1.2.2 Buffer AL (QIAGEN®) 
Red cell lysis buffer, proprietary formulation but contains Guanidium 
Chloride (25-50%) 
7.1.2.3 Buffer AE (QIAGEN®)  
10 mM Tris-Cl  
0.5 mM EDTA; pH 9.0. 
7.1.2.4 Buffer AW1 (QIAGEN®)    
Proprietary formulation but main ingredient is Guanidinium Chloride 50-
100%.  
7.1.2.5 Buffer AW2 (QIAGEN®)    
Proprietary formulation but main ingredient is essentially 70% Ethanol 
7.1.2.6 Other Equipment 
50 mL centrifuge tube 
QIAamp Maxi column 
7.2  Pico-Green DNA Quantitation 
7.2.1 Reagents Supplied in Kit 
- 20 x TE solution 
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- 200 mM Tris-HCl  
- 20 mM EDTA (pH 7.5) 
- Pico-Green solution in Dimethyl Sulphoxide (DMSO) 
- Distilled H2O 
 
7.2.2 Other Equipment  
- Fluorometer (Lambda Fluro 320 plus - MWG Biotech)   
- Fluorometer software (KC4 - supplied as standard)  
 
7.3 PCR Amplification 
7.3.1 SSP-PCR 
7.3.1.1 a) PCR Reaction Reagents 
- 67 mM Tris-Base pH 8.8. (Bioline, UK) 
- 16.6 mM Ammonium sulphate (Bioline, UK) 
- 2 mM MgCl2 (Bioline , UK) 
- 0.01% v/v Tween 20 (Bioline, UK) 
- 0.2 mM each of dATP, dATP, dGTP, dCTP (Bioline, UK) 
- Taq polymerase (Bioline, UK) 
- Mineral Oil (Sigma, UK) 
- Distilled H2O (Baxter, UK) 
7.3.1.2 b) Cresol Red Dye 
62.5 mg/L Cresol Red dye was made by mixing 0.625 mg in 100 mL 
dH2O. This was used at 10 µl/mL in working primer stock solutions 
7.3.1.3 c) Other Equipment 
- MJ PTC-200 Thermal Cyclers (MJ Technologies, USA) 
- Thermowell plate sealers (Costar, Netherlands) 
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- Thermowell 96 and 192 well plates  (Costar, Netherlands) 
7.3.2 TaqMan® SNP allele discrimination Assay 
7.3.2.1 TaqMan® Universal PCR Master Mix: 
Contains AmpliTaq Gold DNA Polymerase, AmpErase UNG, (uridine, 
uracil-N-glycosylase) dNTPs with dUTP, Passive Reference dye 
ROX, and optimized buffer Components (proprietary formulation).  
   
7.3.2.2 TaqMan® Assay Mix (labelled probes and un labelled primers)  
or  
7.3.2.3 Custom made primers and probes 
7.3.2.4 Other Materials 
 Distilled H2O (Baxter, UK) 
Optical 384-Well Reaction Plate 
Optical Adhesive Films  
7.3.2.5 Other Equipment: 
The ABI PRISM 7900HT Sequence Detection System 
 
7.4 Agarose Gel Electrophoresis 
a) Orange G Loading Dye 
- Per 250 mL of Orange G loading dye  
- 250 mL Glycerol (Sigma, UK) 
- 100 mL 0.1 M EDTA (Sigma, UK) 
- 60 mL 1% Orange G (Sigma, UK) 
- 90 mL 1M Tris-HCl (pH 7.5) 
b) Ethidium Bromide (EtBr)  
10mg/mL 
 366 
200 mg EtBr were dissolved in 20 mL dH2O 
c) 2% Agarose Gels 
-    10 grams Molecular biology grade agarose 
- 500 mL 0.5 x TBE solution 
- 0.5 x TBE solution: 
- 89 mM Tris base (ICN Biochemicals, USA) 
- 89 mM Boric Acid (BDH, UK) 
- 2 mM EDTA (pH 8.8) (Sigma UK) 
- 5 µl 0.5 mg/mL Ethidium Bromide per 500 mL gel (Sigma, UK) 
 
d) Other Equipment 
- 0.5 X TBE buffer (as above) 
- Horizontal gel electrophoresis tanks (Sigma, UK) 
- Electrophoresis power units (Pharmacia, UK) 
- Polaroid film (Sigma, UK)  
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8 Appendix B 
 
 
Table 8-1: Classification and Nomenclature for chemokines and receptors 
 
 
 
Copied from: Chemokine/chemokine receptor nomenclature. IUIS/WHO Subcommittee on 
Chemokine Nomenclature. Cytokine. 2003 Jan 7;21(1):48-9 
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CCR2 V64I (G/A)  Patients Control  
GENOTYPE Count  FREQ Count FREQ Chi2x2 p 
GG 61 0.79 247 0.87 3.18 NS 
GA 14 0.18 35 0.12 1.74 NS 
AA 2 0.03 1 0.00 3.69 NS 
Total 77   283   
    
          
    
Allelic Carriage / phenotype         
    
G 75 0.97 282 1.00 3.69 NS 
A 16 0.21 36 0.13 3.18 NS 
          
    
          
    
Allelic Frequency         
    
G 136 0.88 529 0.93 4.55 0.03286 
A 18 0.12 37 0.07 
    
Total 154   566   
    
Table 8-2: Genotypic frequency of CCR-2 V64I in intermediate uveitis and control 
 
 
 
 
 
 
 
 MCP-1 2518 A/G Age less than 40 Age 40 or above Genotype Differences  
GENOTYPE Count  FREQ Count FREQ 
    
p 
AA 57 0.46 55 0.69 Chi2x3= 10.86 0.00116 
AG 58 0.46 20 0.25 p= 0.004 0.00208 
GG 10 0.08 5 0.06   
  
NS 
Total 125   80         
                
Allelic Carriage                
A 115 0.92 75 0.94     NS 
G 68 0.54 25 0.31     0.00116 
                
                
Allelic Frequency               
A 172 0.69 130 0.81     0.00524 
G 78 0.31 30 0.19       
Total 250   160         
Table 8-3: Age of onset of PSU in patients with MCP-1 -2518 genotypes  
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Table 8-4: CCR2 V64I frequencies in Behcet’s patients comparing males versus female. 
 
CCR2 V64I (V=G & I=A) Males  females    P value 
 Count  Count   
GG 18 (82%) 3 (33%)  0.008761 
GA 3 (14%) 6 (67%)  0.003151 
AA 1 (4%) 0 (0%)  NS 
Total 22 9    
         
Allelic Carriage / 
phenotype        
GG/ GA 21 (95%) 9 (100%)  NS 
AA/ GA 4 (18%) 6 (67%)  0.008761 
         
         
Allelic Frequency        
G 39 (88%) 12 (67%)  0.039838 
A 5 (12%) 6 (33%)    
Total 44 18    
 
 
 
 
 
 
 
Table 8-5: The association of CCR5 -59029 A allele and need for long term steroids in 
posterior uveitis 
 
CCR-5 59029 G/A Long term steroids No long term steroids P value  
GENOTYPE Count  Count   
      
AA 11 (37%) 10 (29%) NS 
GA 17 (57%) 15 (45%) NS 
GG 2 (6%) 9 (26%) 0.03 
Total 30 34 NS 
      
Allelic Carriage     
A 28 (93%) 25 (74%) 0.03 
G 19 (63%) 24 (71%)   
Total       
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Table 8-6: Cataract in idiopathic PSU and its relation with CCR5 -3900 SNP 
  Cataract No Cataract P value 
CCR-5 3900 Count  FREQ Count FREQ Chi 2X2 
AA 28 0.51 27 0.31 0.0205 
AC 26 0.47 46 0.53 NS 
CC 1 0.02 13 0.15 0.01001 
Total 55   86     
            
Allelic Carriage / phenotype           
A 54 0.98 73 0.85 0.01001 
C 27 0.49 59 0.69 0.0205 
            
            
Allelic Frequency           
A 82 0.75 100 0.58 0.00497 
C 28 0.25 72 0.42   
Total 110   172     
 
 
 
 
 
 
 
 
Table 8-7: CCR5 -2135 C allele and need for steroids in intermediate uveitis 
 
CCR-5 2135 T/C  steroids No  steroids P value  
GENOTYPE Count  Count   
      
TT 11 (23%) 8 (27%) NS 
TC 13(28%) 18 (60%) 0.004 
CC 23 (49%) 4 (13%) 0.001 
Total 47 30 NS 
      
Allelic Carriage     
T 24 (51%) 26 (87%) 0.001 
C 36 (77%) 22 (73%)   
Total       
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Table 8-8: CCR-5 -1835 SNP and gender in Ocular Behcet’s 
 
  Males    Females   Chi 2X3  Chi 2X2 
GENOTYPE Count  FREQ Count FREQ P value P value 
CC 20 91% 4 44%   0.004977 
CT 1 5% 5 56% 0.004569 0.001102 
TT 1 5% 0 0%   NS 
Total 22   9       
Allelic Carriage              
C 21 95% 9 100%   NS 
T 2 9% 5 56%   0.004977 
Allelic Frequency             
C 41 93% 13 72%   0.025444 
T  3 7% 5 28%     
Total 44   18       
 
 
 
 
 
 
 
 
 
 
Table 8-9: Association of IL-10 592 SNP with permanent visual loss in intermediate 
uveitis 
 
IL-10 -592 C/A PVL   No PVL  P Value P value 
 N=22 % N=45 % 
 Chi2x3 Chi 2X2 
CC 10  0.45 33 0.73  0.02541 
CA 11 0.50 12 0.27 0.045 NS 
AA 1 0.05 0 0.00   NS 
Allelic Carriage             
C 21 0.95 45 1.00   NS 
A 12 0.55 12 0.27   0.02541 
Allelic Frequency             
C 31 0.70 78 0.87   0.02368 
A 13 0.30 12 0.13     
 
 
 372 
9 List of Original Communications 
 
1) Chemokine gene polymorphisms in immune mediated posterior segment 
uveitis. Ahad MA, Missotten T, Abdalla A, Lympany P and Lightman S. 
Molecular Vision 2007; 13:388-396 
 
2) Association between Heat Shock Protein 70/Hom genetic 
polymorphisms and uveitis in patients with sarcoidosis. Spagnolo P, 
Marshall S, Ahad M, Lightman S, du Bois R, Welsh K. Invest Ophthalmol 
Vis Sci. 2007 Jul;48(7):3019-25 
 
3) Chemokine gene polymorphisms in idiopathic anterior uveitis. Yeo TK, 
Ahad MA, Spagnolo P, Lympany P, Lightman S. Cytokine. 2006 
Jul;35(1-2):29-35 
 
 
4) The association of IL-12 and IL-18 gene polymorphisms with retinal 
vasculitis in patients with non-infectious posterior segment uveitis. M. A. 
Ahad, M. Rose-Zerilli, S. Goverdhan, A. Lotery and S. Lightman. Invest 
Ophthalmol Vis Sci 2007;48: E-Abstract 5161. 
 
5) Role of CCR–5 Gene Haplotypes in Immune Mediated Posterior 
Segment Uveitis. Ahad M, Spagnolo P, Lympany P, Lightman S. Invest. 
Ophthalmol. Vis. Sci. 2006 47: E-Abstract 3272 
 
6) CCRV64I polymorphism as a genetic risk marker of Behcet’s related 
uveitis. Ahad M, Missotten T, Lympany P, Lightman S. Ophthalmic 
Research 2005; 37:S1 05 Page193 
 
 
7) Chemokine Genes Polymorphisms in Posterior Non–Infectious Uveitis 
Ahad M, Missotten T, Abdullah A, Lympany P, du Bois R, Lightman S. 
Invest. Ophthalmol. Vis. Sci. 2005 46: E-Abstract 3805. 
 
8) CCL-5 and CCR-5 chemokine gene polymorphism in posterior non-
infectious uveitis Ahad M, Missotten T, Lympany P, Lightman S. 
Ophthalmic Research. 2004; 36: S1 04 Page 37 
 
 
9) RANTES Chemokine promoter gene Polymorphism and need for 
immunosuppressant agents in posterior uveitis Missotten T, Ahad M, 
Abdalla A, Lympany P, Lightman S Ophthalmic Research. 2004; 36: S1 
04 Page 86 
 
10)  CCR-5 Chemokine receptor gene Polymorphism and severe outcome in 
posterior uveitis Missotten T Ahad M, Abdalla A, Menezo V, Kuo NW, 
Lympany P, Lightman S. Ophthalmic Research. 2004; 36: S1 04 Page 
87 
 
 
 
 373 
10 Glossary 
 
1. ADMIXTURE. The mixture of two or more genetically distinct 
populations. This has implications for studies of genotype–disease 
associations if the component populations have different genotypic 
distributions.  
2. ALLELE. Alternative forms of a gene found at the same locus on a 
particular chromosome. 
3. ALLELE FREQUENCY. The number of particular allele divided by the 
number of chromosomes in the study population. 
4. ASSOCIATION STUDY. A genetic variant is genotyped in a population 
for which phenotypic information is available (such as disease 
occurrence, or a range of different trait values). If a correlation is 
observed between genotype and phenotype, there is an association 
between the variant and the disease or trait.  
5. BAYESIAN. A statistical approach that assesses the probability of a 
hypothesis being correct (for example, whether an association is valid) 
by incorporating the prior probability of the hypothesis and the 
experimental data supporting the hypothesis.  
6. BONFERRONI CORRECTION. The simplest correction of individual P-
values for multiple-hypothesis testing: p corrected = 1 - (1 - p 
uncorrected)n, where n is the number of hypotheses tested. This 
formula assumes that the hypotheses are all independent.  
7. CANDIDATE GENE. A gene for which there is evidence of its possible 
role in the pathogenetic mechanism of a disease. It choice can be 
based on evidence from animal model, genetic mapping studies or 
knowledge of biological pathways. 
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8. CARRIER FREQUENCY (PHENOTYPE FREQUENCY). The number of 
individual carrying a particular allele divided by the total number of 
individuals studied.   
9. DEACETYLATION The modification of histones by removal of acetyl 
groups. Acetylation of histones allows transcription to occur, and 
deacetylation inhibits transcription. 
10. DISEASE PHENOTYPE. The manifestation of a disease in terms of 
clinical characteristics, e.g. disease severity, disease subtype, and 
disease prognosis. 
11. EPISTASIS. The interaction between two or more genes to control a 
single phenotype. 
12. FOUNDER POPULATIONS. Those have been derived from a limited 
pool of individuals within the last 100 or fewer generations.  
13. GENE. A region of DNA that encodes a protein. 
14. GENOTYPE FREQUENCY. The number of individuals with a particular 
genotype divided by the total number of individual studied. 
15. GENOTYPE. The genetic constitution of an individual, usually at a 
particular locus. 
16. HAPLOTYPE. The combination of alleles found at neighbouring loci on 
a single chromosome or haploid DNA molecule.  
17.  HAPLOTYPE PHASING. Alleles in linkage within a chromosomal 
segment and found to be inherited as a unit. 
18. HARDY–WEINBERG EQUILIBRIUM. The binomial distribution of 
genotypes in a population, such that frequencies of genotypes AA, Aa 
and aa will be p2, 2pq, and q2, respectively, where p is the frequency of 
allele A, and q is the frequency of allele a. Hardy–Weinberg equilibrium 
 375 
applies in a population when there are no factors such as migration or 
admixture that cause deviations from p2, 2pq and q2.  
19. HERITABILITY. The proportion of the variation in a given characteristic 
or state that can be attributed to (additive) genetic factors.  
20. HETEROZYGOUS. The situation in which an individual carries two 
different alleles at the same locus. 
21. HOMOZYGOUS. The situation in which an individual carries the same 
allele in the same locus. 
22. LINKAGE DISEQUILIBRIUM. Correlation between nearby variants such 
that the alleles at neighbouring markers (observed on the same 
chromosome) are associated within a population more often than if they 
were unlinked.  
23. LINKAGE MAPPING. Where genes are mapped by typing genetic 
markers in families to identify regions that are associated with disease 
or trait values within pedigrees more often than are expected by chance. 
Such linked regions are more likely to contain a causal genetic variant.  
24. MEGABASE. (Mb) Unit of length for DNA fragments equal to 1 million 
nucleotides and roughly equal to 1 cM. 
25. MINOR ALLELE. The less frequent of two alleles at a locus. 
26. MULTIPLE-HYPOTHESIS TESTING. More than one hypothesis within 
an experiment. As a result, the probability of an unusual result from 
within the entire experiment occurring by chance is higher than the 
individual p-value associated with that result.  
27. ODDS RATIO. A measure of relative risk that is usually estimated from 
case-control studies.  
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28. PAIRWISE LINKAGE DISEQUILIBRIUM. (Pair wise LD). The strength 
of association between alleles at two different markers.   
29. PENETRANCE The proportion of individuals with a specific genotype 
who manifest the genotype at the phenotypic level. For example, if all 
individuals with a specific disease genotype show the disease 
phenotype, then the genotype is said to be completely penetrate.  
30. POLYMORPHISM. The occurrence in one population of two or more 
genetically determined forms (alleles), all of which are too frequent to be 
ascribed to mutation. Generally, a polymorphism is defined as a genetic 
variation occurring at least in 1% of the population.   
31. PROMOTER.  Region of DNA that promote transcription 
32. QUANTITATIVE TRAIT. traits are affected by more than one gene, and 
by the environment. 
33. TAG SNPs are SNPs that unambiguously define a particular haplotype 
in a block 
34. TRANSCRIPTION. The process of creating a complementary RNA 
copy of a sequence of DNA 
35. TRANSMISSION DISEQUILIBRIUM TEST. (TDT) A family-based test 
for association that is immune to population stratification. The 
transmission of alleles from heterozygous parents to affected offspring 
is compared to the expected 1:1 ratio 
36. UNPHASED DATA. Sequence data in which the phase of double 
heterozygotes was not determined.  
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